Characterisation of anti-inflammatory and pro-inflammatory

influences on blood-brain barrier phenotype using an in vitro human brain microvascular endothelial model by Rochfort, Keith D.
I 
 
 
 
Characterisation Of Anti-
Inflammatory And Pro-Inflammatory 
Influences On Blood-Brain Barrier 
Phenotype Using An In Vitro Human 
Brain Microvascular Endothelial 
Model 
A dissertation submitted for the degree of Ph.D by 
Keith D. Rochfort, B.Sc 
Under the supervision of Dr. Philip M. Cummins 
September 2013 
Faculty of Science and Health, School of Biotechnology,  
Dublin City University, Dublin 9, Ireland 
II 
 
Declaration 
I hereby certify that this material, which I now submit for assessment on the programme 
of study leading to the award of Doctor of Philosophy is entirely my own work, that I 
have exercised reasonable care to ensure that the work is original, and does not to the 
best of my knowledge breach any law of copyright, and has not been taken from the 
work of others save and to the extent that such work has been cited and acknowledged 
within the text of my work. 
 
Signed:  ______________________________  
(Candidate) ID No.: ____________________ 
 Date: ________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III 
 
Acknowledgements 
First and foremost I have to extend a large amount of gratitude to my supervisor of the last 
few years, Dr. Philip Cummins, who placed a lot of trust in a rookie chemist all those years 
ago that yielded a somewhat capable biologist. I hope I have repaid some of the faith you 
placed in me and I did not make it too difficult at times what with all the ambitious (and 
sometimes expensive) ideas I proposed and of course the edits, the oh so many edits, I 
provided in large and steady supply. You have had such a large part to play in this process 
and I could not be more grateful. I wish you and your group the best of luck in the years to 
come.   
I also need to extend a large thanks to our collaborator; Dr. Ronan Murphy of the IBG, who 
has provided invaluable insight, fresh perspectives and incredible opportunities for the 
members of our research groups over the years. I also wish you and your group the best of 
luck in the years to come. 
Next, I need to thank the ‘old guard’ of our research groups; Tony, Anthony, Paul, Mishan 
and Andrew. Despite being the final stages of their own projects and work they were 
incredibly helpful and particularly patient in bringing not only I, but a number of ‘raw 
talents’ that were introduced into the lab at once, up to speed. They were instrumental in 
making our first year not only productive but incredibly memorable and for that I’m grateful. 
I also need to thank those aforementioned ‘raw talents’; Fiona, Colin, Brian, Ciarán and 
Shan, who I entered the lab alongside. It has been an absolute pleasure to have been a part of 
their projects as much as it has been to have had them as a part of mine. I take away a 
number of incredible memories and I look forward to making many more with you all. I also 
need to thank the ‘future’ of both of the research groups; Alisha, Laura, Rob and Hannah, 
who in their short time look more than capable of carrying on the good work being carried 
out between the groups and were incredibly understanding and accommodating in the build-
up to ‘viva season’. 
I also need to extend my gratitude to Dr. Christine Loscher and Dr. Neal Lemon of the T3 
program, who not only granted me the opportunity to pursue a PhD. but also offered some 
invaluable advice and support along the way. Being a part of said program has also allowed 
me to forge many important friendships that I hope will continue as we all go our separate 
ways. To have had that additional support outside of my own lab was important, and I’m 
grateful to have been a part of that exclusive club for the time that was on it. 
Next, my girlfriend Laura, for whom there are not enough words that I can use to express 
how truly grateful I am. To have had your support, ideas and help over the years-you 
contributed so much to this journey, inside and outside of the lab, that I cannot imagine what 
it would have been like without you there. To have had you in a position that you could 
understand and relate to the trials and tribulations that accompany a PhD. meant so much. I 
can only hope that I can return the gesture in time. 
While I have been lucky enough to have had a lot of support within DCU, I was also lucky 
to have had support outside of it. From those that could relate to those that tried to-my 
friends from home. You guys have never lost patience with the random, and at times 
inconvenient, ‘office hours’ I worked and always tried to accommodate me as such. Whether 
IV 
 
it was a time I needed to talk about science or it was a time I needed to talk about anything 
but-you guys were always on hand and made a lot of hard times easier.      
Last and by no means least I need to thank my family. They have been incredibly supportive 
of me throughout and have been a constant source of encouragement. They have been at the 
forefront of the many highs and lows as much as anyone and I can only hope that now it is 
over, I have made you proud.           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V 
 
Abstract 
Introduction: Within the central nervous system, the cerebral endothelial cells have highly 
specialised structural and functional properties. Compared to the endothelium of the periphery, brain 
endothelial cells are phenotypically unique in that they have enhanced inter-endothelial junction 
complexes that provide a highly restrictive yet controlled paracellular barrier for the brain from the 
constituents of the circulation, effectively embodying a blood-brain barrier. Disruption of the 
proteins that form these junctional complexes (i.e. occludin, claudin-5, VE-cadherin and ZO-1) has 
therefore been implicated in several CNS disease states. 
Endothelial functions can be modulated by both local and systemic environmental factors. The ability 
of the endothelium to sense its humoral and biomechanical environment and modify its functional 
phenotype accordingly plays a pivotal role in the maintenance of vascular homeostasis or the 
development of vascular pathology. However, much remains unknown about how anti- and pro-
inflammatory stimuli modulate blood-brain barrier phenotype at the molecular level, thus framing the 
context of this thesis.  
In the current study, in view of the opposing physiological and pathophysiological actions 
demonstrated thus far in similar yet distinctly different in vivo and in vitro endothelial models, we 
propose to investigate how anti-inflammatory laminar shear stress and pro-inflammatory cytokines 
can differentially modulate BBB phenotype, with functional consequences for endothelial 
homeostasis, particularly with regards to the coordination and maintenance of the BBB 
interendothelial junction complex. 
 
Results: Exposure of cultured human brain microvascular endothelial cells (HBMvECs) to 
physiological levels of laminar shear stress (8 dynes cm
-2
) resulted in a reduction in monolayer 
permeability. The transcription and translation of occludin, claudin-5, VE-cadherin and ZO-1 were all 
upregulated, with an enhanced localisation of said proteins at the cell-cell junctions. Moreover, our 
studies demonstrated laminar shear stress caused a substantial reduction in pTyr and pThr levels on 
each protein, with functional consequences for barrier integrity as determined using dephostatin and 
genistein. In addition, laminar shear stress promoted a number of anti-inflammatory mechanisms, 
which, in the presence of inflammatory cytokines, could partially ameliorate the injurious effects of 
the latter. Sophisticated co-IP techniques, coupled with mass spectrometry analysis, identified several 
isoforms of the 14-3-3 family of proteins as intracellular binding partners to the interendothelial 
junction complex. This family of proteins was implicated in contributing to the protective, barrier-
stabilising effect of laminar shear, whilst inhibition of their activity exacerbated cytokine injury. 
In parallel studies, exposure of cultured HBMvECs to pathophysiological levels of inflammatory 
cytokines, TNF- and IL-6, resulted in an increase in monolayer permeability, an effect directly 
attributable to the reduction in the transcription and translation of the aforementioned tight and 
adherens junction proteins. Moreover, each cytokine caused a substantial increase in pTyr/Thr levels 
on each protein. Noteworthy, all cytokine effects were dose- and time-dependent. This increase in 
injury can be possibly attributed to a correlative reduction in anti-inflammatory mechanisms coupled 
with a correlative increase in the production and release of inflammatory mediators such as ROS and 
other cytokines such as IL-6 into the local environment. 
 
Conclusions: Physiological levels of laminar shear stress and pathophysiological levels of 
inflammatory cytokines, TNF- and IL-6, modulate the expression and post-translational properties 
of BBB tight and adherens junction proteins in an opposing manner. Inflammatory cytokines mediate 
their effects in part through the induced release of injury potentiating agents such as ROS and IL-6. A 
novel role for 14-3-3 isoforms in the modulation of interendothelial junction assembly is also 
implicated in these studies.  
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1.1 Vascular Disease 
Diseases of the heart and circulatory system, including the cerebrovascular system, are the 
main cause of death across the world accounting for over 4 million deaths annually in 
Europe alone (Figure 1.1). Of all the main causes of death, nearly half (47%) are attributed 
to cardiovascular diseases (CVD). Just under half of all deaths from CVD are from coronary 
heart disease with stroke accounting for nearly a third of deaths in women and a quarter of 
deaths in men (Nichols, Townsend et al. 2012).  
 
Figure 1.1: Deaths by cause, men (left) and women (right). CVD is accountable for 42% 
and 52% of fatalities in men and women respectively (applicable to Europe) (Nichols, 
Townsend et al. 2012). 
 
CVD was often thought to be a problem of wealthy, industrialised nations. As research 
techniques and means of gathering and sharing information improved, CVD is now 
recognised as the leading cause of death worldwide, impacting equally across developed and 
middle to low income countries. To put this in perspective, many communicable diseases 
such as malaria, tuberculosis, human immunodeficiency virus/acquired immunodeficiency 
syndrome (HIV/AIDS) and their impact on certain societies garner much spotlight, yet CVD 
causes more than 3 times the annual deaths of these diseases combined (Boerma, Abou-Zahr 
et al. 2008). The impact CVD has had on these once low-risk regions is attributed to 
widespread industrialisation, urbanisation and globalisation of these regions. With these 
processes comes a complementary shift in the behavioural, biological and social risks which 
have a resounding impact on the likelihood of developing CVD (Yusuf, Reddy et al. 2001). 
While some aspects of developing CVD have been attributed to hereditary processes, 
additional risk factors include environmental and lifestyle choices. Tobacco use, unhealthy 
diet, reduced physical activity, blood lipid levels and hypertension are among the factors 
which greatly influence the chances of developing CVD (Roger, Go et al. 2012). As a result, 
governments and health agencies are promoting the idea of tackling CVD in early age in the 
hope such ideals would be carried on throughout life. Recent statistics showed in the US that 
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67.3% of the adult population (≥ 20 years old) are overweight with 33.7% of the total adult 
population clinically obese, while the same studies reported 31.7% of children are 
overweight with 16.9% clinically obese (Roger, Go et al. 2012). While these statistics might 
not seem impressive, progress has been made. From 1998 to 2008, the rate of death 
attributable to CVD has decreased by 30.6% demonstrating that promotion of healthy 
lifestyle and raising awareness of the risk factors that can contribute to it is having a 
significant impact on the world’s population (Roger, Go et al. 2012).  
Efforts in coping with CVD are focussed on furthering the understanding of the science 
behind it and developing therapeutics and strategies to control it. In comparison to some of 
the other leading causes of mortality, CVD related diseases have shown a significant drop in 
their impact (Kochanek, Xu et al. 2011) (Figure 1.2). This is due to the development of 
better in vitro and in vivo models, techniques, instrumentation and assays, all of which have 
enabled the scientific community to better understand the nature of disease onset and 
progression.   
 
Figure 1.2: Age-adjusted death rates for selected leading causes of death in the United 
States, 1958-2008. Circled numbers indicate ranking of conditions as leading causes of 
death as of 2009 (Kochanek, Xu et al. 2011). 
 
What follows is a brief introduction to the vascular system before focussing on the 
endothelium, a key cell type at the forefront of the vasculature which has been identified as 
playing a major role in both preventing, and in certain instances promoting, CVD onset. This 
thesis will focus primarily on the endothelium of the cerebrovasculature network, which 
forms the basis of the blood-brain barrier (BBB), a dynamic interface that separates the 
central nervous system from the circulation, controlling the influx and efflux of biological 
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materials from the blood to the brain and vice versa. The influence of physiological (shear 
stress) and pathophysiological (inflammatory cytokines) stimuli on endothelial phenotype 
will be addressed whilst highlighting the impact of said stimuli on BBB phenotype and thus, 
the potential role they play in the development/progression of cerebral-based pathologies.  
1.1.1 Vascular system 
The earliest understanding of the vasculature system originates in ancient Greece, 250BC. 
Then, based on the works of Erasistratus, it was believed that the heart was connected to two 
entirely separated sets of vessels; the arteries transported oxygen throughout the body whilst 
the veins transported blood. However, strict religious ideologies condemning the practise of 
dissection halted the progression of such studies. Regardless, evidence reports the studies 
evolved to the extent that the concept of ‘exchange’ between the purposed independent 
vascular systems was premised (Singer 1957, Majno 1992).  
It wasn’t until 1628, that William Harvey first described the ‘ceaseless and circular motion’ 
of the complete vascular system in greater detail (Fishman 1982). Since then, the 
understanding of blood vessels has rapidly evolved such that they are now recognised as key 
elements in the maintenance of tissue homeostasis, serving as conduits which facilitate the 
transport of nutrients and oxygen to the body’s tissues and organs, whilst also removing the 
potentially disruptive catabolites and xenobiotics (Furchgott, Zawadzki 1980, Gimbrone, 
Kume et al. 1993, Gimbrone 1995, Cines, Pollak et al. 1998). 
Figure 1.3 illustrates the basic composition of the blood vessels within the vasculature. The 
walls of arteries and veins have three layers; the tunica interna (intima), the tunica media and 
the tunica externa (adventitia). The outermost layer, the tunica externa is made up of fibrous 
connective tissue. The middle layer, the tunica media, is an ‘active’ layer composed of 
smooth muscle cells and elastic fibres. The inner most layer, the tunica interna, is comprised 
of the endothelium. Capillaries are tiny in size and form vast networks or capillary beds 
throughout the body. Their walls are typically a single layer of endothelial cells which 
allows for mediated exchange of materials between the blood and local tissue (Townsley 
2012). 
The entire vascular system is comprised of an extensive range of vessels (over 60,000 
miles). While the diameter, length and degree of branching of the vessels can vary across 
vascular beds, one mainstay in the makeup of the vessels is the endothelium, a layer of 
highly metabolically active, flat squamous cells that line the entire circulatory system 
including the heart (Aird 2007). The following section covers a number of aspects of the 
endothelium discussing some of the important traits it brings to vascular homeostasis.   
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Figure 1.3: Anatomical structure of arteries, veins and capillaries. Blood vessels 
facilitate the transport of blood throughout the body. They are typically comprised of three 
main layers: tunica intima, the innermost layer comprising of endothelium monolayer; tunica 
media, the middle layer comprising of smooth muscle cells and elastic collagen fibres that 
make up the bulk of vessel wall thickness; and the tunica adventitia, the outermost layer that 
contains fibroblasts and elastic collagen fibres. In contrast, the capillaries are typically 
comprised of a single layer of endothelial cells (Tortora, Derrickson 2007).  
 
 
1.1.1.1 Endothelium 
During the 1880’s Von Rocklinghausen described how the conduit-like vessels, lined by 
cells, bore deeply into the underlying tissue (von Rocklinghausen 1860). After Starling 
published his findings on capillary exchanges (Starling 1896), the scientific community 
began to recognise the inner lining of endothelial cells on the blood vessel walls as a 
‘selective’ physical barrier.  
The endothelium provides a cellular lining to all blood vessels within the circulatory tree 
(Aird 2007). It has been shown to form a structural barrier between the vascular space and 
tissue. A single endothelial cell ranges from 25-50 μm in length, 10-15 μm in width and 5 
μm in height (Limaye, Vadas 2006). In an adult, as it lines the entire inner wall of all blood 
vessels, the collective endothelium is said to be comprised of 1.6*10
13
 cells on average 
(Limaye, Vadas 2006), collectively weighing up to 1 kg and covering a surface area of 350 
m
2
 (Augustin, Kozian et al. 1994, Pries, Secomb et al. 2000, Pries, Kuebler 2006). Once 
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thought to be inert, research conducted on the endothelium has redefined it as a dynamic 
organ with a myriad of important endocrine, paracrine and autocrine functions (Ryan, Ryan 
1984, Hunt, Jurd 1998). In order to maintain human vascular homeostasis, the endothelium 
has to continuously monitor the circulatory and locally generated stimuli as well as any 
acute or chronic changes to its environment (Aird 2006). Given the diversity of vessels, their 
dimensions, the environments in which they reside and their associated stimuli, it is 
necessary for the endothelium to be adaptable to its microenvironment (Risau 1995). The 
endothelium can undergo a dynamic shift in phenotype relative to the environment in which 
it resides ensuring the microenvironment’s complex metabolic and structural needs are met. 
However, any stimuli or environmental changes that may disrupt vascular homeostasis may 
cause a disturbance in the neighbouring vasculature beds. If substantially damaging, this in 
turn can alter the endothelium so that it becomes ‘dysfunctional’, which subsequently can 
lead to dysregulation of endothelium-dependent processes, e.g. antihemostatic functions, 
vascular tone, heightened leukocyte adhesion, reduced barrier function, increased production 
of cytokines and growth factors etc (Endemann, Schiffrin 2004). 
 
1.1.1.1.1 Hemostasis 
The vascular endothelium is primarily an anticoagulant surface layer. Normally platelets are 
unable to interact with the endothelium due to release of vaso-relaxant and platelet-
inhibiting nitric oxide and prostacyclin (Gryglewski 1995, Gryglewski, Chlopicki et al. 
1995, Cannon 1998, Cannon 1998). In addition, healthy endothelial cells express a number 
of signalling molecules which in turn can interrupt and quell the coagulation process. For 
example, thrombin is a primary catalyst in the coagulation process (Mann, Golden et al. 
1997). Endothelial cells can nullify thrombin and use it to its own advantage in a number of 
ways. One pathway involves the release of heparin sulphate, which in turn increases the 
potency of anti-thrombin III, which in turn binds to and neutralises thrombin (Marcum, 
Rosenberg 1984, Marcum, Mckenney et al. 1984). Another mechanism involves the surface 
expression of thrombomodulin (Maruyama, Majerus 1985, Maruyama 1992), which can also 
bind to thrombin leading to the activation of the Protein C pathway which functionally 
prevents the conversion of a large number of pro-coagulant mediators, cumulatively halting 
a number of pathways. Endothelial cells also secrete the factors that activate the fibrinolysis 
pathway ensuring coagulation remains at the site of vessel injury (Levin, Santell 1987, 
Sawdey, Loskutoff 1991). 
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1.1.1.1.2 Vaso-regulation 
The endothelium has also been shown to play a role in dynamically regulating its own 
vascular tone. A study by Furchgott and Zawadzki (1980) subjected a number of intact 
arteries to a regime of acetylcholine which induced vasorelaxation. In contrast, when the 
endothelium was removed, acetylcholine caused the arteries to undergo vasoconstriction. 
This led to the idea that an endothelium-derived vascular relaxation factor (EDRF) was 
responsible. Further studies showed that the acetylcholine caused the smooth muscle cells of 
the artery to undergo vasoconstriction, but in the presence of the endothelium, the free 
radical nitric oxide was generated in response to counteract the acetylcholine’s effect clearly 
implicating nitric oxide in having a role in the vasoregulation. In addition to control over 
vessel dilation, endothelial cells also produce potent vasoconstrictors such as endothelin-1 
(Levin 1996). In this way, the endothelium can dynamically regulate and adapt vessel tone 
by delicately balancing the release of these mediators under different conditions (e.g. 
hypoxia, shear stress, and ischemia). 
 
1.1.1.1.3 Barrier Function 
First and foremost, the endothelium was characterised as a compact, uniform monolayer 
which acts as a dynamic barrier between the circulating blood and the vessel’s underlying 
tissue. Given the endothelium’s ability to adapt to its environment, the barrier properties of 
the endothelium reflect the property inducing effects of the vascular beds in which they 
reside. As a result certain properties of the endothelium can be augmented such as the 
expression of certain cell surface binding proteins, the electrostatic charge of the endothelial 
membrane and perhaps most importantly, the effect on the proteins that comprise the 
intercellular junctions (Lampugnani, Dejana 1997). The effect of a particular 
microenvironment on the phenotype of the endothelium as well as some of the associated 
barrier properties that are induced will be addressed in later sections.  
  
1.1.2 Endothelial Dysfunction/Atherosclerosis 
Atherosclerosis is a progressive chronic process which is responsible for the onset of several 
vascular disorders. It is a condition in which an arterial wall undergoes thickening and 
hardening as a result of fatty material deposit and accumulation in the sub intima lining of 
vessel walls (Ross 1999) (Figure 1.4). Atherosclerotic lesions typically originate at the 
bifurcations, branching points, and curvatures of vessels (Giannoglou, Antoniadis et al. 
2010). It is at these points that low or disturbed shear stress occurs, leading to endothelial 
‘activation’. Upon activation, the endothelium transitions to a pro-inflammatory phenotype 
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that contributes to vascular injury. This phenotypic change brings the release of injury 
markers and signalling molecules that attracts various immune cells, including monocytes 
and leukocytes (Hansson 2005, Charo, Ransohoff 2006). In addition to this, the endothelium 
increases expression levels for surface receptors P-Selectin, E-Selectin and vascular cell 
adhesion molecule (VCAM)-1 (Tsao, Buitrago et al. 1996, Chiu, Chen et al. 2003). This 
allows the localised leukocytes to attach to the monolayers surface via the very late antigen 
(VLA)-4 antigen present on their surface (Alon, Kassner et al. 1995). This accumulation of 
immune cells leads to further release of pro-inflammatory cytokines such as tumour necrosis 
factor-α (TNF-α), interleukin (IL)-1 and CD40L, which in turn drive up the expression of 
surface receptors on the endothelium such as E-Selectin, VCAM-1 and intercellular 
adhesion molecule (ICAM)-1 in addition to the secretion of IL-8, IL-6, monocyte 
chemoattractant protein (MCP)-1 and macrophage colony-stimulating factor (M-CSF) in the 
local microenvironment (Libby, Galis 1995, Raines, Ross 1996, Libby, Sukhova et al. 1997). 
Adhered leukocytes may also transmigrate into the sub-intima tissue due compromised 
endothelial barrier function, a process called diapedesis, a key mechanism in atherogenesis. 
This in turn triggers the release of a number of chemoattractants which mediate the 
recruitment of more immune cells to the region of injury. Once within the intima, the 
invading leukocytes undergo differentiation into lipid-laden ‘foam cells’.  Over time, these 
‘foam cells’ contribute to the progression of fatty lesion development via deposition of the 
concentrated cholesterol liquid droplets (Steinberg 1997, Libby, Ridker et al. 2011).    
These fatty lesions have been shown to regress following therapeutic intervention (Pitman, 
Osgood et al. 1998). However as they are ‘clinically silent’ and asymptomatic, more often 
they continue to develop. Chronic inflammation over time results in the sustained 
recruitment of immune cells which in turn leads to the further accumulation of extracellular 
lipids. The resulting plaques are generally stable, and over time grow in size and 
subsequently narrow the vessel wall. Complicated plaques can arise when the fibrous cap 
ruptures or fissures and breaks away from the lipid core (van der Wal, Becker 1999). This 
exposes the underlying tissue and initiates the formation of a thrombus (Falk 1996). This can 
be dangerous in two ways: the continued growth of the thrombus can occlude the vessel or 
alternatively the thrombus can break away and cause an infarction in smaller vessels 
downstream from the site of origin (coronary artery-heart attack, cerebrovasculature-stroke).  
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Figure 1.4: Atherosclerotic plaque progression. (a) represents a healthy, atherosclerotic 
resistant area of the vasculature exposed to undisturbed laminar shear stress. (b) depicts the 
initial steps in atherosclerosis; the recruitment, invasion and maturation into ‘foam cells’ of 
circulating immune cells by a dysfunctional endothelium. (c) lesion progression involves the 
dysfunctional migration and proliferation/production of smooth muscle cells and 
extracellular matrix molecules in the intima layer which over time (d) can result formation 
of an unstable plaque which upon disruption leads to thrombus formation – a potentially 
serious blood impeding complication of atherosclerosis (Libby, Ridker et al. 2011).       
 
The process of atherosclerosis is important for two reasons; firstly it is the primary disease-
initiating process accountable for most cardiovascular related diseases and secondly, since it 
is a naturally occurring mechanism associated with vascular branching it is a certainty to 
develop in all humans. 50% of 10-14 year olds have shown early lesion formation in the 
coronary artery (Hong 2010) and autopsies have even shown the presence of the same in 
unborn foetuses (Napoli, D'Armiento et al. 1997).   
As outlined, atherosclerosis is a mechanism that results in alterations to haemodynamic 
forces with progression related to inflammatory mediators. These two ‘stimuli’ are therefore 
critical in studying and understanding the mechanisms that develop these diseases and will 
form the underlying basis for this thesis with respect to the brain microvascular endothelium.  
Overall there is considerable inconsistency in determining the effect of inflammatory agents 
on the BBB due to a number of models lacking the inductive effect of the other cells of the 
neurovascular unit (NVU) and their potentially critical actions. However, improvements to 
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investigative models have helped to minimise this problem (Cecchelli, Berezowski et al. 
2007, Ogunshola 2011). As will be seen in the next section, the NVU is comprised of a large 
number of cell types which contribute in their own unique way in maintaining an effective 
BBB and stable NVU.    
 
1.2 The Cerebrovasculature 
The brain is an incredibly complex organ with different neural tissues displaying different 
circulatory demands. Studies in rodents have reported that at least a ten-fold change in blood 
flow can be observed between the white matter of the brain (~150 capillaries/mm
2
) to some 
of the circumventricular organs (~1500 capillaries/mm
2
). Areas of the brain that require 
higher degrees of attention are seen to possess a higher density of capillary beds to allow a 
higher rate of material diffusion (Fenstermacher, Tavarekere et al. 2001). 
The microcirculation of the brain is a complex network of capillary vessels. These networks 
are typically served by a small arteriole and drained via a number of collecting venules. The 
collecting venules also facilitate the exchange of materials because like capillaries they are 
thin walled and mostly comprised of endothelial cells (Townsley 2012). Several reports have 
indicated that it is these small venules that are most prone to damage and dysfunction. 
Taking into account that there are 3-4 times more collecting venules than there are small 
arterioles (Fenstermacher, Tavarekere et al. 2001), these make the venules an area of interest 
in identifying the underlying mechanisms associated with BBB disruption. The main area of 
material exchange however resides in the capillaries. Each and every capillary within the 
microcirculatory system is capable of branching and joining endlessly with neighbouring 
vessels, resulting in a vast communicative network of blood vessels in a dense area. Each 
capillary can vary greatly in length, width, connectivity and shape and the capillaries of the 
brain are said to vary from 15-400 µm in length and have a mean diameter of 3-10 µm 
(Kobiler, Shlomo et al. 2012).  
Despite their variance in size and dimensions, all material delivered to the brain, whether 
carried by plasma water, plasma protein or blood cells, has to contend with the 
neurovascular unit and in particular the brain-specific endothelium (Persidsky, Heilman et 
al. 2006, Abbott, Patabendige et al. 2010). The capillaries of the brain have been shown to 
be 100-500 times more restrictive than those associated with muscle, skin or gut tissue 
owing to their specific properties (Butt, Jones et al. 1990). What follows is an introduction to 
the NVU before covering the structural components that comprise the BBB. 
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1.2.1 The Neurovascular Unit 
Paul Ehrlich was the pioneer in this field who first demonstrated that following the injection 
of certain dyes into animal vasculature, the brain and spinal cord were the only two tissues to 
deny entry (Ehrlich 1885). At the time it was believed that the lack of dye uptake was due to 
the nervous tissue having a low affinity for the dyes (Ehrlich 1904) however numerous other 
studies gave credence to the idea of a blood-brain barrier (or ‘Blut-Hirn-Schranke’ 
(Lewandowsky 1900)). A defining study by Ehrlich’s protégé Edwin Goldmann clearly 
demonstrated the presence of a blood-brain barrier, where upon direct injection of the dyes 
into the cerebrospinal fluid (CSF) stained all nervous tissue blue whilst the peripheral tissues 
remained the same (Goldmann 1913) (Figure 1.5). In the years that followed, the hypothesis 
was difficult to develop due to methodological limitations. However the advent of the 
electron microscope in the 1960’s turned the concept of a blood-brain barrier into a reality. 
At a resolution of 100,000x, the ultrastructure of the microvessels, namely the space 
between the basal lamina/astrocytic endfeet and the capillary lumen could be monitored 
(Reese, Karnovsk 1967). It was observed how, upon administration of HRP to the 
vasculature, no transmission occurred beyond the vessel lumen, most likely due to the 
presence of epithelial-like tight junctions in the intercellular clefts (Brightman, Reese 1969). 
 
Figure 1.5: The BBB concept. (A) Intravenous injection of dyes lead to the observation that 
the spinal cord and brain did not permit dye uptake. (B) Direct injection into the CSF 
demonstrated the inverse, (C) suggesting the existence of a ‘blood-brain barrier’ (Zlokovic 
2008).    
  
It was discovered that there are in fact three main barrier layers in the brain and spinal cord; 
the epithelium of the choroid plexus, the arachnoid epithelium, and the endothelium of the 
microvessels (Figure 1.6) (Choi, Kim 2008, Saunders, Ek et al. 2008). While all three types 
of barriers express the tight junctions that significantly reduce the passage of ions and other 
small molecules through the intercellular clefts, it is the endothelium of the microvessels that 
offer a refined means of dynamically and selectively trafficking molecules across the barrier 
(Kimelberg 2004). A series of membrane transporters are available for the uptake and efflux 
of nutrients and waste products across the cellular barrier, primarily by transcytotic 
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pathways (Cecchelli, Berezowski et al. 2007, Herve, Ghinea et al. 2008, Candela, Gosselet 
et al. 2010, Tucker, Yang et al. 2012). These intricate pathways in conjunction with the 
enzymatic and paracellular barrier properties (Dauchy, 2008, Dutheil, 2010) the brain 
microvascular endothelial cells possess make capillary layer the most critical barrier in 
maintaining and regulating the homeostasis of the brain. 
 
Figure 1.6: Barriers of the brain. The three principal barrier sites between the blood and 
brain. (a) The BBB proper, created at the level of the cerebral capillary endothelial cells by 
tight junction formation. (b) The blood-CSF barrier, located at the choroid plexuses in the 
ventricles of the brain where tight junctions are formed between plexus epithelial cells. (c) 
The arachnoid barrier, formed by the tight junctions of the cells of the inner layer of the 
arachnoid membrane which lies under the dura (Abbott 2013). 
 
The brain and the spinal cord are the control centres of the body and make up the central 
nervous system (CNS). In short, the CNS is responsible for a host of integral functions such 
as processing sensory input, regulating motor output and coordinating many of the 
individual and concerted activities of tissues (Abbott, Friedman 2012). The burden of 
activity of the CNS is so large it is accredited for using 20% of oxygen consumption in the 
human body (Rolfe, Brown 1997). To carry out this array of functions, the neurons of the 
CNS utilise a combination of chemical (neurotransmitters and modulaters) and electrical 
signals (synaptic potentials, action potentials) to invoke precise ionic movements across 
their membranes (i.e. cell-cell communication). Proper neuronal function thus requires a 
highly regulated extracellular environment i.e. the concentrations of ions such as Na
+
, K
+ 
and 
Ca
+ 
need to be tightly regulated to within a narrow range to ensure synaptic signalling is 
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precise, reliable and reproducible (Abbott, Patabendige et al. 2010). The ionic environment 
is easily subjected to imbalance via regular everyday process i.e. diet, physical activity etc. 
Therefore, to maintain a healthy balance the CNS has to selectively deliver the derived key 
nutrients, remove the subsequent waste products and restrict the entry of any foreign and 
potentially toxic neuroactive agents or pathogens that may be introduced via metabolic 
reactions. In short, to work effectively, it is critical that the environment of the CNS remains 
stable, an aim which is achieved through the blood-brain barrier (Abbott, Friedman 2012).  
The development of the BBB in humans is regarded an evolutionary advantage. 
Comparisons to other vertebrates or invertebrates that have shown a negligible degree of 
evolution demonstrate a more primitive glial-based ultrastructure as opposed to the 
endothelium (Abbott, Lane et al. 1986, Abbott, Revest et al. 1992). This has led to 
speculation that the glial blood-brain barrier is an ancestral trait, and the development of an 
endothelial-based barrier arose from evolutionary selective pressure in maintaining ionic 
homeostasis of the CNS (Abbott, Lane et al. 1986, Banerjee, Bhat 2007). The consequent 
shift in cell type invoked the development of other now essential, more complex barrier 
functions. Thus, the BBB endothelium is the key cell type in establishing the human BBB 
we know today. 
Whilst the phenotype of the BBB endothelium is the primary restrictive regulatory force of 
the NVU, attention is owed to a variety of other cell types that play key inductive and 
regulatory roles in creating and maintaining such a barrier. What follows is a cellular 
overview of the NVU.  
 
1.2.1.1 Brain Microvascular Endothelium 
A generic ‘default’ phenotype for endothelial cells is believed to exist, with heterogeneity 
evident between numerous different endothelial cells isolated from different vascular beds 
(Aird, 2012). From large vessels such as the aorta to the microvasculature, numerous traits 
and functions are carried over despite the location of the vascular bed (Pasqualini, 2002, 
Trepel, 2002). As vascularisation is seen to occur courtesy of in-growth from external 
vessels (Risau and Wolburg, 1990, Engelhardt and Risau, 1995), it is thought that tissues are 
able to induce the vasculature to generate tissue specific properties and functions.  
A variety of cell culture and tissue grafting studies have clearly demonstrated that the 
endothelial cells of the CNS do not develop into their native BBB phenotype instinctively. 
The pioneer study that purported this idea involved the transplantation of avascular brain 
tissue from a new-born quail into the coelomic cavity of chick embryos. It was reported that 
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the chick endothelial cells which vascularised the quail brain grafts formed a competent 
BBB (Stewart and Wiley, 1981). By contrast, when the complementary study was conducted 
(avascular embryonic quail coelomic grafts transplanted into embryonic chick brain), the 
chick endothelial cells that invaded the mesenchymal tissue grafts were reported to have 
formed leaky blood vessels. Therefore the inductive means of the cerebral tissue is seen to 
be critical in inducing the BBB vascular phenotype.  
The influence of the cerebral environment on the endothelium is substantive. A number of 
key functional aspects are greatly attenuated or amplified depending on the cerebral tissues 
requirements. Some of the key characteristics induced in the BBB endothelium in 
comparison to endothelium of the peripheral tissue include a much higher mitochondrial 
content (Oldendorf, Cornford et al. 1977), a lack of fenestrations (Fenstermacher, Gross et 
al. 1988), minimal pinocytotic activity (Sedlakova, Shivers et al. 1999), and a higher degree 
of transendothelial electrical resistance (TEER) and expression of tight junctions (Kniesel, 
Wolburg 2000) (Figure 1.7). Overall, the endothelium associated with the microvasculature 
of the nervous system shows the most extreme form of phenotypic differentiation compared 
to all other vascular beds within the body (Abbott 2005). This comes from the upregulation 
of features either poorly expressed or absent from the peripheral tissue and down regulation 
of some of the ‘default’ endothelial features. 
 
Figure 1.7: The differences between a general (non-neural) and brain capillary. BBB 
endothelium in comparison to endothelium of the peripheral tissue demonstrate a much 
higher mitochondrial content, less fenestrations, minimal pinocytotic activity and an 
enhanced expression of tight junction proteins (http://www.jhsph.edu/). 
 
Whilst the basic function of the endothelial cell in the peripheral tissue has already been 
discussed it is necessary to address in greater detail the additional blood-brain barrier 
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specific properties of the endothelial cells which reside in cerebral vasculature bed. The 
endothelium in a (~1.3 kg) brain is estimated to cover a surface area of ~20m
2
 (Pardridge 
2003). The cerebrovasculature thus provides the largest surface area for blood-CNS 
exchange with each capillary supplying blood to neurons within proximity of 8-25 μm, 
identifying it as one of the key players in maintaining the homeostasis of the brain (Iadecola, 
Nedergaard 2007).  
The brain’s necessity to maintain a stable ionic environment has already been addressed. 
The BBB endothelial phenotype facilitates this need by not only separating but controlling 
the gradient of the neurotransmitters and neuroactive agents between the brain and the 
peripheral tissue. What follows is an overview of the distinctive barrier functions associated 
with the endothelium of the BBB.    
 
Figure 1.8: Pathways across the blood-brain barrier. A schematic representation of 
cerebral microvascular endothelium at the BBB and the main routes for molecular traffic 
across the barrier. (A) The paracellular pathway, regulated by tight junction proteins, that 
restrict the passage of water-soluble compounds. (B) The transcellular pathway which 
regulates solute flux through B (i) the cell membrane, B (ii) active transporters, B (iii) 
specific receptor-mediated endocytosis and B (iv) absorptive-mediated endocytosis and 
transcytosis (Abbott, Ronnback et al. 2006).   
 
1.2.1.1.1 Paracellular Pathway 
The flux of molecular traffic from the blood to the CNS can occur via two distinctive 
pathways (Figure 1.8, A). The movement of biological material via the interendothelial gaps 
constitutes the paracellular pathway. Here, restrictive barrier properties arise from presence 
of the tight junctions that allow the endothelial cells to fold over on themselves to form the 
vessel circumference and also seal them to neighbouring endothelial cells (Dejana, Corada et 
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al. 1995, Dejana, Lampugnani et al. 2000). Paracellular permeability at the BBB is 
maintained by the equilibrium between the adhesive forces at these cell-cell contact points 
and contractile forces of the endothelial cytoskeleton and (van Hinsbergh, Amerongen 
2002). The dynamic interaction among these constituents of the BBB interendothelial 
junction complex, and the intracellular adapter proteins that link said complexes to the actin 
cytoskeleton, serves as a fundamental mechanism in regulating blood-brain exchange 
(Garcia, Davis et al. 1995). This transport means (in comparison to transcellular routes) is 
exclusively passive, less selective to transcellular pathways, and is driven by 
electrochemical, hydrostatic and osmotic gradients (Bazzoni 2006). Oxygen and carbon 
dioxide can freely diffuse across these intercellular regions though there is an approximate 
size cut-off at 5 kDa (Grieb, Forster et al. 1985). In addition to size playing a key factor in 
traversing this proposed route, lipid solubility is equally important. Overall, the paracellular 
route is incredibly restrictive and diverts the majority of molecular traffic to transcellular 
transport routes (Stamatovic, Keep et al. 2008).   
In general, pathological increases in BBB permeability are associated with increased 
paracellular permeability. The dysregulation of these junctional complexes has been 
associated with a number of neurodegenerative diseases (Stamatovic, Keep et al. 2008) and 
thus, this pathway is the primary focus of this thesis. The interendothelial junction, its 
structure, function and role in the physiology and pathophysiology of the BBB will be 
covered in greater detail in later sections.   
  
1.2.1.1.2 Transcellular Pathway 
One of the obvious characteristics of brain endothelium is the lack of pinocytotic vesicles 
(Sedlakova, Shivers et al. 1999). The absence of these transport vesicles has been identified 
as one of the key factors resulting in the infamously low permeability, particularly to large 
macromolecules, of the BBB endothelial monolayer (Davson, Oldendorf 1967). Contrary to 
its restrictive nature, the BBB has been demonstrated to facilitate bi-directional travel of 
macromolecules across itself i.e. from blood to brain (Broadwell, Balin et al. 1988, 
Broadwell 1989) and vice versa (Vandeurs, Amtorp 1978), primarily by mechanisms of a 
transcytosis nature (Figure 1.8, B).    
Whilst the intercellular junctions of the endothelial cells restrict passive transport, smaller 
lipid soluble molecules such as oxygen and carbon dioxide have been shown to be able to 
traverse not only the paracellular restrictions but also transcellular ones (Grieb, Forster et al. 
1985). Therefore, the barrier presented by the cerebral endothelium appears to be only 
protective against the passive entry of larger, lipid insoluble compounds (Misra, Ganesh et 
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al. 2003). However, due to the sensitive nature of the neural environment it is essential for 
the cerebral endothelium to facilitate the passage of some of these larger molecules that may 
represent essential nutrients across its collective barrier. This comes in the form of a number 
of carrier-mediated transport systems that are primarily located on the abluminal side of the 
cerebral endothelia cells (Sanchez Del Pino, Hawkins et al. 1995). Essential amino acids and 
glucose enter the brain via transporters/carriers/channels present on the plasma membrane 
whereas non-receptor-mediated endocytosis mechanisms facilitate the influx of larger 
molecules (e.g. insulin, leptin, iron transferin) (Pardridge, Eisenberg et al. 1985, Zhang, 
Pardridge 2001, Lossinsky, Shivers 2004). Transport mechanisms are present on the luminal 
side of the endothelium but are more facilitative than active in their function.  
 
1.2.1.1.3 Enzymatic/Efflux Barrier 
While each transport mechanism has designated criteria to meet in order to avail of its use, a 
number of molecules and even computationally designed drugs which meet these criteria 
have been shown to traverse the BBB with difficulty (Misra, Ganesh et al. 2003). These 
restrictions come in the form of enzymatic and efflux mechanisms which counteract the 
transport of said materials. The BBB is enzymatically capable of metabolising both drugs 
and nutrients (Brownson, Abbruscato et al. 1994, Matter, Balda 2003, Matter, Balda 2003). 
The levels of enzymes such as γ-glutamyl transpeptidase (γ-GTP), alkaline phosphatase and 
aromatic acid decarboxylase are found to be elevated in cerebral microvessels in comparison 
to those of non-neuronal origin (Minn, Ghersiegea et al. 1991, Abbott, Romero 1996). These 
enzymes are located on both the abluminal and luminal membrane surfaces of the BBB 
endothelium and principally metabolise neuroactive blood-borne solutes (Betz, Firth et al. 
1980). In addition, efflux transporters monitor the compounds being trafficked across the 
BBB and intervene should they detect anything that may be harmful or toxic. Two of the 
more established and understood efflux transporters are permeability (P)-Glycoprotein and 
Multidrug Resistance-Associated Protein (MRP). These membrane proteins are 
constitutively expressed by cerebral endothelium (Cordon-Cardo, O' Brien et al. 1989, Liu, 
Hu 2000, Demeule, Regina et al. 2002) and are understood to have arisen through evolution 
in order to control the passive influx of lipid-soluble compounds (Tatsuta, Naito et al. 1992). 
Both of these efflux transporters have a large degree of overlap in the substrates they 
recognise and export with non-specific interactions at the forefront of their selectivity. 
Whilst the development of defence mechanisms like these is to our evolutionary advantage, 
they have yielded a new obstacle in targeted drug delivery (Misra, Ganesh et al. 2003).  
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Overall, the endothelial monolayer is the single interface between the blood and extracellular 
fluid. The barrier mechanisms involved in limiting the flux of molecules and ions, ensuring 
that chemical gradients can be established, were of great importance in developing and 
understanding the mechanisms involved in the physiology and pathophysiology of the BBB. 
Early in vitro studies of brain endothelium had proven difficult until a greater understanding 
of the inductive effects which are necessary to maintain these cells (and their barrier 
properties) out of culture were uncovered (Abbott 2013). Culture studies have demonstrated 
that utilising endothelium derived from brain microvessels is more effective than attempting 
induction studies from other tissue derived endothelia (Dehouck, Meresse et al. 1990, 
Reinhardt, Gloor 1997). Primary cells cultured in vitro have been shown to maintain aspects 
of its original phenotype down to the molecular level (Li, Boado et al. 2001, Desai, Marroni 
et al. 2002). Steady culturing of primary derived endothelia are seen to revert back to their 
‘default’ phenotype (Reichel, Begley et al. 2003) unless mimicking or introducing certain 
inductive forces into cell culture techniques has been shown to stabilise the brain phenotype 
and prevent differentiation. Induction is more effective if the endothelium is exposed to 
shear stress (Stanness, Westrum et al. 1997). Different degrees of shear stress in large versus 
small cerebral vessels have been thought to play a part in inducing different functional 
properties in the endothelium. Higher shear rates have yielded brain arterial and arteriolar 
endothelia which have been shown to present subsequent phenotypic properties than lower 
sheared capillary endothelium (Westergaard, Brightman 1973). A number of differentiating 
agents have also been identified (Rubin, Hall et al. 1991, ElHafny, Bourre et al. 1996, 
ElHafny, Chappey et al. 1997). Adrenomedullin has been shown to be an integral agent in 
regulating cerebral circulation and BBB functions (Kis, Abraham et al. 2003). 
Hydrocortisone (Hoheisel, Nitz et al. 1998) and bFGF (Sobue, Yamamoto et al. 1999) have 
also been utilised in culture techniques.  
Now that the primary cell type of the BBB is understood it is essential to address the other 
cell types which comprise the NVU (Figure 1.9). As mentioned earlier, these cell types play 
a key role in the induction of endothelial barrier phenotype; however the overall induction 
process is a controversial subject owing to the fact that the different cell types of the NVU 
establish themselves at different times in development (Saunders, Dziegielewska et al. 
1991). In vivo models have shown that vessels in the initial vascularisation process are 
discontinuous (Kniesel, Risau et al. 1996) owing to the absence of certain inductive cells at 
the time. During development, the barrier layers have also been shown to shift from 
glial/ependymal derivatives to endothelial once blood vessels start to invade the nervous 
system (Abbott, Revest et al. 1992). These factors have led to great debate over when a 
‘barrier’ is in place. Alternative studies that focussed on the presence of serum proteins 
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reported that a protein barrier is in place during embryonic development however the ionic 
barrier is noted to be absent (Saunders, Dziegielewska et al. 1991) and doesn’t appear until 
after birth stemming from studies measuring the resistance of plial vessels (1000-2000 
Ω/cm2) against peripheral vessels (10 Ω/cm2) (Butt, Jones et al. 1990).  
Studies are ongoing in understanding the factors and inductive signals which yield the overly 
unique BBB endothelium phenotype. Early markers of (E10.5) BBB formation have been 
identified (Qin, Sato 1995) though much more is expected to be uncovered. The different 
cell types of the NVU will be covered in the following sections and their role in the 
induction of the BBB and subsequent maintenance will be addressed.     
 
 
Figure 1.9: A representative cross-section of a cerebral capillary of the BBB. The BBB 
is composed of cerebral capillary endothelial cells that are part of an intricate network of 
astrocytes, pericytes, and neurons. Together, they form tight, impermeable junctions, which 
exclude large cells, macromolecules and excess fluid from the central nervous system 
(Francis, van Beek et al. 2003).   
 
1.2.1.2 Astrocytes 
Astrocytes are a major glial cell type associated with the CNS. Of the 11 distinct 
phenotypes, 8 have been shown to have specific interactions with blood vessels 
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(Reichenbach, Derouiche et al. 2004). Each cell creates a number of contact points between 
itself and various other cell types in the CNS via complex cellular processes (e.g. synapses, 
nodes of Ranvier and blood vessels) (Zhang, Barres 2010). This networking ability of the 
astrocytes, in addition to their close anatomical association with the BBB, identified them 
early on as being key players in dynamically regulating a variety of signalling events within 
the CNS (Davson, Oldendorf 1967). It is reported that the outer ridge of the capillary wall 
consists of a mesh-work of astrocytic endfeet that cover as much as 85% of the basement 
membrane surface. 3D visualisation of the microanatomy has given rise to the idea of 
‘microdomains’ in which single endothelial cells associate with a single astrocyte (Kacem, 
Lacombe et al. 1998). These findings demonstrate just how intricate a network the astrocytes 
establish with the BBB endothelium and surrounding neurons.  
Early studies similar to that of Stewart and Wiley (1981) that investigated this concept 
involved grafting purified neonatal astrocytes into the anterior chamber of the eye. Upon 
injection, the astrocytes were observed to have been quickly vascularised and injection of 
Evans blue dye to these newly formed vessels demonstrated the astrocytes excluded the dye 
(Janzer, Raff 1987). Further studies have shown that in endothelial-astrocyte co-culture 
models (Taocheng, Nagy et al. 1987, Neuhaus, Risau et al. 1991) or even astrocyte 
conditioned media (Maxwell, Berliner et al. 1987, Colgan, Collins et al. 2008), BBB 
characteristics are improved in vitro. However for optimal organisation of the vessel wall 
and BBB stability, direct contact between endothelial cells and astrocytic end-feet is 
necessary (Rubin, Hall et al. 1991). 
It has been suggested that astrocytes work in conjunction with neurons, relaying signals to 
control cerebral permeability (Ballabh, Braun et al. 2004). In relation to the BBB, astrocytes 
have been shown to play a part in modulating blood vessel contraction and dilation, 
subsequently influencing region specific blood flow (Attwell, Buchan et al. 2010). In 
addition, astrocytes have been shown to influence junctional and transport properties of the 
BBB, particularly in capillary endothelial cells (Janzer, Raff 1987, Raub 1996). In vitro 
studies have shown that endothelial cultures in the presence of astrocytes or astrocyte 
derived factors such as angiotensin (Ang) II, have shown a decrease in permeability to tracer 
molecules, an increase in TEER, as well as an increase in localised P-glycoprotein (Rubin, 
Hall et al. 1991, Raub 1996, Rist, Romero et al. 1997, Wosik, Cayrol et al. 2007) and 
glucose transport (GLUT)1 (McAllister, Krizanac-Bengez et al. 2001) transporter 
expression. Further studies have shown with regards to barrier function, astrocytes have a 
direct effect on stabilising the tight junction via sonic hedgehog signalling (Alvarez, 
Dodelet-Devillers et al. 2011). Astrocytes have been shown to secrete a wide array of agents 
that can induce several different aspects of BBB phenotype in endothelial cells, among 
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which are transforming growth factor (TGF)-β, basic fibroblast growth factor (bFGF), and 
Ang II in addition to others (Abbott 2002, Haseloff, Blasig et al. 2005).  
Interestingly, it should be noted that while astrocytes are seen to physically envelop the 
microvessels of the cerebrovasculature and also secrete a number of mediators that influence 
barrier function, they don’t physically act as a barrier in vertebrates, the opposite of which 
can be said for invertebrates (Abbott 1987). It was demonstrated quite early on that upon 
injection of horseradish peroxidise (HRP) into intact microvessels, the agent was shown to 
easily migrate through the 20nm gaps between the astrocytic endfeet (Brightman, Reese 
1969).  
Finally, grafting studies have shown that astrocytes alone are not enough to induce a BBB 
phenotype in endothelial cells (Shayan, Shuler et al. 2011). Moreover, the BBB has been 
shown to be already under development before astrocyte generation has commenced 
suggesting that astroyctes are primarily involved in the maintenance of the BBB rather than 
development/induction (Webersinke, Bauer et al. 1992, Bauer, Bauer et al. 1993, Holash, 
Noden et al. 1993). In vivo studies have shown that in microvessels that are induced to 
undergo massive astrocytic loss can survive and continue to maintain a degree of barrier 
integrity (Krum, Kenyon et al. 1997) although other studies suggest the opposite (Willis, 
Nolan et al. 2004).    
 
1.2.1.3 Pericytes 
Pericytes are elongated, polymorphic cells of a mesenchymal origin that are closely 
associated with the vasculature system and are present in almost all tissues and organs 
(Diaz-Flores, Gutierrez et al. 1991). Although widespread, their density and functions can 
vary greatly depending on the vascular bed in which they reside (Armulik, Abramsson et al. 
2005). They are commonly associated with the microvaculature, namely arterioles, venules 
and capillaries and are seen to be wrapped around the abluminal side of endothelial cells at 
irregular intervals along the vessel wall (Tagami, Nara et al. 1990), not unlike the way 
smooth muscle cells cradle the endothelium in larger vessels (Diaz-Flores, Gutierrez et al. 
1991). Pericytes have been shown to have a particular affinity towards endothelial cells 
(Minakawa, Bready et al. 1991) and both cell types are known to become associated early on 
during embryonic development (Simionescu, Ghinea et al. 1988) with ultrastructural studies 
in embryonic mouse brains confirming that along with endothelial cells, pericytes are among 
the first cell type to invade the neural tissue as early as E10 (Bauer, Bauer et al. 1993). 
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Pericytes make several different types of contact with endothelial cells; namely gap 
junctions, adhesion plaques and peg-and-socket junctions, allowing pericytes to remain in 
very close proximity to the vessel wall but also to communicate with the cells that comprise 
it (Diaz-Flores, Gutierrez et al. 1991). Within this close proximity, and drawing on the 
comparison to smooth muscle cells made earlier, they have been shown to provide not only 
structural support to the vessel wall, and but also regulate the vasodynamics of it 
(Bandopadhyay, Orte et al. 2001). For example, Ang II is a vasoactive peptide present in 
numerous parts of the brain, often presented on the neurons and nerve terminals associated 
with microvessels (Healy, Wilk 1993). Pericytes have been shown to express Ang II binding 
sites (FerrariDileo, Davis et al. 1996) and their activity post-uptake of Ang II is well 
documented (Matsugi, Chen et al. 1997, Matsugi, Chen et al. 1997). Aside from Ang II, 
pericytes express a broad range of binding sites for other vasoactive compounds such as 
vasopressin (Vanzwieten, Ravid et al. 1988) and endothelin (ET)-1 (Dehouck, Vigne et al. 
1997). Since ET-1 is produced primarily by endothelial cells, this gives an insight into the 
dynamic communication between the two cell types in regulating blood flow. 
In light of this, pericytes have been shown to be both positive and negative regulators of the 
endothelium (Bergers, Song 2005). Aside from the already discussed dynamic control of 
blood flow, pericytes have been shown to play a key role in striking a balance between 
numerous opposing processes. For example, TGF-β release by pericytes is mediated by 
contact between pericytes and endothelial cells. Upon association, TGF-β becomes active 
and is known to inhibit endothelial cell proliferation thus stabilising developing microvessels 
(Crocker, Murad et al. 1970, Antonelliorlidge, Saunders et al. 1989, Yan, Sage 1998).  In 
contrast to this, pericytes also release bFGF, which promotes cellular growth and 
differentiation in addition to promoting vascular tube formation.  
One of the most important aspects of the endothelium is its barrier function, which pericytes 
have been shown to have a direct influence on. Co-culture models of pericytes and 
endothelium showed pericyte presence was enough to inhibit genes that increase 
permeability. In fact, a direct correlation between the number of pericytes in a region and the 
permeability of the underlying tissue exists (Daneman, Zhou et al. 2010). In pathological 
circumstances such as hypoxia (Gonul, Duz et al. 2002) or traumatic brain injury (TBI) 
(Dore-Duffy, Owen et al. 2000), symptomatic migration of pericytes away from the 
microvasculature coincided with an increase in microvessel permeability.  
Similar to astrocytes, pericytes introduced to endothelial cultures do not appear to induce a 
BBB-specific endothelial phenotype from a gene expression perspective; however co-culture 
studies which combined pericyte, astrocytes and endothelial cells were shown to produce 
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stable, capillary-like structures (Ramsauer, Krause et al. 2002). Knockout mice models for 
pericyte recruitment agents (e.g. platelet-derived growth factor B (PDFGB)) demonstrated a 
poorly developed and maintained BBB (Armulik, Genove et al. 2010) in addition to 
microaneurysm formation (Lindahl, Johansson et al. 1997). Moreover, the concurring 
disruption of transcytosis pathways and an increase in the expression of leukocyte adhesion 
molecules resulting from PDGFB knockout underscores the importance of pericytes in 
microvessel homeostasis. Finally, pericytes have also shown to increase the endothelial 
defence against apoptotic mechanisms in tri-culture models (astrocytes, pericytes, 
endothelium, (Ramsauer, Krause et al. 2002)), giving rise to the argument that pericytes are 
directly involved in maintaining the structural integrity and inception of the BBB. 
 
1.2.1.4 Neurons 
Given the dependency of neural tissue on BBB phenotype, it is natural to assume there is a 
level of communication between the neurons and the microvasculature. Anatomically, direct 
innervations between a number of different types of neurons and the microvascular 
endothelium/astrocytic endfeet have been reported (Kobayashi, Magnoni et al. 1985, 
Vaucher, Hamel 1995, Cohen, Molinatti et al. 1997). Changes to cerebral blood flow and 
pressure have long been associated with BBB dysfunction and are often identified as the 
penultimate event that triggers the initiation of a number of different pathologies (e.g. 
ischemia, hemorrhage, traumatic brain injury) (Hatashita, Hoff 1990, Petty, Wettstein 2001, 
Petty, Lo 2002). Studies have linked this change in the microvasculature’s hemodynamic 
forces to being a compensatory event triggered by the neurons of the NVU rather than as a 
symptom of anatomical disruption (Lee, Hung et al. 1999). With this in mind, a number of 
studies have aimed to demonstrate that while neuronal presence may not be critical in the 
development and induction of a BBB, they do play a key regulatory role in a number of 
BBB functions. Numerous cerebral diseases have shown that neuronal dysfunction often 
correlates with BBB dysfunction e.g. Alzheimers disease (Tong, Hamel 1999).    
 
1.2.1.5 Basal Lamina 
Pericytes and endothelial cells are ensheathed in the basal lamina, a membrane 30-40 nm 
thick and comprised of a myriad of growth factors and matrices such as collagen type IV, 
heparin sulphate, laminin and fibronectin amongst many others (Farkas, Luiten 2001). On 
the abluminal side, the astrocytic endfeet are contiguous with the basal lamina. The basal 
lamina acts as a foundation for the endothelium to anchor to via interactions with matrix 
proteins like laminin and integrins (Hynes 1992), while the growth factors have been shown 
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to have a direct influence on the expression of tight junction proteins (Tilling, Korte et al. 
1998, Savettieri, Di Liegro et al. 2000). Thus, disruption of the basal lamina has been 
identified as a key step in certain pathological states and is linked to increased BBB 
permeability (Rosenberg, Estrada et al. 1993, Rascher, Fischmann et al. 2002). For example, 
cortical spreading depression, a mechanism associated with migraines, has been shown to 
upregulate matrix metalloproteases (MMP). These MMP’s induce the proteolysis of the 
basal lamina (Sanchez-del-Rio, Reuter 2004), which has been shown to be directly linked to 
tight junction protein zonula occludens (ZO)-1 loss in the affected area (Gursoy-Ozdemir, 
Qiu et al. 2004).  This identifies the proteins of the basal lamina as having a respectable role 
in maintaining tight junctions (TJ) and BBB homeostasis.   
 
1.2.2 Tight Junction/Adherens Junction 
What will be addressed in this section are the interendothelial transmembrane proteins 
comprising the tight junction complex. In addition to tight junctions, the adherens junction 
(AJ) complex, the gap junction and the proteins that facilitate the dynamic, reversible nature 
of the junctions will be discussed (Figure 1.10).   
 
Figure 1.10: The proteins of the tight junction/adherens junction of the blood-brain 
barrier. Schematic figure of the proposed associations of the key proteins found at the 
interendothelial junctions of the BBB (Zlokovic 2008).      
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1.2.2.1 Occludin 
Occludin was the first of the integral proteins localised at the tight junction to be identified, 
first in chickens (Furuse, Hirase et al. 1993) and later in mammals (Ando-Akatsuka, Saitou 
et al. 1996). Occludin is a 65 kDa protein whose carboxyl and amino terminals are orientated 
in the cytoplasm, and which displays four transmembrane domains. This orientation yields 
two extracellular loops which span the intercellular cleft (Furuse, Hirase et al. 1993). It was 
the abundance of glycine and tyrosine in the first of the extracellular loops that lead to its 
initial characterisation.  
In comparison to non-neuronal tissues, where it is much more sparsely distributed (Hirase, 
Staddon et al. 1997), occludin is highly expressed in cerebral endothelial cells and cellular 
staining shows a continuous, uninterrupted presence along the cell membranes (Lippoldt, 
Kniesel et al. 2000, Hawkins, Abbruscato et al. 2004). Occludin has been shown to be 
directly related to the high electrical resistance demonstrated by the cerebral endothelium 
(McCarthy, Skare et al. 1996). The cytoplasmic C-terminus of occludin links it to the 
cytoskeleton via adapter proteins such as ZO-1 and ZO-2. Together with the claudins, 
occludin makes up the intramembranous tight junction, which despite their restrictive nature, 
are said to possess channels which facilitate diffusion of ions and hydrophilic molecules via 
paracellular transport (Matter, Balda 2003, Matter, Balda 2003). Evidence has shown that 
phosphorylation of occludin modulates tight junction permeability via G-protein and 
additional mechanisms (Hirase, Kawashima et al. 2001) and studies which utilised C-
terminally truncated occludin demonstrated an increase in paracellular permeability to low 
molecular weight molecules (Balda, Whitney et al. 1996), suggesting its potential 
importance in maintaining a barrier. Despite this, knockout studies for occludin have shown 
that its presence is not actually necessary in facilitating the assembly of the overall tight 
junction. Occludin-deficient mice not only display a fully functioning BBB but other 
junctions that comprised of occludin in addition to other proteins (e.g. gut epithelia) 
remained intact (Saitou, Furuse et al. 2000). While prominent in adult brain, it is not present 
in fetal or newborn brain sections demonstrating it is not essential for BBB development. 
Animal-models have demonstrated that significant levels of occludin only appeared after the 
first post natal week with its appearance coinciding with the complete development of the 
BBB (Hirase, Staddon et al. 1997). This has lead to the belief that an alternative to occludin 
exists during the early developmental stages prior to occludin taking on its roles. Studies that 
did note an intact BBB after occludin silencing did note some anomalies such as chronic 
inflammation, post-natal retardation and calcification of areas of the vasculature, in 
particular the brain, suggesting that while occludin might not be essential in maintaining a 
restrictive barrier, it may be a key player in regulating other junction-associated processes 
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(i.e. calcium flux) across the tight junction (Saitou, Furuse et al. 2000). In spite of these 
studies, other evidence has shown in numerous pathologies associated with BBB 
dysfunction, decreased expression of occludin is at the forefront, indicating it has an integral 
role in maintaining tight junction stability (Bolton, Anthony et al. 1998, Huber, Hau et al. 
2002, Brown, Davis 2005).    
 
1.2.2.2 Claudins 
The first claudin proteins (claudin-1 and -2) were identified in junctional fractions of 
chicken livers and early evidence compounded by the discovery of two isoforms at once 
suggested they were part of a larger family of proteins (Furuse, Fujita et al. 1998, Morita, 
Furuse et al. 1999, Mitic, van Itallie et al. 2000). Since their discovery, over 20 isoforms of 
the 24 kDa proteins have been identified in mammals (Bauer, Traweger et al. 2004). All 
isoforms show similar folding patterns with a very high sequence homology demonstrated in 
the first and fourth transmembrane domains (Heiskala, Peterson et al. 2001). Claudins also 
have a very similar distribution to occludin, displaying four transmembrane domains with 
two extracellular loops, despite almost no sequence homology (Furuse, Fujita et al. 1998). 
Claudins form quite long and branched intercellular strands in contrast to occludins shorter 
ones (Tsukita, Furuse 1999, Furuse, Sasaki et al. 1999). The extracellular loops of the 
claudins can interact via homo- and heterophilic interactions between adjacent cells (Furuse, 
Sasaki et al. 1999, Daugherty, Ward et al. 2007) giving rise to a large number of potential 
interactions. It should be noted that many of the claudins are tissue/cell specific and there is 
accumulating evidence suggesting that the composition of the the claudins directly 
determines the barrier function (Furuse, Hata et al. 2001). Induced expression of claudin-1 in 
Madin-Darby canine kidney (MDCK) cells increased transcellular resistance by four-fold 
with a corresponding drop in paracellular permeability (Inai, Kobayashi et al. 1999), while 
induction of claudin-2 into MDCK cells already expressing claudins-1 and -4 demonstrated 
a drop in barrier function (Furuse, Hata et al. 2001). Thus the stoichiometry of claudin 
species has a direct impact on cell barrier function (Tsukita, Furuse 2000, Furuse, Sasaki et 
al. 1999). 
Within the cerebral endothelium, claudin-3 and -5 have been detected, with questionable 
studies regarding claudin-1 and -12 (Morcos, Hosie et al. 2001, Nitta, Hata et al. 2003, Witt, 
Mark et al. 2003, Wolburg, Wolburg-Buchholz et al. 2003, Hawkins, Abbruscato et al. 
2004). As mentioned, the tight junction can be formed in the absence of occludin, the same 
of which cannot be said of the claudins. In other tight junction forming cell types, claudin-5 
is ubiquitously expressed while other isoforms (-1 and -3) levels are diminished. In vitro 
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culturing of BBB endothelial cells is reported to cause certain claudin levels to decrease 
(Liebner, Fischmann et al. 2000, Liebner, Kniesel et al. 2000) except for claudin-5 which is 
sufficient to mediate tight junction formation (Wolburg, Neuhaus et al. 1994).  This signifies 
claudin-5 as the key member of the claudins in relation to BBB homeostasis. In vivo mouse 
models, which ablate claudin-5, have shown high mortality rates at birth with dissection 
confirming the poor development and permeability of the BBB (Nitta, Hata et al. 2003). 
Moreover, occludin has been shown to only localise to the cell border in the presence of 
claudin (Kubota, Furuse et al. 1999). It is therefore hypothesised that the claudins form the 
primary seal of the tight junction with occludin providing secondary support.  
 
1.2.2.3 JAMs 
Junctional Adhesion Molecules (JAMs) are a family of 40 kDa proteins which are known to 
contribute via homophilic (and potentially heterophilic) interactions in the attachment of 
adjacent cells (Dejana, Lampugnani et al. 2000). JAM-1 (formally JAM) is expressed in a 
number of tight junction-forming cell types (Martin-Padura, Lostaglio et al. 1998), while 
JAM-2 (Aurrand-Lions, Duncan et al. 2001) and JAM-3 (Palmeri, van Zante et al. 2000) are 
mostly expressed in vascular endothelial cells. The JAMs are composed of a single 
membrane spanning chain with a large extracellular domain (Martin-Padura, Lostaglio et al. 
1998). Although important in the initial contact between cells, occludin and the claudins are 
seen to be the primary components of the tight junction. Nevertheless, the JAM’s contribute 
in other ways in mediating tight junction formation. In the absence of other tight junction 
forming proteins, the JAMs have shown to increase cellular resistance (Martin-Padura, 
Lostaglio et al. 1998). Over-expression of JAM-1 has also been shown to reduce 
permeability possibly by mediating occludin translocation to the cell membrane (Dejana, 
Lampugnani et al. 2000). JAM-2 and to a lesser extent JAM-3 were also shown to have a 
critical role in junction formation in the select tissues in which they are expressed (Palmeri, 
van Zante et al. 2000, Aurrand-Lions, Duncan et al. 2001).  
Primarily the JAMs are seen to regulate the transendothelial migration of leukocytes and 
monocytes (Del Maschio, De Luigi et al. 1999, Bazzoni, Martinez-Estrada et al. 2000, 
Aurrand-Lions, Duncan et al. 2001), with blocking of JAM-1 seen to inhibit extravasation in 
vitro and in vivo (Del Maschio, De Luigi et al. 1999).  
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1.2.2.4 Cadherins 
The adherens junctions are ubiquitous within the vasculature and play a key role in 
numerous endothelial processes (Lampugnani, Dejana 2007). Amongst these functions are 
mediating the initial adhesion and subsequent contact inhibition during vascular growth and 
remodelling, initiation of cell polarity, and regulation of paracellular permeability 
(Lampugnani, Dejana 2007, Dejana, Orsenigo et al. 2008). The regulation of cell-cell 
adhesion implies that the formation of the tight junction is linked to the formation of the 
adherens junction and mediated through a class of membrane proteins; cadherins. There are 
currently over 80 different types of cadherin proteins reported that range from being non-
specific and expressed across a host of cell types to being wholly specific. The more 
commonly known cadherins such as E, P and N, are single pass transmembrane 
glycoproteins that form homophilic interactions (Takeichi 1995). However one of the more 
recent cadherins to be discovered was a unique endothelial specific cadherin that plays a 
major role in the adherens junction.   
The primary component of the adherens junction is a Ca
2+
-regulated protein called Vascular 
Endothelial (VE)-Cadherin. VE-Cadherin, like most cadherin proteins, mediates homophilic 
interactions between the extracellular domains of the protein expressed on adjacent cells, in 
this case, the endothelium (Vincent, Xiao et al. 2004). The extracellular domain however is 
not enough to instigate junction formation; what is crucial to forming stable junctions is the 
cytoplasmic tail (Gumbiner, 1996). The cytoplasmic tail binds to β- or γ-catenin and 
plakoglobin, which in turn bind to the actin cytoskeleton via a number of inter-skeletal 
proteins (α-catenin, α-actinin and vinculin), thus stabilising the adherens junction complex 
(Knudsen, Soler et al. 1995, Lampugnani, Corada et al. 1995, Watabe-Uchida, Uchida et al. 
1998).  
As mentioned, the adherens junction is primarily focused on mediating initial cell-cell 
adhesion (Lampugnani 2010). Therefore it is not wrong to suggest that formation of the tight 
junction would be improbable should the adherens junction not be formed. Whilst the tight 
junction resides on the apical point of the intercellular junction and is clearly separate from 
the adherens junction, there have been reports of inter-mixing of the strands (Schulze, Firth 
1993). This sometimes close association is backed up by evidence that through the catenins 
that link the cadherins to the cytoskeleton and other signalling components, the adherens and 
tight junctions can communicate and influence one another (Staddon, Herrenknecht et al. 
1995, Schulze, Firth 1993, Taddei, Giampietro et al. 2008, Walsh, Murphy et al. 2011). 
Accumulating evidence has suggested that maintenance of the tight junction is completely 
dependent on the stability of the adherens junctions. The role of VE-Cadherin in the 
restriction of paracellular permeability is also worth nothing. Whilst the tight junction is the 
29 
 
primary restrictor of paracellular passage of molecules, studies have shown that disruption of 
the adherens junction results in an increase in BBB permeability (Romero, Radewicz et al. 
2003). Whether this is due to an indirect effect on the tight junction or VE-Cadherin itself 
restricting passage is to be further elucidated.     
 
1.2.2.5 MAGUKS 
Although the proteins of the tight and adherens junctions facilitate intercellular contacts, a 
number of cytosolic accessory proteins mediate the cellular remodelling and organisation. 
One of the key instigators of these processes is the membrane-associated guanylate kinase 
(MAGUK) family (Gonzalez-Mariscal, Betanzos et al. 2000). Three MAGUK proteins have 
been identified in being involved with the coordination and clustering of protein complexes 
at the cell membrane, namely the tight junctions; ZO-1, ZO-2, and ZO-3 (Gonzalez-
Mariscal, Betanzos et al. 2000, Shin, Hsueh et al. 2000). All three contain three PDZ 
domains, one SH3 domain and one guanyl kinase-like domain, and can be characterised by 
such. Each of these domains acts as a protein-binding site, thus implicating the zonula 
occludens in facilitating a number of protein-protein interactions.    
ZO-1, a 220 kDa protein, was the very first protein to be positively linked to the tight 
junction (Stevenson, Siliciano et al. 1986). ZO-1 was already an established protein, seen in 
many tissues that lack/contain tight junctions (Howarth, Hughes et al. 1992). As such, ZO-1 
has been shown to be involved in a number of processes outside of the tight junction. 
Among the BBB constituents known to bind to the ZO proteins are the claudins (Itoh, 
Morita et al. 1999), occludin (Mitic, van Itallie et al. 2000) and JAM (Ebnet, Schulz et al. 
2000). In addition, actin has been shown to bind to the carboxyl terminal of ZO-1 and ZO-2 
allowing the crosslink with the transmembrane proteins of the junction.  This signifies how 
critical ZO-1 is in mediating the formation and stability of the junctional complex, as upon 
dissociation, intercellular permeability is seen to increase (Abbruscato, Lopez et al. 2002, 
Fischer, Wobben et al. 2002, Mark, Davis 2002). ZO-1 has been shown to dissociate from 
the junction during proper cellular function (i.e. proliferation) but is more closely associated 
as a response to adverse conditions (Gottardi, Arpin et al. 1996), such as Ca
2+
 depletion 
(Riesen, Rothen-Rutishauser et al. 2002), and injurious stimuli such as nicotine (Hawkins, 
Abbruscato et al. 2004).  
Less is known about ZO-2 in relation to the BBB although studies have demonstrated its 
ability to bind many of the BBB constituents and signalling molecules (Betanzos, Huerta et 
al. 2004). It also localises along the membrane in a similar fashion to ZO-1 but not in nearly 
as consistent a fashion (Schulze, Smales et al. 1997, Hawkins, Abbruscato et al. 2004). In 
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fact, initial immunoprecipitation (IP) experiments that aimed to elucidate the tight junction 
binding partners of ZO-1 led to the discovery of ZO-2 (Gumbiner, Lowenkopf et al. 1991), 
which was named based on the large degree of similarity between the two (Jesaitis, 
Goodenough 1994). An argument has been made that ZO-2 picks up the mantle left by ZO-1 
in its absence. ZO-3 has been shown in some tight junction tissues (Inoko, Itoh et al. 2003) 
but not much has been explored regarding its role within the BBB.      
 
1.3 Haemodynamics 
The entire vascular tree is constantly exposed to haemodynamic forces that vary widely in 
magnitude, frequency and direction (Davies 1995, Chien, Li et al. 1998). The endothelium 
residing on the inner wall of vessels is subjected to these constant fluid-driven mechanical 
forces, directly resulting in the modulation of its molecular, genetic, structural and functional 
properties (Figure 1.11). There is overwhelming evidence that the endothelium is able to 
‘sense’ and discriminate between these fluidic forces and to translate them into regulatory 
events (Gimbrone, Topper et al. 2000).  
The response of the vasculature to these forces needs to be highly dynamic in order to adapt 
to the current situation (Beevers, Lip et al. 2001) and since the endothelium is seen to be at 
the forefront of these forces, an intact monolayer is essential for the processes to occur 
(Langille, O' Donnell 1986). Typically, undisturbed physiological haemodynamic forces are 
seen to promote an ‘atheroprotective’ phenotype, preventing undesirable remodelling of the 
vessel wall. They also facilitate vessel adaptation to external stimuli (Traub, Berk 1998). For 
example, exercise results in an increase in blood pressure. Within moments of this increase, 
the vessel wall of the aortic arch initiates signals to the surrounding neurons which in turn 
trigger the release of vasoregulators to adapt the vessel shape and signals to the kidneys to 
control blood volume. Upon cessation of exercise, the vasculature reverts to normal 
(Furchgott, Zawadzki 1980, Frangos, Eskin et al. 1985, Rubanyi, Romero et al. 1986, 
Vallance, Collier et al. 1989). At the cellular and molecular levels, these forces have been 
implicated in controlling cellular remodelling, proliferation, angiogenesis, migration, 
apoptosis and matrix degradation and/or synthesis (Davies, Remuzzi et al. 1986, Cho, 
Courtman et al. 1995, Dimmeler, Haendeler et al. 1996, Cho, Mitchell et al. 1997, Kaiser, 
Freyberg et al. 1997, Dimmeler, Hermann et al. 1998, White, Haidekker et al. 2001). It 
follows therefore that their dysregulation (e.g. during atherosclerosis and stroke) is central to 
disease pathogenesis.   
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Figure 1.11: The effects of heamodynamic forces on vascular remodelling. The 
prototypical vascular responses stemming from changes in transmural pressure (cyclic strain, 
left) or shear stress (right), that lead, through sequential events, to vascular remodelling 
(Lehoux, Castier et al. 2006). 
 
The following section will cover the direct effects that biomechanical forces have upon the 
vasculature with a focus on the endothelium and shear stress. The rapid and differential 
responses of the cells to the wide variety of haemodynamic forces, the factors that affect the 
haemodynamic forces and the subsequent transcriptional and physical changes upon the cells 
and their effects will also be covered.  
The two major haemodynamic forces associated with blood flow consist of pressure acting 
perpendicular to the vessel wall (cyclic strain) and the frictional shear force acting parallel to 
the vessel wall acting on the surface of the endothelium (shear stress) (Figure 1.12). Both 
these forces have been implicated in inducing biochemical and biological responses that act 
as accelerators or decelerators to overall disease progression (Patrick, McIntire 1995, Hahn, 
Schwartz 2009). Before looking at their individual effects some basic aspects of the 
vasculature need to be addressed. 
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Figure 1.12: Mechanical forces on the vessel wall. A section of a blood vessel 
experiencing haemodynamic forces associated with the vasculature: pressure or ‘cyclic 
strain’ (p), resulting in circumferential stretch of the vessel wall; and shear stress (τ), a force 
acting parallel to the vessel wall and exerted longitudinally in the direction of blood flow 
(Hahn, Schwartz 2009).  
 
1.3.1 Haemodynamic Forces 
1.3.1.1 Shear Stress 
It is well established that shear stress; the frictional drag from blood flow has a potent 
regulatory effect on vascular physiology and pathology (Davies 1995). In vitro modelling 
systems backed up by in vivo measurements have calculated that shear stress can range from 
10-70 dynes/cm
2
 in large arteries (Thorin, Thorin-Trescases 2009). Typically the flow 
pattern of the blood in straight vessels is described as laminar. Laminar flow is associated 
with being ‘healthy’ and is characterised as streamlined flow which is undisturbed. In areas 
of unique geometry such as the points of curvature, branching or bifurcations, vessel 
irregularities cause the steady laminar flow of blood observed in the linear vessel regions to 
become disrupted. Turbulent flow is characterised as ‘unhealthy’ and the flow pattern is seen 
to vary continuously over time despite the rate of flow being stable. Commonly, laminar 
flow can become ‘disturbed’ (typically in areas of bifurcation) which results in flow 
separation, recirculation and reattachment to the forward flow creating a gradient of flow 
profile in that particular area (Feldman, Ilegbusi et al. 2002, Nichols 2005). These regions of 
separated flow can register shear stress readings of 0 dynes/cm
2
 due to the genesis of 
recirculation sites (Benson, Nerem et al. 1980, Langille, O' Donnell 1986, Davies 1995, 
Malek, Alper et al. 1999) (Figure 1.13).      
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Figure 1.13: Vascular bifurcation and flow patterns. In linear regions of blood vessels the 
rate, direction and patterns of blood flow are ‘laminar’ (Blue). In regions that that curve 
sharply (i.e. branching points or ‘bifurcations’), complex flow patterns develop (Red). Flow 
in these regions is reduced or become oscillatory in nature, and is often described as 
‘disturbed flow’. Areas of disturbed flow are known to sustain inflammatory signalling 
pathways and are common sites for atherosclerotic plaque development. Consequential 
endothelial cell fates at the specific sites in the vessel wall are presented in the colour coded 
boxes (Hahn, Schwartz 2009).   
    
As Virchow noted endothelial cells under the influence of shear stress change from a raised 
polygonal to a flattened elongated morphology (del Zoppo 2008). The degree of elongation 
correlates with respect to the magnitude of shear stress applied (Reneman, Arts et al. 2006) 
and orientate to the direction of local blood flow (Malek, Alper et al. 1999). This alignment 
of endothelial cells with the direction of blood flow is seen to reduce the maximum shear 
stress experienced by the vessel wall by up to 50% (Barbee, Davies et al. 1994).    
The composition of the vessel wall is directly controlled by shear-induced 
mechanotransduction with in vivo models demonstrating a reduction in the diameter of 
developing vessels coinciding with a reduction in applied blood flow (Langille, Bendeck et 
34 
 
al. 1989). This control over vessel size is demonstrated in physiological conditions, where 
the mean shear stress to which the vascular endothelium is exposed to is dynamically 
controlled to remain constant.  The best example of this phenomenon is seen in the 
arteriovenous fistula model. In this model increasing the flow rate by up to a factor of 8 is 
seen to trigger a compensatory increase in vessel diameter accordingly (Tronc, Wassef et al. 
1996).  
Several studies have also shown that shear stress activation of the endothelium is directly 
involved in the modulation of expression of a wide array of genes. Initial studies identified 
over 40 genes that were regulated by LSS, either via increased or decreased expression in 
response to flow (Tardy, Resnick et al. 1997, Chien, Li et al. 1998, Chiu, Wang et al. 1998, 
Malek, Alper et al. 1999, Lelkes 1999, Nagel, Resnick et al. 1999, Gimbrone, Topper et al. 
2000, Resnick, Yahav et al. 2000). As techniques developed and gene arrays became readily 
available, more in-depth studies were conducted, examining the endothelial response to 
acute and chronic, laminar and turbulent regimes of shear (Chen, Li et al. 2001, Garcia-
Cardena, Comander et al. 2001, McCormick, Eskin et al. 2001, Brooks, Lelkes et al. 2002). 
While the methodologies and post-experimental analysis between studies varied greatly, the 
principal findings of these studies found that hundreds of endothelial genes are regulated by 
physiological levels of shear stress. A large degree of overlap was found between the studies 
with several gene trends observed to be identical, namely under chronic regimes where more 
genes were suppressed than induced and under acute regimes where the response in gene 
expression directly correlated with the degree of endothelial activation that was induced. 
Chronic regimes were also shown to activate a number of genes associated with inhibiting 
proliferation and inflammatory mechanisms. These studies confirmed that of classical 
thinking that high shear stress is considered atheroprotective (Carlier, van Damme et al. 
2003) while low shear stress is associated with atherogenesis (Caro, Fitzgerald et al. 1971) 
(Figure 1.14). Areas of the vasculature that are subjected to a steady laminar shear, such as 
large arteries, have become associated with inducing low proliferation of endothelial cells 
and the surrounding cell cultures, increasing cell survival times, reorganisation of the 
cellular cytoskeleton, improved cell adhesion and production of anti-thrombotic and 
vasoactive agents (Levesque, Nerem et al. 1990, Korenaga, Ando et al. 1994, Ando, Tsuboi 
et al. 1994, Yoshida, Okano et al. 1995). If you compare this phenotype to that of the aortic 
arch which is prone to atherosclerosis, these regions are absent of lipid deposits and 
mechanisms associated with atherogenesis.  
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Figure 1.14: The role of shear stress in endothelial dysfunction. In areas of disturbed 
flow, reduced levels of shear stress shift the endothelial function and structure towards an 
atheroprogressive phenotype (Chatzizisis, Coskun et al. 2007).  
 
1.3.1.2 Cyclic Strain 
Blood vessels are constantly subjected to the mechanical stretching force of blood due to its 
pulsatile nature. The major factor determining applied stretching force upon the vessel wall 
is blood pressure. Blood pressure creates a radial and tangential force which counteracts the 
effect of intraluminal pressure. While shear stress predominantly affects the endothelium, 
cyclic strain affects all layers of the vessel wall. 
Based on observations made in chick embryos, Thoma (1893) first hypothesized that the 
thickness of the vessel walls depends on the magnitude of the tensional force applied to it by 
the pressure exerted by the blood. Comparing the development of the pulmonary artery and 
aorta from birth demonstrates this; the thickness of the two vessels are identical pre-natal yet 
a drop in blood pressure in the pulmonary artery following birth leads to atrophy and a 
decrease in vessel wall thickness. Conversely, the increase in pressure in the aorta leads to 
an increase in the vessel wall thickness (Leung, Glagov et al. 1977). This is due to a close 
relationship between blood pressure and the smooth muscle cells that surround the vessel 
wall that ensures (via dynamic remodelling of the vessel wall) that the circumferential stress 
applied to the vessel wall remains constant throughout the vascular tree.      
Aside from mechanisms of vascular remodelling, cyclic strain has also been identified in the 
release of signalling molecules. MMPs are known to be released in response to stretch forces 
(Jackson 2002, Asanuma, Magid et al. 2003, Grote, Flach et al. 2003) and have been 
identified in mediating further remodelling processes. For example, MMP-9 activation 
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correlated with increased vessel size, a process which could be attenuated in MMP-9 
knockout animal models that were subjected to similar cyclic strain regimes (Lehoux, 
Lemarie et al. 2004). Acute pressure changes induced by elevated cyclic strain forces are 
also seen to trigger calcium signalling events in the vessels subjected to the force (Davis, 
Wu et al. 2001). The elevated pressure opens non-specific cation channels which results in 
membrane depolarisation.  
Overall, cyclic strain is seen to be a key force in inducing vascular remodelling and is seen 
to do so via initiation of primarily pro-inflammatory mechanisms. However, like shear 
stress, these mechanisms are subject to dysfunction and are often implicated in the 
pathogenesis of disease states. Sustained hypertension has been shown in a variety of models 
to have a negative impact on the overall blood vessel shape leading to increased vessel 
thickness due to SMC hypertrophy which under chronic conditions leads to hyperplasia and 
in turn proportional changes in contractile and matrix proteins often resulting in 
dysfunctional tissue (Integan, Schiffrin 2000), a precursor to the atherogenesis process 
(Chobanian, Alexander 1996). The resulting increase in blood pressure in the carotid artery 
along with the intima thickness offers an index of potential atheroma size (O'Leary, Polak et 
al. 1999). In apolipoprotein E (ApoE)
-/-
 mice models, induction of vessel coarctations is seen 
to facilitate the formation of plaques in vascular segments upstream of the surgically 
modified area (Wu, Hagaman et al. 2002). Increased levels of cyclic strain have also resulted 
in increased expression of adhesion molecules (Wang, Nawata et al. 2004) and production of 
pro-atherogenic factors such as ROS and pro-inflammatory cytokines (Chobanian, 
Alexander 1996). 
 
1.3.2 Mechanotransduction 
The ability of the endothelium to detect and transduce mechanical forces deriving from 
blood flow is due to a collaborative effort by numerous cell receptors (Figure 1.15) (Davies 
1995). Typically the activation of biomechanical receptors and the cellular signalling that 
they invoke are transient effects. As noted in gene studies earlier, a number of genes whose 
expression is acutely induced by either onset of changes in the haemodynamic forces soon 
become quiescent or down regulated under chronic time periods (Hahn, Schwartz 2009). 
This ‘adaptation’ to the fluid microenvironment normally starts with the rapid onset of a 
number of signalling cascades (tyrosine kinases, Rho family guanosine triphosphate 
(GTP)ases, extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinases (JNK) 
etc) (Davies 1995, Takahashi, Ishida et al. 1997) before culminating in the reorganisation of 
the cellular cytoskeleton and yield a new cellular phenotype. Ultimately, the aim of this 
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adaptation to shear stress or cyclic strain is to transform the structure of the vessel to 
accommodate the new conditions and restore the experienced forces back to basal levels 
(Tronc, Wassef et al. 1996). A brief overview of known mechanotransduction systems (some 
of which will be addressed in this thesis) is outlined below.    
 
Figure 1.15: Endothelial mechanotransduction by shear stress. A schematic of the 
luminal endothelial mechanoreceptors such as ion channels, G-proteins, caveolae, tyrosine 
kinase receptors and NAPDH oxidase, and how they transmit their mechano-induced signals 
through the actin cytoskeleton. These signals can transmit to the basal or junctional 
endothelial surfaces, where additional mechano-sensitive receptors such as integrins or 
PECAM-1 can further initiate downstream signalling (Chatzizisis, Coskun et al. 2007).  
 
1.3.2.1 Cytoskeleton 
The number of molecules and structural elements implicated in biomechanical signalling and 
transduction is ever growing. The fact that a number of these elements are localised within 
endothelial compartments and are not directly acted upon by the haemodynamic forces 
suggests there is a common structural framework that can tie all the receptors and mediators 
together (Ali, Schumacker 2002). The requirements of such a structure would be to sense the 
mechanical force as it acts upon the cell and relay the signal to the different cellular 
compartments. The endothelial cytoskeleton meets all these criteria. It is capable of binding 
directly or indirectly to a number of known biomechanical receptors (Barbee, Davies et al. 
1994, Barbee, Davies et al. 1994, Barbee, Mundel et al. 1995, Helmke, Goldman et al. 2000, 
Helmke, Thakker et al. 2001, Helmke, Davies 2002) and has also been shown to relay the 
transduced signal from the apical cell surface to several points of attachment within the 
endothelium that can resist the force and anchor the cell in place (Davies 1995, Maniotis, 
Chen et al. 1997, Ingber 1998, Pourati, Maniotis et al. 1998). The endothelial cytoskeleton 
undergoes rapid morphological and orientation changes of its cortical actin cytoskeletal 
stress fibres and associated vimentin and tubulin filaments in response to flow (Helmke, 
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Goldman et al. 2000, Helmke, Thakker et al. 2001, Helmke, Davies 2002) allowing it to 
dynamically change with respect to the forces acting upon it. It is the associated 
microfilaments of actin that are bound to the large number of intracellular proteins that keep 
the entire actin cytoskeleton in continuous dynamic communication with nearly all cellular 
structures. Collectively, these scaffold proteins localise to the cellular periphery and give the 
cell its shape, typically orientating it in the direction of blood flow and disruption of the 
actin cytoskeleton has been demonstrated to inhibit shear stress mediated signalling 
(Knudsen, Frangos 1997, Imberti, Morigi et al. 2000).  As mentioned, evidence has 
suggested the cytoskeleton mediates the signal relay to a number of endothelial 
compartments in order to facilitate adaptation. What follows are just a few of the structures 
that are linked to the cytoskeleton and are known to receive signals from it.       
 
1.3.2.2 Integrins 
Integrins are heterodimeric α/β chains that are involved in the interaction of the cell and 
extracellular matrix. A number of studies have positively identified integrins as signal 
transducers, typically translating mechanical stimuli into biochemical signals capable of 
modulating transcriptional regulation (Ingber 1998, Schwartz, Ginsberg 2002). Formation of 
new integrin-ligand complexes is a dynamic process and correlates with respect to stretch- or 
shear-based mechanotransduction. Blocking of unbound extracellular matrix (ECM) ligand 
sites with antibodies or arginylglycylaspartic (RGD) peptides inhibits any integrin-specific 
intracellular signalling that may be induced by mechanical forces. In the case of shear stress, 
flow mediated release of nitric oxide (NO) in coronary arteries could be attenuated using 
integrin-extracellular matrix inhibitors (Muller, Endlich et al. 1997, Muller, Endlich et al. 
1998). Other flow-related studies have demonstrated how integrins relay signal transduction 
from the actin cytoskeleton to integral membrane proteins such as platelet endothelial cell 
adhesion molecule (PECAM)-1 and VE-Cadherin (Osawa, Masuda et al. 2002, Jin, Ueba et 
al. 2003, Tzima, Irani-Tehrani et al. 2005) as well as increase integrin binding to the 
subendothelial ECM. In the case of cyclic strain, integrins allow for the endothelial cells to 
cope with both acute and chronic remodelling that may occur. The mechanical stretch 
induces structural reinforcement of integrin adhesions and also stimulates integrin-associated 
signalling (focal adhesion kinases (FAK) and mitogen-activated protein kinases (MAPK)). 
As well as being involved in signalling pathways, integrins also have a physical role to play 
and assist in any cytoskeletal remodellings that are required, particularly in relation to the 
cell binding to the extracellular matrix (Jalali, del Pozo et al. 2001, Tzima, Del Pozo et al. 
2002, Tzima, Reader et al. 2003, Tzima, Kiosses et al. 2003). These studies amongst others 
39 
 
(Bhullar, Li et al. 1998, Chen, Li et al. 1999, Shyy, Chien 2002) support the hypothesis that 
these molecules are involved in mechanotransduction of endothelial cells.    
 
1.3.2.3 Interendothelial Junctions 
Several molecular interactions implicate a role for the interendothelial junctions in mediating 
mechanotransduction. Both the adhererns and tight junction are seen to adapt their structure 
concurrently with the actin cytoskeleton, with many proteins involved in the cell-cell 
junction complex undergoing changes in response to haemodynamic forces (Davies 1995).   
Exposure to acute laminar shear stress causes a redistribution of VE-Cadherin, and its 
associated intracellular proteins (α-catenin, β-catenin and plakoglobin). Chronic exposure 
causes the expression patterns of the aforementioned proteins to change from punctuated 
complexes to continuous structures located along the cell-cell border and associate with the 
concurrent redistribed F-actin stress fibres (Noria, Cowan et al. 1999). Temporary 
translocation of the catenins following onset of shear stress has been observed to activate a 
number of signalling pathways (Noria, Cowan et al. 1999). Vascular endothelial growth 
factor (VEGF) plays an important role in mediating adherens junction formation, inducing 
tyrosine phosphorylation of VE-Cadherin, β-catenin, pakoglobin and p-120 via vascular 
endothelial growth factor receptor (VEGFR)2 (Esser, Lampugnani et al. 1998). This 
complex forms within minutes of laminar shear stress onset and deletion or truncation of 
VE-Cadherin was shown to abolish the formation of this complex with the endothelial 
cytoskeleton and other mechanosensitive signalling pathways (Carmeliet, Ng et al. 1999, 
Carmeliet, Lampugnani et al. 1999, Shay-Salit, Shushy et al. 2002, Walsh, Murphy et al. 
2011).  
PECAM-1, another protein involved in endothelial cell-cell adhesion has also been 
implicated in mechanosensing. Upon application of shear stress, PECAM-1 undergoes 
tyrosine phosphorylation within 30 seconds which in turn mediates the binding of Src 
homology phosphatase (SHP)-2 to PECAM-1’s cytoplasmic tail (Osawa, Masuda et al. 
1997, Osawa, Masuda et al. 2002). Knockout of PECAM-1 or SHP-2 was seen to disrupt the 
activation of signalling pathways by shear stress such as ERK1/2 (Kano, Katoh et al. 2000, 
Fujiwara, Masuda et al. 2001).    
These observations suggest that many of the membrane bound proteins that primarily form 
junctions may also serve as mechanoreceptors or sensors to haemodynamic forces. The 
impact of shear (and cytokines) on the expression and assembly of junctions will form an 
important aspect of this thesis.   
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1.3.2.4 Heterotrimeric G proteins and GTPase family members (Rho/Rac) 
The ability to bind to guanine nucleotides, guanosine diphosphate (GDP) and guanosine 
triphosphate (GTP) conferred G proteins their name. Structurally, G proteins are 
heterotrimers consisting of α-, β-, and γ-subunits. G proteins located within the cell are 
activated by G protein-coupled receptors (GPCR). GPCRs span the cell membrane and are 
comprised of extracellular loops that mediate ligand binding and a cytoplasmic tail which 
interacts with the heterotrimeric G-proteins. Upon successful ligand-binding, the α-subunit 
undergoes a conformational change that facilitates the exchange of GTP for GDP. This 
exchange initiates the dissociation of the α-subunit, bound to GTP, from the βγ complex and 
GPCR. The GPCR continues the cycle with each consequent subunit activating a wide range 
of metabolic pathways resulting in the activation of secondary messengers, enzymes and ion 
channels (Taylor 1990, Wieland, Mittmann 2003) until hydrolysation of GTP to GDP by 
GTPases occurs. There are over 150 small GTPases encoded by the human genome. The 
various subclasses of this protein superfamily (Ras, Rab, Arf, Ran and Rho) have been 
implicated in almost every aspect of cell biology. The members of the GTPase family act as 
binary ‘molecular switches’, whose cycling between active and inactive forms is regulated 
by a number of cellular factors.    
The G-proteins located on the apical surface of BBB have been identified as direct 
transducers of haemodynamic forces (Walsh, Murphy et al. 2011). G-protein activation 
occurs within 1 second of flow onset, characteristic of direct mechanotransduction (Gudi, 
Clark et al. 1996, Frangos, Gahtan et al. 1999, Gudi, Huvar et al. 2003). Gudi (1996) 
reported treatment of endothelial cells with anti-sense oligonucleotides to Gαq inhibited 
shear-induced Ras-GTPase activity (shear stress activation of the Ras superfamily of 
GTPases, the Rho subfamily in particular, has been identified as a critical mediator of 
endothelial signalling pathways associated with cytoskeletal remodelling, barrier function 
and immune cell trafficking (Adamson, Wilbourn et al. 2002, Walsh, Murphy et al. 2011). 
Gudi (1998) further demonstrated that G proteins reconstituted in liposomes in the absence 
of proteins receptors showed an increase in activity in response to shear stress. This increase 
in activity was attenuated following reinforcement of the lipid bi-layer by the addition of 
cholesterol, a finding which potentially links G protein activity to that of the caveolae. 
The application of shear stress is also seen to increase lateral diffusion in the upstream 
portion of the apical membrane, an event which occurred almost immediately in response to 
flow (Butler, Norwich et al. 2001). Whole cell measurements demonstrated increased 
fluidity (Haidekker, L'Heureux et al. 2000) which coincided with G-protein activation 
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(Frangos, Gahtan et al. 1999). Artificially decreasing whole cell fluidity subsequently 
blocked activation of G-proteins. 
 
1.3.2.5 Caveolae 
Caveolae are rigid, cholesterol-rich membrane domains which have been shown to contain a 
myriad of signalling molecules including serine and tyrosine kinases and NO (Kurzchalia, 
Parton 1999). The plasma membrane phospholipid bilayer and its constituents have often 
been implicated as a transducer of force and caveolae given their location have been 
hypothesized to mediate flow-dependent responses (Rizzo, McIntosh et al. 1998, Park, Go et 
al. 2000). Upon subjection to shear stress, NO was seen to be rapidly released including 
from one of its binding partners, caveolin within the caveolae, into the cytoplasm where it 
binds to calmodulin (Rizzo, McIntosh et al. 1998). Blockade of caveolin has been shown to 
allow eNOS activation and subsequently the unregulated production of NO suggesting the 
caveolae are required to suppress this event (Bernatchez, Bauer et al. 2005). Caveolae are 
also seen to mediate shear-dependent cholesterol signalling within the endothelium. 
Treatment of endothelial cell cultures with cholesterol inhibiting antibiotics such as filipin 
and digitonin prior to shearing disrupted the shear-mediated activation of ERK1/2 (Park, Go 
et al. 1998).   
 
1.3.2.6 Glycocalyx 
The luminal surface of the endothelium is covered by a ~300-500 nm membrane bound 
macromolecular coating that forms a barrier layer (Weinbaum, Tarbell et al. 2007) such that 
the mechanical forces at the apical plasma membrane are zero (Vink, Duling 2000, Smith, 
Long et al. 2003). It is reported that mechanical forces applied to the glycocalyx are 
transmitted through glycosaminoglycan chains to the transmembrane anchors, relaying the 
mechanotransduction signals (Weinbaum, Zhang et al. 2003). Studies have shown that 
digestion of the glycosaminoglycan chains interfered with established flow-mediated NO 
production (Florian, Kosky et al. 2003, Mochizuki, Vink et al. 2003), however it is also 
possible the digestion enzymes employed disrupted signalling mediators at the basal cell 
surface. It is believed that the glycocalyx is the primary mechano-transducer of shear stress 
to the cytoskeleton and plays an integral part in dynamic response of the vessel wall 
(Pahakis, Kosky et al. 2007). 
As mentioned, biomechanical forces are necessary in maintaining normal vascular 
homeostasis and atheroprotection. In certain areas these forces are disturbed and a number of 
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regulatory processes are seen to become disrupted, typically leading to an inflammatory 
response. These two processes are seen to coincide with onset of endothelial dysfunction, 
barrier disruption and lesion formation (Malek, Alper et al. 1999, Gimbrone, Topper et al. 
2000, Stone, Coskun et al. 2003, Stone, Coskun et al. 2003, Cunningham, Gotlieb 2005). A 
good example of this is nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB), a transcription factor shown to be involved in the expression of a number of key 
molecules implicated in the early stages of endothelial dysfunction (Nagel, Resnick et al. 
1999, Orr, Sanders et al. 2005). Seen to be activated in regions of disturbed flow among 
others, this is just one of many pathways closely associating haemodynamic and 
inflammatory forces with endothelial activation. As will be discussed in the next section, 
inflammation plays a critical a role in the onset of endothelial dysfunction and vascular 
diseases.  
 
1.4 Inflammation 
In vivo, areas predisposed to develop atherosclerotic plaques (e.g. bifurcations) are seen to 
have their endothelium in an elevated activated state (Hahn, Schwartz 2009). In this state, 
the expression and release of inflammatory mediators is widely reported. The effect of a 
number of these agents on the development of atherosclerosis has already been covered. In 
this section, the mechanisms by which these inflammatory mediators are induced/released 
and their subsequent effects, primarily in the brain and the cerebrovascualture, will be 
examined.  
The vascular beds in which the endothelial cells reside can have an influential inductive role 
on the endothelium and its function (Hawkins, Davis 2005). In comparison to the peripheral 
endothelium for example, the cerebrovascular endothelium is remarkably resistant to 
inflammatory mediators (Hickey 2001). This has primarily been attributed to the brain 
endothelium restricting the passage of potentially damaging leukocytes across the vessel 
wall and protecting the brain from any disruption of neural networks. In vivo experiments 
have shown that systemic injections of the bacterial endotoxins (e.g. lipopolysaccharide 
(LPS)) known to induce severe illness in rodents had no obvious impact on the BBB 
integrity (Perry, Anthony et al. 1997). Other studies however which extended this premise 
found simultaneous injection with another inflammatory mediator (Arsenijevic, Girardier et 
al. 1998) or a course of LPS injections (Xaio, Banks et al. 2001) did have a pronounced 
effect on the BBB. Other in vitro and in vivo studies have also confirmed the negative 
impact of inflammatory mediators on BBB endothelium, in particular the ability to induce an 
increase in the monolayers permeability (Kim, Wass et al. 1992, Megyeri, Abraham et al. 
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1992, Deli, Joo 1996, DeVries, BlomRoosemalen et al. 1996, DeVries, BlomRoosemalen et 
al. 1996, DeVries, Kuiper et al. 1997). This would suggest that the cerebrovascular 
endothelial cells are more resistant to circulating cytokines whose origin may be in the 
peripheral vasculature however when in situ damage is caused and multiple factors 
commonly seen to trigger CNS pathologies are present and in high concentration, injury, 
primarily to the barrier, will be induced (it should be noted however that the injury inflicted 
upon the cerebrovasculature is not uniform across all cell types of the brain).  
Inflammation of the cerebral endothelium can originate from a diverse range of insults 
(Abbott 2000). Alteration or imbalance of the local levels of cytokines, viral infection, the 
formation and action of free radicals to name but a few have all been shown to induce 
endothelial activation in the cerebral tissue and subsequently alter or disrupt cellular 
function. The key source for these inflammatory agents comes from the surrounding cells 
within the NVU (Minagar, Alexander 2003) though evidence has shown that these 
inflammatory mediators do not necessarily have to originate within the cerebral tissue to 
induce injury. In vivo studies have demonstrated that injection of inflammatory mediators 
into the hind paw of rodents increased BBB susceptibility to sucrose uptake (Huber, Witt et 
al. 2001). Further studies demonstrated a corresponding decrease in occludin and ZO-1 
expression at the cell membrane and a decrease in association with the actin cytoskeleton 
(Huber, Hau et al. 2002). This, and similar observations, demonstrate that upon initiation of 
inflammatory injury, the integrity of the BBB is seen to go into decline with an overall loss 
of barrier function (Megyeri, Abraham et al. 1992). This presents a window of opportunity 
for leukocytes and other potentially harmful substances to enter the brain and trigger a 
variety of signal transduction pathways leading to further damage (Kim, Wass et al. 1992). 
A number of reasons have been presented for the onset of this inflamed barrier state 
including natural barrier disruption due to atherogenesis, to blood flow disruption and 
ischemia, to onset of neurological conditions including HIV-associated dementia, multiple 
sclerosis and Alzheimer’s disease to name but a few (Petty, Lo 2002).  
Numerous transport systems have been identified in assisting the passage of cytokines across 
the BBB (Banks 2005). Generally, the BBB offers cytokine binding sites that serve a dual 
function; namely they can alter intracellular functions or facilitate the passage of the 
cytokine across the BBB. In some unique cases, the transporter binding site is a product of 
the same gene which encodes for the cytokine receptor involved in triggering an intracellular 
response. These concepts will be discussed below with respect to TNF-α, IL-6 and reactive 
oxygen species (ROS), pro-inflammatory mediators prevalent in the disruption of 
neurovascular barrier integrity during diseases of the cerebrovasculature and which form 
central aspects of investigation in this thesis.  
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1.4.1 TNF-α 
The potent pro-inflammatory cytokine, TNF-α, is a member of the TNF superfamily of 
ligands, which are heavily involved in promoting inflammatory signalling (Wallach, 
Varfolomeev et al. 1999, Wajant, Pfizenmaier et al. 2003, Shen, Pervaiz 2006). Isolated 
from mouse serum, TNF-α was initially discovered via its effects on tumour viability in vivo 
(Carswell, Old et al. 1975). Initially described as a ‘necrotic factor of peripheral 
inflammation’, TNF-α has lived up to its original description and is one of the best 
characterised pro-inflammatory cytokines to date.  
TNF-α is constitutively expressed in its 26 kDa transmembrane form (tTNF-α) where it 
resides in an inactive state. In a process called ectodomain shedding (Black, Rauch et al. 
1997), transmembrane TNF-α is cleaved at its extracellular domain to yield a newly-active 
17kDa form (sTNF-α). Therefore the synthesis and release of soluble TNF-α is regulated by 
the matrix metalloproteinase which facilitates the cleavage of TNF-α from the membrane 
surface; TNF-α converting enzyme (TACE). The newly active form is then free to exert its 
effects in both an autocrine and/or paracrine manner. In vivo models which abolish the 
actions of TACE have demonstrated an ablation in automimmune pathology suggesting 
soluble TNF-α is the primary mediator of the inflammatory response.   
TNF-α has been reported in a number of varied functions, such as cell proliferation, cell 
differentiation (Jelinek, Lipsky 1987, Murphy, Perussia et al. 1988) and gene transcription 
(Collins, Lapierre et al. 1986, Grilli, Chentran et al. 1993). It is TNF-α’s ability to induce 
selective function of some cells whilst sparing others that has led researchers to discover its 
role in multiple signalling cascades.  
The pleiotropic actions of TNF-α are mediated through two distinct transmembrane 
glycoprotein receptors; tumour necrosis factor receptor-1 and -2 (TNFR1 and TNFR2) 
(Figure 1.16). Whilst a degree of overlap exists between the receptors with regard to the 
signalling pathways they can elicit, both receptors differ greatly in their expression profiles, 
cytoplasmic tail structure and downstream signalling pathway activation (Aggarwal, Eessalu 
et al. 1985, Aggarwal 2003), which presents the opportunity for each to activate their own 
unique signalling events (Hsu, Xiong et al. 1995, Hsu, Shu et al. 1996, Declercq, Denecker 
et al. 1998, Quintana, Giralt et al. 2005). 
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Figure 1.16: TNF-α signalling through TNFR1 and TNFR2 
(http://www.sabiosciences.com). 
 
TNFR1 is expressed in most cell types and can be activated via binding of tTNF-α and 
sTNF-α with a partial preference to the soluble form. Overall, TNFR1 is capable of binding 
more adaptor proteins via its intracellular domain and thus presents a greater choice of 
signalling pathways which can be activated as compared to TNFR2. Upon binding of sTNF-
α to TNFR1, a biphasic reaction occurs in which the silencer of death domains (SODD) 
dissociates from the TNFR1 signalling complex while TNFR-Associated Death Domain 
(TRADD) binds in its place (Tartaglia, Ayres et al. 1993, Tartaglia, Pennica et al. 1993, 
Tartaglia, Rothe et al. 1993, Ware, VanArsdale et al. 1996). TRADD then actively recruits 
additional adaptor proteins; Fas-Associated Death Domain (FADD), Receptor-Interacting 
Protein (RIP) and TNF-α Receptor Associated Factor 2 (TRAF2) (Hsu, Xiong et al. 1995, 
Hsu, Shu et al. 1996, Hsu, Shu et al. 1996, Jiang, Woronicz et al. 1999) which can activate 
very distinct pathways. The complex leads to the RIP-dependent activation of NFκB to 
trigger pro-survival signalling, cellular proliferation and cytokine production. The 
cumulative effect of TRADD, TRAF2 and RIP also activates cellular inhibitor of apoptosis 
proteins-1 and -2 (cIAP-1 and -2) which themselves can activate ERK, JNK, p38 MAP 
kinase and ceramide/sphinomyelinase pathways (Winston, Langecarter et al. 1995, Shu, 
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Takeuchi et al. 1996, Schievella, Chen et al. 1997). The kinetics of JNK activation is of 
particular importance in the resulting effect of TNF-α binding. Transient levels of TNF-α 
induce JNK activation which is pro-survival. If JNK activation is sustained this can lead to 
apoptosis signal-regulating kinase 1 (ASK1) phosphorylating JNK, which can then promote 
apoptosis via caspase dependent pathways (Tobiume, Matsuzawa et al. 2001). Finally, 
binding of TRADD and FADD can lead to the recruitment and activation of Caspase 8. 
Activation of Caspase 8 subsequently leads to the recruitment of fellow caspases and 
cleavage of BH3 Interacting Death Domain ultimately resulting in a proteolytic cascade 
ending in cellular apoptosis.  
TNFR2 is restricted to endothelial, hematopoietic and neural cells in addition to some 
immune cell types. TNFR2 shares a number of pro-survival and inflammatory responses as 
TNFR1, with signalling occurring through the recruitment of the TRAF1 and TRAF2 
proteins and subsequent activation of cIAPs and NFκB (Rothe, Wong et al. 1994, Rothe, 
Sarma et al. 1995). TNFR2 also lacks a DD and unlike TNFR1, induction of caspase-driven 
apoptosis is absent. Overall, TNRF2 activation is believed to be pro-survival. However it 
should be noted that TNFR2 has preferential binding to the transmembrane form of TNF-α, 
which in conjunction with its limited expression, results in a far more muted biological 
impact as compared to TNFR1 (Grell, Douni et al. 1995). In fact, TNFR2 has been 
demonstrated to enhance TNFR1 signalling via a ‘ligand-passing’ mechanism. It is thought 
this enhancement of TNFR1 is the primary contribution of TNFR2 in TNF-α mediated 
signalling as compared to signalling events which occur through the intracellular domain of 
TNFR2 (Tartaglia, Pennica et al. 1993, Tartaglia, Rothe et al. 1993, Tartaglia, Ayres et al. 
1993). 
There are a number of critical factors which determine whether TNF-α will have a protective 
or injurious role; the differential patterns of localisation of TNFR1 and TNFR2 and their 
expression, in conjunction with the activation state of the cells, all play a cumulative role in 
the resulting beneficial or harmful effect (Dopp, MackenzieGraham et al. 1997, Sairanen, 
Lindsberg et al. 2001, Sairanen, Carpen et al. 2001, Fontaine, Mohand-Said et al. 2002, 
Akassoglou, Douni et al. 2003). NFκB, p38, JNK are just some of the pathways activated by 
TNF-α which have been reported in influencing a number of key physiological process; 
inflammation, proliferation, cell migration, apoptosis and necrosis (Tartaglia, Ayres et al. 
1993, Tartaglia, Pennica et al. 1993, Tartaglia, Rothe et al. 1993, Eissner, Kirchner et al. 
2000, Harashima, Horiuchi et al. 2001, Eissner, Kolch et al. 2004, Ware 2005).  
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1.4.1.1 TNF-α in the CNS 
The biological function of TNF-α in the CNS was not considered until 1987 when microglia 
were the first cell type found to produce the cytokine in that region (Frei, Siepl et al. 1987). 
Since then, other cell populations of the CNS have been shown to synthesise and secrete 
high levels of sTNF-α and tTNF-α including astrocytes (Lieberman, Pitha et al. 1989) and 
some distinct populations of neurons (Tchelingerian, LeSaux et al. 1996, Kogo, Takeba et al. 
2006). When regulated, TNF-α signalling has been indentified as having several important 
functions within the CNS (Tansey, Wyss-Coray 2008). This can include activation of 
microglial and astrocyte populations, regulation of blood brain barrier permeability, febrile 
responses, glutamatergic transmission and synaptic plasticity (Selmaj, Farooq et al. 1990, 
Merrill 1991, Merrill, Chen 1991, Sedgwick, Riminton et al. 2000, Leon 2002, Beattie, 
Stellwagen et al. 2002, Pickering, Cumiskey et al. 2005). However, like most inflammatory 
agents, imbalances in the microenvironments levels can result in local cellular dysfunction. 
A rapid increase in TNF-α expression is reported in response to both acute and chronic 
injuries (Allan, Rothwell 2001, Viviani, Bartesaghi et al. 2004). As a result, sustained 
expression of TNF-α and its receptors have been linked in the pathogenesis of a number of 
neurodegenerative disorders such as Parkinson’s (Nagatsu, Mogi et al. 2000) and 
Alzheimer’s disease (Perry, Dewhurst et al. 2002), Multiple Sclerosis (Hofman, Schulte et 
al. 1989, Rieckmann, Albrecht et al. 1995), prion diseases (Veerhuis, Hoozemans et al. 
2002), neurotrauma and stroke (Barone, Parsons 2000).  
As has been detailed, TNF-α can contribute to the pathophysiology of disease in a variety of 
means. For example, TNF-α is seen to play a critical role in ischemic brain injury with high 
levels reported in ischemic stroke models (Tarkowski, Blennow et al. 1999, Vila, Castillo et 
al. 2000). Increased levels (3-fold) of TNF-α have been observed in the serum and CSF of 
patients having incurred an ischemic event with the elevated levels persisting for up to 
ninety days post-ischemia (Ferrarese, Mascarucci et al. 1999). Real time PCR analysis 
conducted on tissue isolated from rats subjected to middle cerebral artery occlusion 
(MCAO) also showed an increase in TNF-α transcription levels within 3 hours of ischemia 
onset. This change was closely followed by changes in the messenger ribonucleic acid 
(mRNA) for IL-1β, IL-6, E-Selectin and ICAM-1, and an increase in NFκB activity and 
infiltration of inflammatory cells (Berti, Williams et al. 2002). The sites at which TNF-α 
propagates also changes with increases seen not only in neurons but in astrocytes, microglia, 
choroid plexus, endothelial cells and leukocytes (Buttini, Appel et al. 1996, Meistrell, 
Botchkina et al. 1997). In addition, separate studies utilising MCAO reported that the 
induction of TNF-α coincided with exacerbation of neurological deficits and infarct size 
(Barone, Arvin et al. 1997). Complementary studies demonstrated that inhibition of TNF-α 
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activity was seen to reduce the infarct volume and to suppress any neurological deficits in 
BALB/c mice which underwent similar MCAO procedures (Nawashiro, Martin et al. 1997, 
Nawashiro, Martin et al. 1997, Nawashiro, Tasaki et al. 1997, Meistrell, Botchkina et al. 
1997).  
While there is much evidence identifying TNF-α as a neurotoxic agent in the CNS, scientists 
are now questioning whether TNF-α actively contributes to neuronal injury or attempts to 
limit the affliction. Several studies have demonstrated its role in promoting not only neural 
survival but differentiation, proliferation and growth. TNF-α has been shown to assist in the 
survival of oligodendroglia which in turn negate the effect of demyelation by reparative 
means (Plant, Arnett et al. 2005). Studies have reported an acquired means of 
neuroprotection in rat ischemia models post-administration of excitotoxic stimuli (Hurtado, 
Cardenas et al. 2001, Hurtado, Lizasoain et al. 2002). The suppression of cerebral damage 
coincided with an increase in the level of TACE. It is hypothesised this results in an elevated 
level of freely available TNF-α which is predicted to play a critical role in mounting the 
cerebral defence. Complimentary studies showed in TNFR1- and TNFR2-deficient mice, 
post-ischemic and excitotoxic brain injury, that neural populations in the CNS were more 
susceptible to and incurred more damage than their normal counterparts (Bruce, Boling et al. 
1996, Gary, Bruce-Keller et al. 1998). In another study, TNF-α was shown to protect against 
cell death in the presence of β-amyloid peptide via activation of NFκB and antioxidant 
pathways (Barger, Horster et al. 1995, Goodman, Mattson 1996).  
The dual role of TNF-α is therefore evident. However, despite its protective function TNF-α 
is recognised solely as a pro-inflammatory cytokine which is more heavily involved in the 
progression of disease than preventing it.  
 
1.4.2 IL-6 
IL-6 is a 20-30 kDa glycoprotein which has been shown to have pleiotropic properties and 
play a critical role in host defence (Akira, Taga et al. 1993). Initially discovered in the 
secretory profile of lymphocytes, IL-6, amongst other agents, was reported to drive the 
differentiation of naive B-cells into an antibody-producing mature state (Hirano, Taga et al. 
1985). Since then IL-6 has not only been investigated within the immune system, but in 
monocytes, macrophage, fibroblasts, keratinocytes, mesangial cells, chondrocytes, 
osteoblasts, smooth muscle cells, T cells, B cells, mast cells and endothelial cells to name a 
few (Akira, Taga et al. 1993) (Figure 1.17). IL-6 has since been studied within a number of 
systems; nervous, endocrine and cardiovascular, and has been reported to play an integral 
role within numerous signalling pathways (Kishimoto, Akira et al. 1995).  
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Figure 1.17: IL-6 producing cells and subsequent biological activities. IL-6 is produced 
by a wide range of lymphoid and non-lymphoid cells and is linked to a wide range of 
biological activities on various target cells (Naka, Nishimoto et al. 2002). 
 
IL-6 is the prototypical member within its cytokine family. Whilst the members of this 
family share little homology in their amino acid sequences, they all share a similar tertiary 
structure; four α-helices in an up up down down topology (Bazan 1990, Bazan 1990). 
Molecules sharing this structure can be further subclassified into short- and long-chain α-
helix bundle cytokines (Nicola 1994) with the latter subgroup comprised of IL-6, IL-11, 
leukemia-inducing factor (LIF), oncostatin M, ciliary neurotrophic factor (CNTF) and 
cardiotropin-1 amongst others. Given the homology of their structures, each of the preceding 
molecules can signal via a common receptor; glycoprotein (gp)130 (Heinrich, Behrmann et 
al. 2003)-explaining the name of the IL-6 family of cytokines; the gp130 family.      
The nature of gp130 signalling is complicated (Figure 1.18). Signal transduction through the 
receptor is modular and requires each member of the gp130 complex to bind with ligand-
specific receptors prior to binding with the surface receptor (Heinrich, Behrmann et al. 
2003). In the case of IL-6, it must first bind to the IL-6 receptor, (IL-6R), of which there are 
two forms, a transmembrane 80 kDa form with a short cytoplasmic domain (tIL-6R) and a 
soluble form (sIL-6R) (Yamasaki, Taga et al. 1988, Kishimoto, Akira et al. 1992). The 
resulting IL-6/tIL-6R/sIL-6R complex can then associate with gp130 (Hibi, Murakami et al. 
1990, Kishimoto, Akira et al. 1992), which upon binding, assists in the homodimerization of 
gp130 forming an overall hexameric structure (Boulanger, Chow et al. 2003).  
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The existence of a soluble form of the IL-6R represents a unique feature in IL-6 signalling. 
The gp130 surface receptor has been shown to be ubiquitously expressed throughout in 
contrast to tIL-6R whose expression is quite limited (Saito, Yoshida et al. 1992). Early 
studies confirmed not only could sIL-6 in the presence of IL-6 could elicit a response from 
gp130 presenting cells but it was also naturally occurring being detected in urine (Novick, 
Engelmann et al. 1989) and serum (Honda, Yamamoto et al. 1992). The origin of sIL-6R is 
thought to be a product of alternative splicing of tIL-6R mRNA (Lust, Donovan et al. 1992) 
and/or proteolytic shedding of the surface expressed extracellular domain of tIL-6R by 
metalloproteases (Mullberg, Schooltink et al. 1993). Either way, sIL-6R presents an 
untypical feature of soluble forms of cytokines receptors in that it appears to act in a 
agonistic fashion, enabling cells lacking tIL-6R to undergo a ‘trans-signalling‘ means of IL-
6 signal transduction provided gp130 is present (Rose-John, Scheller et al. 2006, Jones, 
Scheller et al. 2011). To complicate matters further, a soluble form of gp130 exists which 
can act in an antagonistic fashion to trans-signalling mechanisms, competing with tgp130 to 
complex with available IL-6-sIL-6R (Narazaki, Yasukawa et al. 1993).  
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway has 
been identified as the primary pathway initiated by IL-6 binding to gp130. Upon binding, 
tyrosine kinases of the JAK family (JAK1, JAK2, Tyk2) become activated and induce the 
phosphorylation of the cytoplasmic tail of gp130. Several of the newly phosphorylated 
phosphotyrosine (pTyr) sites on the cytoplasmic tail can now act as docking points for 
STAT factors which present similar SH2 domains. STAT1, and in particular, STAT3 
(Cattaneo, Conti et al. 1999), are most commonly associated with IL-6 signalling (Stahl, 
Farruggella et al. 1995) and upon interaction with the cytoplasmic tail become themselves 
phosphorylated, form dimers, then translocate to the nucleus where they regulate the 
transcription of target genes (Lutticken, Wegenka et al. 1994, Stahl, Boulton et al. 1994, 
Darnell, Kerr et al. 1994). While the JAK/STAT pathway remains the key signalling 
pathway of IL-6, this cytokine has also been identified in activating other signalling 
pathways to a lesser degree i.e. MAPK, PI3/Akt, MEK/ERK1/2, NFκB (Stahl, Farruggella et 
al. 1995, Heinrich, Behrmann et al. 2003).  
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Figure 1.18: IL-6 signalling through the gp130 receptor, (http://www.sabiosciences.com). 
 
1.4.2.1 IL-6 in the CNS 
Given the breadth of cells from which IL-6 can originate, IL-6 is seen to have a prominent 
presence in the CNS. Early studies classified IL-6 as a pro-inflammatory cytokine with 
subsequent studies focussed on elucidating its role in the development and progression of 
various CNS disorders. As a result, much work on IL-6 identifies it as an injury mediator 
involved in numerous inflammatory, automimmune and degenerative disorders (Van 
Wagoner, Benveniste 1999). Neural, glial and endothelial cells are all capable of 
constitutively producing IL-6 (Loddick, Turnbull et al. 1998, Suzuki, Tanaka et al. 1999, 
Orzylowska, Oderfeld-Nowak et al. 1999, Suzuki, Tanaka et al. 2009). Of these cells types, 
various agents have been shown to provoke IL-6 stimulation; from neurotransmitters to 
inflammatory cytokines activating various transcription pathways such as NFκB, activator 
protein (AP)-1 and cyclic adenosine monophosphate (cAMP) response element binding 
protein, a substantive increase in IL-6 production is observed within the CNS (Dendorfer, 
Oettgen et al. 1994, Van Wagoner, Benveniste 1999). An increase in IL-6 in the serum 
levels of acute ischemic stroke patients has been reported to occur within 24 hours of the 
ischemic event with the elevated levels peaking by day 4 but persisting for 90 days 
thereafter. The elevated levels coincided with other inflammatory biomarkers such as CRP, 
fibrinogen, IL-1 receptor antagonist and TNF-α (Fassbender, Rossol et al. 1994). In addition, 
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as the responsiveness of a given cell type to IL-6 correlates with the local levels of the 
respective receptor ligands, the elevation of sIL-6R has also been noted in a number of 
cerebrovascular injuries also implicating it in several pathophysiological process. This is of 
particular relevance to endothelial cells which lack tIL-6R (Schobitz, Pezeshki et al. 1995, 
Marz, Otten et al. 1999).   
With regards to cerebral endothelial cells, IL-6 has been reported to have a negative impact, 
promoting injury through different inflammatory responses. IL-6 has been shown to increase 
permeability and induce angiogenesis via direct release of VEGF (Nakahara, Song et al. 
2003), in addition to inducing the production of adhesion molecules and chemokines 
(Prudhomme, Sherman et al. 1996, Penkowa, Moos et al. 1999), all of which are key factors 
in facilitating leukocyte infiltration and promoting cerebral inflammation (Huang, Upadhyay 
et al. 2006).   
The ease and volume at which IL-6 can be produced within the CNS made it of particular 
focus in delineating CNS disease. However as injury models for CNS diseases were refined 
and improved, secondary data to the initial findings yielded interesting fresh perspectives. 
Particularly in models for cerebral ischemia, while IL-6 was shown to elicit its typical 
inflammatory response, it also demonstrated positive neurotrophic effects. For the first time, 
researchers started to question whether IL-6 was a driving force in the progression of 
inflammatory damage or whether it was attempting to adopt a neuroprotective role. As a 
result IL-6 has since been reclassified as also being an anti-inflammatory cytokine and has 
been shown to inhibit the actions of typical cytokines within the CNS (Ulich, Yin et al. 
1991, Xing, Gauldie et al. 1998) amongst other protective actions. However, this new 
perspective presents a new outlook on a number of diseases in which over-production of IL-
6 in its attempt to be protective force can elicit autoimmune damage. This ‘over-protective’ 
effect of IL-6 has been implicated in the onset and development of Crohn’s disease, 
rheumatoid arthritis and multiple sclerosis as well as other disease states such as 
atherosclerosis (Hirano, Akira et al. 1990). Concentrated levels of IL-6 have been detected in 
areas afflicted with atherosclerotic plaques (Schieffer, Schieffer et al. 2000) and as a result, 
IL-6 serum levels are now being looked upon as early prognostic markers for myocardial 
necrosis, ischemia reperfusion damage and severe coronary atherosclerosis (Ridker, Rifai et 
al. 2000, Libby 2002). In addition, elevated serum levels of IL-6 are now a tool utilised in 
identifying unstable plaques and assist in the early detection of potential cerebral infarction 
events (Yamagami, Kitagawa et al. 2004).  
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1.4.3 Reactive Oxygen Species 
Reactive oxygen species are a key signalling component involved in both vascular 
homeostasis (Griendling, Harrison 1999) and in disease progressing pathways (Zalba, 
Beaumont et al. 2000). Free radicals are a natural by-product of normal metabolism with 
oxygen being the most influential free radical utilised in a variety of processes (Miller, 
Buettner et al. 1990). Free radicals and ROS can be produced via a number of cellular 
sources; nicotinamide adenine dinucleotide phosphate (NAPDH) oxidases (Mohazzab-H, 
Kaminski et al. 1994), nitric oxide synthases (NOS) (Pritchard, Groszek et al. 1995, Wang, 
Pagano et al. 1998), xanthine oxidoreductase (Phan, Gannon et al. 1989) and to a lesser 
extent lipooxygenases, cyclooxygenases and mitochondrial oxidases (Figure 1.19). These 
enzyme complexes facilitate the reduction of molecular oxygen to its superoxde anion form; 
O2
-
 (Miller, Buettner et al. 1990). Superoxide while harmful in itself also acts as a source for 
other detrimental oxygen-centred radicals such as hydrogen peroxide and hydroxide anion 
(Nickenig, Harrison 2002). Normally in times of ROS or free radical production, local 
antioxidant defence mechanisms counteract the production of these dangerous molecules. 
However, whether due to dysfunction of the defence mechanisms or stimulated increased 
production of the harmful ROS species, oxidative stress can occur. As a consequence ROS 
can be initiators or secondary players in endothelial dysfunction leading to the onset and 
development of a number of cardiovascular related diseases (Harrison 1997).  
 
Figure 1.19: Sources of superoxide in the vasculature, (Leopold, Loscalzo 2005). 
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Two of the primary transcription factors affected by oxidative stress are AP-1 and NFκB 
(Collins 1993, Luft, Mervaala et al. 1999). These pathways have been shown to modulate 
the expression of some of the key genes in early onset atherogenesis such as MCP-1, 
VCAM-1 and ICAM-1 along with a host of pro-inflammatory cytokines (Luft, Mervaala et 
al. 1999, Pueyo, Gonzalez et al. 2000, Usui, Egashira et al. 2000).  
NO’s role in vasoregulation of blood vessels walls has already been described. In a highly 
oxidative environment, ROS not only plays a role in activating the endothelium and 
disrupting its production of NO (Harrison 1997), but it also targets and destroys any 
bioavailable NO to generate the highly destructive peroxynitrite species, a potent damaging 
oxidant (Babior 2000).  
ROS species are a typical mediator of the atherosclerosis process and have been shown to 
modify low-density lipoprotein (LDL) particles at the site of endothelial injury (Podrez, 
Abu-Soud et al. 2000). Superoxide acts as both reactive oxygen radical for the mediated 
oxidation of LDL or can also act as a substrate or cofactor in the reaction. The conversion of 
the LDL assists in the generation of ‘foam cells’, and therefore directly ties ROS formation 
to atheromas in prone areas. In addition, arteries afflicted with atherosclerotic plaques have 
been shown to display elevated levels of p22phox and subsequent elevation in NADPH 
activity (Azumi, Inoue et al. 1999). This surge in superoxide production coincides with a 
reduced bioavailability of NO in that area (Gryglewski, Palmer et al. 1986, Rubanyi, 
Vanhoutte 1986). Evidence has shown that increased production of ROS coincides with 
endothelial activation and through the induction of redox-sensitive genes, ROS may activate 
inflammatory cascades that lead to the production of numerous pro-inflammatory mediators 
(e.g. TNF-α, IL-1β and interferon (IFN)γ) (Collins 1993, Wung, Cheng et al. 1997, Pun, Lu 
et al. 2009). These agents in turn can have a direct effect on NADPH oxidase and other ROS 
producers which results in further saturation of the environment by superoxide species 
(Behrendt, Ganz 2007). This vicious feedback loop of inflammatory and oxidative processes 
contributes greatly to atherosclerotic progression (Figure 1.20) (Marumo, Schini-Kerth et al. 
1997, De Keulenaer, Alexander et al. 1998, Behrendt, Ganz 2007, Pun, Lu et al. 2009).   
As previously mentioned, there are a number of in-built defence mechanisms available to the 
vasculature which scavenge for superoxide and its counterparts (Valko, Leibfritz et al. 
2007). Under physiological conditions, endogenous anti-oxidant defense mechanisms 
include superoxide dismutase (SOD), catalase and glutathione. The former is a major 
antioxidant enzyme that assists in the release of NO from the endothelium and also 
accelerates the removal of O2
-
. However as outlined, patients suffering from coronary artery 
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disorder have been shown to display a diminished SOD activity similar to that of the other 
ROS defences (Landmesser, Merten et al. 2000).  
Uniform laminar shear stress has been shown to upregulate the genes associated with 
endothelial NOS, cyclooxygenase (COX)-2 and Mn-SOD, which collectively have a vaso-
protective effect on the associated vessel. Oscillatory shear, often seen in regions of 
vasculature branching has been shown to significantly increase the levels of p22phox and 
subsequently drive up superoxide expression via increased NADPH oxidase activity 
(Behrendt, Ganz 2007).  
 
 
Figure 1.20: Cardiovascular risk factors that augment ROS and activate pro-
atherogenic pathways, (Harrison, Griendling et al. 2003).  
 
1.5 Signalling in the BBB 
There are two key signal transduction pathways necessary to maintain a competent BBB; (i) 
signals sent from the junction complex to the cell interior i.e. gene expression, cell 
proliferation and differentiation and; (ii) signals sent from the cell interior to the junctional 
complex to mediate its assembly and regulate paracellular permeability (Matter, Balda 2003, 
Matter, Balda 2003). Given the nature of the NVU, a multitude of signalling pathways are 
involved. The following section focuses on a couple of the classic signalling mechanisms 
involved in NVU signalling, in addition to one of the more novel proteins involved in BBB 
signalling; 14-3-3, a primary focus of this thesis.    
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1.5.1 Calcium 
It has long been known that calcium signalling plays an integral role in modulating BBB 
permeability. Calcium has been shown to act both intracellularly and extracellularly with 
respect to influencing the tight junction. In vitro models demonstrated that upon switch over 
to Ca
2+
-deficient media, the tight junction demonstrated a significant loss of ZO-1, ZO-2 and 
occludin from the cell membrane in conjunction with a subsequent increase in paracellular 
permeability (Klingler, Kniesel et al. 2000). Complementing this effect, other studies 
showed that increasing extracellular levels of calcium induced the translocation of ZO-1 
from the nucleus to the membrane and an increase in membrane resistance and decrease in 
permeability (Stevenson, Begg 1994). Numerous other studies exist demonstrating the 
sensitive nature of the tight junction to environmental Ca
2+
 levels (Nagy, Goehlert et al. 
1985, Abbott, Revest 1991). This accumulating evidence quickly led to the belief that the 
environmental calcium levels were critical in maintaining a stable signalling environment, 
whilst inducing abnormally high (Stuart, Sun et al. 1996) or abnormally low (Ye, Tsukamoto 
et al. 1999) levels of available calcium was seen to disrupt a number of key properties other 
than the tight junction. Later studies confirmed that a number of known BBB permeability 
modulators were seen to be exacting the effect on the barrier via indirect targeting of 
intracellular calcium.  
Since Ca
2+
 can influence cells in a number of ways, different signalling pathways are 
activated/deactivated as a result. In the same study which utilised Ca
2+
-deficient media to 
disrupt the tight junction, the effects could be reversed upon addition of Protein Kinase A 
inhibitors (Klingler, Kniesel et al. 2000). In a separate study, activation of Protein Kinase C 
could also overcome the negative impact of extracellular calcium deficiency (Balda, 
Gonzalez-Mariscal et al. 1993). These studies amongst others heavily implicates Ca
2+
 in 
using kinase signalling cascades leading to the activation of a number of transcription factors 
(e.g. NFκB, cAMP) that have significant impact on the tight junction and consequently, the 
BBB (Brown, Davis 2002).  
 
1.5.2 Phosphorylation 
Phosphorylation is a major regulatory mechanism involved in the modulation of both the 
transmembrane junction and cytosolic accessory proteins (Staddon, Herrenknecht et al. 
1995, Sakakibara, Furuse et al. 1997) of the BBB. Given the number of proteins involved in 
forming the intercellular junctions and the multiple sites on these proteins that can undergo 
modification of their phosphorylation state, it is highly unlikely that any one clear 
mechanism exists between phosphorylation and intercellular junction formation and 
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function. It is more likely the change and combinatorial effect of the phosphorylation states 
of distinct serine, threonine and tyrosine residues that produce distinct and functional effects 
(Sakakibara, Furuse et al. 1997).     
Occludin and ZO-1 were targeted in early studies to link post-translational modifications to 
junction modulation (Sakakibara, Furuse et al. 1997). Early studies suggested that the 
phosphate content of ZO-1 was the determinant of junction permeability (Stevenson, 
Anderson et al. 1989), although further studies have expanded on this idea and indicated that 
phosphorylation of ZO-1 is critical to its membrane targeting during tight junction formation 
(Kurihara, Anderson et al. 1995). Similar studies have identified a number of 
phosphorylation changes in occludin with serine phosphorylation playing a large part in 
regulating the subcellular localisation of occludin (Andreeva, Krause et al. 2001) and both 
phosphorylation of serine and threonine residues on occludin highly correlate with tight 
junction reassembly post-disruption (Farshori, Kachar 1999, Tsukamoto, Nigam 1999).  
Whilst much can be said about serine and threonine residues and their subsequent effects 
post-phosphorylation on protein function, tyrosine phosphorylation however has been 
identified as the key event in regulating cell-cell junctions. Tyrosine phosphorylation levels 
of tight junction proteins are seen to be diminished during development suggesting that this 
event coincides with acquisition of barrier function (Maher, Pasquale 1988). Studies also 
show that inhibition of protein tyrosine phosphatases leads to the significant increase in 
tyrosine phosphorylation state of the intercellular junction proteins which is seen to lead to 
an increase in permeability (Staddon, Herrenknecht et al. 1995).  Tyrosine kinases have also 
been reported to localise at the adherens junctions (Tsukita, Oishi et al. 1991) and the 
susceptibility of components such as β-catenin and ZO-1 to undergo phosphorylation at this 
junction suggests all junctions within the intercellular complex were targets for tyrosine 
kinases. Complementary studies have suggested that tyrosine phosphorylation of junctional 
proteins decreases following cell-cell contact and maturation of junctions (Lampugnani, 
Corada et al. 1997).     
 
1.5.3 14-3-3 
The 14-3-3 family of proteins were first discovered during a routine characterisation of 
bovine brain proteins. The name was given to the protein owing to its particular elution (14
th
 
fraction of bovine brain homogenate) and migration pattern (fraction 3.3) demonstrated on 
2D diethylaminoethyl (DEAE) cellulose chromatography and subsequent starch gel 
electrophoresis (Moore, Perez 1967). 
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The highest tissue concentration of 14-3-3 proteins is found in the brain, estimated to 
comprise 1% of total soluble protein (Boston, Jackson et al. 1982, Boston, Jackson et al. 
1982, Pawson, Scott 1997, Baxter, Fraser et al. 2002, Baxter, Liu et al. 2002) though it has 
been found to be ubiquitously expressed in almost every other tissue in the human body 
including testes, liver and heart (Celis, Gesser et al. 1990). Within a eukaryotic cell, 14-3-3 
is predominantly found in the cytoplasm however it has also be shown at the plasma 
membrane and within intracellular organelles such as the nucleus and Golgi apparatus 
(Celis, Gesser et al. 1990, Freed, Symons et al. 1994, Tang, Suen et al. 1998, Fanger, 
Widmann et al. 1998, Garcia-Guzman, Dolfi et al. 1999). 
In humans there are seven known isoforms categorised by Greek letters (β, γ, ε, η, σ, τ and ζ) 
after their elution profile on reversed phase high performance liquid chromatography 
(Ichimura, Isobe et al. 1988, Martin, Patel et al. 1993). The species initially designated α and 
δ were later found to be the phosphorylated forms of β and ζ respectively (Aitken, Howell et 
al. 1995). They are a highly homologous family of proteins with a very high degree of 
sequence conservation between species (Wang, Shakes 1996) (Figure 1.21).  
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Initially described as activators of neurotransmitter synthesis, 14-3-3 has since been shown 
to bind to protein kinases, enzymes, receptor proteins, cytoskeletal and other structural 
proteins. Over 200 proteins have been shown to interact with members of the 14-3-3 family 
with the list continuing to expand (Pozuelo Rubio, Geraghty et al. 2004, Jin, Smith et al. 
2004, Meek, Lane et al. 2004, Benzinger, Popowicz et al. 2005). This broad array of binding 
partners has identified 14-3-3 in mediating various physiological cellular processes such as 
cell signalling, cell growth, adhesion, division, differentiation, apoptosis and ion channel 
regulation. Whilst extensive research has been conducted on the 14-3-3 family, they are still 
not completely understood in terms of their overall role however certain functional 
properties of the family have been established. These functions include regulating enzyme 
activity, acting as localisation anchors which dictate the subcellular localisation of proteins 
and acting as adapter molecules thus facilitating protein-protein interactions.  
 
Figure 1.22: The structure of 14-3-3. Helices αA-αI are represented by cylinders (Yaffe 
2002). 
X-ray diffraction studies of 14-3-3 ζ and τ led to a greater understanding of how 14-3-3 
facilitates the binding of so many ligands (Liu, Bienkowska et al. 1995, Xiao, Smerdon et al. 
1995). These studies identified the 14-3-3 members as existing as dimers and being highly 
helical. Each 14-3-3 monomer consists of nine anti-parallel alpha helices (αA-αI) organised 
into an N terminal and C terminal domains (Figure 1.22). The nine α-helices form an ‘L’ 
shaped structure which forms walls around a negatively charged channel. The helices within 
this channel (αC, E, G, I) are highly conserved throughout the 14-3-3 family while the 
surface layer of each isoform is highly variable (Xiao, Smerdon et al. 1995, Liu, 
Bienkowska et al. 1995, Petosa, Masters et al. 1998, Yaffe 2002). This highly conserved 
interior channel suggests that the specific isoform binding to diverse targets rests on the 
interaction on the outside of the protein.  
The N termini on 14-3-3 proteins, where dimer formation occurs, is highly variable and it is 
the residues present here that limit the number of possible homo- and heterodimer 
combinations which may confer some specificity to 14-3-3 function (Jones, Ley et al. 1995, 
Chaudhri, Scarabel et al. 2003). αA on one monomer binds with αC and αD on a 
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complimentary 14-3-3 protein forming a ‘U’ shaped dimer. This dimerisation process is an 
important functional characteristic of the 14-3-3 family as it facilitates the binding of two 
different regions on proteins. In the case of two interacting motifs with a weak affinity for 
one another, a more stable interaction can be facilitated, whereas in the case of two motifs 
with a strong affinity towards one another, unique conformation of the protein might be 
facilitated (Fu, Subramanian et al. 2000). Alternatively the dimer can bind two identical or 
different target proteins thereby acting as an adapter bringing disparate target ligands 
together, which in turn may modulate the activity of one another for better or for worse 
(Vincenz, Dixit 1996, Fu, Subramanian et al. 2000, Sehnke, DeLille et al. 2002). In almost 
every known organism, multiple (at least two) isoforms of 14-3-3 have been observed to 
allow for the formation of these variable dimer conformations (Aitken, Baxter et al. 2002). 
The reason why organisms require more than one isoform is unknown. Certain isoform 
expression is stress regulated of cell-type specific. It is thought this regulated expression of 
the 14-3-3 isoforms allows the organism improved control over the levels of the 14-3-3 
proteins. While much has been muted about how the family share many biochemical 
properties, subtle differences have been reported suggesting potential unique roles for 
certain isoforms.   
It should be noted that aside from the various characteristics that define what can bind with 
14-3-3, the state of the 14-3-3 proteins themselves plays a critical determinant in their 
function within particular pathways. Regulatory mechanisms placed upon 14-3-3 include 
isoform specificity, post-translational modification and expression levels in cells.  
One of the key problems with delineating the complete function of the 14-3-3 proteins is the 
sheer complexity of potential interactions they can be involved in. Their basic mechanisms 
in regulating enzyme activity, subcellular localisation of binding partners, and stimulation of 
protein-protein interactions occur on many, many levels and thus make them a complex 
family to study (van Hemert, de Steensma et al. 2001, Yaffe 2002). Given the abundance of 
the 14-3-3 family in brain tissue and the substantial amount of signalling that occurs within 
the organ, this makes them an attractive molecule to examine in relation to modulation of the 
BBB.  
 
1.6 BBB Pathophysiology 
1.6.1 BBB Models 
Until the 1970’s, studies on the barriers of the CNS were conducted primarily in in vivo 
models and in situ tissue preparations (Bradbury 1979). These studies mostly focussed on 
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monitoring dyes or tracer extravasation from parenchymal vessels or examining 
permeability changes in vessels in real time (Butt, Jones et al. 1990, BUTT 1995, Abraham, 
Deli et al. 1996). The introduction of methods which allowed the isolation of cerebral 
capillaries (Joo, Karnushi 1973) sparked a new generation of studies in vitro which have 
enabled the scientific community to examine the mechanisms responsible for barrier 
function in greater detail, on both a cellular and molecular level (Kramer, Abbott et al. 
2001). In using primary cell cultures (Revest, Abbott et al. 1991) it became apparent quite 
quickly that cell culture of these isolated fractions perturbed the cells from their quiescent in 
vivo states (0.1% replications per day) to an activated phenotype (1 to 10% replications per 
day) with a severe loss of specialised functions associated with diverse vessels and organ 
systems. This not only led to improved culture conditions (e.g. co-culture models (Deli, 
Abraham et al. 2005)) but also opened up a search for alternative models which have granted 
a greater understanding overall of the mechanics of these cell cultures. Immortalised cell 
lines that lack the entire in vivo phenotype have proved useful in examining specific signal 
transduction pathways and their interactions (Nobles, Revest et al. 1995, Nobles, Abbott 
1998). Similarly, the overlap of properties between epithelial and endothelial cell types has 
led to the utilisation of epithelial models (e.g. MDCK and Caco2) in establishing numerous 
generic regulatory mechanisms (Balda, Whitney et al. 1996, Balda, Matter 2000, Balda, 
Matter 2000, Balda, Flores-Maldonado et al. 2000). More intricate cell models exist (e.g. 
ECV304 cell line-brain endothelial phenotype with epithelial features) and have also proved 
useful in furthering our understanding of the BBB (Hurst, Fritz 1996, Easton, Abbott 2002) 
(Figure 1.23).  
 
Figure 1.23: Linear evolution of blood-brain barrier methodologies from vital dyes to 
molecular biology, (Pardridge 2003). 
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1.6.2 BBB Disruption 
Physiologically sound BBB models are essential to understanding CNS pathologies and 
developing therapeutic strategies. As already mentioned, most of the work conducted on 
understanding the NVU and the mechanisms related to vascular permeability has been 
carried out using animal models or isolated-perfused organ preparations (Takasato, Rapoport 
et al. 1984), making the understanding of certain CNS based diseases difficult to interpret. In 
time, it became possible to isolate intact, functional and morphologically correct cerebral 
microvessels (Joo, Karnushi.i 1973). Upon development of this method (Panula, Joo et al. 
1978), CNS-based BBB diseases were much easier to dissect and understand. What follows 
is an outline of some of the key CNS-based diseases manifesting BBB disruption that afflict 
the population and the difficulties that are associated in treating them.  
 
1.6.2.1 Stroke 
Stroke is a transient or permanent reduction to the cerebral blood flow, originating from 
ischemia or haemorrhage based injury.  Stroke, and its subsequent damaging after-effects, is 
one of the major contributors to global disease (Lopez, Mathers 2006). It is the third most 
leading cause of death and the most frequent cause of permanent disability in the world 
(Donnan, Fisher et al. 2008). In the acute phase of stroke, neurological complications such 
as cerebral edema and hemorrhagic transformation are a major contributor to stroke-based 
fatalities (Balami, Chen et al. 2011), however the majority of deaths arise from the medical 
complications in the aftermath of the event (Slot, Berge et al. 2009, Kumar, Selim et al. 
2010) (Figure 1.24).  
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Figure 1.24: The relationship between BBB dysfunction and different neurological 
disorders. BBB dysfunction typically occurs as an acute consequence of stroke and 
traumatic brain injury resulting in an inflammatory response, the consequence of which may 
lead to development of other neurological disorders (Schoknecht, Shalev 2012). 
 
Since the events resulting in stroke are acute and time is critical, a greater understanding of 
time-dependent recruitment of immune cells and their contribution to ischemic brain injury 
is essential for developing effective therapeutics. As already detailed, local cerebral ischemia 
results in a time-dependent recruitment and activation of wide variety of inflammatory cells 
including T cells, monocytes,  macrophage and neutrophils results in the onset of a number 
of inflammatory processes. These inflammatory responses are geared towards repairing the 
damaged tissue but in fact can often result in the development of other neuronal diseases. In 
early stages, ROS and proinflammatory cytokines and chemokines are released from injured 
tissue. These agents assist in the expression of adhesion molecules. In the latter stages (days 
later) infiltrating leukocytes release further amount of cytokines and induce the excessive 
release of MMPs and ROS which amplify the brain’s inflammatory response further causing 
extensive activation of resident immune cells. This can frequently lead to further disruption 
of the BBB resulting in brain edema, neuronal death and hemorrhagic transformation. 
However some of the inflammatory mediators have been shown to have dual roles. For 
example while MMP-9 has been shown to greatly pronounce brain injury in the early stages 
it has been shown to play a role in brain regeneration and neurovascular remodelling in the 
latter stages. Each individual’s systemic inflammatory processes vary greatly and it’s these 
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collective mechanisms that potentially reveal the susceptibility and outcome of an individual 
to stroke and its aftermath.  
BBB dysfunction has been identified as a critical step in the acute phase of stroke, although 
the means by which in contributes to the anomalies listed above is diverse. Release and 
action of ROS, MMP’s, pro-inflammatory cytokines and chemokines are among the 
mechanisms shown to influence the BBB following cerebral ischemia. As mentioned the 
aftermath of stroke is often the more complicated aspect of the injury. Long term 
consequences of stroke include delayed cognitive deterioration, dementia, depression and 
epilepsy, with stroke being identified as the most common cause of epilepsy in the elderly 
(Herman 2002). As a result, stroke has now being examined from the perspective that it acts 
as a key initiator of cerebrovascular inflammation (Balami, Chen et al. 2011, Gorelick, 
Scuteri et al. 2011).  
 
1.6.2.2 Traumatic Brain Injury 
Traumatic Brain Injury is shown to be the biggest cause of disability and death in adults 
younger than 45 in developed countries (Bruns, Hauser 2003). Similar to stroke, TBI is often 
an initiator of BBB dysfunction which can have an acute effect or with a delay of several 
days (Lenzlinger, Marx et al. 2002, Rodriguez-Baeza, La Torre et al. 2003, Shlosberg, 
Benifla et al. 2010, Chodobski, Zink et al. 2011). TBI damage often results in the formation 
of edema at the site of injury which in turn triggers a rise in intracellular pressure with 
consequences for cerebral blood flow and ischemic lesion development. The cells of the 
NVU can also be affected by this surge in intracranial pressure often leading to disruption of 
the NVU structure. The mechanisms involved in TBI in relation to BBB dysfunction do not 
differ excessively from stroke in that the subsequent aftermath is often the most damaging in 
the long term. In addition to the onset of ischemia, there is an increase in the production of 
free radicals, pro-inflammatory cytokines and MMPs, all of which have been detailed in 
causing BBB dysfunction and resulting in an increase in permeability.   
 
1.6.2.3 Epilepsy 
Epilepsy is one of the more common neurological disorders with a prevalence of 0.5-1% on 
a global scale and a cumulative incidence of 3% by the age of 74. As already mentioned, 
stroke is the primary cause of epilepsy development (20%) (Herman 2002, Sander 2003). 
Stroke-dependent epilepsy onset is accredited to the generation of brain lesions associated 
with ischemia in the months to years after stroke occurrence. Like most CNS injuries, 
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epilepsy can be accredited to inflammatory-based damage and subsequent dysfunction of the 
BBB. Healthy animal models that utilise BBB-disrupting techniques have shown onset of 
epileptic activity (Seiffert, Dreier et al. 2004, van Vliet, Araujo et al. 2007). 
Numerous studies have already targeted the signalling cascades associated with BBB 
dysfunction in preventing seizures and onset of epilepsy. TGF-β and its signalling pathways 
pertaining to albumin extravasation have emerged as a potential candidate for nullifying 
epileptogenesis (Ivens, Kaufer et al. 2007, Kim, Buckwalter et al. 2012) as well as 
neutralising inflammatory mediators such as TNF-α, IL-6 and IL-1β which have been shown 
to promote seizures (Vezzani, Balosso et al. 2008). Patients have responded to anti-
inflammatory treatments which were shown to reduce seizure frequency (Sotgiu, Murrighile 
et al. 2010, Marchi, Granata et al. 2011).    
 
1.6.2.4 Multiple Sclerosis 
Sophisticated MRI studies have shown that BBB disruption is one of the early symptoms of 
multiple sclerosis development, preceding the onset of any well known clinical symptoms. 
Most investigators believe MS to be an autoimmune disease with experimental models 
attempting to replicate the environment for MS development identifying the actions of T 
Cells (Seeldrayers, Syha et al. 1993) and monocytes (Morrissey, Stodal et al. 1996) as the 
primary instigators for BBB disruption.  These cells have been known to release pro-
inflammatory mediators such as MCP-1 (Song, Pachter 2004), TNF-α, IL-1β and IFNγ 
amongst others (Minagar, Alexander 2003).  
Studies into these immune responses have uncovered antigen-specific receptors on particular 
T-cell lines in MS patients that recognise peptides presented on microglia (Lang, Jacobsen et 
al. 2002). This targeting mechanism to the site of the BBB in conjunction with the release of 
pro-inflammatory mediators noted earlier results in the interference of the myelination 
processes that occur in the nervous tissue (Merrill, Ignarro et al. 1993, Chao, Hu et al. 1995). 
As a result, the myelin sheath undergoes serious damage, exposing the underlying axons to 
further injury (Wekerle, Hohlfeld 2003).   
Further investigations into areas suffering from MS lesions have subsequently shown a loss 
of occludin and ZO-1 in the underlying tissues of the microvasculature (Bolton, Anthony et 
al. 1998, Plumb, McQuaid et al. 2002, Kirk, Plumb et al. 2003). Similar observations have 
been noted in post-mortem studies of brain tissue originating from sufferers of HIV-
encephalitis (Dallasta, Pisarov et al. 1999) and Alzheimers disase (Fiala, Liu et al. 2002).   
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1.6.2.5 Alzheimer’s Disease 
A key factor in the development of Alzeimer’s disease is the effect of β-amyloid (Aβ) on the 
NVU’s astrocytes and microglia (Braak, Braak 1991). Once considered the result of Aβ 
overproduction that subsequently lead to the generation of plaques (Blennow, de Leon et al. 
2006), recent hypothesis suggest that a toxic oligomeric form of Aβ is the main cause of 
Alzheimer’s disease (Selkoe 2000) (though this hypothesis, amongst many others relating to 
Alzheimer’s disease, remain unproven and greatly disputed (Van Broeck, Van Broeckhoven 
et al. 2007, Huang, Potter et al. 2012)). Regardless of form, deficient clearance of Aβ from 
the CNS to the peripheral circulation for degradation and systematic removal exacerbates 
any potential for Aβ-driven damage to be incurred (Hardy, Selkoe 2002, Mawuenyega, 
Sigurdson et al. 2010). Recent studies claim that Alzheimer’s disease is directly linked to the 
dysfunction of the specific transport systems of the BBB (P, glycoprotein, LDL-receptor 
protein (LRP)-1 and the receptor for advanced glycation end products (RAGE) (Zlokovic, 
Yamada et al. 2000, Zlokovic, Deane et al. 2005, Deane, Zlokovic 2007, van Assema, 
Lubberink et al. 2012) that maintain CNS Aβ concentrations. In addition, development of 
Alzheimer’s disease has itself been linked to inducing BBB-disruption, facilitating the entry 
of Aβ from the systemic circulation into the brain creating a vicious circle (Kalaria 1992). 
Conversely, Aβ directly (and indirectly via production of toxic metabolites) induces a 
number of signalling events in the brain, (such as NFκB), resulting in the release of 
inflammatory mediators such as IL-1β, TNF-α, IL-6, MCP-1, NO and ROS (Rubio-Perez, 
Morillas-Ruiz 2012) that are known to not only cause the neuronal damage and synaptic 
dysfunction associated with Alzheimer’s disease, but also potentiate BBB-disruption 
(Giulian 1995, Giulian, Haverkamp et al. 1995, Klegeris, McGeer 1997, Klegeris, Walker et 
al. 1997). Clinical evidence demonstrates immunotherapy with monocolonal antibodies 
reduces amyloid burden in the cerebral microvessels. Such amyloid-lowering strategies have 
been hypothesised to rescue BBB function (Zlokovic, Deane et al. 2005, Dickstein, Biron et 
al. 2006) with successful clinical trials hinging on such.   
 
1.7 Summary and study rationale 
CVD begins in childhood, progressing silently through a long preclinical stage before 
manifesting clinically from middle age. The initiation, progression, and eventually 
activation, of CVD depends on profound dynamic changes in vascular biology. The 
endothelium has emerged as the key regulator of vascular homeostasis. Once assumed an 
inert barrier, the endothelium has been shown to participate in a number of important 
endocrine, paracrine and autocrine vascular functions. However it can also act as an active 
signal transducer for environmental influences that can induce a change in its overall 
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phenotype (Figure. 1.25). Alteration in endothelial function precedes the development of 
phenotypic changes that can contribute to clinical complications. For example, systemic 
factors such as growth factors, hormones, bacterial and viral products, and in particular, 
cytokines, can activate the endothelial monolayer, resulting in the establishment of a 
procoagulant surface, the active recruitment of immune cells, the release of inflammatory 
cytokines and perhaps most importantly, the disruption of the selective permeability barrier. 
Concurrently, local stimuli such as haemodynamic forces exerted by pulsatile nature of 
blood flow, can adapt endothelial function resulting in both short-term vasoactive responses 
and long-term remodelling of the vessel wall. The ability of the endothelium to sense its 
biochemical and biomechanical environment, and generate an integrative response to these 
stimuli, results in the alteration of cellular structure and function. This adaptation plays a 
defining role in the maintenance of vascular homeostasis or the development of vascular 
pathologies. 
 
Figure 1.25: The effect of the endothelial environment on vascular health and disease. 
Local and systemic environmental factors impact endothelial phenotype. The integrative 
response of the endothelium to these stimuli results in the alteration of cellular structure and 
function that can lead to vascular health or disease. Inflammatory cytokine and shear stress 
were aspects that were integrated into our experimental paradigm (Wasserman, Topper 
2004). 
 
The endothelium of the cerebral microvasculature constitutes the BBB, a physical and 
metabolic barrier that controls the flux of blood-borne neurotransmitters and neuroactive 
agents between the brain and the peripheral tissue and vice versa. This barrier plays an 
important role in the homeostatic regulation of the brain microenvironment that is necessary 
for proper neuronal and glial function. The majority of molecular traffic proceeds via 
transcellular routes due to the presence of tight and adherens junctions, a series of 
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transmembrane and cytoplasmic proteins located between adjacent cells that effectively seal 
the paracellular pathway from passive diffusion of solutes. These proteins, like many others, 
are subject to change in response to local and systemic environmental influences. 
Pathological levels of these influences are associated with the dysfunction of the processes 
involved in coordinating the formation, maintenance and sustainment of BBB junctions. In 
the cerebral vasculature, disruption of these processes and others, particularly those 
pertaining to proper barrier function, are poorly understood and have been strongly 
implicated in the initiation, progression and activation of several disease states of the CNS 
(e.g. stroke, multiple sclerosis, Alzheimer’s disease).       
The purpose of this study is to build on previous published findings from our laboratory in 
which the effects of a physiological stimulus, laminar shear stress, on BBB phenotype were 
examined. Our previous studies employed a bovine culture model so in part we were 
assessing the translation of our previous findings into a newly established human culture 
model. In parallel, the effects of pathophysiological stimuli, inflammatory cytokines, on 
BBB phenotype were also examined. This thesis will primarily focus on the effect each 
stimulus has on the modulation of barrier function within an in vitro, monoculture model of 
the BBB. Peripheral objectives entail the examination of some of the mechanisms and 
processes that mediate such modulation, whilst the effects of each stimulus on the anti-
inflammatory response of the BBB are also explored. Elucidation of how the BBB responds 
to these physiological and pathophysiological stimuli will not only provide a greater 
understanding of the mechanisms involved in mediating diseases of the CNS, but also those 
that can be potentially manipulated and implemented in the development of novel 
therapeutic strategies that involve controlled modulation of barrier function, impacting on 
drug delivery strategies to the brain and thus the treatment of several neurological diseases.             
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1.8 Thesis Overview 
The research data presented herein describes the effects of a physiological (shear stress) and 
pathophysiological (inflammatory cytokines) stimuli on a human brain microvascular 
endothelial cell blood-brain barrier model. The data focuses on the effect of each stimulus on 
blood-brain barrier phenotypic properties, in particular barrier function, before investigating 
whether shear stress could ameliorate the effects of cytokine injury in vitro, and if so, by 
which anti-inflammatory mechanism/s. The effects of cytokine-induced released 
inflammatory mediators; ROS and IL-6, from HBMvECs on overall cytokine-induced injury 
were also investigated. Finally, the identification and delineation of the role of a potentially 
novel binding partner of the brain interendothelial junction; 14-3-3, is explored with respect 
to our physiological and pathophysiological stimuli. The findings are presented in the 
following manner.   
Chapter 3:  
 
The effects of laminar shear stress on HBMvEC blood-brain barrier properties. 
 
Chapter 4: 
 
The effects of inflammatory cytokines; TNF-α and IL-6, on HBMvEC blood-
brain barrier properties. 
 
Chapter 5:  
 
The independent contribution of reactive oxygen species, and IL-6 to cytokine-
induced modulation of HBMvEC blood-brain barrier properties.  
 
Chapter 6: 
 
The role of 14-3-3 in shear- and cytokine-induced modulation of HBMvEC 
junction assembly and barrier function. 
 
 
See Figure 1.26 below for a schematic depiction of the experimental approaches used in this 
thesis.  
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Figure 1.26: Schematic depiction of experimental approach. Primary human brain 
microvascular endothelial cells (HBMvECs) were subjected to different experimental 
paradigms; physiological shear conditions (dark green, chapter 3) and pathophysiological 
inflammatory cytokines (red, chapter 4) and monitored for genetic, molecular, structural and 
functional changes in BBB phenotype, particularly pertaining to the interendothelial 
junction. The effect of co-exposing the HBMvECs to both stimuli was then investigated on 
barrier function, in parallel with further mechanistic studies related to each stimulus’s 
experimental outcomes; the influence of ROS of cytokine-induced damage (orange, chapter 
5) and the role of 14-3-3 in shear-mediated barrier enhanced (light green, chapter 6).  
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Chapter 2: 
Materials and Methods. 
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2.1 Materials 
2.1.1 Reagents and Chemicals 
Abcam (MA, USA)       Catalogue No. 
Mouse anti-thrombomodulin IgG antibody    AB6980 
Mouse anti-VE-cadherin monoclonal IgG2a antibody   AB7047 
Rabbit anti-14-3-3 polyclonal IgG antibody     AB9063 
Rabbit anti-vWF polyclonal IgG antibody    AB6994 
 
Aktiengeselischaft and Company (Numbrecht, Germany)  Catalogue No. 
1.5 ml micro tube with safety cap     72.706.200 
10 µl pipette tips        70.1130 
200 µl pipette tips       70.760.002 
1000 µl pipette tips        70.762 
15 ml reagent and centrifuge tubes      62.554.502 
50 ml reagent and centrifuge tubes      62.559.001 
2 ml serological pipettes      86.1252.001  
10 ml serological pipettes      86.1254.001 
25 ml serological pipettes       86.1685.001 
6-well tissue culture plates      83.1839  
24-well tissue culture plates       83.1836 
96-well tissue culture plates      83.1835 
58 cm
2
 tissue culture dishes      83.1802 
T-25 tissue culture flasks      83.1810.002 
T-75 tissue culture flasks      83.1813.002  
Cell scrapers        83.1830 
Cryopure tubes        72.380.992  
Filtopur 0.2 μm syringe filters      83.1826.001 
Multiply® PCR Cup, 200ul      72.737.002  
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Multiply® PCR Cup, 500ul      72.735.002 
Reagent and centrifuge tube      62.515.006 
Weigh boats        71.9923.212 
 
Ambion (TX, USA)       Catalogue No. 
CDH5 Silencer Select small interfering RNA (siRNA)   4392420 
RNase AWAY Spray Solution       10328-011 
 
Applied Biosystems (CA, USA)      Catalogue No. 
Fast Optical 96-well reaction plates     4346906 
Fast Optical 384-well reaction plates     4309849 
High Capacity cDNA Reverse Transcription Kit    4368814  
Microamp Optical Adhesive Film     4311971 
CLDN5 Stealth siRNA       1299001 
 
Becton Dickinson (NJ, USA)      Catalogue No. 
FACS Rinse Solution        340346 
FACSFlow™ Sheath Fluid      342003 
Microlance Hypodermic Needle 19G     BD301750 
Round-bottomed FACS tubes      352054 
 
Cell Applications (CA, USA)      Catalogue No. 
Bovine Brain Microvascular Endothelial Cells (BBMvEC)  B840-05 
 
Cell Signalling (MA, USA)      Catalogue No. 
Anti-mouse IgG, HRP-linked antibody     7076S 
Anti-rabbit IgG, HRP-linked antibody     7074S 
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Cell Systems Inc., (WA, USA)      Catalogue No.  
Attachment Factor™       4Z0-210 
Human Brain Microvascular Endothelial Cells (HBMvEC)  ACBRI 376 
 
Clontech Laboratories Inc. (CA, USA)     Catalogue No. 
pEGFP-N1        pEGFP-N1 
 
DAKO (CA, USA)       Catalogue No. 
Fluorescent Mounting Media      53023 
 
Davidson and Hardy (Belfast, Northern Ireland)    Catalogue No. 
Carl Zeiss High Performance Coverslips     474030-9000 
 
eBioscience (CA, USA)       Catalogue No. 
Human IL-6 ELISA Ready-SET-Go!®     88-7066 
 
Eurofins MWG Operon (Edersberg, Germany)      
Claudin 5 Primers (Human and Bovine) 
GAPDH Primers (Human and Bovine) 
Occludin Primers (Human and Bovine) 
VE-Cadherin Primers (Human and Bovine)  
ZO-1 Primers (Human and Bovine) 
vWF Primers (Human) 
IL-6 Primers (Human) 
TNF-α Primers (Human) 
TNFR1 Primers (Human) 
TNFR2 Primers (Human) 
gp130 Primers (Human) 
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sIL-6R Primers (Human) 
14-3-3β Primers (Human) 
14-3-3ζ Primers (Human) 
14-3-3ε Primers (Human) 
14-3-3γ Primers (Human) 
14-3-3θ Primers (Human) 
 
GE Healthcare (Buckinghamshire, UK)     Catalogue No. 
Bovine Brain Microvascular Endothelial Cells (BBMvEC)  B840-05 
Donkey anti-rabbit HRP-linked IgG antibody    NA9340 
Sheep anti-mouse HRP-linked IgG antibody    NA931V 
 
Gibco (Scotland, UK)        Catalogue No. 
Fetal Calf Serum       10106169 
 
ibidi (Martinsried, Germany)      Catalogue No. 
Fluorescent Mounting Medium       50001 
Olaf Humidifying Chamber       80008 
µ-slide I
0.6
 Leur        80186 
µ-slide y-shaped       80126 
 
Invitrogen (Groningen, Netherlands)      Catalogue No. 
Alexa Fluor® 488 Donkey Anti-Goat IgG (H+L)   A11055 
Alexa Fluor® 488 Donkey Anti-Mouse IgG (H+L)   A21202 
Alexa Fluor® 488 Donkey Anti-Rabbit IgG (H+L)   A21206 
Alexa Fluor® 546 Donkey Anti-Mouse IgG     A10036 
Alexa Fluor® 546 Donkey Anti-Rabbit IgG    A10040 
Alexa Fluor® 488 Phalloidin      A12379 
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Alexa Fluor® 546 Phalloidin      A22283 
Dead Cell Apoptosis Cytometry Kit     V13241  
Claudin-5 Monoclonal Antibody, Mouse (4C3C2)    35-2500 
Occludin Monoclonal Antibody, Mouse (OC-3F10)   33-1500 
Phosphothreonine (pTyr) Mouse Monoclonal Antibody   13-9200 
Phosphotyrosine (pThr) Mouse Monoclonal Antibody Cocktail  13-6600 
ZO-1 Monoclonal Antibody, Mouse (ZO1-1A12)   33-9100 
Neon™ Transfection System 100 µl Kit      MPK10096 
SYBR®Safe DNA Gel Stain       S33102 
TRIzol®         15596-018 
 
Lonza (Basel, Switzerland)      Catalogue No. 
Mycozap™ Antibiotics       VZA-2022 
 
Meso Scale Discovery (MD, USA)     Catalogue No. 
Human ProInflammatory-4 1 Ultra-Sensitive Kit    K15009C-1 
Human Vascular Injury 1 Kit      K15135C-1 
 
Millipore (MA, USA)       Catalogue No. 
Amicon Ultra-2 Centrifugal Filter Unit with Ultracel-30 membrane UFC203024 
Apocynin (APO)       178385 
EndoGRO-MV Complete Culture Media Kit    SCME004  
GAPDH, Polyclonal Antibody, Rabbit     ABS16 
Immobilin-P polyvinylidene fluoride (PVDF) 0.45 µm Membrane  IPVH00010 
Luminata Forte Western HRP substrate      WBLUF0100 
Millicell Hanging Cell Culture Transwell Inserts     PIHT30R48 
Recombinant Human Basic Fibroblast Growth Factor (bFGF)  GF003 
Recombinant Human IL-6       IL006 
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Recombinant Human Monocyte Chemotactic Protein-1 (MCP-1)  GF012 
Recombinant Human Tumour Necrosis Factor-Alpha (TNF-α)  GF023 
 
Miltenyl Biotec (Cologne, Germany)     Catalogue No. 
Propidium Iodide (PI) Solution      130-093-233 
 
NanoEntek (Seoul, South Korea)     Catalogue No. 
ADAM Accuhip
4x
 Kit       AD4K-200 
 
Pall (Portsmouth, UK)       Catalogue No. 
Biotrace
TM
 NT Nitrocellulose Transfer Membrane   66485 
 
Pierce Chemicals (Cheshire, UK)     Catalogue No. 
BCA Protein Assay Reagent       23225 
Co-Immunoprecipitation Kit      26149 
 
Promega (WI, USA)       Catalogue No.  
CellTiter 96® AQueous One Solution Cell Proliferation Assay   G3580 
Sequencing Grade Modified Trypsin     V5111 
 
PromoCell (Heidelberg, Germany)     Catalogue No. 
Freezing Medium       C-29912 
 
Qiagen (West Sussex, UK)      Catalogue No. 
HiSpeed Midi-Prep Kit       12643 
 
R&D Systems (MN, USA)      Catalogue No. 
Goat anti-IL-6 polyclonal IgG antibody     AF-206-NA 
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Human Thrombomodulin DuoSet ELISA    DY3947 
 
Roche Diagnostics (Basal, Switzerland)     Catalogue No. 
Complete EDTA-free Protease Inhibitor Cocktail Tablets   04693132001 
E-Plate xCELLigence™ plates       05469830001 
FastStart Universal SYBR Green Master Mix    04673492001 
 
Sigma-Aldrich (Dorset, UK)      Catalogue No. 
2-Mercaptoethanol        M6250 
2’,7’-Dichlorofluorescin diacetate     D6883 
4’,6-Diamidino-2-Phenylindole Dihydrochloride (DAPI)   32670 
Acetone        34850 
Acetonitrile (ACN)        271004 
Acrylamide/Bis-acrylamide Solution     A3574  
Agarose         A5093 
Albumin from bovine serum      A2153 
Ammonium Bicarbonate       A6141 
Ammonium Chloride       A9434 
Ammonium Persulfate       A9164  
Ampicillin sodium salt       A9518 
Brilliant Blue R        B0149 
Brilliant Blue G Colloidal Concentrate      B2025 
Bromophenol Blue Sodium Salt      B8026 
Catalase from bovine liver (CAT)     C-9322 
Chloroform         C2432 
Crystal Violet        C3886 
Dihydroethidium       37291 
Dimethyl Sulfoxide (DMSO)       D8418 
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DNase 1 Kit         AMPD1 
Dulbecco’s Modified Eagle’s Medium-High Glucose (DMEM)   D5796 
Ethylenediaminetetraacetic Acid Disodium Salt Dihydrate (EDTA)  E5134 
Fluorescein Isothiocyanate-Dextran-40kDa (FITC-Dextran)   FD40S 
Formaldehyde Solution        F8775 
Formic Acid         F0507 
Gelatin from cold water fish skin     G7765 
Glycerol         G6279 
Glycine         G8898 
Heparin Sodium Salt        H3149 
HEPES         H4034 
Hydrogen Peroxide Solution       H1009 
Kanamycin sulphate from Streptomyces kanamyceticus   K4000 
Lysogeny broth (LB) Agar EZMix™ Powder    L7533 
LB Broth EXMix™ Powder      L7658 
Magnesium Chloride       M8266 
Magnesium Sulfate       M7506 
Methanol         34860 
Methyl-3,4-dephostatin       M9440 
N-Acetyl-L-Cysteine (NAC)       A9165 
N,N,N’,N’-Tetramethylethylenediamine (TEMED)    T9281 
PAP Pen, 2 mm        Z672548 
PAP Pen, 5 mm        Z377821 
Paraformaldehyde       P6148 
Penicillin-Streptomycin       P0781 
Phosphate Buffered Saline (PBS) Tablets     P4417 
Ponceau S solution        P7170 
Potassium Chloride       P9541 
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R18 trifluoroacetate       SML0108 
RNA Sample Loading Buffer without Ethidium Bromide   R1386 
Saponin from quillaja bark      S7900 
Sodium Azide         13412 
Sodium Chloride       S3014  
Sodium Deoxycholate        D6750 
Sodium Dodecyl Sulfate (SDS)       L3771 
Sodium Fluoride        S7920 
Sodium Orthovanadate        S6508 
Sodium Phosphate Dibasic       S3264 
Sucrose         S0389 
Superoxide Dimutase  from bovine erythrocytes (SOD)   S5395   
Thrombin from bovine plasma      T9549 
Tris Acetate-EDTA Buffer       T9650 
Triton™X-100         X-100 
Trizma Base        T6066 
Trypsin-EDTA Solution       T4174 
Tryptone        T7293 
Water         W4502 
Yeast Extract        Y1625 
 
Terumo Medical (NJ, USA)       Catalogue No. 
10cc Syringes        SS-10ES 
 
Thermo Fisher Scientific (Leicestershire, UK)    Catalogue No. 
6x DNA Loading Dye        R0611 
10x Phosphate Buffered Saline Solution     BP399-20 
Acetic Acid Glacial        A35-500 
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Buffer Solution pH4 (phthalate)      J/2825/15 
Buffer Solution pH7 (phosphate)      J/2855/15 
Buffer Solution pH10 (borate)       J/2885/15 
DreamTaq DNA Polymerase Kit      EP0702 
GeneRuler™ 100 bp DNA Ladder Plus      SM0321 
PageRuler Plus Prestained Protein Ladder     26619 
Parafilm Wrap        PM-992 
Propan-2-ol         P/7490/15 
Spectra Multicolor High Range Protein Ladder     26625 
Tris Base        T1503  
Western Blot Stripping Reagent      10057103  
White Microtitre Plates       611F96WT 
 
vWR International Ltd. (Maidstone, UK)    Catalogue No. 
Cover slips 24*24 mm       631-0127  
L-Shaped Spreaders        612-1561 
Microscopy Slides       631-0103 
Tween®20        66368 
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2.1.2 Apparatus  
Applied Biosystems 7900HT Fast Real Time PCR  Applied Biosystems (CA, USA) 
FACSAria      Becton Dickinson (NJ, USA) 
Mini PROTEAN® Trans Blot Module   Bio-Rad (CA, USA) 
MJ Mini Thermal Cycler    Bio-Rad (CA, USA) 
ELx800 Microplate Reader    Biotek (VT, USA) 
Centrifuge      Eppendorf, (Cambridge, UK) 
ibidi pump and flow system    ibidi (Martinsried, Germany) 
SECTOR® Imager 6000    Meso Scale Discovery (MD, USA) 
Cryo-freezing container     Nalgene, (NY, USA) 
ADAM-MC       NanoEntek (Seoul, South Korea) 
Microporator Mini MP-100    NanoEntek (Seoul, South Korea) 
Nikon Eclipse Ti     Nikon (Tokyo, Japan)  
Nikon Eclipse TS100 phase-contrast microscope  Nikon (Tokyo, Japan) 
Olympus Fluoview FV10i Confocal Microscope  Olympus (Tokyo, Japan) 
xCELLigence Real Time Cell Analyzer (RTCA) DP Roche (Basal, Switzerland) 
Vortex, Orbital Shaker     Stuart Scientific (UK) 
See-Saw Rocker      Stuart Scientific (UK) 
Block Heater       Stuart Scientific (UK) 
Rotator       Stuart Scientific (UK) 
G-Box chemi-luminescence analysis system  Syngene (Cambridge, UK)  
TECAN Safire 2 Fluorospectrometer   Tecan, (Männedorf, Switzerland) 
Nanodrop 1000 Spectrophotometer   Thermo Fisher (UK) 
Zeiss 710 Confocal Microscope    Carl Zeiss (Oberkochen, Germany) 
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2.1.3 Preparation of stock solutions and buffers  
2.1.3.1 Molecular Biology 
Super Optimal Broth with Catabolite Repression (SOC) Media 
Tryptone    2% (w/v) 
Yeast Extract    0.5% (w/v) 
Sodium Chloride   10 mM 
Potassium Chloride   2.5 mM 
Magnesium Chloride   10 mM 
Magnesium Sulfate   10 mM 
Glucose    20 mM 
 
Tris-EDTA (TE) Buffer 
Tris     10 mM 
EDTA     1 mM 
 
2.1.3.2 SDS-PAGE and Immunoblotting 
RIPA Cell Lysis Buffer Stock (1.28x) 
HEPES, pH7.5    64 mM 
Sodium Chloride   192 mM 
Triton X-100    1.28% (v/v) 
Sodium Deoxycholate   0.64% (v/v) 
SDS     0.128% (w/v) 
  
RIPA Cell Lysis Buffer (1x) 
1.28x RIPA Stock   1x  
Sodium Fluoride   10 mM 
EDTA, pH8.0    5 mM 
Sodium Phosphate   10 mM 
Sodium Orthovanadate   1 mM 
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Protease Inhibitors   1x 
 
Running Buffer (1x) 
Tris     25 mM 
Glycine     192 mM 
SDS     0.1% (w/v) 
 
Sample Solubilisation Buffer (4x) 
Tris-HCl, pH6.8   250 mM 
SDS     8% (w/v)    
Glycerol                                            40% (v/v)  
2-Mercaptoethanol   4% (v/v) 
Bromophenol Blue   0.008% (w/v) 
Filter the Sample Solubilisation Buffer using a 0.25 µm filter 
 
Tris Buffered Saline (10x) 
Tris-HCl, pH6.8   152 mM 
Tris Base    46 mM 
Sodium Chloride   1.5 M 
 
Transfer Buffer (1x) 
Tris-HCl, pH6.8   25 mM 
Glycine     192 mM 
SDS     0.1% (w/v) 
Methanol    20% (v/v) 
 
Tris Buffered Saline (10x) 
Tris     2.4% (w/v) 
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Sodium Chloride   8.8% (w/v) 
 
Coomassie R-250 Stain 
Coomassie Brilliant Blue R250  1% (w/v) 
Glacial Acetic Acid   10% (v/v) 
Methanol    40% (v/v) 
Distilled (DI) Water   50% (v/v) 
Filter the Coomassie stain using a 0.25 µm filter 
 
Coomassie R-250 Destain 
Methanol    20% (v/v) 
Glacial Acetic Acid   10% (v/v) 
DI Water    70% (v/v) 
 
2.1.3.3 Immunoprecipitation 
SDS-PAGE Gel Fixative 
Methanol    40% (v/v) 
DI Water    53% (v/v) 
Glacial Acetic Acid   7% (v/v) 
 
Coomassie G-250 Stain 
DI Water    64% (v/v) 
Brilliant Blue G Colloidal Concentrate 16% (v/v) 
Methanol    20% (v/v) 
 
Coomassie G-250 Destain 
Methanol    25% (v/v) 
Glacial Acetic Acid   10% (v/v) 
DI Water    65% (v/v)    
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2.1.3.4 Mass Spectrometry 
Coomassie G-250 Destain 
100 mM Ammonium Bicarbonate 50% (v/v) 
Acetonitrile    50% (v/v) 
 
Digestion Buffer 
Trypsin, sequencing grade  12.5 ng/µl 
Ammonium Bicarbonate  10 mM 
Acetonitrile    10% (v/v) 
 
Extraction Buffer 
5% Formic Acid   33% (v/v) 
Acetonitrile    66% (v/v) 
 
2.1.3.5 Agarose Gel Loading Buffer (6x) 
Sucrose     40% (w/v) 
Bromophenol Blue   0.25% (w/v) 
 
2.1.3.6 FACS Buffer 
Fetal Calf Serum   2% (v/v) 
Sodium Azide    0.1% (w/v) 
PBS     98% (v/v) 
Filter the FACS Buffer using a 0.25 µm filter 
 
2.1.3.7 Microscopy 
Paraformaldehyde 
Paraformaldehyde   3% (w/v) 
0.1M NaOH    500 ml 
Place in a 70
o
C water bath until dissolved. Cool to room temperature and pH with HCl to 7.2 
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Permablock Solution 
Saponin    0.1% (v/v) 
Fish gelatine    0.25% (v/v) 
Sodium Azide    0.02% (w/v) 
PBS     10 ml    
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2.2 Methods 
2.2.1 Cell Culture Techniques 
All cell culturing techniques were undertaken in a clean and sterile environment using a 
Holten Lamin Air laminar flow cabinet. Cells were visualised using a Nikon Eclipse TS100 
phase-contrast microscope.  
 
2.2.1.1 Human Brain Microvascular Endothelial Cell (HBMvEC) Culture  
HBMvEC’s are a strongly adherent cell line which over time form a confluent, contact-
inhibited monolayer with distinct cobblestone morphology. HBMvEC’s (Cell Systems Inc.) 
were initiated by isolation of dispase-dissociated normal human brain cortex tissue and 
subsequent culturing in the presence of serum free medium and a naturally derived human 
astrocyte extracellular matrix. Cells were reported to test negative for the presence of 
Mycoplasma spp. and characterised via the cytoplasmic uptake of Di-l-Ac-LDL and 
expression of vWF/Factor VIII.  Cells at <9 cumulative population doublings in vitro 
(Passage 2) were cryopreserved serum-free in aliquots of ~1*10
6
 cells per millilitre prior to 
shipping.  Cells were cultured onto Attachment Factor™ (AF) coated tissue culture grade 
plastic-ware containing ENDO-Gro MV Basal Medium and Supplement Kit and Mycozap™ 
antibiotic. To summarise, the final constituents and their concentrations in each bottle of 
medium were Foetal Bovine Serum (FBS) (5%), L-Glutamine (10 mM), Ascorbic Acid (50 
µg/ml), Heparin Sulfate (0.75 U/ml), Hydrocortisone Hemisuccinate (1 µg/ml), recombinant 
human Epidermal Growth Factor (rhEGF) (5ng/ml), EndoGRO-LS Supplement (0.2%) and 
Mycozap (100 µg/ml). Cells were cultured onto T25 and T75 flasks for early passage/freeze-
stock generation, whilst 58 cm
2
 dishes were routinely used for experimental work alongside 
6-, 24- and 96-well plates. For experimental purposes, cells were used between passages 5-
12. Cells were maintained in 5% CO2/95% humidity at 37
o
C. 
 
2.2.1.2 Bovine Brain Microvascular Endothelial Cell (BBMvEC) Culture 
BBMvEC’s are the bovine equivalent of HBMvEC’s. BBMvEC’s (Cell Applications Inc.) 
were isolated directly from microvessels located in the bovine brain and cultured using 
Bovine Brain Endothelial Cell Culture Medium. Cells were reported to test negative for 
bacterial, mycoplasma and fungal contaminants and characterised via cytoplasmic uptake of 
Dil-l-Ac-LDL prior to cryopreservation and shipping. Cells at <9 cumulative population 
doublings in vitro (Passage 2) were cryopreserved in Bovine Brain Endothelial Cell Basal 
Medium containing 10% FBS and 10% Dimethyl Sulfoxide (DMSO) in aliquots of >5*10
5
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cells per millilitre prior to shipping. Cells were cultured onto tissue culture grade plastic-
ware containing high glucose DMEM supplemented with FBS (10%), Heparin (3 µg/ml), 
human recombinant basic fibroblast growth factor (bFGF) (3 ng/ml), penicillin (100 U/ml) 
and streptomycin (100 µg/ml). Cells were cultured onto T25 and T75 flasks for early 
passage/freeze-stock generation whilst 58 cm
2
 dishes were routinely used for experimental 
work alongside 6-well plates. For experimental purposes, cells were used between passages 
5-12. Cells were maintained in 5% CO2/95% humidity at 37
o
C. 
 
2.2.1.3 Trypsinisation of cells 
As both HBMvECs and BBMvECs are an adherent cell type, trypsinisation was required to 
perform sub-culture. Cells were typically passaged at approximately 70-90% confluency 
confirmed via light microscopy. In preparation, all solutions used for sub-culturing; Sterile 
Phosphate Buffered Saline (PBS), Growth Medium, Trypsin/EDTA and AF (HBMvEC’s 
only), were pre-warmed to 37
o
C in the water bath. In the laminar hood, culture medium was 
added to the prospective dishes and placed in an incubator to equilibrate the medium to 37
o
C 
with 5% CO2. In the case of HBMvEC’s the plastic-ware required a coating to facilitate 
attachment prior to the addition of the medium. Briefly, an appropriate amount of attachment 
factor relative to the surface area onto which the cells were to be seeded was added (~20-70 
µl). A sterile cell spreader was then used to coat the well with any residual AF removed 
using a sterile aspirator before growth medium was added. 
For trypsinisation, first the growth medium was removed using a sterile aspirator. Following 
this the culture dish was washed briefly 2-3 times using sterile PBS to ensure the removal of 
any residual α1-antitrypsin (Trypsin inhibitor found in serum). An appropriate volume of 
Trypsin-EDTA, enough to cover the cell population, was then added to the dishes and then 
the dishes were placed into the incubator for 5-10 minutes. Cells were routinely observed 
over this time course until they had displayed a rounded morphology but had not yet fully 
detached. Following a gentle tap to facilitate detachment, an equal volume of growth 
medium to Trypsin-EDTA was added to the dish and the cell suspension then pooled into a 
15 ml tube. Following centrifugation at 700 rpm for 5 minutes, the Trypsin-EDTA/growth 
medium was aspirated and the resulting cell pellet was gently resuspended via pipetting in 1 
ml of fresh growth medium. This cell suspension was then counted and either seeded to an 
appropriate density for experimental purposes or split 3,000 cells/cm
2
 of a cell dish for sub-
culturing.  
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2.2.1.4 Cell Counting 
In order to ensure accurate reproducibility of experiments and assess cell densities and 
viability for experiments, sub-culturing and cryopreservation, cell counts were routinely 
performed via two platforms; a Neubauer haemocytometer and the Advanced Measurement 
and Accurate Detection (ADAM™) Counter.  
2.2.1.4.1 Haemocytometer 
In order to perform a cell count, a square glass coverslip was mounted onto the centre 
chamber of the haemocytometer (Figure 2.1) and adjusted until Newton rings were visible. 
To assess cell viability, 100 µl of cell suspension was mixed with 20 µl of trypan blue and 
the mixture was set aside for 2 minutes. 10 µl of the mixture was then added to the 
haemocytometer chamber via capillary action and the cells were visualised under a 4x 
magnification via phase-contrast microscopy. Typically each corner square of the grid had 
their contents counted, noting the numbers of viable vs. non-viable cells (dead cells take up 
the trypan dye due to their compromised membrane and appear blue, whilst live cells with 
an intact membrane exclude it). Viable cells which fell on the top and/or within the left hand 
margin of the grids were included in the counts whilst those that fell on the bottom and right 
hand side of the grid were excluded. The total number of cells in each of the four corner 
quadrants were added then divided by four to obtain an average count per 1 mm
2
. The 
number of viable cells was calculated utilizing the following equation: 
                                                                                  
In order to assess cell viability, the total average cell count (live cells PLUS dead cells) was 
substituted into the above equation and using the two values, cell viability could be 
expressed as a percentage of the total population.    
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Figure 2.1: The Haemocytometer. 
 
2.2.1.4.2 ADAM™ Counter 
The ADAM™ counter is based on the concept of using fluorescent microscopy to detect and 
count cells. Combining sensitive fluorescence dye staining, LED optics and CCD detection 
technologies, the ADAM™ counter eliminates often encountered problems associated with 
using a haemocytometer; false positives, limitation of the human eye, limited sample volume 
and cell aggregation. To count, 2x 15 µl aliquots of cell suspension were put aside in sterile 
micro tubes. One micro tube had 15 µl of N Accustain Solution added to it whilst the other 
micro tube had 15 µl of T Accustain Solution added. Both were mixed gently before 20 µl of 
each micro tube was added to the respective channel on a fresh ADAM Accuchip. The 
ADAM™ Accuchip is then processed by the counter and 40-60 images are taken of preset 
coordinates along the Accuchip channels. Any fluorescent signal detected is recorded via a 
sensitive CCD array and the average cell number and viability are computed by integrated 
image analysis software.  
Solution N contains Propidium Iodide (PI), a stain which has the ability to intercalate with 
DNA and stains cell nuclei a distinctive red colour. When in contact with a cell suspension, 
only the cells with ruptured membranes will allow the dye to permeate giving all ‘injured’ or 
non-viable cells a distinct fluorescent tag with which the ADAM counter can detect. 
Solution T on the other hand contains both PI and a detergent, the detergent acting to destroy 
every cell in the suspension and the PI acting as earlier described allowing the ADAM 
counter to assess a total cell count. As both suspensions are from the same source, an 
accurate and fast total viable cell count can be obtained (Figure 2.2). 
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Figure 2.2: The principle of the ADAM
TM
 Counter, (http://www.nanoentek.com/). 
 
2.2.1.5 Cryogenic preservation and recovery of cells 
For long term storage, HBMvEC’s and BBMvEC’s were preserved in a liquid nitrogen cryo-
freezer unit. Following trypsinisation, cells were centrifuged at 700 rpm for 5 minutes and 
the supernatant removed. The resulting pellet as resuspended in the appropriate freeze-down 
medium; for HBMvEC’s PromoCell Cell Freezing Medium was used, for BBMvEC’s; high 
glucose DMEM supplemented with 20% v/v FBS, DMSO (20% v/v), Heparin (3 ug/ml), 
bFGF (3 ng/ml), Penicillin (3 U/ml), Streptomycin (100 µg/ml). Cell suspensions were 
typically in the range of 0.5-1.0*10
6
 cells/ml. 1 ml aliquots were placed in sterile CryoPure 
cryovials and stored in a Mr. Freeze® cryo-freezing container before being placed in a -80
o
C 
freezer. The Mr. Freeze® ensured the cryovials were cooled at a rate of -1
o
C/min. Following 
this, the cryovials were transferred to a liquid nitrogen cryo-freezing container until further 
required. 
For the recovery of cells, cryovials were heated rapidly to 37
o
C in a waterbath. Upon 
entering a full liquid phase the contents were quickly transferred to 58 cm
2
 dishes containing 
pre-warmed growth medium and AF if necessary (HBMvECs). After 24 hours the plates 
were inspected via phase-contrast microscopy to inspect the adherence and morphology of 
the cells before all growth medium was aspirated and the dishes washed with sterile PBS to 
remove any residual DMSO. This was replaced by fresh pre-warmed growth medium. 
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2.2.2 Cell Treatments    
2.2.2.1 Cytokine Injury 
For cytokine injury studies, cells were seeded onto 58 cm
2
 dishes, 6-well dishes or 96-well 
dishes. The cell number seeded depended entirely on the experiment setup though the aim 
was typically to have a confluent monolayer to achieve a more physiologically relevant 
model (for proliferation assays, cells were seeded to sub-confluent levels to monitor the rate 
of proliferation over a time course, Section 2.2.8.2 and 2.2.8.3).  
Cytokines used in the early investigation of the induction of endothelial injury included 
Tumour Necrosis Factor-Alpha (TNF-α), Interleukin-6 (IL-6), Monocyte Chemotactic 
Protein-1 (MCP-1) and Interleukin-1 Beta (IL-1β) with a subsequent shift in focus onto the 
effects of TNF-α and IL-6 for the majority of the thesis. For all experiments involving 
cytokine injury, four concentrations were employed; 0, 1, 10 and 100 ng/ml and two 
incubation times; 6 and 18 hours. Following cytokine stimulation, the cells were either: (i) 
harvested for mRNA to conduct Real-Time PCR measurement of particular gene expression 
levels; (ii) harvested for protein to examine protein expression levels via Western Blotting; 
(iii) fixed in situ for immunocytochemical staining; or (iv) transplanted into Millicell 
hanging cell culture inserts for transendothelial permeability assays. 
2.2.2.2 Shear Stress Experiments 
2.2.2.2.1 Orbital Shear 
For laminar shear stress studies, orbital rotation was applied as in previous publications 
(Fitzpatrick, Guinan et al. 2009, Walsh, Murphy et al. 2011). HBMvEC’s and BBMvEC’s 
were seeded at 0.5-1.0*10
5
 cells/well of a sterile, cell culture grade 6-well plate and allowed 
to adhere for 24 hrs. Fresh growth medium was added the following day and the cells were 
cultured to >90% confluency (typically 4-7 days). Culture medium was then removed and 
replaced with 4 ml of fresh pre-warmed culture medium. Cells were then exposed to laminar 
shear stress (0-10 dynes/cm
2
, 0-48 hrs) using an orbital rotator (Stuart Scientific Mini Orbital 
Rotator) set to 0-230 rpm depending on the required shear level (Figure 2.3). The calibration 
of the rotator was determined by the following equation (Hendrickson et al., 1999). 
                        
Where:  α = radius of orbital rotator circumrotation (cm) 
  ρ = density of liquid (g/L) 
  n = 7.5 * 10
-3
 (dynes/cm
2
 at 37
o
C) 
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  f = rotation per second 
The ‘dyne’ or ‘dyne/cm2’ us one of the smallest units of pressure for measuring force and is 
defined as ‘the force required to accelerate a mass of one gram at a rate of one centimetre per 
second squared’. It is one of the most commonly used units in fluid mechanics and is often 
associated with surface tension (dyne/cm) and thus shear stress (dynes/cm
2
).  
Control plates containing un-sheared ‘static’ cells were also routinely cultured in the same 
incubator but on a different shelf to avoid any vibrations that may be caused by the presence 
of the orbital rotator. Studies were carried out over different periods of time (0-48 hrs) and 
shear rates (0-10 dynes/cm
2
) in the absence and presence of inflammatory cytokines (TNF-α 
or IL-6) at varying concentrations (0, 1, 10 and 100 ng/ml) and exposure times (6 and 18 
hrs). Following shearing experiments, the cells were harvested for analysis as described in 
Section 2.2.2.1. 
 
Figure 2.3: Orbital rotation model used in laminar shear stress studies. 
 
2.2.2.2.2 ibidi® Flow System 
The ibidi® pump system is a novel perfused flow system. It is a refined means of replicating 
vascular shear profiles in that it: (i) allows for the culture, simultaneous perfusion and 
observation to occur on the same platform; (ii) delivers a range of uni-directional shear 
stress profiles (oscillatory and laminar) and µ-slides dimensions that simulate the 
physiological spectrum of veins and arteries; (iii) allows for long term studies with its cost-
effective requirement of cell culture reagents, the modest volumes required also allowing for 
the effective examination of secreted soluble factors by cells (Figure 2.4).  
This method was applied as in previous publications (Kowalsky, Byfield et al. 2008, Walsh, 
Murphy et al. 2011). Prior to cell seeding, all removable tubing and medium reservoirs were 
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autoclaved and kept in a sterile environment until required. The slides, tubing and cell 
culture medium were then equilibrated overnight at 37
o
C in a tissue culture incubator. The 
following day, BBMvEC’s or HBMvEC’s were trypsinised and counted as previously 
described. The cells were then seeded onto µ-slides (HBMvEC slides were AF pre-treated) 
200 µl at a time at a density of 1*10
6
 cells/ml taking care not to introduce any air bubbles. 
The µ-slides were filled until the reservoirs on each end of the slide were full before being 
covered with the provided reservoir caps. The µ-slides were incubated within the confines of 
a humidity chamber at 37
o
C and observed over the next 24-48 hrs, with the medium changed 
at least twice a day until a confluent and healthy morphology was observed. The µ-slides 
were then connected to the pump system via the luer connectors in accordance with the 
manufacturer’s instructions and previous publications (Walsh, Murphy et al. 2011), taking 
the utmost care not to introduce air bubbles. The cells were then exposed to laminar shear 
stress for the required time before the immunocytochemistry protocol was carried out as 
described in Section 2.2.10.  
 
Figure 2.4: The ibidi® flow system. (A) The principle of the ibidi® system which allows 
for a continuous unidirectional shear to be applied to the cultured cells in the µ-slide. (B) 
The ibidi® setup. (C) A close-up of a µ-slide. 
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2.2.2.3 Treatment with Pharmacological Inhibitors 
Prior to treatment with anti-oxidants or pharmacological inhibitors, HBMvECs or 
BBMvECs were grown to their experimentally required degree of confluency before having 
their growth medium removed and the cells washed twice using PBS. Inhibitors and anti-
oxidants were reconstituted in a suitable solvent. Working concentrations were then made up 
in EndoGRO-MV Growth Medium or DMEM containing antibiotics. For DMSO-soluble 
compounds, a suitable stock concentration was prepared so that the final concentration of 
DMSO in the working solutions was less than 0.5%.  
Inhibitor concentrations used in experiments were taken from current literature (Sweeney, 
Morrow et al. 2004, Du, Khuri et al. 2008, Fitzpatrick, Guinan et al. 2009, Walsh, Murphy et 
al. 2011, Guinan, Rochfort et al. 2013) and based on manufacturers recommendations in 
tandem with an inhibitor concentration gradient. 
Inhibitor Effective Dosage 
Apocynin 10 mM 
Catalase 250 U 
Dephostatin 20 µM 
Genistein 50 µM 
N-Acetyl-L-Cysteine 5 mM 
R18 100-1000 nM 
Superoxide Dismutase 100 U 
Table 2.1: The effective doses of inhibitors used. 
2.2.2.4 Treatment with Pre-Conditioned Medium 
Prior to treatment with pre-conditioned medium, HBMvECs or BBMvECs were grown to 
their experimentally required degree of confluency before having their growth medium 
removed and the cells washed twice using PBS. For conditioned medium experiments, 
serum-free medium was employed. Conditioned medium from stimulated cultures were 
harvested and 2 ml volumes were aliquoted into Amicon Ultra-2 centrifugal filter devices. 
The filters were spun at 4,000 g for 15 mins before device was reassembled as per the 
manufacturer’s instructions and centrifuged once more at 1000 g for 2 mins. The collected 
concentrate was then used immediately or stored at -80
o
C for further use. 
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2.2.3 Molecular Biology  
2.2.3.1 Reconstituting Plasmid cDNA 
Plasmid deoxyribonucleic acid (DNA) constructs were received as small amounts of DNA 
air-dried onto filter paper, which were stored at 4
o
C until required. To reconstitute the DNA, 
a region of the filter paper containing the air-dried plasmid (~1 cm
2
) was sectioned from the 
filter paper and handled using a flame sterilised set of scissors and forceps. The section was 
added to a 1.5 ml micro-centrifuge tube before 100 μl of sterile, endotoxin-free, TE buffer 
was added also. The tubes contents were then vortexed gently for 5-10 seconds, incubated at 
room temperature for 5 mins and subsequently vortexed again. The tube was then 
centrifuged for 15 sec at 1000 rpm. Approximately 1-10 μl of the supernatant was used for 
subsequent bacterial transformations.  
 
2.2.3.2 Transformation of competent cells 
Approximately 1-10 μl of reconstituted plasmid DNA (10-50 ng) or 10 μg of purified DNA 
construct was gently added to 25-50 μl of competent DH5α Escherichia. Coli bacterial cells. 
The DNA-bacterial mixture was then incubated on ice for 30 min. The tube was ‘heat-
shocked’ at 42oC for 30 sec before a further incubation on ice was carried out for 2 min. 
Following this step, 500 µl of room temperature SOC medium was added to the tube and the 
mixture was incubated for a further 30 min at 37
o
C on a bacterial culture shaker at 150 rpm. 
The resulting transformed cells were spread on two LB agar plates containing the 
appropriate selective antibiotics (Table 2.2) in volumes of 50 μl and 500 μl. Approximately 
5 μl of competent cells (without plasmid DNA) were spread on selective agar plates to serve 
as negative controls for bacterial growth. The spread plates were inverted and incubated at 
37
o
C overnight to facilitate optimal bacterial growth. Transformed colonies were isolated the 
following day for broth cultures and subsequent DNA midi-preparations. 
Antibiotic Solvent Final Concentration (μg/ml) 
Ampicillin dH2O 50 μg/ml 
Kanamycin dH2O 50 μg/ml 
Table 2.2: Antibiotic Concentrations.  
2.2.3.3 Purification of plasmid DNA       
Following bacterial transformation, successfully transformed colonies were isolated from the 
selective agar plates using a flame-sterilized inoculating loop. The transformed colony was 
used to inoculate 150 ml of LB broth supplemented with the appropriate antibiotics in 
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sterilised baffled flasks. The flasks were incubated overnight at 37
o
C on a bacterial shaker at 
150 rpm.  
The next day the plasmid DNA was purified from the culture using a Qiagen plasmid midi-
prep kit as per the manufacturer’s instructions. Briefly, the cultured bacteria were 
centrifuged at 4000 rpm for 15 min at 4
o
C. The supernatant was carefully decanted by tube 
inversion and the resultant pellet was dissolved via the addition of 6 ml of chilled P1 buffer 
and subsequent vortexing. 6 ml of P2 lysing buffer was then added to the tube and the 
mixture was vortexed vigorously for 30 sec before being left to rest at room temperature for 
a further 5 mins. The P2 lysing buffer was then neutralised by the addition of 6 ml of chilled 
P3 buffer and a thorough vortexing for 30 sec. The resulting cell lysate mixture was 
transferred into the barrel of a Qia Midi-cartridge and incubated at room temperature for 10 
minutes to settle any debris. Following this, a Qia Midi-filter was attached to the Midi-
cartridge and the cell lysate was filtered into a previously equilibrated Hi-speed Midi-prep 
tip containing a resin column to which DNA binds. The column was then washed with 20 ml 
of QC buffer to eliminate any bacterial cell proteins which might be present. The DNA was 
then eluted from the column with the addition of 5 mls of QF buffer into a sterile 15 ml tube. 
3.5 mls of isopropanol was then added to the tube and the contents were mixed via gentle 
inversion before being left to incubate for 5 mins at room temperature. This was to 
precipitate the DNA before the mixture was filtered through a Qia-precipitator. The bound 
plasmid DNA was then washed with 2 ml of 70% v/v ethanol before air was flushed through 
the filter to air dry the contents. 700 μl of TE buffer was then added to the Qia-precipitator 
and the contents were eluted into a sterile 1.5 ml centrifuge tube. Finally the eluate was then 
passed through the Qia-precipitator once more to remove any unbound DNA. The purified 
plasmid was ready for quantification via spectrophotometric analysis (Section x).    
 
2.2.3.4 Preparation of glycerol stocks 
Glycerol enables the long term storage of bacteria by the prevention of water in the bacterial 
culture producing ice crystals which can subsequently damage the frozen samples. Glycerol 
stocks were prepared by mixing 0.5 ml of a 50% (v/v) glycerol solution with 0.5 ml of the 
bacterial culture of interest and storing at -80
o
C for future use.     
 
2.2.3.5 Microporation 
Microporation is a unique transfection technique that utilises a gold-plated pipette tip as an 
electroporation device (Kim, Cho et al. 2008) (Figure 2.5). This allows for a more uniform 
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electric field to be generated with minimal heat generation, metal ion dissolution, pH 
variation and oxide formation- consistent difficulties in conventional electroporation 
protocols. Microporation was carried out using a microporation solution kit in accordance 
with the manufacturer’s instructions.  
This method was applied as in previous publications (Walsh, Murphy et al. 2011, Guinan, 
Rochfort et al. 2013). Cells were trypsinised and centrifuged at 700 rpm for 5 minutes at 
room temperature as outlined in Section 2.2.1.2. The growth medium was aspirated off so 
that 1 ml remained and a cell count was performed. Once the cells were counted the required 
number of cells to carry out each transfection study aliquoted into individual tubes, 
centrifuged at 700 rpm for 5 minutes and washed gently in sterile PBS before being pelleted 
again at the same conditions. The PBS was carefully aspirated off and the cell pellet was 
resuspended in R Buffer at a typical concentration of 5*10
5
 cells/100 µl. 120 µl of the cell 
suspension was then aliquoted into sterile 1.5 ml micro tubes and 1-100 nM siRNA/5*10
5
 
cells was added. Upon addition of 3 ml of Buffer E, a microporation tube was inserted into 
the Microporation Pipette Dock. The microporation pipette was then fitted with a 100 µl 
gold-tip and the cell/siRNA suspensions were reverse pipetted taking extra care to avoid 
introducing air bubbles into the tip. After insertion of the pipette/gold-tip into the docking 
station, the cells were subjected to the programmed transfection procedure (for HBMvEC’s 
and BBMvEC’s the Microporator’s optimal settings were determined to be 1000 V, a pulse 
width of 30 ms, and pulse number of 3) and the cells were quickly ejected from the tip into a 
pre-equilibrated 6-well dish; in parallel with the transfection protocol, for every transfection 
to be conducted, one well of a 6-well dish was prepared by coating with AF (for HBMvEC’s 
only) and adding 2 ml of pre-warmed culture medium containing serum and supplements but 
omitting antibiotics. The plate was left to equilibrate at 37
o
C/5% CO2 in a tissue culture 
incubator until further required. Cells were allowed to adhere overnight and the culture 
medium was changed the next day.    
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Figure 2.5: The Microporation System. (A) The Microporation unit that generates the 
electrical parameters necessary for electroporation which is transmitted to (B) the 
Microporation pipette dock consisting of a microporation tube containing electroporation 
buffer and the microporation pipette used to deliver electroporation to the cells through a 
gold plated pipette tip. (C) Microporation kit with all the necessary solutions, 
(http://www.invitrogen.com/). 
For the optimisation of transfection, GFP protein was routinely used as means of 
determining transfection efficiency. GFP can be detected using a FITC laser and thus can be 
detected via microscopy and flow cytometry (Section 2.2.9.2). 
 
2.2.4 Quantitative Polymerase Chain Reaction (qPCR) 
2.2.4.1 RNase-free Environment 
As RNA is easily degraded by ubiquitous RNases, standard procedures were employed in an 
effort to avoid this potential hazard. Prior to any RNA work, any surface, instrument or 
apparatus which was to be used was treated with RNaseAWAY™ Spray and/or wiped down 
with RNase wipes to remove any potential residing RNases. Latex gloves were worn 
throughout the procedures. 
 
2.2.4.2 RNA Isolation 
TRIzol® Reagent is a ready-to-use reagent for the isolation of high-quality total ribonucleic 
acid (RNA), (or the simultaneous isolation of RNA, DNA, and protein) from a wide range of 
biological samples and sources. An improvement on the method developed by Chomcynski 
and Sacchi (Chomczynski, Sacchi 1987, Chomczynski, Sacchi 2006), this monophasic 
solution of phenol and guanidine isothiocyanate, as well as other proprietary components, 
facilitates the disruption and digestion of cells and their contents, as well as effective 
inhibition of all present RNAses whilst maintaining the integrity of all present RNA.  
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Following experimental procedures, cells were lysed in situ with typically 1 ml of TRIzol® 
per sample. Cells were then scraped with a sterile cell scraper to assist in the lysing process, 
and then incubated for 5 minutes at room temperature to allow the complete dissociation of 
nucleoprotein complexes. The solution was then transferred to an RNAse-free micro tube 
and 0.2 ml of chloroform was added per ml of TRIzol®. The contents of the micro tube were 
then shaken vigorously for 15 seconds and then left at room temperature for 10 minutes. The 
micro tubes were then centrifuged at 13,000 rpm for 20 minutes on a balanced, refrigerated 
centrifuge (preset to 4
o
C). The resulting mixture consisted of three distinct phases: the lower 
red phenol-chloroform phase (~45-50% of total volume), a white viscous layer (>5% of total 
volume), and a clear upper aqueous phase (45-50% of total volume) (Figure 2.6).  As RNA 
is retained in the aqueous phase, this was carefully removed and placed into another RNAse-
free micro tube taking extra precaution not to introduce any of the other layers with the 
extraction. Next, the RNA was precipitated following the addition of 0.5 ml of 100% 
Propan-2-ol to each tube containing the extracted aqueous phase.  Samples were inverted 5-8 
times before being stored at -20
o
C overnight. 
 
Figure 2.6: The three distinct phases of TRIzol extractions. 
The following day, samples were removed from the freezer and left to reach ambient room 
temperature for 10-15 minutes. Samples were then transferred to a balanced, refrigerated 
centrifuge (4
o
C) and spun at 13,000 rpm for 15 minutes. Following centrifugation, careful 
examination yielded a gel-like pellet on the wall of the micro tube; this is the pelleted RNA.  
The supernatant was carefully removed and the gel-like pellet was gently washed off the 
wall of the tube using 1 ml of 75% ethanol, taking care not to resuspend it. The micro tubes 
were once again centrifuged at 13,000 rpm for 10 minutes at 4
o
C before the supernatant was 
once again removed and the resultant pellets left to air dry in the fume hood for ~ 5 – 10 
min. The pellet was then resuspended in 50 µl of RNAse-free water and then heated to 60
o
C 
in a water bath for 10 min to homogenise the sample prior to quantification. The 
concentration of total RNA was determined by means of a Nanodrop, outlined in Section 
2.2.4.3. The samples were stored at -80
o
C until further required.  
103 
 
2.2.4.3 Nanodrop® 
In the analysis of nucleic acid samples, the Nanodrop® (Figure 2.7) examines the sample at 
absorbances at 230 nm, 260 nm and at 280 nm with the ratios (ABS260/ABS280 and 
ABS260/ABS230) acting as means of assessing the purity of the nucleic acids present. Pure 
DNA which is free of protein impurities has a ratio of 1.8 whereas pure RNA has a ratio of 
2.0 (due to the spectophotometric reading of uracil compared to thymidine). Lower ratios 
indicate the presence of proteins and carbohydrates or organic solvents such as phenol, 
guanidine or any other organic solvent commonly used in nucleic acid extraction. Further 
purification of RNA samples was achieved by means of a DNAse 1 treatment kit (Section 
2.2.4.5). 
 
Figure 2.7: The Nanodrop® System. (A) The Nanodrop®. (B) The principle of 
spectrophotometrically reading biological samples. (C) A sample’s typical data readout, 
(http://www.nanodrop.com/). 
 
2.2.4.4 RNA Integrity Gel 
RNA samples were routinely run on agarose gels to assess their quality and check for 
genomic DNA contamination. RNA samples were diluted using RNA Sample Loading 
Buffer in a ratio of 3:1, ensuring at least 1 µg of RNA was being loaded (Section 2.2.4.3). 
Prior to loading, the samples were heated at 65
o
C for 10 minutes using a heating block and 
then chilled on ice. The samples were then loaded onto an agarose gel (as described in 
Section 2.2.4.11) and run at 100 V for 60-120 minutes or until sufficiently resolved.  RNA 
was then visualised using a G-BOX fluorescence gel documentation and analysis system and 
the images saved for densitometric analysis (Figure 2.8). 
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Figure 2.8: Assessing RNA integrity. Intact RNA displays two distinct bands at 4.5 kb 
(28S) and 1.9 kb (18S) in a ratio of 2:1 respectively. Partially degraded RNA will lack the 
sharp band definition and have a smeared appearance, whilst completely degraded RNA will 
appear as a very low molecular weight smear 
 
2.2.4.5 DNase 1 Treatment 
Deoxyribonuclease 1 (DNase 1) is an endonuclease isolated from bovine pancrease. It has 
the ability to digest any present double- and single-stranded DNA it comes in contact with 
into oligo- and mono-nucleotides. 1000 ng of RNA sample was diluted down to a final 
volume of 8 µl in RNase-free water. 1 µl of 10 x DNase Buffer and 1 µl of RNase-free 
DNase 1 was added to each prospective tube and left for 15 minutes at room temperature. 1 
µl of DNase Stop Solution was added then to each tube and the tubes were further incubated 
for 10 minutes in a water bath at 70
o
C to denature the DNase enzyme. The samples were 
then chilled on ice and typically processed immediately into cDNA.  
 
2.2.4.6 cDNA Synthesis 
In this process, genomic DNA-free mRNA was transcribed into cDNA by the enzyme 
Reverse Transcriptase (RT). A High Capacity cDNA Reverse Transcription Kit was used 
according to the manufacturer’s specifications.  
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10x RT Buffer 2 µl 
10x Random Primers 2 µl 
Multiscribe Reverse Transcriptase, 50 U/µl 1 µl 
25x dNTP Mix, 100mM 0.8 µl 
Nuclease-free Water 3.2 µl 
Total volume 9 µl 
Table 2.3: cDNA Transcription Mixture. 
This was added to a 0.2 ml Rnase-free polymerase chain reaction (PCR) tube containing 
1000 ng of genomic DNA-free RNA diluted in nuclease-free water to 11 µl. Samples were 
mixed gently before being centrifuged briefly to ensure complete mixing. All tubes were 
then placed into a MJ Mini Thermal Cycler and run at 25
o
C for 10 minutes, 37
o
C for 120 
minutes and finally 85
o
C for 5 minutes, before being held at 4
o
C until retrieved. cDNA 
products were then quantified on the Nanodrop® (Section 2.2.4.3) to assess final working 
concentrations and purities of the samples.  
 
2.2.4.7 Primer Design 
For PCR, DNA primers were designed using the online website http://frodo.wi.mit.edu/ with 
the parameters changed to fall into accordance with standard rules of primer design in 
addition to some additional parameters implemented in our lab. Using the website 
http://www.basic.northwestern.edu/biotools/OligoCalc.html, the potential primer candidates 
were then verified by BLAST (to check their sequence homology and specificity) and mFold 
(to check for any hairpin formations).  
 
2.2.4.8 Benchtop PCR 
Benchtop PCR was routinely undertaken to optimise primer amplification conditions and 
ensure a single product at the pre-determined location, as well as the absence of secondary 
products and primer dimers. A number of parameters such as primer concentration and 
annealing temperatures could be optimised here before Quantitative Real Time PCR was 
conducted.  
Before starting, cDNA samples were analysed by means of the Nanodrop® and 
appropriately diluted using RNase-free water to a final concentration of 500 ng/µl. Each 
reaction mixture was made up in a 0.2 ml RNase-free PCR tube and was comprised of the 
following: 
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Forward Primer (10 µM) 1 µl 
Reverse Primer (10 µM) 1 µl 
cDNA Sample (500 ng/µl) 2 µl 
10x Reaction Buffer 2.5 µl 
dNTP (10 mM) 2 µl 
MgCl2 (25mM) 1.5 µl 
DreamTaq Polymerase (5 U/µl) 0.2 µl 
Rnase Free Water 14.8 µl 
Total Volume 25 µl 
Table 2.4: Standard PCR Reaction Mixture. 
Each tube was then placed into an MJ Mini Thermal Cycler and samples were subjected to 
the following reaction cycle: 
Denature  95
o
C 5 minutes 
 Denature 95
o
C 15 seconds 
Cycling Annealing 55-63
o
C 30 seconds 
 Extension 72
o
C 15 seconds 
Extension  72
o
C 5 minutes 
Hold  4
o
C Forever 
Table 2.5: Standard PCR Method. 
Annealing temperatures varied depending on the primer in question:  
Target Sequence Product 
Size 
Annealing Temp. 
o
C 
Human GAPDH F 5’ gag tca acg gat ttg gtc gt 3’ 238 bp 59.97
 o
C 
Human GAPDH R 5’ ttg att ttg gag gga tct cg 3’  60.01
 o
C 
Human Occludin F 5’ cct tca ccc cca tct gac ta 3’ 224 bp 59.92
 o
C 
Human Occludin R 5’ gca ggt gct ctt ttt gaa gg 3’  59.99
 o
C 
Human Claudin 5 F 5’ gag gcg tgc tct acc tgt tt 3’ 240 bp 59.50
 o
C 
Human Claudin 5 R 5’ agt act tca cgg gga agc tg 3’  59.35
 o
C 
Human VE-Cad F 5’ cag ccc aaa gtg tgt gag aa 3’ 185 bp 59.87 
o
C 
Human VE-Cad R 5’ cgg tca aac tgc cca 106act t 3’  59.99 
o
C 
Human ZO-1 F 5’ gaa cga ggc atc atc cct aa 3’ 218 bp 60.04
 o
C 
Human ZO-1 R 5’ cca gct tct cga aga acc ac 3’  59.99 
o
C 
Human vWF F 5’ cca gat ttg cca ctg tga tg 3’ 232 bp 60.11
 o
C 
 
40 
cycles 
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Human vWF R 5’ aaa ggc ctt cag cac ttc aa 3’  59.99
 o
C 
Human TNF-α F 5’ ccc acg gct cca ccc tct ctc 3’ 220 bp 60.11 
o
C 
Human TNF-α R 5’ ttc cct ctg ggg gcc gat ca 3’  60.02 
o
C 
Human IL-6 F 5’ aaa gag gca ctg gca gaa aa 3’ 183 bp 59.99
 o
C 
Human IL-6 R 5’ agc tct ggc ttg ttc ctc ac 3’  59.60 
o
C 
Human TNFR1 F 5’ gtg cct acc cca gat tga ga 3’ 175 bp 60.07 
o
C 
Human TNFR1 R 5’ tgt cga ttt ccc aca aac aa 3’  59.94 
o
C 
Human TNFR2 F 5’ gga aac tca agc ctg cac tc 3’ 224 bp 60.00 
o
C 
Human TNFR2 R 5’ tgc aaa tat ccg tgg atg aa 3’  59.89 
o
C 
Human GP130 F 5’ tca act tgg agc cag att cc 3’ 159 bp 60.20 
o
C 
Human GP130 R 5’ ccc act tgc ttc ttc act cc 3’  59.84 
o
C 
Human sIL-6R F 5’ tgc cag tat tcc cag gag tc 3’ 227 bp 60.07 
o
C 
Human sIL-6R R 5’ tct tgc cag gtg aca ctg ag 3’  60.02 
o
C 
Human 14-3-3β F 5’ acc caa ttc gtc ttg gtc tg 3’ 249 bp 59.99 oC 
Human 14-3-3β R 5’ tcc gat gtc cac aga gtg ag 3’  60.01 oC 
Human 14-3-3γ F 5’ ctg aat gag cca ctg tcg aa 3’ 155 bp 59.98 oC 
Human 14-3-3γ R 5’ gca cgg acc atc tca atc tt 3’  60.08 oC 
Human 14-3-3ζ F 5’ ttc ttg atc ccc aat gct tc 3’ 211 bp 60.01 oC 
Human 14-3-3ζ R 5’ agt taa ggg cca gac cca gt 3’  59.99 oC 
Human 14-3-3θ F 5’ gag cag aag acc gac acc tc 3’ 206 bp 59.99 oC 
Human 14-3-3θ R 5’ cac gca act tca gca agg ta 3’  60.05 oC 
Human 14-3-3ε F 5’ aat ttg cca cag gaa acg ac 3’ 171 bp 59.98 oC 
Human 14-3-3ε R 5’ cac ggt cag ggg aat taa ga 3’  59.93 oC 
Bovine GAPDH F 5’ agg tca tcc atg acc act tt 3’ 337 bp 59.97 
o
C 
Bovine GAPDH R 5’ ttg aag tcg cag gag aca a 3’  59.98 
o
C 
Bovine Occludin F 5’ tgg aac ctt aat ggg agc tg 3’ 186 bp 60.07
 o
C 
Bovine Occludin R 5’ atc acc aat gca gca atg aa 3’  60.08
 o
C 
Bovine Claudin 5 F 5’ aga ttc tcg gct tgg tgc t 3’ 167 bp 59.97
o
C 
Bovine Claudin 5 R 5’ cat gtg ccc tgt gct ctg 3’  59.97
 o
C 
Bovine VE-Cad F 5’ gac atc cgt ggt tct gga ct 3’ 172 bp 59.97 
o
C 
Bovine VE-Cad R 5’ aga tgg gga agt tgt cgt tg 3’  59.97 
o
C 
Bovine ZO-1 F 5’ gaa cga ggc atc atc cct aa 3’ 218 bp 60.04
 o
C 
Bovine ZO-1 R 5’ cca gct tct cga aga acc ac 3’  59.99 
o
C 
Table 2.6: Primer Information. The primers utilised over the course of this study, their 
sequences, their expected product size and their annealing temperatures. 
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2.2.4.9 Quantitative Real-Time PCR 
After the primers had been optimised the conditions yielded were then carried over for use in 
qPCR. qPCR allows for real time monitoring of gene amplification as it accumulates in the 
reaction well. This quantification is facilitated by means of SYBR Green, a nucleic acid 
stain which has the ability to bind to double-stranded DNA. Upon exposure to blue light 
(~497 nm), SYBR Green produces a detectable green signal (~520 nm), that is recorded at 
the end of each PCR cycle allowing the amount of amplified cDNA product to be quantified 
and graphed in real time (Figure 2.9). To normalise the SYBR Green signal, ROX, a passive 
dye, is incorporated into the SYBR mastermix. The signal generated by the reporter dye 
(SYBR Green) is measured against the signal generated by the passive reference dye (ROX) 
and the non-PCR-related fluorescence anomalies occurring based on well-to-well variation 
is removed via normalisation algorithms. The threshold cycle represents the refraction cycle 
number at which a positive amplification reaction was measured and was set at 10 times the 
standard deviation of the mean baseline emission calculated for PCR cycles 3 to 15. The 
results were then analysed according to the Comparative CT method (ΔΔCT) as described by 
(Livak and Schmittgen, 2001).    
 
Figure 2.9: The qPCR system. (A) The Applied Biosystems 7900HT Fast Real Time PCR 
system, (B) the principle of how SYBR Green quantifies gene amplification products and 
(C) Real Time PCR data readout, (http://www.lifetechnologies.com/). 
 
qPCR was carried out using an Applied Biosystems 7900HT Fast Real-Time PCR machine. 
This method was applied as in previous publications (Guinan, Rochfort et al. 2013). Each 
reaction was set up in triplicate as follows: 
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Forward Primer (10 µM) 3.2 µl 
Reverse Primer (10 µM) 3.2 µl 
cDNA (500 ng/µl) 6.5 µl 
SYBR Green 39.1 µl 
RNase Free Water 29.4 µl 
Total Volume 81.5 µl 
Table 2.7: qPCR Reaction Mixture. 
In addition, for every sample which was being analysed a ‘Non-RT Control’ was included. 
This is essentially a sample which had the Reverse Transcriptase omitted from the reaction 
mixture when cDNA was being generated (Section 2.2.4.6). If a product is seen in the Non-
RT Control wells contaminating genomic DNA can be said to be present.  
Samples were placed in 25 µl aliquots in 96-well Fast Optical PCR plates and sealed with an 
adhesive optical film. After a short centrifugation to pool the samples and remove bubbles, 
the plate was loaded onto the ABI 7900HT and subjected to the following procedure: 
Denature  95
o
C 10 minutes 
 Denature 95
o
C 15 seconds 
Cycling Annealing 58-60
o
C 60 seconds 
 Extension 72
o
C 15 seconds 
Extension  72
o
C 5 minutes 
Hold  4
o
C Forever 
Table 2.8: qPCR Method 
Quantification of cDNA targets was normalised for differences across experiments/samples 
using an endogenous control; GAPDH.  
Routinely, melt curve analysis was conducted to ensure single product formation and to rule 
out possible contamination by non-specific binding and primer dimerisation. Samples from 
both standard PCR and qPCR were then visualised on 1% agarose gels as described in 
Section 2.2.4.11. 
 
2.2.4.10 Primer Efficiency Curves 
Primer efficiencies for each primer pair were calculated by means of a standard curve 
analysis (Figure 2.10). To conduct primer efficiency curves the same reaction mixture used 
for qPCR is utilised with the exception that the template cDNA is omitted. Instead, a dilution 
 
50 
cycles 
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of a PCR product which had been run previously using the same primer set is substituted. 
Briefly, the PCR product was excised from the reaction plate and a 1/1000 dilution was 
made in RNase-free water. From here a 7-fold 1/10 serial dilution of this 1/1000 dilution 
was made with 6.5 µl of each dilution substituting for the raw cDNA in each reaction 
mixture. An additional reaction mixture was made substituting the PCR product for RNase-
free water. This acted as a non-template control. 
The temperature profile run for standard qPCR was utilised and the software was 
programmed to recognise the serial dilutions and plot their Threshold Cycle (CT Value) 
versus the immunofluorescent signal (number of copies of the target gene). To calculate 
primer efficiency: 
                            
The Minimum Information for publication of Quantitative real-time PCR Experiments 
(MIQE) guidelines has set a standard that all qPCR results considered for publication must 
fall under (Bustin, Benes et al. 2009). Ideally primer sets should have an efficiency of 
between 90 and 105%, (Section A.27).  
 
Figure 2.10: Principal of primer validation. (A) An amplification plot of a serial dilution 
of cDNA and (B) the interpreted standard curve, (http://www.sabiosciences.com/).    
 
2.2.4.11 Agarose Gel Analysis 
Agarose gel electrophoresis was often used as a quality control to visualise and assess PCR 
product sizes (standard and qPCR) as well as mRNA (Section 2.2.4.2), cDNA and 
oligonucleotide primer sets (quality and purity). A 1% agarose gel was typically used by 
adding 1 g of ultra-pure agarose to a conical flask and adding 100ml of 1 x Tris acetate-
EDTA (TAE) buffer (40 mM Tris-Acetate pH 8.2, 1 mM EDTA). The mixture was brought 
to a boil until the solution had turned clear and the agarose had fully dissolved. Once cooled 
(~50-60
o
C), 10 µl of (1 x) SYBR® Safe was added to the solution and swirled to ensure a 
thorough mixing. The mixture was then poured into a casting plate which had been pre-
sealed using masking tape. A gel comb was then inserted and the presence of any bubbles 
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was eliminated. The gel casket was then covered with tin foil to protect the light sensitive 
SYBR® Safe and left for ~20 minutes as the gel polymerised. The masking tape was then 
removed and the solid agarose gel was placed within a suitable gel rig and filled to the 
specified mark with 1 x TAE buffer ensuring the gel was completely submerged. For 
standard PCR product analysis, the reaction mixture already contains a dye for tracking the 
product as it migrates electrophoretically through the gel. This allows for direct loading into 
the wells. qPCR samples however require 4 x Loading Buffer (Section 2.1.3.4) to be added 
for tracking purposes before being loaded onto the gel (this also applied to any primer 
dilutions and primer stocks that were to be examined). After sample loading, approximately 
6 µl of GeneRuler™ 100 bp DNA Ladder Plus was added to the lanes flanking the samples 
loaded onto the gel for relative band size comparison. The gel was resolved for ~90 minutes 
at 100 V or until the tracking dye had been deemed to have resolved sufficiently. DNA was 
visualised using a G-BOX fluorescence gel documentation and analysis system and the 
images saved for densitometric analysis.        
 
2.2.5 Protein Isolation and Quantification 
2.2.5.1 Protein Extraction 
This method was applied as in previous publications (Harhaj, Felinski et al. 2006). For the 
purposes of Western Blotting and Immuno-precipitation pulldown assays, cells were 
harvested in the following manner. The culture dishes were placed on ice and had the growth 
medium removed. The dishes were washed three times with PBS before 
radioimmunoprecipitation assay (RIPA) Buffer (Section 2.1.3.1) was added (20 µl per well 
of a 6-well or 100 µl per 58cm
2
 dish). A sterile cell scraper was taken and the cells were 
harvested. The cell/RIPA Buffer suspension was relocated to sterile 1.5 ml micro tubes and 
the mixture was rotated at 4
o
C in a cold room for 1 hour. The micro tubes were subsequently 
centrifuged at 10,000 rpm for 20 minutes at 4
o
C to pellet any present triton-insoluble 
material. After the supernatant was removed into a fresh tube, the cell lysate samples were 
aliquoted and stored at -80
o
C until further required with one aliquot used to establish the 
concentration immediately by BCA Assay (Section 2.2.5.2).  
 
2.2.5.2 Bicinchoninic Acid (BCA) Assays 
This method was applied as in previous publications (Smith, Krohn et al. 1985). The BCA or 
Smith Assay is an accurate means of determining protein concentration in whole cell lysates 
and affinity-column fractions. The assay is based upon two key reactions, the first of which 
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is the ability of peptide bonds to reduce Cu
2+
 to Cu
1+
. The degree of reduction depends 
entirely on the amount of peptide bonds present i.e. a direct correlation to the amount of 
protein present. The second reaction is the ability of bicinchonic acid, (a green reactant), to 
bind to each Cu
1+
 ion forming a distinctive purple complex, which can strongly absorb light 
at 562 nm.  
To carry out the assay first a sterile 96-well plate was used to plate out 10 µl aliquots of 11 
BSA standards (concentration range of 0 – 2 mg/ml) in triplicate along with the RIPA lysis 
buffer used to extract the protein and all protein samples to be analysed. Next, the 
commercially available BCA kit provides two solutions; Reagent (A); an alkaline 
bicarbonate solution and Reagent (B); a copper sulphate solution. Reagents (A) and (B) were 
mixed in a ratio of 50:1 respectively so that 200 µl of reaction solution could be added to 
each test well. Once added, the plate was covered in tin foil and incubated at 37
o
C for 30 
minutes. The absorbance was then read at 562 nm on an ELx800 Microplate Reader and the 
unknown concentrations calculated using standard curve analysis.     
 
2.2.6 Immunoprecipitation and Mass Spectrometric Analysis 
2.2.6.1 Immunoprecipitation 
2.2.6.1.1 Column Preparation 
Immunoprecipitation to investigate the putative binding partners of occludin and other tight 
junctions under static and shear conditions was performed using a Pierce Co-
Immunoprecipitation Kit. All reagents were prepared and pre-equilibrated as per the 
manufacturer’s instructions beforehand. All centrifuge steps for this section were performed 
at 1000 g for 1 minute.  
50 µl of AminoLink Plus Coupling Resin was added to a Pierce Spin Column. The column 
was placed in a collection tube, centrifuged and the flow-through discarded. The resin was 
then washed twice with 200 µl aliquots of 1 x Coupling Buffer with the tube centrifuged and 
the flow-through discarded each time. The column was then dried for excess liquid before 10 
µg of capture antibody was diluted down to a final volume of 200 µl using 1 x Coupling 
Buffer. The mixture was then added to the column once a plug was added to the column to 
retain the liquid. 3 µl of Sodium Cyanoborohydride Solution was added to the column 
within the confines of a fume hood before the column was capped and the mixture turned 
over on a rotator for 120 minutes at room temperature.  
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Following incubation, the bottom plug was removed and the tube was placed in a fresh 
micro tube before being centrifuged. The flow-through was retained to later verify if the 
antibody coupling had been successful. 200 µl of 1 x Coupling Buffer was added to the 
column which was then centrifuged before the flow-through was discarded. This step was 
repeated once more before 200 µl of Quenching Buffer was added to the column, which was 
then centrifuged and the flow-through discarded.  The column was dried of any excess liquid 
before the bottom plug was inserted again and 200 µl of Quenching Buffer was added to the 
column. In a fume hood, 3 µl of Sodium Cyanoborohydride Solution was added and the 
column sealed before being incubated for 15 minutes with gentle rotation. The plug was 
removed and the column centrifuged in a fresh collection tube before being centrifuged and 
the flow-through discarded. The column was then washed twice with 200 µl of 1 x Coupling 
Buffer followed by centrifugation. The column was then washed six times with 150 µl of 
Wash Solution followed by centrifugation. The column was then either used immediately or 
stored by first washing the column twice with 200 µl of 1 x Coupling Buffer followed by 
centrifugation before inserting the bottom plug, adding a further 200 µl of 1 x Coupling 
Buffer supplemented with 0.02% (w/v) sodium azide and stored at 4
o
C. 
In order to carry out the co-immunoprecipitation experiments, a number of controls had to 
be implemented. In addition to the column containing the capture antibody, two additional 
control columns were made; one which replaces the AminoLink Plus Coupling Resin with a 
Control Resin composed of the same support material as the co-IP resin but is not activated, 
and another which replaces the capture antibody/1 x Coupling Buffer mixture with 200 µl of 
Quenching Buffer. 
 
2.2.6.1.2 Co-Immunoprecipitation 
All reagents were prepared and pre-equilibrated as per the manufacturer’s instructions 
beforehand. All centrifuge steps for this section were performed at 1000 g for 1 minute. 
Prior to preparing the columns, protein lysate from cells cultured under static and shear 
conditions (Section 2.2.2.2.1) were prepared and lysed as outlined in Section 2.2.5.1. The 
protein lysate was diluted down to a final volume of 300 µl using IP Lysis/Wash Buffer and 
placed on ice. Meanwhile, the column along with the additional two control columns were 
washed twice using 200 µl of IP Lysis/Wash Buffer followed by centrifugation and the flow-
through discarded. The column was dried of any excess liquid before the bottom plug was 
inserted. The protein lysate/IP Lysis/Wash Buffer mixture was added to the three columns 
and the columns sealed before being rotated for 4 hours at 4
o
C in a cold room.  
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Following incubation, the columns had the bottom plug removed and were placed in fresh 
collection tubes. The columns were then centrifuged and the flow-through stored for future 
analysis. The columns were placed into fresh collection tubes and then washed with 200 µl 
of IP Lysis/Wash Buffer before being centrifuged and the flow-through stored for future 
analysis. This was repeated twice more before the columns were transferred to fresh 
collection tubes and 10 µl of Elution Buffer added. The tubes were then centrifuged and an 
additional 50 µl of Elution Buffer added. The columns were incubated for five minutes at 
room temperature before being centrifuged once more and the flow-through stored for future 
analysis. This was repeated twice more with each elution stored for future analysis (Figure 
2.11). To preserve the columns, they were then washed with 100 µl of 1 x Coupling Buffer 
and centrifuged twice before being prepped for long term storage as described at the end of 
Section 2.2.6.1.1.         
 
Figure 2.11: An overview of the immunoprecipitation procedure 
 
2.2.6.1.3 Co-Immunoprecipitation Sample Analysis 
Samples which had been eluted from the columns were ready for analysis via Mass 
Spectrometry (Section 2.2.6.2.2). Occasionally samples had to undergo electrophoretic 
separation in order to confirm that occludin had been successfully immunoprecipitated. 
Samples which were run out on SDS-PAGE gels could be analysed for target verification 
and then directly digested for analysis as outlined in the following sections.   
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2.2.6.1.4 Coomassie Blue G-250 
Similar to the Coomassie Blue R-250 (Section 2.2.7.3) in principal, Coomassie Blue G-250 
is a colloidal suspension of coomassie suspended in a trichloroacetic acid solution 
eliminating the presence of methanol. The result is a stain which specifically visualises only 
the protein bands within the gel. This results in the elimination of non-specific background 
and the accompanying wash steps and it allows the samples to be analysed via Mass 
Spectrometry analysis.      
Briefly, the gel was washed with two lots of DI water. The gel was then fixed (Section 
2.1.3.2) for ~10 minutes. Next the gel was stained using the prepared colloidal coomassie 
solution (Section 2.1.3.2) for 90 minutes on a gentle setting with a 3D orbital rotator. The 
gel was briefly destained with colloidal coomassie destain (Section 2.1.3.2) for 1 minute and 
then a further rinse with 25% Methanol in DI Water. The gel was then imaged using a G-
BOX fluorescence gel documentation and analysis system and the images saved for 
densitometric analysis. For long term storage, the gel was kept hydrated in DI Water until all 
samples were procured for band excision and digestion.  
 
2.2.6.2 Mass Spectrometry 
2.2.6.2.1 Band Extraction and Digestion 
SDS-PAGE gel bands were excised from Coomassie Blue G-250 stained protein gels and 
placed in a 1.5 ml micro tube. The bands were then destained (Section 2.1.3.3) for 30 
minutes with occasional vortexing. Samples were then dehydrated with the addition of neat 
ACN then swelled to rehydration in digestion buffer (Section 2.1.3.3) before being incubated 
at 37
o
C overnight. 
The next day, the peptides were extracted using extraction buffer (Section 2.1.3.3) and 
incubated at 37
o
C in a shaker for 15 minutes. Samples were then dried down in a vacuum 
centrifuge. Tryptic peptides were re-dissolved in 15 µl of 0.1% formic acid containing 2% 
ACN.  Samples were then ready for analysis via Mass Spectrometry.   
 
2.2.6.2.2 Mass Spectrometry 
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) was performed on an 
Ultimate 3000 NanoLC System (Dionex) interfaced to a Linear Trap Quadrupole Orbitrap 
XL (Thermo Fisher Scientific). 5 µl of sample was loaded onto a trapping column packed 
with C18 PepMAP100 (Dionex) at a flow rate of 20 µl/minute in 0.1% formic acid. After 5 
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minutes of washing, peptides were eluted into a C18 PepMAP100 nanocolumn (15 cm * 75 
µm ID, 3 µm particles) (Dionex) at a flow rate of 350 nl/min. Peptides were separated using 
the mobile phase gradient : from 5% to 50% of Solvent B in 30 minutes, and from 50% to 
90% of Solvent B in 5 minutes. Solvent A was comprised of Water and #acn (v/v) (98:2) 
containing 0.1% formic acid. Solvent B was Water:ACN (v/v) (2:98) containing 0.08% 
formic acid.  
LC-MS/MS data was acquired in data-dependent acquisition (DDA) mode controlled by 
Xcalibur 2.0.7 software (Thermo Fisher Scientific). A typical DDA cycle consisted of an 
MS scan within m/z 300-1800 performed under the target mass resolution of 60,000 (full 
width at half maximum) followed by MS/MS fragmentation of the six most intense 
precursor ions under normalised collision energy of 35% in the linear trap. Database 
searches were performed using TurboQUEST software (Bioqorks Browser v. 3.3.1) (Thermo 
Fisher Scientific) using the SWISSPROT database. The following filters were applied: for 
charge state 1, XCorr>2.0; for charge state 2, XCorr>2.2; for charge state 3, XCorr>2.5. Artificial 
modifications of peptides (carbamidomethylation of cysteines and partial oxidation of 
methionines) were considered. Searches were also carried out allowing for one missed 
cleavage. Protein identifications were accepted if they had at least two matched identified 
peptides and passed relevant statistical criteria. 
 
2.2.7 Western Blotting 
2.2.7.1 Polyacrylamide Gel Electrophoresis 
Sodium Dodecylsulphate-Polyacrylamide Electrophoresis (SDS-PAGE) resolution of 
protein lysates was carried out according to the protocol of Laemmli (Laemmli 1970). In 
brief, a pair of 10 * 100mm glass plates (one short and one long with a 1.0 mm spacing) 
were washed with 70% (v/v) IMS and then rinsed with water before being dried completely. 
The componenets of the Mini-PROTEAN electrophoresis system were assembled according 
to the manufacturer’s instructions. Accordingly, the short plate was placed over the long 
plate so that the spacers created an interstitial space between them. Both plates were then 
clamped together using the casting frame and the unit was sealed tight when docked onto the 
casting stand. To test the assembly, DI water was poured between the plates and the level 
monitored throughout the mixing of the gel solutions. Any drop in level suggested the 
assembly was compromised and in such an event the plates were taken apart and 
reassembled examining for cracks or chips in the glass that may be causing such problems.  
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Meanwhile the resolving gel was setup. Depending on the protein of interest, different 
percentage gels could be utilised in order to better resolve the area of interest relative to 
protein size. The components for polyacrylamide gels and their respective percentages and 
resolutions are listed in order in the table below. The TEMED was added only once the 
casting plate assembly had been tested for leaks and dried afterwards by pouring the 
majority of the water out and placing a folded piece of Whatman paper between the plates to 
remove any trace of water that might remain.  
 6% 8% 10% 12% 14% 
Gel Resolution (kDa) 60-300 40-250 30-200 20-150 10-80 
Distilled Water 5.2 ml 4.6 ml 4.0 ml 3.4 ml 2.7 ml 
1.5M Tris-HCl pH 8.8 2.5 ml 2.5 ml 2.5 ml 2.5 ml 2.5 ml 
Acrylamide/Bis-Acrylamide 30% 2.0 ml 2.6 ml 3.3 ml 4.0 ml 4.6 ml 
10% SDS 100 µl 100 µl 100 µl 100 µl 100 µl 
10% Ammonium Persulfate 50 µl 50 µl 50 µl 50 µl 50 µl 
TEMED 5 µl 5 µl 5 µl 5 µl 5 µl 
Total Volume 10 ml 
Table 2.9: SDS-PAGE resolving gel compositions. 
Approximately 6-8 ml of the mixture was gently poured between the glass plates taking care 
to avoid bubbles. Next, ~2-3 ml of DI water was added gently to the top of the gel between 
the plates. This was to remove any bubbles that might be present on the top of the gel and 
also give an even surface to the cusp of the gel. The gel was then left to set for ~30-45 
minutes.   
A 4% (v/v) polyacrylamide stacking gel was used throughout all experiments. Its 
components were assembled in the order listed.  
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 4% 
Distilled Water 6.0 ml 
0.5M Tris-HCl, pH 6.8 2.5 ml 
Acrylamide/Bis-Acrylamide 30% 1.3 ml 
10% SDS 100 µl 
10% Ammonium Persulfate 100 µl 
TEMED 10 µl 
Total Volume 10 ml 
Table 2.10: SDS-PAGE stacking gel composition.   
Following the pouring of the stacking gel on top of the polymerised resolving gel, the gel 
comb was inserted. Any spill-over was carefully removed with tissue and the stacking gel 
was then left to set for 15-20 minutes.      
Upon polymerisation, the glass plates were removed from the docking station and the 
casting frame removed. The glass plates were then assembled, using a buffer dam if 
necessary, into the electrophoresis rig and placed into the tank. The inner chamber of the 
electrophoresis rig was filled to the brim and the tank to the designated marker using ~700 
ml of Running Buffer (Section 2.1.3.1) in total. The unit was left in this manner until the 
protein samples were ready to load. 
Based on the results obtained from the BCA Assay (Section 2.2.5.2), all protein samples 
were equally loaded (10-50 µg) and had 6.25 µl of 4x Sample Solubilisation Buffer (SSB) 
(Section 2.1.3.1) added then made up to a 25 µl volume with DI water. Samples were then 
heated on a heating block at 95
o
C for 5 minutes before being centrifuged briefly to collect 
any sample that may have condensed onto the walls and lid of the tube, and then chilled on 
ice.     
The samples were then loaded into the gel wells (~25 µl). 6 µl of molecular weight marker 
(PageRuler Plus Prestained Protein Ladder and/or Spectra Multicolor High Range Protein 
Ladder) were added individually to the lanes flanking either side of those containing 
samples. The electrophoresis tank was then sealed and underwent electrophoresis at a 
constant voltage of 80 V for 20 minutes (until the samples migrated from the stacking gel 
into the resolving gel) and then an increase to 100 V for approximately 90-180 minutes 
(until the gel had resolved sufficiently which in turn depended on the percentage acrylamide 
used in the resolving gel) (Figure 2.12).   
119 
 
 
Figure 2.12: A workflow of running an SDS-PAGE gel, (http://www.bio-rad.com/). 
 
2.2.7.2 Electrophoretic Transfer 
Electrophoretic transfer is the transfer of proteins from a gel to a membrane whilst 
maintaining their relative position and resolution. The wet transfer technique (Towbin, 
Staehelin et al. 1979) was the method of choice for all Western Blot experiments. Upon 
completion of the SDS-PAGE procedure, gels were removed from the glass plates encasing 
it and the stacking gel was removed. The gel was then left to soak in pre-chilled transfer 
buffer (Section 2.1.3.1) for ~10 minutes to remove any residual SDS that may be bound to 
the gel and have an inhibitory effect on protein transfer. Meanwhile, Polyvinylidene 
Difluoride (PVDF) membrane was trimmed to the size of the gel and soaked in methanol for 
5-10 minutes. The transfer cassette was then assembled as indicated below.      
 
Figure 2.13: The assembly of the electrophoretic transfer system, (http://www.bio-
rad.com/). 
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Prior to inserting the transfer cassette into the electrophoresis system, the cassette was rolled 
using a 15 ml tube to remove any potential air bubbles that may hinder the transfer process. 
The cassette was then placed into the electrophoresis system along with an ice pack and a 
stirring bar and sealed shut. The tank, along with a power pack and stirring plate, were 
transferred to a cold room (4
o
C) and the tank placed on a stirring plate on a low setting. The 
power pack was then attached and set to run at a constant voltage of 50 V overnight (Figure 
2.13). 
 
2.2.7.3 Coomassie Blue R-250 
CoomassieBlue R-250 is a general gel stain used to visualise protein bands on an SDS-
PAGE gel. This was used as a quality control in order to assess the efficiency of the transfer 
method. Briefly, following transfer, the SDS-PAGE gel was washed gently in DI water 
before pre-filtered (0.25 µm) coomassie blue solution was overlaid. The gel was left on a 3D 
rotator overnight swirling gently.  
The next day the gel was destained using coomassie destain solution (Section 2.1.3.1). The 
destain solution was left to act on the gel for 10-15 minutes before being replaced with fresh 
destain solution. This process was repeated until distinct protein bands were left on the gel 
with little to no background. The gels were imaged by a G-BOX fluorescence gel 
documentation and analysis system and the images saved for densitometric analysis. 
2.2.7.4 Ponceau S 
Ponceau S staining of the nitrocellulose or PVDF membrane is a rapid and reversible stain 
used for Western Blots that allows for the visualisation of the proteins that did complete the 
transfer from the SDS-PAGE gel to the membrane allowing for the estimation of efficiency 
of both electrophoretic transfer and protein loading. Briefly, Ponceau S stain was applied to 
the membrane for ~3 minutes under gentle agitation. Transferred bands were represented as 
pink bands against the white membrane. Following confirmation, the membrane was washed 
in DI water until the Ponceau stain was removed entirely. Once removed the membrane was 
used for immuno-blotting.       
 
2.2.7.5 Immunoblotting 
Following transfer, the PVDF membrane was blocked for 1 hour at room temperature in a 
5% Bovine Serum Albumin (BSA) + 0.1% Tween-Tris Buffered Saline solution with gentle 
rocking. After an hour, the membrane was cut into manageable sections for the protein of 
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interest and incubated overnight in a cold room (4
o
C) with gentle rocking with the 
appropriate primary antibody (made up in 1% BSA-0.1% Tween-TBS). The appropriate 
dilutions are summarised in the table below.  
1
o
 Antibody 1
o
 Antibody 
Stock  
1
o
 Antibody 
Dilution 
2
o
 Antibody 2
o
 Antibody 
Dilution 
Occludin (Invitrogen) 0.5 mg/ml 1/1000 Anti-Rabbit 1/2000 
Claudin 5 (Invitrogen) 0.5 mg/ml 1/1000 Anti-Mouse 1/2000 
VE-Cadherin 
(Invitrogen) 
0.5 mg/ml 1/500 Anti-Rabbit 1/1000 
ZO-1 (Invitrogen) 0.5 mg/ml 1/1000 Anti-Mouse 1/2000 
Thrombomodulin 
(Abcam) 
1 mg/ml 1/1000 Anti-Mouse 1/2000 
vWF (Abcam) 8 mg/ml 1/1000 Anti-Rabbit 1/2000 
IL-6 (R&D) 0.2 mg/ml 1/500 Anti-Goat 1/1000 
14-3-3 (Abcam) Whole Sera 1/1000 Anti-Rabbit 1/2000 
P-Tyrosine (Invitrogen) 0.5 mg/ml 1/500 Anti-Mouse 1/1000 
P-Serine (Millipore) 0.5 mg/ml 1/500 Anti-Mouse 1/1000 
P-Thymine (Invitrogen) 0.5 mg/ml 1/500 Anti-Mouse 1/1000 
GAPDH (Santa Cruz) 0.2 mg/ml 1/1000 Anti-Rabbit 1/2000 
Table 2.11: Antibody concentrations used for immunoblotting. 
 
The next day, the blots were left for 1 hour to return to room temperature before being 
washed three times for 5 minutes in 1% Tween-TBS using vigourous agitation. The blots 
were then incubated with the appropriate Horse Radish Peroxidase (HRP)-conjugated 
secondary antibody in 1% BSA-1% Tween-TBS solution for 2 hours at room temperature 
with gentle rocking (refer to Table X for corresponding secondary antibody concentrations). 
Membranes were then washed three times for 5 minutes using 1% Tween-TBS with 
vigourous agitation and then stored in TBS until used for detection of targets via chemi-
luminescence.  
Luminata chemi-luminescent substrate was used to detect HRP-conjugated secondary 
antibody binding. The blots were dried carefully removing all residual PBS before applying 
the substrate. Immediately the blot was transferred to the G-BOX fluorescence gel 
documentation and analysis system and the blots were exposed for different times. Images 
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were saved for densitometric analysis using NIH Image J software (http://rsbweb.nih.gov/ij/) 
to obtain a relative comparison between protein bands. 
 
2.2.7.6 Immunoblot Stripping 
For phosphorylation work, immunoblots were commonly subjected to two different primary 
antibodies targeting the same protein. To facilitate this, immunoblots had to be initially 
probed with one antibody (phosphorylation antibody) and analysed, before being stripped of 
that antibody and probed with the second (target protein antibody). To do this, Restore 
Western Blot Stripping Buffer was used. Briefly, post analysis of the first antibody, the 
immunoblot was washed in TBS-Tween to remove the substrate before being immersed in 
stripping buffer under agitation for 10 mins. The blot was then washed in 1% Tween-TBS 
wash buffer for 5 mins before being checked for complete removal of the first antibody. The 
membrane was once again coated in Luminata chemi-luminescent substrate and exposed 
using the G-BOX fluorescence documentation and analysis software. If no signal was 
present, the blot was successfully stripped of secondary antibody. The blot was once again 
washed with 1% Tween-TBS wash buffer and incubated with the same secondary antibody 
regime as before prior to analysis using the G-BOX. Once again, if no signal was present, 
successful removal of the primary antibody was achieved. After another wash with 1% 
Tween-TBS the blot was blocked with 5% Bovine Serum Albumin (BSA) + 0.1% Tween-
Tris Buffered Saline for 1 hr before the standard Immunoblotting procedure (Section X) for 
the second antibody was carried out. 
         
2.2.8 Physiological Assays 
2.2.8.1 Trans-Endothelial Cell Permeability Assay 
This method was applied as in previous publications (Collins, Cummins et al. 2006, Walsh, 
Murphy et al. 2011). Following cell treatments (e.g. exposure to cytokines, shear stress etc), 
HBMvEC’s and BBMvEC’s were trypsinised and counted as previously described. Sterile 
transwell inserts were placed into a sterile 6-well dish and fresh pre-warmed culture medium 
was added to the upper (apical) and lower (baso-lateral) chambers of the Millicell hanging 
cell culture insert (6-well format, 0.4 µm pore size, 24 mm filter diameter) within the 6-well 
dish (1 ml – Upper Compartment, 4 ml – Lower Compartment). The cells were replated at a 
high density (4*10
5
 cells/insert) within the Millicell inserts. After the cells had adhered 
overnight, transendothelial permeability was assessed as previously described (Walsh et al., 
2011, Collins et al., 2006). Briefly, a FITC-labelled dextran (40 kDa) was added to fresh 
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pre-warmed growth medium at a pre-determined concentration. All medium in the apical 
and baso-lateral chambers of the transwell apparatus were replaced, with the apical medium 
containing 250 µg/ml of FITC-Dextran. At time (t) = 0, 28 µl was collected from the baso-
lateral chambers, and diluted to 400 µl with 372 µl fresh medium. As the FITC-Dextran was 
left to diffuse across the monolayer, medium samples were taken in a similar fashion every 
30 minutes (for up to 3 hours) from the baso-lateral chamber with each diluted aliquot plated 
in triplicate on a white 96-well microplate (3*100 µl volumes). Using a TECAN Safire 2 
fluorospectrometer (Tecan Group, Switzerland), excitation and emission wavelengths of 490 
and 520 nm respectively were selected. % Transendothelial Exchange (%TEE) of FITC-
Dextran 40 kDa was expressed as the total baso-lateral fluorescence at a given time point 
(from 0 – 180 minutes) expressed as a percentage of total apical fluorescence at (t) = 0 min 
(Figure 2.14).      
 
Figure 2.14: Trans-Endothelial Cell Permeability Assay. (1) Cells are counted and seeded 
equally across transwell inserts and left to adhere. (1a) 24hrs later, treatments such as adding 
inflammatory cytokines or pharmacological inhibitors may be added if required. (2) FITC-
Dextran supplemented medium replaces the medium in the apical chamber and (t)=0 is 
recorded. (3) Samples are collected over 30 minute timepoints from the baso-lateral chamber 
and the samples are prepared to be read by a flourimeter. 
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2.2.8.2 Adhesion Assay 
96-well plates were coated with Attachment Factor (~10 μl) before 50 μl of pre-warmed 
medium was added to each well. The plate was stored was placed in an incubator until 
further required. Meanwhile cells were trypsinised, pelleted and counted before being 
resuspended at a concentration of 2.5*10
5
 cells/ml and 100 μl of the suspension was added 
via a multichannel pipette in triplicate to the pre-prepared 96-well plate. All wells were 
brought to a final volume of 200 μl before the plate was returned to the incubator and left 
there overnight. The experimental procedure was performed in replicate as required for a 
pre-determined number of time points. 
The next day the cell culture medium was aspirated and replaced with 200 μl of fresh 
medium. If required, peptide inhibitors were added to the medium before addition to the 
necessary wells. Upon return to the incubator, (t)=0 min was established. Upon completion 
of each time point, the plate corresponding to said timepoint was removed from the 
incubator and the medium was aspirated from the wells. The wells were washed briefly with 
PBS before 100 μl of 3.75% formaldehyde was added to each well and left to incubate for 15 
mins at room temperature. The wells were then briefly washed with PBS before 100 μl of a 5 
mg/ml crystal violet solution was added to each well. The plate was left to incubate at room 
temperature for 5 mins before being washed briefly with water. The plates were turned 
upside down and left to air dry for 10 mins. Once completely dry, 50 μl of a 2% SDS 
solution was added to each well and the plate was left to incubate for 30 mins at room 
temperature. The absorbance was then read at 562 nm on an ELx800 Microplate Reader and 
treated samples were compared against the control cells.           
 
2.2.8.3 xCELLigence™ 
The xCELLigence™ system monitors cellular events in real time without the incorporation 
of labels. The system measures electrical impedence across micro-electrodes integrated on 
the bottom of tissue culture E-Plates. The presence of the cells on top of the electrodes 
affects the local ionic environment at the electrode/solution interface leading to an increase 
in the electrode impedance. The more cells attached on the electrodes, the larger the 
increases in electrode impedance and vice versa. In addition, the impedance depends on the 
quality of the cell interaction with the electrodes so increased cell adhesion or spreading will 
lead to a larger change in electrode impedance. Thus electrode impedance, represented as 
cell index (CI) values, can be used to monitor cell viability, number, morphology, monolayer 
integrity and adhesion in a number of cell-based assays (Figure 2.15). This system was used 
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to monitor the effect of inflammatory cytokines and peptide inhibitors on viability and 
proliferation on HBMvEC’s. 
This method was applied as in previous publications (Luissint, Federici et al. 2012, 
Kobayashi, Tsubosaka et al. 2013). Cells were trypsinised and a cell count performed 
(Section 2.2.1.3). For proliferation studies, 2,500 cells were added to each AF coated well on 
a 16-well E-plate in duplicate whereas for viability studies 25,000 cells per well was 
employed. Initial adhesion of the cell was measured every 15 minutes for 24 hours. After 
this, measurements were extended to every 25 minutes for up to 4 days afterwards. Normally 
after the initial 24 hour adhesion phase, conditions could be inflicted on the cells in situ. 
Typically this would entail spiking the fresh growth medium intended for the cells with 
inflammatory cytokines of varying concentrations or inhibitors to block specific protein-
protein interactions. The cells were fed with fresh growth medium every 24 hours directly 
after a measurement had been taken in order to have as minimal an effect on the results. This 
was achieved by removing 100 µl of growth medium from each well and replacing it with 
100 µl of fresh medium. Water levels were also maintained in reservoirs surrounding the 
wells to ensure the cells were kept humidified at all times.     
 
Figure 2.15: The principle of the xCELLigence system, (http://www.roche-applied-
science.com). 
 
2.2.8.4 MTS Assays 
MTS assays are a colorimetric method for determining the number of viable cells in a 
proliferative or chemosensitive manner. The CellTiter 96 AQueous Assay is composed of 
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solutions containing a novel tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)) and an electron coupling 
reagent (phenazine methosulfate, PMS). MTS is reduced by cells into a formazan product 
that is soluble in tissue culture medium (Figure 2.16). The conversion of MTS into formazan 
is accomplished by dehydrogenase enzymes found in metabolically active cells. The 
absorbance of the produced formazan can be measured at 490 nm by means of a plate reader 
and the signal acquired correlates directly to the cell number present.  
 
Figure 2.16: MTS assay principle. The reduction of MTS by metabolically active cells 
results in formazan, a product which is detectable at 490 nm and correlates to the number of 
live cells present.    
The MTS reagent was used as both a means of measuring proliferation and viability. The 
key difference between the two was the starting number of cells in each well; proliferation 
used 1,000 cells/well and viability used 25,000 cells/well.  
Following trypsinisation of the cells, the cells were counted and resuspended at the required 
cell number/100 µl of cell culture medium. The cells were then plated in triplicate onto AF-
coated 96-well plates and left to adhere overnight. The following day the cells were 
stimulated accordingly (Section 2.2.2.1) and left to incubate for the required time. Following 
the experimental design, 20 µl of MTS/PMS solution was added to each well on the assay 
plate containing 100 µl of culture medium. The plate was then incubated for 4 hours at 37
o
C 
in a humidified 5% CO2 tissue culture incubator. The absorbance was then read at 490 nm on 
an ELx800 Microplate Reader.   
 
2.2.8.5 Lactate Dehydrogenase Assays 
Another means of assessing viability was the measurement of cellular lactate dehydrogenase 
(LDH) release, a trait of cells which have undergone damage or are under stress. Lactate 
dehydrogenase is released rapidly into the culture medium from damaged cells. This excess 
of LDH facilitates the conversion of lactate to pyruvate. This is turn facilitates the reduction 
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of NAD
+ 
to NADH/H
+
. Concurrently, the catalyst diaphorase transfers the H/H
+
 from the 
NADH/H
+
 to the tetrazolium salt INT (pale yellow) which is reduced to formazan (red) 
(Figure 2.17).  An increase in the amount of dead or membrane-damaged cells results in an 
increase in LDH activity in the cell culture supernatant. This increase correlates directly to 
the amount of formazan formed over a controlled time period. Therefore the farther the 
supernatant colour is pushed into the red end of the spectrum the greater the amount of LDH 
released which is inversely proportional to the cell viability. 
 
Figure 2.17: LDH assay principle. The release of LDH from damaged cells creates a 
cascade effect initiating a number of reactions. The end result is the production of formazan, 
a detectable product which correlates directly to the number of damaged cells present, 
(http://flipper.diff.org/)   
Following cell treatments, culture medium was harvested for LDH analysis. Untreated cells 
and lysed cells served as ‘Low’ and ‘High’ LDH Controls respectively. 100 µl of the 
medium samples were plated in triplicate on a sterile 96-well plate. 100 µl of Reaction 
Mixture was added to each well and the plate was incubated for 30 minutes at room 
temperature protected from light. 50 µl of Stop Solution was then added to each well and the 
plate was shaken gently for 10 seconds. The plate was then read at 490 nm on an ELx800 
Microplate Reader. The percentage cytotoxicity was calculated as follows: 
 
                  
                                
                          
     
 
2.2.8.6 ELISA 
2.2.8.6.1 Multiplex ELISA 
Compared to regular ELISAs (Section 2.2.8.5.2), Multiplex ELISA allows for the 
simultaneous screening of up to 10 targets of interest in each well. The principal revolves 
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around the capture antibodies of interest being coated onto distinct spots in each well. 
Samples are added to the wells along with a solution containing the detection antibodies 
labelled with an electrochemiluminescent compound. Following an incubation period in 
which the samples bind to the capture antibodies immobilised on the working electrode 
surface, which in turn bind the detection antibody completing the sandwich. Finally, the 
addition of the Read Buffer provides the appropriate chemical environment for 
electrochemiluminescence and the MSD® SECTOR instrument applies a voltage to the 
electrodes causing the bound labels in the well to emit a quantitative measure of light 
proportional to the amount of captured analyte which can be measured and interpreted by the 
instrument (Figure 2.18).   
 
2.2.8.6.1.1 Human ProInflammatory 1 4-Plex Ultra-Sensitive Kit 
This plate could detect levels of Interferon Gamma (IFN-γ), Interleukin 1-Beta (IL-1β), 
Interleukin 6 (IL-6) and Tumour Necrosis Factor Alpha (TNF-α) in a biological sample. All 
reagents were previously made up as per the manufacturer’s instructions. 25 µl of Diluent 2 
was added per well and the plate sealed and shaken vigorously (300-1000 rpm) for 30 
minutes. 25 µl of sample or calibrator was then added per well with the plate sealed and 
shaken vigorously (300-1000 rpm) overnight. The following day the plate was washed three 
times using PBS-Tween (0.05%) before 150 µl of 2 x Read Buffer T was added per well 
taking care not to introduce bubbles. The plate was then analysed on the SECTOR Imager 
Instrument.   
 
2.2.8.6.1.2 MULTI-SPOT Vascular Injury Panel 1 Assay 
This plate could detect levels of Thrombomodulin, Intercellular Adhesion Molecule 3 
(ICAM-3), P-Selectin and E-Selectin in a biological sample. All reagents were made up 
prior as per the manufacturer’s instructions. 150 µl of Blocker A Solution was added to each 
well and the plate was sealed and shaken overnight at 4
o
C. The following day the plate was 
washed with 200 µl per well of PBS-Tween (0.05%) three times. 40 µl of Diluent 10 was 
added to each well followed by 10 µl of sample or calibrator before the plate was sealed and 
incubated overnight at 4
o
C. The following day the plate was washed with 200 µl per well of 
PBS-Tween (0.05%) three times. 25 µl of 1 x Detection Antibody Solution was added to 
each well and the plate sealed and incubated at room temperature for 1 hour with shaking. 
The plate was washed a further three times. 150 µl of 1 x Read Buffer T was added to each 
well taking care not to introduce bubbles and the plate was read on the SECTOR Imager 
instrument.        
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Figure 2.18: Multiplex ELISA system and principle. (A) The SECTOR® Imager 6000 
Multiplex ELISA Reader and (B) the experimental setup and principal behind the spotwells 
on the Multiplex ELISA plate, (http://www.meso-scale.com/). 
 
2.2.8.6.2 Standard ELISA  
96-well plates were coated with 100 µl/well of capture antibody in coating buffer. The plate 
was then sealed and incubated overnight at 4
o
C.  
The following day the wells were aspirated and washed five times with >250 µl of wash 
buffer per well. 1 x Assay Diluent was prepared (5 x Assay Diluent and DI water, 1:4) and 
the wells were blocked using 200 µl/well. The plate was incubated for 1 hour at room 
temperature. The 1 x Assay Diluent was removed from the wells and the plate was washed 
five times as before. Using 1 x Assay Diluent, the provided standards were diluted according 
to the manufacturer’s instructions and 100 µl was added to the appropriate wells. A two-fold 
serial dilution was performed across the plate using the top standard to create a standard 
curve. In addition, all samples to be analysed were added to the plate and the plate then 
sealed and incubated overnight at 4
o
C.  
The following day the wells were aspirated and washed five times as before. 100 µl/well of 
detection antibody (diluted in 1 x Assay Diluent as per the manufacturer’s instructions) was 
added to each well and the plate was sealed and incubated at room temperature for 1 hour. 
The plate was aspirated and washed five times as before. 100 µl/well of Avidin-HRP 
(diluted in 1 x Assay Diluent as per the manufacturer’s instructions) was added to each well 
and the plate sealed and incubated at room temperature for 30 minutes. The plate was 
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aspirated and washed seven times. 100 µl/well of Substrate Solution was added to each well 
and the plate sealed and incubated at room temperature for 15 minutes. 50 µl of Stop 
Solution was then added to each well and the plate read at 450 nm on an ELx800 Microplate 
Reader (Figure 2.19).  
 
Figure 2.19: The principle steps in an ELISA. (1) Coating of the wells of a 96-well plate 
with a capture antibody and blocking the non-specific sites in the well with a blocking 
buffer; (2) incubation of samples and standards on the plate; (3) incubation with a suitable 
detection antibody for the antigen of interest; (4) the addition of Avidin-HRP that binds to 
any biotin-labelled detection antibody present and; (5) addition of TMB substrate to generate 
a detectable product that correlates to the amount of antigen of interest present, 
(http://www.abcam.com/). 
 
2.2.9 Flow Cytometry Analysis 
Flow cytometry is a technology that allows a cell suspension to be counted and have each 
individual cell measured for a variety of characteristics, determined by examining how they 
flow in a liquid. Each cell suspension under investigation is entered into a 
hydrodynamically-focused stream of liquid which has a beam of laser light of a single 
wavelength directed on it. A number of detectors are aimed at the point where the stream 
passes through the light beam; one in-line with the light beam (Forward Scatter-overall cell 
size) and several perpendicular to it (Side Scatter-cell granularity) in addition to multiple 
fluorescent detectors (fluorescent labelling). Each suspended particle that passes through the 
beam scatters the ray, and any fluorescent chemicals found on the surface of the particle can 
become excited into emitting light at a longer wavelength than the light source. The 
strategically placed detectors pick up all these signals and interpret the fluctuations in 
brightness detected to build a profile on the physical and chemical structure of each 
individual particle and thus the overall cell suspension. All flow cytometry experiments were 
performed on the FACSAria  
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2.2.9.1 Viability 
In order to assess cell health following exposure to different concentrations of cytokine over 
different incubation times, or to assess the effect of different inhibitors, an Alexa Fluor 488 
Annexin V/Dead Cell Apoptosis Kit was utilised. The advantage to using this kit is the 
ability to distinguish the degree of cell health rather than labelling a cell live or necrotic. To 
do this, fluorescent labelling of characteristic morphological and biochemical changes in the 
cell is employed highlighting key changes in the cell which act as a detectable readout for 
assessing overall health of a cell population. In normal live cells, phosphatidylserine (PS) is 
located on the cytoplasmic surface of the cell membrane. In apoptotic cells, PS is 
translocated from the inner to the outer leaflet of the plasma membrane thus exposing PS to 
the extra cellular environment. The human anticoagulant, Annexin V, is a phospholipid-
binding protein that has a high affinity for PS, which when tagged with a fluorophore makes 
the identification of apoptotic cells achievable. The other dye utilised in the kit is propidium 
iodide (PI), a red fluorescent nucleic-binding dye. PI is impermeant to live cells and 
apoptotic cells but stains dead cells with red fluorescence. By utilising the two dyes, distinct 
populations of dead cells (red and green), apoptotic cells (green) and live cells (neglible 
fluorescence) can be easily distinguished from one another using the FACS Aria with the 
488 nm line of an argon-ion laser for excitation.       
Briefly, cells were exposed to experimental treatments as required. An untreated culture of 
cells was employed as a control. Cells were trypsinised and pelleted before being washed in 
warmed PBS. 1 x Annexin-binding buffer was prepared (5 x Annexin binding Buffer and DI 
Water, 1:4) and a 100 µg/ml aliquot of PI was prepared by diluting 5 µl of PI stock solution 
in 45 µl of 1 x Annexin-binding buffer. The cells were re-centrifuged and the pellet was 
resuspended in 100 µl of 1 x Annexin-binding buffer. The cell suspensions were transferred 
to sterile FACs tubes and 5 µl of Alexa Fluor 488 Annexin V and 1 µl of the PI 100 µg/ml 
aliquot were then added to the cell suspension. The cells were then incubated for 15 minutes 
at room temperature in the dark. Following incubation, 400 µl of Annexin-binding buffer 
was added to each tube and the samples were mixed gently. The cells were kept on ice and 
protected from light until read as soon as was possible by flow cytometry.  
Note: This kit could also be used for microscopy work. See Section 2.2.10. 
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2.20: Annexin V/PI Viability Principle. Distinguishing between ‘live’ (no label), 
‘apoptotic’ (Annexin V - green label) and late-apoptotic (Propidium Iodide - red label) cells. 
 
2.2.9.2 Transfection Efficiency 
Post-transfection with green fluorescent protein (GFP), cells were trypsinised and pelleted 
(Section 2.2.1.2). The resultant pellet was washed in PBS before being centrifuged once 
more. Following aspiration of the growth medium, the pellet was resuspended in 100 µl of 
FACS Buffer (Section 2.1.3.4). 6 µl of PI stain was added to the tubes and the tubes were 
left to incubate for 15 minutes at room temperature in the dark. The tubes were then brought 
to a final volume of 500 µl with the addition of 400 µl of FACS Buffer. The tubes were then 
kept on ice and protected from light until read as soon as was possible by flow cytometry.    
 
2.2.9.3 Oxidative Stress 
This method was applied as in previous publications (Gertzberg, Neumann et al. 2004, 
Mozo, Ferry et al. 2006, Lee, Lee et al. 2010). 2’,7’-dichlorofluorescein diacetate (DCFDA) 
is a fluorogenic dye that measures hydroxyl, peroxyl and other ROS activity within a cell 
culture. Once taken up by the cell, cellular esterases cause DCFDA to become deacetylated. 
This non-fluorescent compound can then become oxidized upon interaction with ROS to 
yield the highly fluorescent 2’, 7’ – dichlorofluorescin (Figure 2.21). For the DCFDA assay, 
cells were treated with the compound at a final concentration of 5 μM at (t) = 0, with the 
compound present for the entire incubation period of the treatment. 
Dihydroethidium (DHE) is a superoxide indicator. It stains the cytoplasm of living cells blue 
until it becomes oxidised by ROS yielding ethidium which is free to intercalate with DNA. 
(Figure 2.21). For the DHE assay, cells were treated with the compound at a concentration 
of 3 μM for 30 mins prior to completion of the treatment incubation period.    
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Figure 2.21: CFDA and DHE Principle, (http://www.biotek.com/). 
The cells were exposed to experimental treatments as required. An additional culture of 
untreated cells was employed as an unstained control. Cells were trypsinised and pelleted 
before being washed in warmed PBS. The cells were re-centrifuged and the pellet was 
resuspended in 500 µl of FACS buffer before being transferred to sterile FACs tubes. The 
cells were then kept on ice and protected from light until read as soon as was possible by 
flow cytometry.  
Note: These stains could also be used for microscopy work. See Section 2.2.10. 
 
2.2.10 Immunofluorescent Microscopy 
In order to monitor the expression and/or subcellular localisation of proteins, BBMvEC’s 
and HBMvEC’s were prepared for immunofluorecent analysis according to the method of 
previous publications (Walsh, Murphy et al. 2011, Guinan, Rochfort et al. 2013) with minor 
modifications. Immunofluorescent staining was carried out on cells seeded onto ibidi® 
slides (Section 2.2.2.2.2) or glass coverslips. This section will refer to the more common 
practice of using coverslips (but the procedure is the same for ibidi® slides). Briefly, 
coverslips were immersed in 100% IMS and flame sterilised before being placed in a well of 
a sterile 6-well dish. The six-well dish was then exposed to UV exposure for 1 hr in the 
laminar flow cabinet.  
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The coverslips had ~20 µl of AF added and gently smeared over their surface using a sterile 
cell scraper. 1 ml of growth medium was then added to each well and the plate was 
incubated at 37
o
C/5% CO2 in a tissue culture incubator until further required. Cells were then 
trypsinised, pelleted and resuspended (as outlined in Section 2.2.1.2) at a density of 1.0*10
6
 
cells/ml. 1 ml of the cell suspension was added onto coverslips and the cells left to adhere 
overnight. 
The next day prior to carrying out the immunofluorescence protocol, the adhered cells could 
be subjected to a set of conditions depending on the experimental setup if necessary. Post-
treatment, the following steps were done as quickly as possible. All growth medium was 
removed and the cells washed with pre-warmed (37
o
C) PBS. Cells were then fixed in situ 
with 3.7% (v/v) para-formaldehyde on ice for 10 minutes.  Coverslips were then washed 
twice with PBS and briefly dried before having the perimeter marked with a PAP pen. 100 ul 
of ammonium chloride was added to each coverslip before being left to incubate for 10 
minutes. Following incubation, the ammonium chloride was aspirated and 100 ul of 
permablock solution was then added to the coverslip. After 30 minutes incubation, cells 
were then incubated with 100 µl of primary antibody in a fresh aliquot of permablock 
solution (1
o 
and 2
o
 antibody dilutions and Incubation times are listed in the table below) 
overnight at 4
o
C. Following incubation, if the primary antibody was unconjugated (i.e. 
lacking a fluorescent probe) the coverslips were washed twice with permablock before the 
specific secondary antibody was made up in permablock and 100 µl added. The coverslips 
were incubated in the dark. They were then washed twice with permablock before carrying 
out the optional incubation step of F-Actin antibody made up in permablock. Alternatively, 
post-secondary antibody incubation, the cells had their nuclei stained as a positive control 
with either DAPI or PI. Coverslips were then washed twice more before being inverted and 
mounted onto 100% IMS washed microscope slides using DAKO fluorescent mounting 
medium. The slides were kept in a slide box for 1-2 hours to allow the DAKO medium to set 
before being sealed using nail varnish. The slides were stored at 4
o
C until visualised by 
standard fluorescent microscopy or confocal microscopy.  
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1o Antibody/Stain 1o Antibody 
Concentration 
Incubation Time 2o Antibody 
Concentration 
Incubation 
Time 
14-3-3 (Abcam) 1:50 Overnight 1:500 2 hours 
Claudin 5 (Invitrogen) 1:50 Overnight 1:500 2 hours 
VE-Cadherin (Abcam) 1:50 Overnight 1:500 2 hours 
vWF (Abcam) 1:50 Overnight 1:500 2 hours 
ZO-1 (Invitrogen) 1:50 Overnight 1:500 2 hours 
DAPI (Sigma) 1:2000 3 mins   
F-Actin (Invitrogen) 1:50 30 mins   
Annexin V (Invitrogen) 1:5 15 mins   
Propidium Iodide 
(Invitrogen) 
1:100 15 mins   
DCFDA (Sigma) 1:6000 0-24 hrs   
DHE (Sigma) 1:3000 30 mins   
Table 2.12: Antibody/stain concentrations for immunofluorescence. 
 
2.2.11 Statistical Analysis 
Results are expressed as mean ± SD. Experimental points were performed in triplicate with a 
minimum of three independent experiments (n=3). Statistical comparison between control 
and experimental groups were by ANOVA in conjunction with a Dunnett’s post-hoc test for 
multiple comparisons. A Student’s t-test was also employed for pairwise comparisons. A 
value of P≤0.05 was considered significant. 
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Chapter 3: 
The effects of laminar shear stress on 
HBMvEC blood-brain barrier properties. 
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3.1 Introduction 
The concept of the BBB has been recognised for more than 100 years, following the 
demonstration that most organs could be stained by dye injected intravenously, with the 
exception of the brain and spinal cord (Ehrlich 1885, Goldmann 1913). Since then, the BBB 
is now recognised as the key regulator of the molecular and cellular traffic between blood 
and brain, providing a natural defence against circulating toxic and infectious agents. 
Several groundbreaking anatomical studies (Reese, Karnovsk 1967, Brightman, Reese 1969) 
provided a reasonable knowledge of the functions and capabilities of the BBB; however 
after decades of research the responsible factors or induction signals are still not 
characterised in detail. Over the years, several cellular and molecular studies have been 
conducted in an effort to elucidate the underlying biology of the BBB (Stewart, Wiley 
1981); however discrepancies tarnish many founding bodies of work as a result of the 
restrictions and limitations at the time. Perhaps the greatest obstacle at the time, and one 
which remains today, albeit to a much smaller degree, is the procurement of a fully 
representative model of the BBB.  
To date, the majority of studies have focussed on the effects of local and systemic influences 
that drive the induction of the highly specialised brain endothelial cells that comprise the 
BBB. Of these studies, the vast majority have focussed on the inductive effects of systemic 
factors such as growth factors, hormones and cytokines (Abbott 2002). Historically, the 
BBB was considered to encompass the structural, physiological and biochemical processes 
of the endothelial cells of the cerebral microvasculature. However, recent studies have 
demonstrated the interaction of the endothelium with cell types of the vessel wall and CNS 
such as neurons and glial cells, thus constitutes a functional unit termed the neurovascular 
unit (NVU). There is an ever-growing recognition directed towards the secreted agents and 
physical contact of the cell types that comprise the NVU, in contributing to the formation of 
a fully functional BBB. However, local influences such as haemodynamic forces play 
perhaps as great a part as that played by the neighbouring cell types in the induction of 
these specialised endothelial cells (Krizanac-Bengez, Mayberg et al. 2004, Krizanac-
Bengez, Hossain et al. 2006, Krizanac-Bengez, Mayberg et al. 2006, Cucullo, Hossain et al. 
2011). Several studies in other vascular beds have demonstrated the mechanotransductive 
effect of haemodynamic forces on endothelial phenotype from a genetic through to 
molecular, functional and morphological levels (Davies 1995, del Zoppo 2008, Hahn, 
Schwartz 2009). These adaptive responses have been identified in promoting vascular 
homeostasis, and are said to exert a protective effect against the pathophysiology of several 
vascular disorders. With regards to the cerebrovasculature, studies pertaining to the effect of 
haemodynamic forces are limited. Difficulties attributed to recreating the cerebral 
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microenvironment resulted in several earlier studies being conducted in macrovessels from 
which a larger cell number could be obtained and with greater ease (Rubin, Staddon 1999). 
At present, far superior models exist (Joo, Karnushi.i 1973), and only now are the true 
effects of haemodynamic forces on the cerebral microvasculature being uncovered. Several 
robust human models are readily available and with this in mind, we re=revisited in chapter 
3 the works of Walsh (2011) and Colgan (2007) with the objective of clarifying the 
translative effects of previously examined shear-induced upregulation of BBB barrier 
function, and further expand on this with specific relevance to tight junction assembly 
and anti-inflammatory mechanisms.           
 
3.1.1 Study Aims 
In this chapter we examined the effects of physiological levels of laminar shear stress on 
HBMvEC blood-brain barrier phenotypic properties. Therefore, the overall aims of this 
chapter include: 
 To conduct basic characterisation studies on HBMvECs  
 To investigate the effect of physiological levels of laminar shear stress on TJ/AJ 
protein (occludin, claudin-5, VE-Cadherin, ZO-1) transcriptional and translational 
expression. 
 To investigate the effect of physiological levels of laminar shear stress on TJ/AJ 
protein phosphorylation. 
 To investigate the effect of physiological levels of laminar shear stress on HBMvEC 
barrier function.  
 To investigate the effect of inflammatory cytokines; TNF-α and IL-6, on HBMvEC 
barrier function following pre-conditioning by physiological levels of laminar shear 
stress. 
 To determine if physiological levels of laminar shear stress influence HBMvEC 
anti-inflammatory properties.     
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3.2 Results 
3.2.1 The positive characterisation of commercially obtained HBMvECs 
HBMvECs were characterised for a number of specific markers to confirm effective 
culturing of the cerebral endothelial phenotype (Figure 3.1).  Endothelial cells present a 
number of biomarkers that are easily characterised to ensure the validity of commercially-
sourced cell lines. von Willebrand Factor; a key glycoprotein involved in hemostasis, is a 
common biomarker of endothelial cells. Confluent HBMvEC cultures were harvested for 
whole cell protein lysate and mRNA, following which vWF presence was demonstrated at 
both a translational (i) and transcriptional (ii) level by western blotting and qPCR 
techniques, respectively. Furthermore, vWF presence was further confirmed by 
immunofluorescence microscopy (iii-vi). Confluent HBMvECs were fixed in situ and 
stained for vWF which was evident by the characteristic shape of the Wiebel-Palade bodies 
which are known to store the protein in its native form.  To ensure the HBMvECs were 
effectively maintaining their BBB properties and that the culture regime adopted had not 
driven the cultures into reverting to a ‘default’ endothelial phenotype, a number of proteins 
located at the intercellular junctions that are involved in the unique barrier expressed by 
CNS endothelial cells were examined. Confluent HBMvECs were fixed in situ and stained 
for immunofluorescence examination of ZO-1 (vii), Claudin-5 (viii) and VE-Cadherin (ix). 
Each protein was highly expressed and localised at the cell-cell borders.  
 
3.2.2 Exposure of HBMvECs to laminar shear stress induces morphological and 
cytoskeletal realignment in the direction of the flow vector 
The effect of laminar shear stress on morphological and cytoskeletal organisation was 
examined (Figure 3.2). Confluent cultures were maintained in static environments (left hand 
side; LHS) or subjected to laminar shear stress (8 dynes cm
-2
) (right hand side; RHS) for 24 
hrs. Under brightfield microscopic conditions, static cultures demonstrated the characteristic 
endothelial growth patterns; a ‘cobblestone’ morphology (i). Under shear conditions 
HBMvECs realigned in the direction of the flow vector (ii). When fixed in situ and stained 
for filamentous F-actin, a similar trend was observed; in static cultures the actin filaments 
lacked any organisation (iii) versus sheared cultures where the actin filaments had realigned 
in the direction of the flow vector (iv). 
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3.2.3 Exposure of HBMvECs to laminar shear stress enhances the cell-cell border 
localisation of intercellular junction proteins, ZO-1, claudin-5 and VE-Cadherin 
The effect of laminar shear stress on the expression and localisation patterns of proteins 
involved forming the intercellular junctions of HBMvECs was examined (Figure 3.3). 
Confluent HBMvECs were maintained in static environments (LHS) or subjected to laminar 
shear stress (8 dynes cm
-2
) (RHS) for 24 hrs before being fixed in situ for 
immunofluorescence microscopy. Cultures were stained for ZO-1 (i, ii), claudin-5 (iii, iv) 
and VE-Cadherin (v, vi) to assess the subcellular localisation of the intercellular junction 
proteins in the absence and presence of laminar shear stress. In unsheared cultures, the 
staining pattern for each protein displayed an irregular and discontinuous presence at the 
cell-cell border. In contrast, the staining pattern of cultures exposed to shear stress displayed 
enhanced immunoreactivity and a more consistent and stable localisation pattern at the cell-
cell borders for each of the proteins.      
 
3.2.4 Exposure of HBMvECs to laminar shear stress induces an upregulation of 
interendothelial junction proteins; occludin, claudin-5, VE-Cadherin and ZO-1 
The effect of laminar shear stress on the expression of proteins involved in forming the 
intercellular junctions of the BBB was examined on both a transcriptional level in 
HBMvECs and BBMvECs and on the translational level in HBMvECs (Figure 3.4).  
Confluent BBMvECs and HBMvECs were maintained in static environments or subjected to 
laminar shear stress (8 dynes cm
-2
) for 24 hrs before being harvested for whole cell mRNA 
or protein lysate. The transcriptional levels of occludin, claudin-5, VE-Cadherin and ZO-1 
were examined by qPCR. In both species, each gene demonstrated a moderate increase in 
their transcription levels following exposure to laminar shear stress (i, ii). The translational 
levels of each protein in response to shear were then examined in HBMvECs by western blot 
(iii). A similar trend was observed in which each protein experienced a significant increase 
in protein levels in response to laminar shear stress (iv). The importance of these 
intercellular junction proteins; claudin-5 and VE-Cadherin, in barrier formation was further 
examined utilising siRNA technology. Briefly, transfection parameters were optimised using 
recombinant GFP protein and GFP expressing plasmid (Figure A.1) before optimisation of 
siRNAs specifically targeting claudin-5 (Figure 3.5) and VE-Cadherin (Figure 3.6) were 
carried out. The silencing of claudin-5 and VE-Cadherin was demonstrated to induce a 
significant increase in paracellular flux of 40kDa FITC-Dextran (%TEE of FD40) across the 
cell monolayer. (Note: Figures A.1-A.3 are located in Appendix) 
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3.2.5 Exposure of HBMvECs to laminar shear stress reduces phosphotyrosine and 
phosphothreonine levels of occludin, claudin-5 and VE-Cadherin 
The effect of laminar shear stress on the phosphorylation levels of tyrosine and threonine 
residues of intercellular junction proteins occludin, claudin-5 and VE-Cadherin was 
examined (Figure 3.5).  Confluent HBMvECs were maintained in static environments or 
subjected to laminar shear stress (8 dynes cm
-2
) for 24 hrs before being harvested for whole 
cell protein lysate. Samples were then subjected to immunoprecipitation and western blot 
analysis for phosphotyrosine (pTyr)- (LHS) and phosphothreonine (pThr)-levels (RHS). 
pTyr- and pThr-levels for occludin, claudin-5 and VE-Cadherin were seen to be very 
significantly reduced following exposure to laminar shear stress. 
 
3.2.6 Exposure of HBMvECs to laminar shear stress induces an upregulation of barrier 
function in-part via tyrosine phosphatase activity 
The effect of laminar shear stress on the barrier function of HBMvECs was examined with a 
focus on the role to tyrosine phosphatases in mediating such activity (Figure 3.6). Confluent 
HBMvECs were maintained in static environments or subjected to laminar shear stress (8 
dynes cm
-2
) for 24 hrs before being assessed for transendothelial permeability. Exposure of 
HBMvECs to laminar shear stress results in a significant drop in FITC-Dextran paracellular 
flux across the cell monolayer (i, ii). In comparison to static cultures, the significant 
reduction in permeability reflects a significant increase in barrier function.  To investigate 
the role of tyrosine phosphatases in modulating barrier function, confluent HBMvECs were 
maintained in static environments or subjected to laminar shear stress (8 dynes cm
-2
) for 24 
hrs in the absence or presence of the phosphatase inhibitor dephostatin, before being 
assessed for transendothelial permeability. The shear-induced reduction of permeability in 
HBMvECs was significantly attenuated when dephostatin was present during exposure of 
the cultures to laminar shear stress (iii, iv).  
 
3.2.7 Cytokine-mediated injury is reduced by shear in HBMvECs 
The concurrent effect of laminar shear stress and inflammatory cytokines on the barrier 
function of HBMvECs was examined (Figure 3.7; LHS). Confluent HBMvECs were 
maintained in a static unsheared condition or pre-conditioned with laminar shear stress (8 
dynes cm
-2
) for 24 hrs (i). TNF-α (0-100ng/ml) was then added to the cultures. The cultures 
were then either maintained in static environments or subjected to further laminar shear 
stress (8 dynes cm
-2
) for a further 6 or 18 hrs (ii). Post-treatment the cultures were 
trypsinised and seeded at a known density into transwell inserts and left to adhere overnight 
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(iii) prior to assessment for transendothelial permeability (iv). Exposure of static HBMvECs 
to TNF-α resulted in a significant increase in FITC-Dextran paracellular flux (%TEE of 
FD40) across the cell monolayer in a dose- and time-dependent manner. Moreover, exposure 
of HBMvECs to laminar shear stress demonstrated a significant drop in FITC-Dextran 
paracellular flux (%TEE of FD40) across the cell monolayer. In the presence of shearing, 
TNF-α induced significantly lower absolute increases in paracellular flux of FITC-Dextran 
label (Figure 3.8; i, ii). A similar observation was made in cultures treated with IL-6 in place 
of TNF-α (Figure 3.9; i, ii).  
An alternative means of examining the concurrent effect of laminar shear and inflammatory 
cytokines on the barrier function of HBMvECs was performed (Figure 3.7; RHS). Confluent 
HBMvECs were maintained in static environments or pre-conditioned with laminar shear 
stress (8 dynes cm
-2
) for 24 hrs (i). Cultures were then seeded at a known density into 
transwell inserts and left to adhere overnight (ii). TNF-α or IL-6 (0-100 ng/ml) were then 
added to the cultures for 6 or 18 hrs (iii) prior to assessment for transendothelial 
permeability (iv). Results obtained were identical to those reported above for TNF-α (Figure 
A.4) and IL-6 (Figure A.5). 
 
3.2.8 Laminar shear stress induces changes in transcriptional levels of cytokines and 
their signal-transducing receptors in HBMvECs 
The effect of laminar shear stress on cytokines and their signal-transducing receptors over 
time was examined on a transcriptional level (Figure 3.10). Confluent HBMvECs were 
maintained in static environments or subjected to laminar shear stress (8 dynes cm
-2
) for 0-
24 hrs before being harvested for whole cell mRNA. The transcriptional levels of TNF-α 
receptors TNFR1 (i) and TNFR2 (ii) and IL-6 receptor GP130 (iii) were examined from 0-
24 hrs by qPCR. A significant change was observed for all three receptors in response to 
acute shear exposure (0-2 hrs); TNFR1 and GP130 transcription levels were significantly 
increased in response to acute laminar shear stress before returning to baseline levels within 
8 hrs of shear onset. Unlike TNFR1, GP130 levels continued to decrease in response to 
laminar shear stress, resulting in a significant overall decrease in levels at 24 hrs. 
Conversely, TNFR2 demonstrated an initial decrease followed by an increase in levels in 
response to laminar shear stress resulting in significantly higher mRNA levels after 24 hrs. 
IL-6 mRNA levels followed a pattern similar to that of its GP130 receptor, with a net 
reduction in IL-6 mRNA levels after 24 hrs laminar shear (iv). Conversely, a slight increase 
in IL-6 protein expression was observed in response to laminar shear stress after 24 hrs in 
comparison to static cultures. Interestingly, an initial increase in IL-6 release levels was 
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observed in the acute onset of laminar shear stress (0-8 hrs), yet this surge plateaued 
thereafter with static IL-6 release levels comparable by 24 hrs (Figure A.6).  
 
3.2.9 Laminar shear stress induces an increase in the expression and secretion of 
thrombomodulin from HBMvECs    
The effect of laminar shear stress on HBMvEC levels of thrombomodulin over time was 
examined on a translational level (Figure 3.11).  Confluent HBMvECs were maintained in 
static environments or subjected to laminar shear stress (8 dynes cm
-2
) for 0-24 hrs before 
being harvested for whole cell protein lysate and spent medium. The translational levels of 
thrombomodulin were examined by western blot, in which a significant increase in 
thrombomodulin expression was observed in response to laminar shear stress after 24 hrs in 
comparison to static cultures (i, ii). Conditioned medium harvested at different timepoints 
during the static and shear conditions were analysed for thrombomodulin levels by ELISA. 
In response to laminar shear stress, a significant increase in thrombomodulin release into 
medium was observed after 4 hrs with levels climbing sharply up to 24 hrs. Static cultures in 
contrast released considerably smaller amounts of thrombomodulin across all timepoints up 
to 24 hrs (iii).  
The thrombin-binding activity of the released thrombomodulin in response to laminar shear 
stress was also examined. Confluent HBMvECs were subjected to laminar shear stress (8 
dynes cm
-2
) for 24 hrs before being harvested for spent medium. The collected medium was 
then concentrated using centrifugal filtration. In parallel, confluent HBMvECs were seeded 
at a known density into transwell inserts and left to adhere overnight. The following day the 
cell monolayers were stimulated with 2U of thrombin in the absence and presence of 
different volumes of concentrated conditioned medium for 30 mins. Post-stimulation, the 
cultures were assessed for transendothelial permeability.  Exposure of static HBMvECs to 
thrombin resulted in a significant increase in FITC-Dextran paracellular flux across the cell 
monolayer. This thrombin-induced increase in permeability in HBMvECs was significantly 
attenuated when conditioned medium was present during exposure of the cultures to 
thrombin (iv).  
Complimentary studies on another factor involved in hemostasis; vWF were conducted 
(Figure A.7). A significant increase in vWF protein expression was observed in response to 
laminar shear stress after 24 hrs in comparison to static cultures. By contrast, an initial 
increase in vWF transcriptional levels was observed in the acute onset of laminar shear 
stress (0-2 hrs), yet a significant decrease in mRNA expression was observed by 24 hrs.  
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Figure 3.1: Characterisation of HBMvEC’s. HBMvECs were initially grown to 
confluency for characterisation studies. The presence of the endothelial cell marker vWF as 
detected by Western blot (i), qPCR (ii) and fluorescence microscopy (green) (iii), (vi). In all 
fluorescence imaging studies, brightfield images of the cultures were obtained (iv) and 
cultures were typically counterstained for the nuclei (blue) as a control parameter (v). The 
resulting overlaid image series thus facilitated localisation studies (vi). Additional cell 
markers in the intercellular junction regions were examined in the form of ZO-1 (green) 
(vii), Claudin-5 (red) (viii) and VE-Cadherin (red) (ix). Images are representative.  
Note: Human Aortic Smooth Muscle Cells (HAoSMCs) were used as a control in vWF 
protein studies (i).    
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Figure 3.2: The effect of laminar shear stress on HBMvEC morphology and F-actin 
alignment. Confluent HBMvECs were exposed to laminar shear stress (8 dynes cm
-2
, 24 hr) 
and examined for morphological realignment by brightfield microscopy (i-ii) and fluorescent 
microscopy (rhodamine phalloidin staining of F-Actin) (iii-iv). The white arrows represent 
the direction of the flow vector. DAPI was used to counterstain the nuclei of the cells (iii-iv). 
Images are representative. 
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Figure 3.3: The effect of laminar shear stress on HBMvEC intercellar junctional 
protein localisation. Confluent HBMvECs were exposed to laminar shear stress (8 dynes 
cm
-2
, 24 hr) and examined for changes in the expression and localisation patterns of 
intercellular junction proteins. Static cultures (LHS) were compared to that of sheared (RHS) 
for ZO-1 (green) (i, ii), VE-Cadherin (red) (iii, iv) and Claudin-5 (red) (v, vi). Membrane 
localisation is indicated by the small white arrow. The larger white arrow indicates the 
direction of the flow vector. All cultures were counterstained for F-actin (red – i, ii, green – 
iii, iv, v, vi) and the nuclei (blue). Images are representative. 
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Figure 3.4: The effect of laminar shear stress on interendothelial junction protein 
expression. Confluent BBMvECs and HBMvECs were exposed to laminar shear stress (8 
dynes cm
-2
, 24 hr), following which they were harvested for whole cell mRNA and protein 
lysate. The histograms represent the mRNA expression changes in selected interendothelial 
junction proteins in BBMvECs (i) and HBMvECs (ii). The translational effect on these 
proteins was also investigated by western blot in HBMvECs (iii, iv). Results are averaged 
from three independent experiments ± SD; δP≤0.05 vs. Unsheared Control. Blots are 
representative. 
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Figure 3.5: The optimisation and subsequent effect of claudin-5 knockout on HBMvEC 
barrier function. HBMvECs were grown to 70-80% confluency and transfected with 
claudin-5 siRNA (0-50 nM) as described in section 2.2.3.5. The following day, cells were 
harvested for mRNA and protein lysate. The samples were analysed by qPCR for the 
transcriptional levels (i) and by western blot for the translational levels (ii, iii, iv) of claudin-
5 with respect to siRNA concentration. The transfection of a scrambled siRNA at 
concentrations equal to the claudin-5 siRNA was employed as a control. HBMvECs were 
thus transfected with the optimised concentration of claudin-5 siRNA, plated into transwell 
inserts and left to adhere overnight. The following day, the cultures were examined by 
transendothelial permeability assay. The histograms (v, vi) reflect the change in permeability 
(% TEE FD40) at a given time point(s) (t) = 180 mins. Results are averaged from three 
independent experiments ± SD; *P≤0.05 vs. 0 nM (i) or Untransfected Control (iv, v, vi) 
respectively. δP≤0.05. Blots are representative. 
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Figure 3.6: The optimisation and subsequent effect of VE-Cad knockout on HBMvEC 
barrier function. HBMvECs were grown to 70-80% confluency and transfected with VE-
Cadherin siRNA (0-50 nM) as described in section 2.2.3.5. The following day, cells were 
harvested for mRNA and protein lysate. The samples were analysed by qPCR for the 
transcriptional levels (i) and by western blot for the translational levels (ii, iii, iv) of VE-
Cadherin with respect to siRNA concentration. The transfection of a scrambled siRNA at 
concentrations equal to the VE-Cadherin siRNA was employed as a control. HBMvECs 
were thus transfected with the optimised concentration of VE-Cadherin siRNA, plated into 
transwell inserts and left to adhere overnight. The following day, the cultures were examined 
by transendothelial permeability assay. The histograms (v, vi) reflect the change in 
permeability (% TEE FD40) at a given time point(s) (t) = 180 mins. Results are averaged 
from three independent experiments ± SD; *P≤0.05 vs. 0 nM (i) or Untransfected Control 
(iv, v, vi) respectively. δP≤0.05. Blots are representative. 
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Figure 3.7: The effect of laminar shear stress on interendothelial junction protein 
tyrosine and threonine phosphorylation. Confluent HBMvECs were exposed to laminar 
shear stress (8 dynes cm
-2
, 24 hr), following which they were harvested for whole cell 
protein lysate. The lysates were subjected to IP/IB analysis for relative pTyr and pThr levels 
of the target protein against total target protein levels. The histograms represent the relative 
pTyr (LHS) and pThr (RHS) levels for Claudin-5 (i, iv), Occludin (ii, v) and VE-Cadherin 
(iii, vi) derived by scanning densitometry from western blots. Results are averaged from 
three independent experiments ± SD; δP≤0.05 vs. Unsheared Control. Blots are 
representative.  
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Figure 3.8: The effect of laminar shear stress on HBMvEC barrier function – effect of 
dephostatin. Confluent HBMvECs were exposed to laminar shear stress (8 dynes cm
-2
, 24 
hr) following which they were examined by transendothelial permeability. The histogram (i) 
and line graph (ii) show the change in permeability (% TEE FD40) at a given time point(s) 
(t) = 180 mins and 0-180 mins, respectively. In an independent study, HBMvECs were either 
maintained under static conditions or exposed to laminar shear stress (8 dynes cm
-2
, 24 hr) in 
the absence and presence of the protein tyrosine phosphatase inhibitor, dephostatin and 
examined for transendothelial permeability. The histogram (i) and line graph (ii) show the 
change in permeability (% TEE FD40) at a given time point(s) (t) = 180 mins and 0-180 
mins respectively. Results are averaged from three independent experiments ± SD; *P≤0.05 
vs. Control, δP≤0.05 vs. Unsheared Control (i) and Shear (ii), respectively.      
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Figure 3.9: The experimental paradigms to investigate the protective effect of laminar 
shear stress on cytokine-induced injury of HBMvECs. Two approaches were taken to 
investigate this effect; exposing confluent pre-sheared HBMvECs to laminar shear stress and 
cytokines in tandem (LHS), and exposing confluent pre-sheared HBMvECs to cytokines 
without further shear (RHS). In both setups, confluent HBMvECs were exposed to laminar 
shear stress (8 dynes cm
-2
, 24 hr) (i, v). In the first setup (LHS), the HBMvEC cultures were 
exposed to TNF-α or IL-6 (0-100 ng/ml) for 6 to 18 hr whilst the laminar shear stress was 
applied (ii). Following this the cultures were replated into transwell inserts and left to adhere 
overnight (iii) before being examined by transendothelial permeability assay (iv). In the 
second setup (RHS), HBMvECs were exposed to laminar shear stress and then replated into 
transwell inserts and left to adhere overnight (vi), following which they were exposed to 
TNF-α or IL-6 (0-100 ng/ml) for 6 to 18 hr (vii). The cultures were then examined by 
transendothelial permeability assay (viii). 
Legend: Red Stars-Cytokines (TNF-α/IL-6), Green Stars-FITC dextran    
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Figure 3.10: The effect of laminar shear stress on TNF-α-induced injury of HBMvECs. 
Confluent HBMvECs were pre-conditioned by laminar shear stress (8 dynes cm
-2
, 24 hr), 
following which TNF-α (0-100 ng/ml) was added to the cultures. The laminar shear stress 
was continued for an additional 6 or 18 hr. Post-treatment, the cultures were replated into 
transwell inserts and left to adhere overnight before being examined by transendothelial 
permeability. The histograms and line graphs show the change in permeability (%TEE 
FD40) at a given time point(s) (t) = 180 mins and 0-180 mins after 6 hr (i) and 18 hr (ii) 
exposure to TNF-α (0-100 ng/ml). Results are averaged from three independent experiments 
± SD; *P≤0.05 vs. Unsheared Control. εP≤0.05 vs. Sheared Control. 
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Figure 3.11: The effect of laminar shear stress on IL-6-induced injury of HBMvECs. 
Confluent HBMvECs were pre-conditioned by laminar shear stress (8 dynes cm
-2
, 24 hr), 
following which IL-6 (0-100 ng/ml) was added to the cultures. The laminar shear stress was 
continued for an additional 6 or 18 hr. Post-treatment, the cultures were replated into 
transwell inserts and left to adhere overnight before being examined by transendothelial 
permeability. The histograms and line graphs show the change in permeability (%TEE 
FD40) at a given time point(s) (t) = 180 mins and 0-180 mins after 6 hr (i) and 18 hr (ii) 
exposure to TNF-α (0-100 ng/ml). Results are averaged from three independent experiments 
± SD; *P≤0.05 vs. Unsheared Control. εP≤0.05 vs. Sheared Control. 
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Figure 3.12: The effect of laminar shear stress on cytokines and their signal-
transducing receptors.  Confluent HBMvECs were exposed to laminar shear stress (8 
dynes cm
-2
, 0-24 hr) following which they were harvested for whole cell mRNA. The 
samples were analysed by qPCR for the transcriptional levels TNFR1 (i), TNFR2 (ii), 
GP130 (iii) and IL-6 (iv). Results are averaged from three independent experiments ± SD; 
*P≤0.05 vs. 0 hrs 
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Figure 3.13: The effect of laminar shear stress on thrombomodulin expression, 
secretion and activity. Confluent HBMvECs were maintained under static conditions or 
exposed to laminar shear stress (8 dynes cm
-2
, 0-24 hr) following which they were harvested 
for whole cell protein and conditioned medium. Whole cell protein lysate was examined by 
western blot to investigate the translational change in thrombomodulin expression (i, ii). The 
conditioned medium was examined by ELISA to monitor the effect on thrombomodulin 
release in the absence or presence of shear forces (iii). The activity of released 
thrombomodulin in conditioned medium was also examined by implementing barrier-
permeabilising thrombin into a permeability assay. Conditioned medium was concentrated to 
a specific concentration of thrombomodulin as monitored by the ELISA (3 ng and 6 ng of 
TM) and added in tandem with 2U of thrombin to confluent HBMvEC cultures in transwell 
inserts for 30 mins. Post treatment, the confluent monolayers were examined for 
transendothelial permeability. The histograms shows the change in permeability (%TEE 
FD40) at (t) = 180 mins. Results are averaged from three independent experiments ± SD; 
*P≤0.05 vs. 0 hrs, *P≤0.05 vs. Unsheared Control, δP≤0.05 vs. Static         
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3.3 Discussion 
Given the functional diversity and broad metabolic requirements of the brain, sustainment of 
homeostasis is of utmost importance. In vivo, the BBB is physiologically regulated by a 
number of signalling mediators that includes both humoral and hemodynamic stimuli. 
Together, these stimuli promote a BBB phenotype functionally capable of protecting the 
CNS from the fluctuations in concentrations of ions, neurotransmitters, blood-borne factors 
and particularly toxins/pathogens in the microenvironment that may disrupt neuronal/glial 
function. The majority of experimental data to date has focussed on co-culturing models that 
aim to recreate the BBB-inducing microenvironment, and whilst these models have proven 
invaluable in broadening our understanding of BBB, many lack the fundamental 
hemodynamic aspect. Shear stress plays a crucial role in neural homeostasis and 
pathophysiology of the cerebral microvasculature (Krizanac-Bengez, Kapural et al. 2003, 
Krizanac-Bengez, Mayberg et al. 2004, Krizanac-Bengez, Hossain et al. 2006, Krizanac-
Bengez, Mayberg et al. 2006). In this chapter the aim was to investigate the effect of 
physiological levels of laminar shear stress on HBMvECs and to assess what impact (if any) 
was imparted on some of the key functional parameters associated with the BBB phenotype.      
Our initial objective was to establish a culture regime in which HBMvEC phenotype could 
be sustained and thus characterised. Our HBMvECs were commercially bought and were 
primary-derived, thus expressing the phenotypic properties associated with BBB. However, 
differentiation to a ‘default’ endothelial phenotype is problem commonly associated with 
primary-derived endothelial cultures. Culture techniques absent of the requisite inductive 
forces necessary to stabilise phenotypic properties are the primary cause of such 
(Ballermann, Ott 1995, Ott, Ballermann 1995, Reichel, Begley et al. 2003). A number of 
molecular cell markers were selected for examination by qPCR, western blot and 
immunofluorescence. Once an effective culturing regime was established based on typical 
cell doubling time and morphological characteristics, the HBMvECs were harvested and 
prepared for analysis. vWF is a typical marker of endothelial cells (Jaffe, Nachman et al. 
1973, Jaffe, Hoyer et al. 1973) and, according to the cell datasheet, is a routinely examined 
marker for confirming successful isolation of the cerebral endothelial tissue. We examined 
the expression of vWF and successfully verified its presence in the cell population in 
response to our culture conditions. An additional marker utilised by both the company from 
whom we procured the cells was ZO-1, an important physiological mediator of tight junction 
assembly (Lee, Zeng et al. 2006). As a primary focus of this thesis was to monitor the effect 
of different stimuli on HBMvEC barrier function, the sustained expression of intercellular 
junction proteins was of utmost importance. We examined the expression of ZO-1, claudin-
5, VE-Cadherin and occludin and successfully verified their presence in the cell population 
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in response to our culture conditions, thus confirming we could effectively culture and 
maintain BBB properties in our primary-derived cultures, (Weksler, Subileau et al. 2005).  
We next shifted our focus onto examining the effect of laminar shear stress on HBMvECs. 
In the absence of haemodynamic forces, confluent cultures of endothelial cells present a 
‘cobblestone’-like morphology. When we examined structural components of the cells, such 
as the actin cytoskeleton, we observed a lack of orientation, with the cell alignment random 
and multidirectional. Following exposure of the cell cultures to physiological levels of 
laminar shear stress (8 dynes cm
-2
) (Desai, Marroni et al. 2002), the cell population became 
elongated with the primary axis orientated to the direction of the haemodynamic force 
(Goode, Davies et al. 1977, Nerem, Levesque et al. 1981). Subsequent examination of the 
actin cytoskeleton showed that the actin fibres had also become orientated in the direction of 
the flow vector, presenting a much more organised structure (Wechezak, Wight et al. 1989, 
Kim, Gotlieb et al. 1989, Kim, Langille et al. 1989, Galbraith, Sheetz 1998, Galbraith, 
Skalak et al. 1998). As one of our primary objectives was to examine the effect of laminar 
shear on barrier function and we had optimised a number of immunofluorescence labels for 
some of the intercellular junction proteins, we subsequently conducted some preliminary 
work on the localisation and expression of each protein following exposure to our shear 
stress regime. Cultures maintained in a static environment demonstrated consistent 
expression of each of the examined intercellular junction proteins of interest, with 
predominant localisation at the cell-cell border (Weksler, Subileau et al. 2005). In 
comparison, following exposure to laminar shear stress, a sharper, more well-defined 
localisation of each protein along the cell border was observed. Expression of each protein 
was enhanced with distribution more constant in comparison to static cultures. Previous 
work in our group demonstrated a similar response in ZO-1, claudin-5 and occludin in 
BBMvECs (Colgan, Ferguson et al. 2007, Walsh, Murphy et al. 2011).  
In the early stages of model development, BBMvECs were often employed as a control 
given our groups experience with that particular cell line in the past (Colgan, Ferguson et al. 
2007, Colgan, Collins et al. 2008, Walsh, Murphy et al. 2011). Previous work in our group 
using BBMvECs had demonstrated an increase in the expression of intercellular junction 
proteins following exposure to laminar shear stress by immunofluorescence techniques 
(Colgan, Ferguson et al. 2007, Walsh, Murphy et al. 2011). We decided to explore this 
increase in expression on a molecular level in both HBMvECs and BBMvECs.  Following 
24 hrs exposure to laminar shear stress the transcription levels for occludin, claudin-5, VE-
Cadherin and ZO-1 displayed a significant increase in comparison to control static cultures. 
We carried this paradigm forward with HBMvECs to examine the effect of this increase on a 
translational level with a similarly significant increase in protein levels observed. Colgan 
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(Colgan, Ferguson et al. 2007) noted a similar increase in transcription and translation levels 
of both occludin and ZO-1 in BBMvECs following exposure to laminar shear stress. A 
number of other studies have reported similar trends with regards to the transcription and 
translation for both occludin and ZO-1 in addition to VE-Cadherin and claudin-5 in response 
to shear stress (Schnittler 1998, Cucullo, Hossain et al. 2011).    
Following the shear-dependent trends observed with the intercellular junction proteins, we 
then decided to investigate whether any post-translational modifications were taking place 
following exposure to laminar shear stress. We found with regards to claudin-5, occludin 
and VE-Cadherin, that a significant reduction in the phosphorylation of tyrosine and 
threonine residues took place following 24 hrs exposure to laminar shear stress. This 
objective expanded on work previously done within our group; Walsh (2011) demonstrated 
a shear-induced reduction in pTyr levels of occludin in BBMvECs following exposure to 
laminar shear stress. A number of studies based in other vascular beds have also implicated 
tyrosine (Demaio, Chang et al. 2001, Young, Sui et al. 2003) and threonine (Soma, Chiba et 
al. 2004) in modulating endothelial barrier function. Additionally, this study primarily 
focussed one (i.e. the phosphorylation state) of many potential post-translational 
modifications of a number of key proteins examined can undergo. Protein turnover, 
trafficking and ubiquitination to name a few are critical aspects presently unexplored with 
respect to our body of work and are expected to play potentially as large a role of the 
phosphorylation state in HBMvEC barrier dynamics.    
To summarise at this point, we could successfully maintain the HBMvEC phenotype and 
demonstrated that upon exposure to laminar shear stress, an upregulation in the key 
intercellular junction proteins was observed, in parallel with changes in their 
phosphorylation state (likely affecting tight junction assembly). We also decided to examine 
the impact of these expressional changes on HBMvEC barrier function. Induced expression 
of occludin and ZO-1 has previously been correlated to improved barrier function in 
BBMvECs (Colgan, Ferguson et al. 2007, Siddharthan, Kim et al. 2007, Colgan, Collins et 
al. 2008). Collins (Collins, Cummins et al. 2006) demonstrated that physiological cyclic 
strain of BAECs caused an increase in occludin expression in parallel with a reduction in 
phosphorylation of tyrosine and threoine residues, the cumulative effect of which coincided 
with an increase in barrier function. Using our established transwell permeability assay, we 
found that cultures pre-exposed to laminar shear stress demonstrated a significant reduction 
in permeability (ergo, a significant increase in barrier function) in comparison to control 
static cultures. Logically, the reduction in permeability could be attributed to the increase in 
intercellular junction protein levels (Colgan, Ferguson et al. 2007, Siddharthan, Kim et al. 
2007, Colgan, Collins et al. 2008). In a parallel study, we utilised siRNA techniques to 
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ablate the presence of claudin-5 and VE-Cadherin independent of one another to investigate 
the impact of each protein’s expression on barrier integrity. We found that independent 
knockout of claudin-5 and VE-Cadherin induced a significant increase in monolayer 
permeability. This reduction in barrier was consistent with similar studies in which 
interference with/knockout of VE-Cadherin (Xu, Waters et al. 2007) and claudin-5 (Nitta, 
Hata et al. 2003, Argaw, Gurfein et al. 2009, Morrow, Tyagi et al. 2009) lead to disruption 
of the cellular barrier properties. Thus, if knockout of their expression induces a significant 
reduction in barrier function, an increase in their expression should (as was demonstrated) 
result in a subsequent increase in barrier function.  
The effect of interfering with phosphorylation events on shear-induced barrier enhancement 
was also investigated. Interestingly, cultures pre-exposed to laminar shear stress in the 
presence of a tyrosine phosphatase inhibitor, dephostatin, demonstrated a significant 
blockade in the shear-mediated reduction of permeability, strongly implicating tyrosine 
dephosphorylation as a key mechanism in the protective effect of laminar shear stress on 
HBMvEC cultures. Walsh (2011) demonstrated a similar effect in BBMvECs based on the 
blockade of shear-induced occludin pTyr dephosphorylation using dephostatin. A study by 
Takenaga (2009) adds weight to this notion by showing that inhibition of tyrosine 
phosphorylation of occludin reduced BBB leakage in isolated brain capillaries. Whilst much 
has been reported on the phosphorylation of TJ/AJ proteins with respect to barrier 
modulation, data specific to the human brain microvasculature is limited. Whilst studies 
have demonstrated that injury-induced elevation of pTyr and pThr levels on the 
interendothelial junction proteins correlated with increased BBB dysregulation (Soma, 
Chiba et al. 2004, Haorah, Knipe et al. 2005, Haorah, Heilman et al. 2005, Stamatovic, 
Dimitrijevic et al. 2006, Yamamoto, Ramirez et al. 2008, Willis, Meske et al. 2010), very 
little focus has been placed upon the relationship between protective forces (i.e. shear stress) 
and phosphorylation (and in particular on pThr phosphorylation events). In one of the few 
studies pertaining to this area, Walsh (2011) demonstrated silencing of VE-Cadherin in 
BBMvECs had a significant impact on the shear-induced dephosphorylation of occludin 
which in turn had a negative impact on monolayer barrier function. This identified a novel 
cross-talk between VE-Cadherin and occludin suggesting occludin’s functional capacity 
would reduce in the absence of VE-Cadherin underlying the importance of VE-Cadherin in 
BBB formation and sustainment. Our studies represent the first comprehensive approach to 
examining these events within the human BBB.    
Having confirmed that laminar shear stress can induce barrier ‘strengthening’ in confluent 
HBMvEC cultures, we decided to test the degree of barrier protection exerted by shear in the 
presence of an injurious stimulus. A number of inflammatory cytokines have been shown to 
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exert a destabilising effect on endothelial barriers (the effect of TNF-α and IL-6 is covered in 
more detail in Chapter 4). We aimed to investigate the co-exposure of HBMvECs to laminar 
shear stress and inflammatory cytokines to determine if the protective influence of shear 
extends to a pro-inflammatory injury. We found that exposure of HBMvECs to laminar 
shear stress in the presence of either TNF-α or IL-6 (1-100 ng/ml) gave lower absolute 
increases in FITC-Dextran flux when compared to treatment of static cultures with cytokines 
alone. We concluded from this that shear stress can protect barrier phenotype within the 
cerebral endothelium from other pro-inflammatory stimuli. Consistent with this, Yoshizumi 
(2003) demonstrated in HUVECs that steady laminar flow inhibited cytokine-activation of 
MAPK pathways. A number of other studies corroborate the protective influence shear stress 
has in tissue simultaneously exposed to inflammatory stimuli (Surapisitchat, Hoefen et al. 
2001, Berk, Abe et al. 2001, Berk, Min et al. 2002, Yamawaki, Lehoux et al. 2003, Ni, 
Hsieh et al. 2004).   
Overall, the reduction in cytokine induced damage could be possibly accredited to the 
increase in the expression of intercellular junction proteins and/or the shear-dependent 
tyrosine and threonine dephosphorylation of interendothelial junction proteins. Other 
mechanisms cannot be excluded. For example, nitric oxide is a key component in the 
regulation of vascular tone, and has been shown to induce a number of protective properties 
within the vascular walls (Harrison, Widder et al. 2006). Physiological laminar shear stress 
represents the most potent stimulus for continuous production of NO by the endothelium, an 
effect mediated at both the transcriptional level (via upregulation of eNOS (Lam, Peterson et 
al. 2006)) or at the translational level (via eNOS protein phosphorylation and activation (Go, 
Boo et al. 2001)). Thus, disturbance or removal of shear stress drastically reduces the 
bioavailability of NO in the afflicted area exposing the endothelium to the dysfunctional 
effect of local and systemic risk factors (Ziegler, Bouzourene et al. 1998, Ziegler, Silacci et 
al. 1998, Qiu, Tarbell 2000, Cheng, van Haperen et al. 2005, Harrison, Widder et al. 2006, 
Gambillara, Chambaz et al. 2006). Reduction or removal of shear forces has also been seen 
to promote damaging effects such as ROS (Mohan, Koyoma et al. 2007) (examined in 
greater detail in Chapter 5). Enhancement of the transcription and post transcriptional 
activity of major oxidative enzymes such as (NADPH) oxidase and xanthine oxidase has 
been reported in endothelium in the absence of non-physiological levels of shear stress 
(McNally, Davis et al. 2003, Hwang, Saha et al. 2003, Hwang, Ing et al. 2003, Harrison, 
Widder et al. 2006). Parallel to this, a reduction in ROS scavengers such as manganese 
superoxide dismutase and glutathione may further augment ROS damage (Mueller, Widder 
et al. 2005). Importantly, our work also demonstrated the influence of shear on cytokine 
signal-transducing receptors; TNFR1, TNFR2 and gp130. We found that within 2 hrs of 
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exposure to laminar shear stress, each cytokine receptor demonstrated a significant change in 
mRNA levels; TNFR1 and gp130 both increased while TNFR2 was decreased. Within 8 hrs, 
transcription levels for all three returned to baseline levels and in the case of TNFR1, this 
level was sustained up to 24 hrs. In contrast, TNFR2 transcription levels continued to rise 
with a significant increase observed after 24 hrs. Several experimental paradigms have 
investigated the independent effects of cytokine-receptor expression and hemodynamic 
forces on mediating cytokine-receptor signalling, however studies are scarce in relation to 
the effect of said hemodynamic forces on cytokine-receptor expression, particularly in the 
microvasculature of the brain. Whilst we have yet to examine the effect of shear stress on 
cytokine-receptor protein level, similar studies in other cell models have noted a similar 
‘protective’ effect imparted by hemodynamic forces in relation to the expression, and mostly 
cleavage, of cytokine receptors. Wang (Wang, Lv et al. 2011) observed a reduction in TNF-
α-induced apoptosis via shear stress-induced reduction of TNFR1 cell-surface expression.   
We expanded this study to include some of the factors known to be released by HBMvECs 
and in some cases transduce their signal through these surface receptors. For instance, we 
found in the case of IL-6, mRNA levels spiked within 2 hrs of shear exposure. However, 
within 24 hrs an overall decrease in IL-6 levels was observed. Given the parallel reduction in 
gp130 receptor expression in conjunction with IL-6 ligand, this relationship may represent 
an additional reason for the shear-induced reduction in cytokine afflicted damage to 
HBMvEC barrier integrity. Interestingly, a significant increase in IL-6 protein expression 
was observed following shear, in contrast to our mRNA studies. We also examined the 
effect of laminar shear stress on IL-6 release. Interestingly, laminar shear stress drove up the 
release of IL-6 within 2 hrs as compared to static control cells. However, this spike in IL-6 
release plateaued from 8 hrs onward in contrast to control static cultures. It is plausible that 
laminar shear stress, despite causing a surge in the acute phase of exposure, downregulates 
cytokine production and release over chronic time frames (i.e. beyond the experimental 24 
hrs). This is consistent with a study by Passerini (Passerini, Polacek et al. 2004) that 
demonstrated a reduction in the transcription levels in vivo for a number of pro-
inflammatory cytokines (IL-6 included) in areas pre-disposed to uniform laminar shear stress 
as compared to areas of disturbed flow. Conversely, in vitro, shear stress has been shown to 
stimulate the release of IL-6 from endothelial cells (Sterpetti, Cucina et al. 1993, Krizanac-
Bengez, Kapural et al. 2003) though studies examining this relationship in the 
microvasculature, much like that of the cytokine-receptors, are scarce.        
Laminar shear stress appeared to be a positive influence on our HBMvEC cultures, inducing 
a ‘protected’ phenotype via augmentation of integral proteins (i.e. the intercellular junctions) 
and repression of pro-inflammatory mediators and their receptors (e.g. IL-6 and gp130). 
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Tian (2013) previously demonstrated how exposure of rat BMvEC to laminar shear stress 
reduced ischemia-induced apoptosis. Song (2001) demonstrated how chronic exposure of 
BMvECs to laminar shear stress reduced the expression of adhesion molecules implicated in 
the recruitment of immune cells which accelerate inflammatory responses (i.e. ICAM-1). 
Aside from driving down the release of pro-inflammatory mediators, we investigated 
whether laminar shear stress could induce the release of any anti-inflammatory mediators. 
Since a pivotal function of the endothelium is to regulate the coagulation cascade by 
maintaining anticoagulant activity and an anti-thrombotic surface, we investigated this 
hypothesis via thrombomodulin, an endothelial surface molecule capable of converting pro-
inflammatory/pro-coagulant thrombin to an anti-coagulant molecule upon binding (Dittman, 
Majerus 1990). Following exposure to laminar shear stress, thrombomodulin protein 
expression and release was significantly increased in comparison to control static cultures. 
This was consistent with results obtained in other microvascular endothelial cell models 
(Takada, Shinkai et al. 1994, Kawai, Matsumoto et al. 1997, Ishibazawa, Nagaoka et al. 
2011). We decided to further expand this concept by attempting to test the potency/activity 
of the shear-released thrombomodulin. HBMvEcs were prepared for assessment of barrier 
function in response to pro-inflammatory thrombin by our transwell permeability assays. 
Binding of thrombin to its receptor PAR-1 has been proven to cause a number of pro-
inflammatory gene expressional changes in ECs that induces an increase in paracellular 
permeability (Bogatcheva, Garcia et al. 2002, Guan, Sun et al. 2004), in addition to 
promoting coagulation via platelet activation and several pro-coagulant factors. We observed 
that shear-conditioned medium (containing released thrombomodulin) could neutralise the 
ability of thrombin to induce HBMvEC barrier dysfunction. This not only confirmed our 
hypothesis that laminar shear stress also induced the release of barrier-protective agents, but 
also confirmed a role for laminar shear stress in mediating the anti-coagulative phenotype 
associated with a healthy endothelium. The concept that increased endothelial release of 
thrombomodulin acts as a protective agent within the vasculature has been explored in vivo 
and is consistent with our data (Giwa, Williams et al. 2012).  
In parallel studies, the effect of laminar shear stress on vWF; a co-factor for a number of 
molecules involved in the coagulation cascade, was investigated. Although vWF release in 
has yet to be explored in our model, its transcription levels displayed a significant decrease 
after 24 hrs exposure to laminar shear. In contrast, a significant increase in translational 
levels was observed in whole cell protein lysate. Galbusera (1997) observed an increase in 
endothelial release of vWF following exposure to shear stress. Having observed a negligible 
change in the transcription levels of the protein, they accredited the consequent increase in 
vWF release to shear-mediated enhancement of secretory pathways. However, their 
164 
 
exposure times were within the confines in which we also saw very little change. Similar to 
the trends seen with IL-6, it is possible that laminar shear stress may downregulate vWF 
production and release over chronic time frames. In vivo studies have shown areas 
predisposed to disturbed shear demonstrate elevated vWF expression and release, 
highlighting the potential role of laminar shear stress on regulating vWF pro-coagulant 
activity (Rand, Badimon et al. 1987, Wu, Drouet et al. 1987, Badimon, Badimon et al. 
1993).   
In conclusion, we have comprehensively demonstrated how laminar shear stress plays a 
pivotal role in the maintenance of vascular homeostasis and BBB phenotype through 
modulation of interendothelial protein expression and post-translational modification, as 
well as modulation of endothelial anti-inflammatory mechanisms and responsiveness to 
cytokine injury. 
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Chapter 4: 
The effects of inflammatory cytokines; TNF-
α and IL-6, on HBMvEC blood-brain barrier 
properties. 
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4.1 Introduction 
In chapter 3, the effects of physiological levels of blood flow-associated laminar shear stress 
on HBMvEC cultures were investigated. Following exposure, several aspects of the BBB 
phenotype were seen to be enhanced. Transcription and translation of most of the key 
proteins that comprise the tight and adherens junctions were seen to be upregulated. Parallel 
immunofluorescence studies demonstrated this increase coincided with an enhancement in 
said protein localisation at the cell-cell borders. In addition, each protein was seen to 
undergo post-translational modification, with tyrosine and threonine residues 
dephosphorylated; a process that upon inhibition partially reduced the shear-mediated 
increase in HBMvEC barrier function implicating phosphorylation as a key regulatory event 
in HBMvEC barrier regualtion. Moreover, laminar shear stress also appeared to exert a 
‘protective’ effect on the endothelium by promoting a number of anti-inflammatory 
mechanisms as seen by the simultaneous release of anti-inflammatory molecules, and 
reduction in pro-inflammatory mediators and their signal-transducing receptors. Taken 
together, laminar shear stress was seen to promote a protected BBB phenotype, so much so 
that in the presence of inflammatory cytokines, laminar shear stress exerted a protective 
effect, partially ameliorating their well characterised BBB-destabilising effects. 
Overall, the inductive and protective effect of laminar shear stress on BBB phenotype was 
comprehensively investigated in chapter 3. Several studies have demonstrated the inductive 
effect of haemodynamics forces on the endothelium across several vascular beds, with 
abrogation of these forces promoting entirely different endothelial phenotypes (Davies 
1995). Several points within the vasculature (i.e. bifurcations, branching points and 
curvatures) experience low or disturbed shear stress profiles. Several mechanoreceptors 
detect these changes and generate an integrative response which typically results in changes 
in the profiles of nitric oxide and reactive oxygen species, while several classical signalling 
pathways involving kinases and GTPases are altered in parallel to multiple transcription 
factors. Chronic attenuation of shear stress activates several pro-inflammatory pathways, 
resulting in a drastic remodelling of the endothelium that coincides with altered functions; 
causing a pro-coagulant surface, increased expression of adhesion receptors, the active 
recruitment of immune cells and an overall reduction in barrier function (Hahn, Schwartz 
2009). With regards to the NVU, said dysfunction of the cerebral endothelium that 
comprises the BBB is associated with the pathophysiology of several neurological disorders 
(e.g. stroke, multiple sclerosis, Alzheimer’s disease). Therefore, understanding the 
mechanisms that underlie BBB dysfunction may lead to the identification of new therapeutic 
targets.   
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Aside from haemodynamic forces, several other local and systemic environmental factors 
can mediate inflammatory events in the brain, leading to BBB dysfunction. Growth factors, 
cytokines, hormones, lipids, electrolytes, bacterial and viral products are just some of the 
many factors present in the circulation or secreted by cell-types in the microenvironment that 
can impact greatly on endothelial phenotype and thus function (Charo, Ransohoff 2006). 
For chapter 4, we decided to focus the parallel pathophysiological aspect of our study on a 
selection of inflammatory cytokines known to be present in the cerebromicrovasculature; 
TNF-α, IL-6 and MCP-1. Cytokines can activate a myriad of signalling pathways that at 
times can be beneficial, although increased levels are more commonly associated with the 
initiation, progression and activation of several neurological diseases, mediated in part via 
dysfunctional endothelium and BBB disruption (Abbott 2000, Hawkins, Davis 2005). Unlike 
laminar shear stress, a wealth of data is available directly linking the effects of cytokines to 
numerous cerebral processes, be they beneficial or harmful. However, the direct and indirect 
effect of these cytokines on interendothelial TJ/AJ properties, particularly on primary human 
brain microvascular endothelial cultures, is limited. 
 
4.1.1 Study Aims 
In this chapter we examine the individual impact of inflammatory cytokines; TNF-α and IL-
6, on HBMvEC blood-brain barrier phenotypic properties. Therefore, the overall aims of this 
chapter include: 
 To conduct basic characterisation studies of TNF-α and IL-6 on HBMvECs.  
 To investigate the effect of TNF-α and IL-6 on TJ/AJ protein (occludin, claudin-5, 
VE-Cadherin, ZO-1) transcriptional and translational expression. 
 To investigate the effect of TNF-α and IL-6 on TJ/AJ protein phosphorylation. 
 To investigate the effect of TNF-α and IL-6 on HBMvEC barrier function.  
 To determine if TNF-α and IL-6 influence HBMvEC anti-inflammatory properties.     
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4.2.1 Exposure of HBMvECs to TNF-α or IL-6 has no significant impact on cell 
viability 
The effect of TNF-α and IL-6 on HBMvEC viability was examined (Figure 4.1-4.5). 
Confluent HBMvECs were stimulated with TNF-α or IL-6 (0-100 ng/ml) for 6 or 18 hrs. 
Post-treatment, cells were harvested and prepared for analysis by flow cytometry. Annexin 
V and PI stains were employed to assess the stage and respective degree of cytokine-induced 
damage. Using parameters deduced from positively stained cells (Figure 4.1), there were no 
significant changes in cell viability, membrane disruption or necrosis induced by TNF-α or 
IL-6 with respect to either dose or time (Figure 4.2-4.4). Complimentary studies examined 
the effect of TNF-α and IL-6 on other aspects pertaining to endothelial homeostasis (Figure 
4.5). Confluent HBMvECs of a known density were stimulated with TNF-α or IL-6 (0-100 
ng/ml) for 6 or 18 hrs. Post-treatment the conditioned medium was harvested and replated 
into fresh cultures dishes. The metabolic activity of treated cells was examined using MTS 
reagent. A significant decrease in metabolic activity with respect to time and dose was 
observed in response to TNF-α and IL-6 treatment (i, iv). In parallel, the replated harvested 
medium was examined for LDH release. No significant changes in LDH levels were 
observed after 6 hrs treatment with TNF-α or IL-6 across all doses; although slight-to-
moderate increases after 18 hrs treatments were observed with both cytokines (ii, v). Finally 
the cellular morphology and adhesion profile of HBMvECs in response to TNF-α and IL-6 
was examined using the xCelligence® system. HBMvECs were seeded to a known density 
on E-Plates and allowed to adhere overnight. The following day the cultures were treated 
with TNF-α or IL-6 (0-100 ng/ml) and monitored for 24 hrs. The xCelligence® data showed 
a slight non-significant decrease in HBMvEC Cell Index (%) in response to TNF-α and IL-6 
with respect to dose and time indicating that the cellular monolayer remained intact 
throughout the treatment (iii, vi). This data was backed up by bright field microscope 
observations. 
 
4.2.2 Exposure of HBMvECs to either TNF-α, IL-6 or MCP-1 initiates the expression 
and release of inflammatory mediators 
The effect of TNF-α, IL-6 and MCP-1 on the secretory profile of HBMvECs was examined 
(Figure 4.6). Confluent HBMvECs were stimulated with TNF-α, IL-6 or MCP-1 (0-100 
ng/ml) for 6 or 18 hrs. Post-treatment, cells were harvested for whole cell protein lysate and 
conditioned medium for analysis by multiplex ELISA. The multiplex ELISA facilitated the 
concurrent examination of four well known inflammatory mediators; IFNγ, IL-1β, IL-6 and 
TNF-α (i, ii). Post-analysis, interesting trends such as the release of IL-6 were repeated on 
standard single-plex ELISAs to verify multiplex results. TNF-α, IL-6 and MCP-1 all induced 
169 
 
a significant increase in IL-6 release from HBMvECs in both a time- and dose-dependent 
manner in comparison to control cultures (iii).  
The effect of TNF-α and IL-6 on the release of other injury markers, namely 
thrombomodulin (Figure A.8) and vWF (Figure A.9) was also investigated. These cytokines 
had contrasting effects on each marker. A significant decrease in thrombomodulin protein 
expression was observed in HBMvECs in response to TNF-α with respect to dose and time 
(Figure A.8; i, iii). However, a significant increase was observed in secreted 
thrombomodulin in conditioned medium (v, vii). In contrast a significant increase in vWF 
protein and mRNA expression was observed in response to TNF-α with respect to dose and 
time (Figure A.9; i, iii, v, vii).  A similar trend is observed in parallel experiments utilising 
IL-6 in place of TNF-α (Figure A.8 and A.9; ii, iv, vi, viii).    
 
4.2.3 Exposure of HBMvECs to TNF-α and IL-6 induces a downregulation of barrier 
function 
The effect of TNF-α and IL-6 on the barrier function of HBMvECs was examined (Figure 
4.7). HBMvECs were seeded at a known density into transwell inserts and left to adhere 
overnight. The following day the confluent HBMvECs were stimulated with TNF-α or IL-6 
(0-100 ng/ml) for 6 or 18 hrs. Post-stimulation, the cellular monolayers were assessed for 
transendothelial permeability. Exposure of HBMvECs to either cytokine results in a 
significant increase in FITC-Dextran paracellular flux (%TEE of FD40) across the cell 
monolayer with respect to dose and time (i-viii).  
 
4.2.4 Exposure of HBMvECs to TNF-α and IL-6 induces a downregulation of the 
transcriptional levels of interendothelial junction proteins; occludin, claudin-5, VE-
Cadherin and ZO-1 
The effect of TNF-α and IL-6 on the expression of proteins involved in forming the 
intercellular junctions of the BBB was examined on the transcriptional level (Figure 4.8).  
Confluent HBMvECs were stimulated with TNF-α or IL-6 (0-100 ng/ml) for 6 or 18 hrs 
before being harvested for whole cell mRNA. The mRNA levels of occludin, claudin-5, VE-
Cadherin and ZO-1 were examined by qPCR. Each protein demonstrated a significant 
decrease in their mRNA levels following exposure to either TNF-α or IL-6 in both a time- 
and dose-dependent manner in comparison to control cultures (i-viii).  
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The effect of TNF-α and IL-6 on cytokine signal-transducing receptors over time was also 
examined on a transcriptional level (Figure A.10). Confluent HBMvECs were stimulated 
with TNF-α or IL-6 (0-100 ng/ml) for 0-24 hrs before being harvested for whole cell mRNA. 
The mRNA levels of TNF-α receptors TNFR1 and TNFR2 and IL-6 receptor GP130 were 
examined from 0-24 hrs by qPCR. A significant increase was observed for all three receptors 
in response to acute cytokine treatment (0-4 hrs). TNFR1 and GP130 transcription levels 
continued to increase in response to either cytokine up to 24 hrs. Conversely, TNFR2 
returned to baseline levels within 8 hrs of TNF-α or IL-6 stimulation and continued to 
decrease thereafter.   
4.2.5 Exposure of HBMvECs to TNF-α and IL-6 induces a downregulation of the 
translational levels of interendothelial junction proteins; occludin, claudin-5, VE-
Cadherin and ZO-1 
The effect of TNF-α and IL-6 on the expression of proteins involved in forming the 
intercellular junctions of the BBB was examined on the translational level (Figure 4.9).  
Confluent HBMvECs were stimulated with TNF-α or IL-6 (0-100 ng/ml) for 6 or 18 hrs 
before being harvested for whole cell protein lysate. The protein levels of occludin, claudin-
5, VE-Cadherin and ZO-1 were examined by western blot (i, ii). Each protein demonstrated 
a significant decrease in their transcription levels following exposure to TNF-α or IL-6 in 
both a time and dose-dependent manner in comparison to control cultures (iii-x).  
 
4.2.6 Exposure of HBMvECs to TNF-α and IL-6 increases phosphotyrosine and 
phosphothreonine levels of occludin, claudin-5 and VE-Cadherin 
The effect of TNF-α and IL-6 on the phosphorylation levels of tyrosine and threonine 
residues of interendothelial junction proteins occludin, claudin-5 and VE-Cadherin was 
examined (Figure 4.10, 4.11).  Confluent HBMvECs were stimulated with TNF-α or IL-6 
(0-100 ng/ml) for 6 or 18 hrs before being harvested for whole cell protein lysate. Samples 
were then subjected to immunoprecipitation and western blot analysis for phosphotyrosine 
(pTyr)- and phosphothreonine (pThr)-levels. pTyr- and pThr-levels for occludin, claudin-5 
and VE-Cadherin were seen to be significantly increased in both a time- and dose-dependent 
manner following exposure to TNF-α (Figure 4.10) or IL-6 (Figure 4.11) in comparison to 
control cultures. 
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4.2.7 Exposure of HBMvECs to TNF-α and IL-6 induces a downregulation of barrier 
function via tyrosine kinase activity 
The effect of TNF-α and IL-6 on the barrier function of HBMvECs was examined with a 
focus on the role to tyrosine kinases (Figure 4.12). HBMvECs were seeded at a known 
density into transwell inserts and left to adhere overnight. The following day the confluent 
HBMvECs were pre-treated with genistein 1 hr prior to stimulation with either TNF-α or IL-
6 (0-100 ng/ml) for 6 or 18 hrs. Post-stimulation, the cellular monolayers were assessed for 
transendothelial permeability. Exposure of HBMvECs to TNF-α (i-iv) and IL-6 (v-viii) 
results in a significant increase in FITC-Dextran paracellular flux (%TEE of FD40) across 
the cell monolayer with respect to dose and time. The cytokine-induced increase of 
permeability in HBMvECs was significantly attenuated when genistein was present during 
exposure of the cultures to TNF-α or IL-6.  
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Figure 4.1: The effect of H2O2 on HBMvEC Viability-Flow Cytometry, Positive 
Controls. In order to effectively gate cell viability by means of flow cytometry, positively 
stained cells were required. Confluent HBMvECs were stimulated with 1 mM H2O2 
overnight. The following day the entire cell population was harvested and prepared for flow 
cytometry analysis accordingly. The dot plots represent unstained control (i), injured cells 
single stained with PI (ii), injured cells single stained with Annexin V (iii) and injured cells 
double stained with PI and Annexin V (iv). The efficacy of the flow cytometry stains was 
also examined by immunofluorescence. HBMvECs were seeded onto coverslips and grown 
to confluency before being treated with 1mM H2O2 overnight. The following day the 
coverslips were stained with Annexin V and PI and examined by immunofluorescence 
microscopy (v). Images are representative.    
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Figure 4.2: The effect of TNF-α on HBMvEC viability-Flow Cytometry. Confluent 
HBMvECs were stimulated with TNF-α (0-100 ng/ml) for 6 and 18 hr, respectively. Post-
treatment the entire cell population was harvested and subsequently prepared for flow 
cytometry analysis using Annexin V and PI stains.  The dot plots represent the spread of the 
cell populations as a result of the flow cytometry stains, which reflect the degree of injury 
inflicted by TNF-α. Dot plots are representative of three independent experiments. 
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Figure 4.3: The effect of IL-6 on HBMvEC viability-Flow Cytometry. Confluent 
HBMvECs were stimulated with IL-6 (0-100 ng/ml) for 6 and 18 hr, respectively. Post-
treatment the entire cell population was harvested and subsequently prepared for flow 
cytometry analysis using Annexin V and PI stains.  The dot plots represent the spread of the 
cell populations as a result of the flow cytometry stains which, reflect the degree of injury 
inflicted by IL-6. Dot plots are representative of three independent experiments. 
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Figure 4.4: The effect of TNF-α and IL-6 on HBMvEC viability-Flow Cytometry 
Analysis. Confluent HBMvECs were stimulated with TNF-α or IL-6 (0-100 ng/ml) for 6 and 
18 hr. Post-treatment, cells were harvested and subsequently prepared for flow cytometry 
analysis using Annexin V and PI stains. The dot-plots for each cytokine-treated sample (Fig. 
4.2 and 4.3) were analysed using FlowJo Flow Cytometry Analysis Software to identify the 
viable (i, iv), injured (ii, v) and cytotoxic (iii, vi) cell populations in response to TNF-α 
(LHS) and IL-6 (RHS). Results are averaged from three independent experiments ± SD. 
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Figure 4.5: The effect of TNF-α and IL-6 on HBMvEC metabolism, LDH release and 
adherence. HBMvECs were seeded at a known density then stimulated with TNF-α or IL-6 
(0-100 ng/ml) for 6 and 18 hr, respectively, following which the conditioned medium was 
harvested. Fresh medium was applied to the cell cultures with MTS reagent added to 
quantify the % of metabolically active cells post-treatment with TNF-α (i) or IL-6 (iv). The 
conditioned medium was transferred to an empty plate and examined for LDH release from 
the cell cultures following treatment with TNF-α (ii) or IL-6 (v). HBMvECs were also 
seeded at a known density on xCelligence plates and had their Cell Index (%) monitored 
over 18 hrs in real-time in response to TNF-α (iii) or IL-6 (vi). Results are averaged from 
three independent experiments ± SD; *P≤0.05 vs. Untreated Control.  
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Figure 4.6: The effect of TNF-α, IL-6 and MCP-1 on HBMvEC’s secretory profile. 
Confluent HBMvECs were stimulated with TNF-α, IL-6 or MCP-1 (0-100ng/ml) for 6 and 
18 hr respectively, after which the whole cell protein lysates and conditioned medium were 
harvested. Samples and controls were loaded onto multiplex ELISAs which facilitate the 
simultaneous analysis of a number of cell injury markers at once. Data from the harvested 
conditioned medium is presented here (i, ii). Several findings (e.g. IL-6 release) were 
confirmed by standard single-plex ELISAs (iii). *P≤0.05 vs. Untreated Control. 
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Figure 4.7: The effect of TNF-α and IL-6 on HBMvEC Barrier Function. HBMvECs 
were seeded at a known density and allowed to adhere prior to stimulation with TNF-α or 
IL-6 (0-100 ng/ml) for 6 and 18 hr, respectively. Following this they were examined by 
transendothelial permeability. The line graphs (i, iii, v, vii) and histograms (ii, iv, vi, viii) 
show the change in permeability (% TEE FD40) at a given time point(s) (t) = 0-180 mins or 
180 mins, respectively, in response to TNF-α (i-iv) or IL-6 (v-viii). Results are averaged 
from three independent experiments ± SD; *P≤0.05 vs. Untreated Control. 
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Figure 4.8: The effect of TNF-α and IL-6 on interendothelial junction protein 
transcription. Confluent HBMvECs were stimulated with TNF-α or IL-6 (0-100 ng/ml) for 
6 and 18 hr, following which they were harvested for whole cell mRNA. The samples were 
analysed by qPCR. The histograms represent the changes in occludin, claudin-5, VE-
Cadherin and ZO-1 on a transcriptional level in response to TNF-α (i-iv) or IL-6 (v-viii). 
Results are averaged from three independent experiments ± SD; *P≤0.05 vs. Untreated 
Control.  
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Figure 4.9: The effect of TNF-α and IL-6 on interendothelial junction protein 
expression. Confluent HBMvECs were stimulated with TNF-α or IL-6 (0-100ng/ml) for 6 
and 18 hr, following which they were harvested for whole cell protein lysate. The 
translational effect on these proteins was investigated by western blot (i, ii). The histograms 
represent the changes in ZO-1, VE-Cadherin, occludin and claudin-5 expression in response 
to TNF-α (LHS) or IL-6 (RHS). Results are averaged from three independent experiments ± 
SD; *P≤0.05 vs. Untreated Control. Blots are representative. 
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Figure 4.10: The effect of TNF-α on interendothelial junction protein tyrosine and 
threonine phosphorylation. Confluent HBMvECs were stimulated with TNF-α (0-100 
ng/ml) for 6 and 18 hr following which they were harvested for whole cell protein lysate. 
The lysates were subjected to IP/IB analysis for relative pTyr (i) and pThr (iii) levels of the 
target protein against total target protein levels. The histograms represent the relative pTyr 
(ii) and pThr (iv) levels for claudin-5, occludin and VE-Cadherin as derived by scanning 
densitometry from western blots. Results are averaged from three independent experiments ± 
SD; *P≤0.05 vs. Untreated Control. Blots are representative.  
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Figure 4.11: The effect of IL-6 on interendothelial junction protein tyrosine and 
threonine phosphorylation. Confluent HBMvECs were stimulated with IL-6 (0-100 ng/ml) 
for 6 and 18 hr, following which they were harvested for whole cell protein lysate. The 
lysates were subjected to IP/IB analysis for relative pTyr (i) and pThr (iii) levels of the target 
protein against total target protein levels. The histograms represent the relative pTyr (ii) and 
pThr (iv) levels for claudin-5, occludin and VE-Cadherin as derived by scanning 
densitometry from western blots. Results are averaged from three independent experiments ± 
SD; *P≤0.05 vs. Untreated Control. Blots are representative.  
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Figure 4.12: The effect of genistein on cytokine-induced HBMvEC barrier modulation. 
HBMvECs were seeded at a known density and allowed to adhere prior to examination by 
transendothelial permeability. HBMvECs were then maintained in the presence of TNF-α or 
IL-6 (0-100 ng/ml) for 6 or 18 hrs in the absence or presence of the protein tyrosine kinase 
inhibitor, genistein, prior to examination by transendothelial permeability assay. The 
histograms and line graphs show the change in permeability (% TEE FD40) at a given time 
point(s) (t) = 0-180 mins or 180 mins, respectively, in response to TNF-α (i-iv) or IL-6 (v-
viii). Results are averaged from three independent experiments ± SD; *P≤0.05 vs. Untreated 
Control. 
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4.3 Discussion 
While the endothelium is primarily recognised as a restrictive interface between tissue and 
the circulation, it also plays a key role in active endocrine, paracrine and autocrine functions, 
indispensable in the maintenance of vascular homeostasis. In order to maintain this stance, 
the endothelium must continuously monitor all blood-borne and locally produced stimuli and 
adapt accordingly to cope with the immediate or long-term imbalance in its environment. 
Disruption of haemostasis by a particular stimulus can in certain instances cause ‘endothelial 
dysfunction’. In Chapter 3 we examined the effect of a positive stimulus (i.e. laminar shear 
stress) on HBMvECs and the positive influence imparted on barrier phenotype. In one study, 
we demonstrated the protective effects of laminar shear stress towards inflammatory 
cytokine injury. Inflammatory cytokines are one of the key agents implicated in triggering, 
sustaining and exacerbating endothelial dysfunction (DeVries, Kuiper et al. 1997, Zhang 
2008). In this section, we characterise the effect of two prominent inflammatory cytokines of 
the cerebrovasculature; TNF-α and IL-6, on HBMvEC homeostasis and barrier phenotype.     
A number of inflammatory mediators have been identified and characterised in the cerebral 
tissue. In selecting a panel of agents known to elicit and/or mediate inflammatory processes 
within the NVU, certain criteria needed to be fulfilled; of significant importance was the 
source of the inflammatory agents. Peripheral injury is known to facilitate inflammation via 
the transport of agents from the site of injury to the cerebrovasculature, where they have 
been reported to have an effect (Huber, Hau et al. 2002, Huber, Hau et al. 2002, Semmler, 
Okulla et al. 2005, Xanthos, Puengel et al. 2012). We wanted to select our agents solely 
from the perspective that they were known to be produced from the cell types that comprise 
the NVU, including the microvascular endothelium. For example, a significant increase in 
TNF-α level is observed within 1 hr of cerebral injury implicating it in the acute mechanisms 
of early injury (Shohami, Novikov et al. 1994, Fassbender, Rossol et al. 1994, Hallenbeck 
2002). Conversely, IL-6 serum levels are also seen to increase significantly within the first 
hours of disease/injury onset (Shohami, Novikov et al. 1994, Fassbender, Rossol et al. 
1994). In addition to cytokine release, a number of chemokines such as MCP-1 are released 
in the acute injury phase of CNS inflammation. Whilst a number of these chemokines 
mediate leukocyte influx across the BBB, they are also implicated in directly promoting 
aspects of endothelial dysfunction (Losy, Zaremba 2001, Weber, Blumenthal et al. 2003, 
Stamatovic, Shakui et al. 2005). In addition, all three have been shown to be a secretory by-
product of BMvEC injury (Fabry, Fitzsimmons et al. 1993, Simpson, Newcombe et al. 1998, 
Reyes, Fabry et al. 1999, Lee, Hennig et al. 2001, Lee, Hennig et al. 2001, Verma, Nakaoke 
et al. 2006). For these reasons we chose to examine TNF-α, IL-6 and MCP-1.          
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Our primary aim was to ultimately examine endothelium barrier function following 
induction of an inflammatory response; therefore we wanted to ensure that the cell 
monolayer was not significantly compromised throughout our treatment regimes. Cells 
which undergo apoptosis may compromise monolayer integrity and release further apoptotic 
factors resulting in an ever-escalating injury process (Woywodt, Bahlmann et al. 2002). 
Thus, our first objective was to establish a working concentration range for each cytokine in 
which injury could be potentially pronounced with respect to the cytokine’s concentration 
while firmly maintaining cell viability. Cellular viability was initially assessed by flow 
cytometry using a dual-stain protocol; Annexin V and PI. The employment of dual stains not 
only allowed for accurate measurement of cytotoxicity (PI), but also an assessment of 
membrane integrity (Annexin V). Several studies have previously implemented this protocol 
for assessing the effect of TNF-α and IL-6 on cell viability (Barnes, Spiller et al. 2011, 
Alejandro Lopez-Ramirez, Fischer et al. 2012). 
Flow cytometry gates were established using cultures subjected to critical levels of oxidative 
stress (H2O2) after which HBMvEC cultures exposed to different concentrations (0-100 
ng/ml) of TNF-α, IL-6 and MCP-1 over different exposure times were assessed. In 
comparison to control cultures, no significant change in cell viability was observed in 
cultures exposed to either TNF-α, IL-6 or MCP-1 (1-100 ng/ml) over acute (6 hrs) and 
chronic (18 hrs) timeframes. Similarly, no significant change in membrane integrity or 
cytotoxicity levels was observed. NOTE: MCP-1 data not presented.  
We also examined other markers of injury. A significant reduction in the cellular reduction 
of MTS salt to formazan was observed in HBMvECs in response to TNF-α and IL-6. This 
reduction in metabolic activity was exacerbated with respect to both cytokine concentration 
(0-100 ng/ml) and exposure time (6 or 18 hrs). Concurrently, a moderate increase in the 
release of the cytoplasmic enzyme LDH into culture medium was observed only in response 
to 18 hr TNF-α and IL-6 treatments. A possible reason for the reduction in metabolic activity 
and slight increase in LDH release was induction of apoptotic mechanisms and subsequent 
loss of some cells. Microscopy evaluations of the cultures in response to TNF-α and IL-6 in 
conjunction with screenings of culture medium for cellular debris by flow cytometry 
suggested otherwise. However, such estimations are subjective, and so we investigated the 
impact of the working concentrations of our cytokines on membrane integrity by way of the 
xCelligence® system; a real-time recording of membrane integrity, to further delineate our 
viability study. Following exposure of HBMvECs to TNF-α and IL-6 (0-100 ng/ml) a slight 
reduction (≤5%) in Cell Index (%) was observed over 24 hrs of recording implying no 
significant disruption in membrane integrity had occurred. The xCelligence® system has 
been previously utilised in monitoring barrier function of endothelial cells (Schubert-
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Unkmeir, Konrad et al. 2010, Chen, Nam et al. 2012, Luissint, Federici et al. 2012) and such 
reductions are characteristic of cell contractility as opposed to cell loss in the monolayer. 
This allowed us to interpret the MTS data as a reduction in metabolic activity rather than cell 
apoptosis. LDH release is typically a marker of plasma membrane compromisation, however 
we observed via flow cytometry that the cytokine parameters did not induce a significant 
change in membrane integrity. Therefore we interpreted the minor increase in LDH levels in 
culture medium (~7%) to a dose- and time-dependent increase in cellular activity, as 
opposed to apoptotic-driven membrane disruption which would be represented by a much 
larger percentage (Woywodt, Bahlmann et al. 2002).  
Following confirmation that our working concentrations were having no significant impact 
on the viability and integrity of the HBMvEC monolayer, we next aimed to assess whether 
or not our concentrations were inducing an inflammatory response and to what degree. A 
key response of ECs during the inflammatory process is the release of inflammatory 
mediators (Verma, Nakaoke et al. 2006). Therefore we assessed the release of some of the 
best characterised inflammatory mediators of CVD (IFNγ, IL-1β, IL-6, TNF-α) 
simultaneously using a multiplex ELISA system. HBMvECs were stimulated with TNF-α, 
IL-6 and MCP-1 (0-100 ng/ml) at acute (6 hrs) and chronic (18 hrs) exposure times and the 
culture medium containing the released (if any) mediators was harvested and assayed. Each 
of the targeted inflammatory mediators was released from HBMvECs, the levels of which 
increased with respect to both dose and time. The more robust and significant events were 
repeated on standard single-plex ELISAs for verification. One of the key responses observed 
in HBMvECs was the substantial release of IL-6 in response to our inflammatory cytokines, 
in particular; TNF-α. We therefore decided to primarily focus on the effects of TNF-α 
treatment on HBMvEC barrier phenotype. In addition, we also decided to examine the 
effects of IL-6 on HBMvEC barrier in view of its significant release levels in response to 
other inflammatory stimuli. It can be noted that a potent event in the early stages of tissue 
injury or infection is the stimulated release of IL-6 from local immune cells such as 
monocytes, macrophage and toll-like receptors (Janeway, Medzhitov 2002, Matzinger 
2002). This acute surge in IL-6 levels has thus implicated it in a host of early phase 
mechanisms with IL-6 demonstrated to actively promote (Clark, Rinker et al. 2000) and 
prevent (Swartz, Liu et al. 2001) damage depending on the area of interest. Regarding the 
cerebral tissue, the exact role of IL-6 is subject to much debate, yet it can originate from a 
number of cell types in response to cerebral injury; neurons, glial cells and as we have 
shown, the endothelium (Loddick, Turnbull et al. 1998, Suzuki, Tanaka et al. 1999, 
Orzylowska, Oderfeld-Nowak et al. 1999, Suzuki, Tanaka et al. 2009). Stroke patients have 
been shown to display a significant increase of IL-6 in both the CSF and serum, the level of 
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which correlates to infarct size (Beamer, Coull et al. 1995, Tarkowski, Rosengren et al. 
1995). In addition, genomic studies have identified clear links between IL-6 and its related 
pathways in advancing aspects of CVD (Sarwar, Butterworth et al. 2012).  
Having confirmed that our working concentrations of TNF-α induced an inflammatory 
response in HBMvEC we shifted our focus on examining the effect of the induced 
inflammation on HBMvEC barrier function.  We assessed barrier function following 
exposure to TNF-α (1-100 ng/ml) and found barrier function suffered a significant dose-
dependent reduction. A strong reduction in barrier function was also observed with respect 
to time, with a significant increase in monolayer permeability observed when comparing 
acute (6 hrs) and chronic (18 hrs) treatments. Mark (1999) noted a similar relationship 
between TNF-α concentration and endothelial barrier function, which they monitored using 
different size fluorescein tracers. This injurious trend is consistent with several cerebral 
injury models (Kim, Wass et al. 1992, Deli, Descamps et al. 1995, Anda, Yamashita et al. 
1997, Yang, Gong et al. 1999, Tsao, Hsu et al. 2001, Lv, Song et al. 2010). Our parallel 
studies showed IL-6 elicited a similar response to TNF-α over similar concentrations (1-100 
ng/ml) and exposure times (6 and 18 hrs). A study by Bamforth (1996) using an in vivo 
retinal endothelial cell model clearly demonstrated a similar response in endothelial barrier 
function to TNF-α yet noted no change in response to IL-6. A number of other studies noted 
similar or conflicting effects and implicated endothelial IL-6 release as a regulator of barrier 
function (Maruo, Morita et al. 1992, Ali, Schlidt et al. 1999, Krizanac-Bengez, Kapural et al. 
2003). Nakahura (Nakahara, Song et al. 2003) reported increases in vessel wall permeability 
and enhanced angiogenesis in regions of lesion formation in patients suffering with 
rheumatoid arthritis. He accredited these changes in the inflammatory state to IL-6-induced 
release of VEGF. Similar injury models noted a link between IL-6 and increased 
permeability at the BBB (Brett, Mizisin et al. 1995, Saija, Princi et al. 1995) yet note such a 
relationship is complex (Paul, Koedel et al. 2003). It is entirely likely, based on the wealth of 
data available, that IL-6 release exerts different actions depending on the environment in 
which it has the opportunity to induce a response. The release of these IL-6 induced factors 
then have the potential to invoke barrier deterioration, suggesting a possible transignaling 
means for IL-6 in exacerbating endothelial permeability. Regardless, our model only utilises 
a lone cell type and IL-6 has been shown to activate numerous pathways implicated in 
inducing an inflammatory response in ECs (i.e. p38 MAP kinase, NFκB, (Birukova, Tian et 
al. 2012) protein kinase C (Desai, Leeper et al. 2002)).  This evidence, in conjunction with 
the effect on endothelial barrier function and the secretory profile obtained by the multiplex 
and standard ELISAs effectively confirmed IL-6 was capable of inducing a pro-
inflammatory response in HBMvECs.  
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Several studies have linked dysregulation of the BBB to down regulation or degradation of 
the interendothelial junction proteins (Mark, Davis 2002, Fischer, Wiesnet et al. 2004, 
Andras, Pu et al. 2005, Koto, Takubo et al. 2007, Afonso, Ozden et al. 2007, Schreibelt, 
Kooij et al. 2007, Argaw, Gurfein et al. 2009, Stamatovic, Keep et al. 2009, Tai, Holloway 
et al. 2010, Jiao, Wang et al. 2011). The significant reductions in barrier function in response 
to TNF-α and IL-6 led us to examine the effect of these cytokines at the interendothelial 
junction on a molecular level. Hoffman (2009) demonstrated in cerebral tissue of subjects 
suffering from severe diabetic ketoacidosis, a neuroinflammation-induced reduction in BBB 
function coincided with a marked reduction in occludin, claudin-5 and ZO-1. Focussing on 
occludin, claudin-5, VE-Cadherin and ZO-1, a significant decrease in the mRNA levels was 
observed in response to TNF-α and IL-6. The reduction in transcription levels was 
exacerbated with increasing concentration (1-100 ng/ml) and exposure times (6 and 18 hrs). 
Aveleira (2010) demonstrated a reduction in endothelial barrier function in response to TNF-
α, noting a decrease in transcription and translation of claudin-5 and ZO-1. This study was 
further developed, noting TNF-α caused repression of claudin-5 through NFκB signalling. 
Hofmann (Hofmann, Grasberger et al. 2002) demonstrated a similar effect in relation to VE-
Cadherin. We saw a similarly significant decrease in the protein levels of TJ/AJ proteins in 
response to TNF-α and IL-6, again with respect to both dose and time. Duchini (Duchini, 
Govindarajan et al. 1996) previously demonstrated a similar effect in that TNF-α and IL-6 
had a direct impact on endothelial paracellular diffusion via a decrease in the tight junction. 
This is consistent with similar trends observed at the tight junction in other injury models 
(Lv, Song et al. 2010, Wang, Lv et al. 2011, Valeria Perez, Marcelo Sobarzo et al. 2012). 
While we have yet to examine the effect of TNF-α and IL-6 on the distribution of the 
aforementioned proteins at the cell-cell junction, Desai (2002) demonstrated IL-6 induced 
disruption of ZO-1 expression patterns at the cell-cell borders that coincided with a decrease 
in barrier function. Similarly, Lopez-Ramirez (Alejandro Lopez-Ramirez, Fischer et al. 
2012) demonstrated the redistribution of ZO-1 and VE-Cadherin in response to TNF-α. This 
is consistent with observations made in similar tight junction injury models (Zeissig, Buergel 
et al. 2007, Aveleira, Lin et al. 2010) however information pertaining to the 
microvasculature of the brain is limited, particularly with respect to IL-6. We plan to 
investigate the localisation patterns of occludin, claudin-5, VE-Cadherin and ZO-1, to not 
only verify whether a reduction in expression (as seen by western blot) is observed at the 
cell-cell junction but also to investigate the effect if any on translocation of the proteins in 
question.  
We next hypothesized that cytokines may have the inverse effect on junctional protein 
phosphorylation at tyrosine and threonine residues as that exhibited by shear stress. Shen 
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(2011) demonstrated an increase in the tyrosine levels of claudin-5 and VE-Cadherin in 
response to TGF-β1, an effect which coincided with an increase in paracellular permeability. 
This trend of increased tyrosine phosphorylation levels coinciding with a reduction in barrier 
function has been observed independently with occludin, VE-Cadherin and claudin-5 in a 
number of other endothelium-injury models (Andriopoulou, Navarro et al. 1999, Antonetti, 
Barber et al. 1999, Lohmann, Krischke et al. 2004, Persidsky, Heilman et al. 2006, 
Yukitatsu, Hata et al. 2013). In contrast, little has been explored by way of the effect of 
phosphorylation of threonine residues pertaining to barrier function, though some isolated 
studies possibly indicate a similar trend as seen with pTyr (Soma, Chiba et al. 2004, Haorah, 
Knipe et al. 2005, Stamatovic, Dimitrijevic et al. 2006, Yamamoto, Ramirez et al. 2008, 
Willis, Meske et al. 2010). We observed following exposure of HBMvECs to TNF-α, that 
pTyr and pThr levels of occludin, claudin-5 and VE-Cadherin were significantly increased 
with respect to both dose (0-100 ng/ml) and time (6 and 18 hrs). This contrasts with the 
decrease in protein expression for these junctional proteins observed following cytokine 
treatments. We subsequently decided to test the effect of blocking tyrosine phosphorylation 
on the cytokine-induced elevation of HBMvEC permeability. Genistein, a tyrosine kinase 
inhibitor, was used to pretreat HBMvECs grown in transwell inserts for barrier function 
assays. Following exposure of the HBMvEC cultures to TNF-α and IL-6, barrier function 
was assessed and we observed that inhibition of tyrosine kinase activity reduced in-part the 
impact TNF-α and IL-6 on HBMvEC barrier function. This data, in conjunction with the 
relationship demonstrated between the phosphotyrosine levels of the interendothelial 
junction proteins in response to laminar shear stress in Chapter 3 (as tested with 
dephostatin), suggests that phosphorylation, particularly of pTyr, plays an integral part in 
modulating HBMvEC barrier integrity. Several BBB studies add credence to these 
observations with regards to occludin (Andras, Pu et al. 2005, Takenaga, Takagi et al. 2009), 
claudin-5 and VE-Cadherin (Shen, Li et al. 2011) and even ZO-1 which was omitted from 
our studies (Staddon, Herrenknecht et al. 1995). The impact of phosphothreonine changes, 
which displayed parallel trends to phosphotyrosine changes, has yet to be explored in greater 
detail by our group. However, several other studies have established similar links between 
increased pThr of claudin-5, occludin and ZO-1 and BBB dysregulation (Soma, Chiba et al. 
2004, Haorah, Knipe et al. 2005, Haorah, Heilman et al. 2005, Stamatovic, Dimitrijevic et al. 
2006, Yamamoto, Ramirez et al. 2008, Willis, Meske et al. 2010). It should be noted, as 
stated in the discussion of Chapter 3, that the impact of other post-translational 
modifications are recognised as potentially playing as critical a role as phosphorylation in 
HBMvEC barrier dynamics. These aspects, amongst others, are currently being considered 
in furthering this body of work and furthering our understanding of HBMvEC barrier 
mechanics. 
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To summarise at this point our working concentrations of TNF-α and IL-6 were shown to 
elicit an inflammatory response in conjunction with negative impacts upon HBMvEC barrier 
function. We also expanded our cytokine studies to explore other aspects of endothelial 
biology and their impact (if any) on other functional roles the endothelium encompasses. We 
decided to examine the effect of inflammation on some of the regulatory molecules the 
endothelium provides in maintaining hemostasis. In normal physiological conditions, the 
endothelium acts as an antiplatelet, anticoagulant and fibrinolytic surface (Stern, Esposito et 
al. 1991). In contrast, during inflammation this phenotype is compromised and the resulting 
dysfunctional EC provides a prothrombotic, antifibrinolytic surface. In Chapter 3, we 
examined two key factors involved in the coagulation cascade which are associated with 
injury and wound repair in the vasculature; vWF and thrombomodulin. We demonstrated 
that laminar shear stress promoted anti-coagulant activity with respect to these two proteins. 
In contrast, exposure of HBMvECs to our working range of inflammatory cytokines appears 
to manipulate these mechanisms to promote a pro-coagulation environment. We observed a 
significant decrease in thrombomodulin protein levels in response to TNF-α and IL-6 in both 
a dose- and time-dependent manner. This is consistent with other endothelial injury models 
(Lentz, Tsiang et al. 1991, Lin, Hsieh et al. 2009). Concurrently, a significant increase in the 
release of soluble thrombomodulin levels into culture medium was observed. This is 
consistent with other studies (Nawroth, Stern 1986, Bauer, Rosenberg 1987). Boehme 
(Boehme, Deng et al. 1996) observed a concurrent increase in endothelial release of 
thrombomodulin and decrease in intracellular levels following exposure to TNF-α. Together 
these observations may suggest a natural acute defensive response by the endothelium, 
attempting to nullify any inflammatory, pro-coagulant mechanisms encountered in the local 
environment (Takahashi, Ito et al. 1992). Interestingly, our data in Chapter 3 demonstrated a 
substantial and sustained increase in thrombomodulin expression and release following 
exposure of HBMvECs to laminar shear stress. This increase in endothelial release of 
thrombomodulin is consistent with observations made in similar cerebral injury models in 
vivo (Macko, Killewich et al. 1999, Giwa, Williams et al. 2012). In parallel studies, vWF 
mRNA and protein expression is significantly increased in response to inflammatory 
cytokines, an increase which is augmented with respect to increasing cytokine concentration 
and exposure times. While vWF release was not examined, the increase in its expression was 
observed by confocal microscopy. Increases in vWF expression and release have long been 
considered a marker of vascular injury (Boneu, Abbal et al. 1975). Indeed, elevated levels of 
vWF have been observed in several vascular pathologies (Kahaleh, Osborn et al. 1981, 
Pedrinelli, Giampietro et al. 1994), including those of the cerebrovasculature (Mettinger 
1982). Lip (Lip, Blann et al. 2002) observed an increase in serum levels of a number of pro-
coagulant (vWF included) molecules in acute stroke patients. This inverse relationship; the 
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reduction in expression of anti-coagulant thrombomodulin and increase in expression of pro-
coagulant vWF leads us to conclude that exposure of HBMvECs to our working cytokine 
concentrations is likely inducing whole cell endothelial dysfunction. This data is consistent 
with observations made in similar cerebral injury models (Tsuchida, Salem et al. 1992, 
Zarifis, Blann et al. 1996, Wang, Tran et al. 1997, Faust, Levin et al. 2001, Isermann, 
Hendrickson et al. 2001).  
Finally, the effect of inflammatory cytokines on the expression of their signal-transducing 
receptors was investigated. The expression profiles and localisation of the receptors in 
conjunction with local levels of the necessary adapter proteins are what determines which 
potential pathways become activated and exert physiological changes in the cell population. 
We found that both TNF-α and IL-6 drove up the transcriptional levels of TNFR1 and gp130 
in a time- and dose-dependent manner, likely culminating in elevated inflammatory 
signalling. Interestingly, Cook, (2008) noted the increase in TNFR1 levels coincided with an 
increase in TACE activity. They concluded that targeting TNFR1 expression as opposed to 
the cytokine itself may be a more effective strategy in the regulation of TNF-α-mediated 
events. Similarly, Pradillo (2005) demonstrated that ischemic pre-conditioning led to an 
upregulation of TNFR1 and TACE activity that in turn promoted ischemic tolerance. Whilst 
there is little evidence of a similar adaptive mechanism involving soluble gp130 in the 
microvasculature, studies suggest it is plausible (Hirota, Izumi et al. 2004, Inta, Weber et al. 
2009). In contrast, a number of cerebral diseases have reported a correlation between 
elevated levels of cytokine receptors and the onset of such diseases. The IL-6 transignalling 
molecule; sIL-6R, which transduces IL-6 signals through gp130, has been reported to have a 
significant impact on endothelial cells, mediating the recruitment and assisted invasion of 
leukocytes via induction of leukocyte adhesion molecules; E-Selectin, ICAM-1 and VCAM-
1, in addition to stimulating the release of a number of cytokines known to provoke an 
inflammatory response in endothelial cells; IL-6, IL-8 and MCP-1 (Modur, Li et al. 1997). It 
is worth noting that endothelial cells characteristically do not express IL-6R, the precursor to 
sIL-6R, so for the purposes of our studies, transignalling via IL-6 likely occurred through 
naturally occurring sIL-6R that may be present in the culture medium supplements. Whilst 
the effects of elevated levels of sIL-6R were not investigated, the elevated levels of gp130 
would work in a comparative way to facilitate/modulate the binding and signal transduction 
of gp130 ligands. Yu (2007) demonstrated TNF-α caused an increase in the transcription and 
translation of gp130 via NFκB.   
TNFR2, by contrast, showed a significant increase in transcription levels within 4 hrs of 
cytokine exposure. This increase was normalised within 8 hrs with levels returning to 
baseline levels with further reductions incurred giving an overall significant decrease in 
192 
 
transcription levels after 24 hrs of exposure. TNFR1 is the predominantly expressed TNF 
receptor in endothelial cells (Nadeau, Rivest 1999) and any increase in its expression results 
in increased NFκB signalling and an increased inflammatory state (Wosik, Biernacki et al. 
2007). TNFR2 is also capable of mediating an inflammatory response in the CNS, similar to 
TNFR1 albeit with a reduced functional capacity (Akassoglou, Douni et al. 2003). Ferrero 
(2001) demonstrated via agonists and antagonists for both receptors, that endothelial 
permeability is primarily mediated via signalling through TNFR1, though barrier degree was 
observed to be regulated to a small extent through TNFR2 signalling. Further studies 
exploring endothelial dysfunction reached a similar conclusion (Slowik, Deluca et al. 1993). 
TNFR2 has also been implicated in initiating pro-survival signalling (Zhang 2008). Thus the 
differential expression patterns of each of the TNFRs play a significant role in shaping the 
TNF-α-induced inflammatory response in HBMvECs (e.g. malaria (Lucas, Juillard et al. 
1997a, Lucas, Lou et al. 1997, Lucas, Lou et al. 1997b)).    
In conclusion, we have comprehensively demonstrated how inflammatory cytokines, such as 
TNF-α and IL-6, play a pivotal role in the disruption of vascular homeostasis and BBB 
phenotype. Aside from inducing the release of pro-inflammatory mediators, both cytokines 
are capable of promoting an injured BBB phenotype through the modulation of 
interendothelial protein expression and post-translational modification, as well as 
modulation of endothelial anti-inflammatory mechanisms. 
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Chapter 5: 
The independent contribution of reactive 
oxygen species, and IL-6, to cytokine-
induced modulation of HBMvEC blood-
brain barrier properties.  
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5.1 Introduction 
In chapter 4, the effects of a pathophysiological stimulus in the form of well-known 
inflammatory cytokines, TNF-α and IL-6, on HBMvEC cultures were investigated. 
Following exposure, several aspects of the BBB phenotype previously demonstrated to be 
enhanced by laminar shear stress were seen to regress. Exposure of HBMvEC monolayers to 
each cytokine was seen to cause a reduction in barrier integrity. This was likely due to an 
observed cytokine-induced reduction in the transcription and translation of the key proteins 
of interest at the tight and adherens junctions. Similar to laminar shear stress, each protein 
was seen to undergo post-translational modification, however the inverse was observed in 
that tyrosine and threonine residues become increasingly phosphorylated with direct 
consequences for barrier function. In addition, several anti-inflammatory mechanisms were 
modulated such that the resulting HBMvEC phenotype was susceptible to further 
inflammatory injury. Of note, all observed effects were seen to be potentiated with 
increasing cytokine concentration or exposure time.  
Several pathways have been identified in initiating BBB dysfunction. The kinin system, 
excitotoxicity, neutrophil recruitment, mitochondrial alterations and macrophage/microglial 
activation are just some of the events affiliated with BBB disruption and interestingly they 
all share a common characteristic, namely reactive oxygen species (ROS) (Pun, Lu et al. 
2009). Several cerebral pathologies have accredited their initiation and progression to the 
oxidative stress imparted by ROS wherein the oxidant-antioxidant ratio of the 
microenvironment becomes imbalanced, resulting in a surge in the local levels of free 
radicals. Increased levels of ROS are now a hallmark of numerous cerebral pathologies (e.g. 
multiple sclerosis, stroke) and several studies have associated ROS with direct influence on 
BBB dysfunction, specifically barrier function (Collins-Underwood, Zhao et al. 2008). This 
has resulted in several clinical trials aiming to develop antioxidant therapies; however 
translation from animal models into an efficient therapeutic remains evasive (Steinhubl 
2008). The lack of success to date is attributed to a lack of underlying knowledge of the 
biology of ROS in the microvasculature. It has been suggested that the time of 
administration of antioxidant therapies is crucial to the success, with several studies 
indicating the therapeutic window is limited (within 1-2 hrs of injury). For these reasons, in 
chapter 5 we focussed our attention on whether the release and effects of ROS were 
attributable to the cytokine-induced injury of HBMvECs.        
In addition, chapter 4 focussed in large part on the secretory profile of HBMvECs in 
response to inflammatory cytokines. In parallel with our ROS studies therefore, we decided 
to investigate the impact of any mediator we felt had a substantial presence in the culture 
microenvironment post-treatment. In chapter 4, the secretory profile of our HBMvEC model 
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in response to TNF-α and IL-6 was examined. The release of several well-known influential 
promoters of CVD was investigated in response to a number of experimental paradigms, and 
for chapter 5 we focussed on one of the more robust trends in the acute increase in IL-6 
levels following exposure to TNF-α. As a result of this, in chapter 4 we afforded IL-6 the 
same level of characterisation as the well known mediator of inflammatory responses; TNF-
α. For chapter 5, we focussed on the effects of IL-6 release following TNF-α, 
investigating whether the subsequent injury could be attributable in part to the production 
and release of IL-6. Several stimuli, from neurotransmitters to inflammatory cytokines as 
we have seen can induce IL-6 release in several cell types within the CNS (including those 
that comprise the NVU (Akira, Taga et al. 1993)), with several of the aforementioned also 
expressing the appropriate receptor for IL-6 signal transduction. Thus, IL-6 was implicated 
in potentially having several roles within the CNS. Since its discovery, a wealth of data has 
been generated demonstrating the role of IL-6 in development and normal physiology as 
well as injury and disease (Erta, Quintana et al. 2012). However, its ever-growing list of 
responsibilities and functions, of which there is much contradictory data, has lead to it being 
routinely re-characterised (Paul, Koedel et al. 2003). Having already extensively 
characterised the effects IL-6 had on HBMvECs in chapter 4, we decided to revisit it but 
focus our efforts on evaluating its role from the context of TNF-α inducing its release. 
Together with ROS, we were tackling both an unverified and verified mediator of 
inflammatory injury in HBMvECs, allowing us to further delineate the means by which both 
our inflammatory cytokines, TNF-α and IL-6, impart their injury on the BBB endothelium.  
 
5.1.1 Study Aims 
In this chapter we examine the potential roles of reactive oxygen species, and IL-6, in the 
cytokine-induced disruption of HBMvEC blood-brain barrier properties. Therefore, the 
overall aims of this chapter include: 
 To investigate the effect of TNF-α and IL-6 on ROS production in HBMvECs.  
 To determine whether TNF-α- and IL-6-induced levels of ROS contribute to the 
cytokine-induced disruption of TJ/AJ protein (occludin, claudin-5, VE-Cadherin, 
ZO-1) translational expression. 
 To determine whether TNF-α- and IL-6-induced levels of ROS production 
contribute to the cytokine-induced disruption of HBMvEC barrier function.  
 To further investigate the effect of TNF-α on IL-6 production in HBMvECs. 
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 To determine whether TNF-α-induced levels of IL-6 contribute to the TNF-α-
induced dysfunction of HBMvECs with respect to the aforementioned injury indices 
(ROS, TJ/AJ, barrier function). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
197 
 
5.2.1 Exposure of HBMvECs to TNF-α and IL-6 increases cellular production of ROS 
over time 
The effect of TNF-α and IL-6 on cellular ROS production with respect to time was examined 
(Figure 5.1). Confluent HBMvECs were stimulated with TNF-α or IL-6 (100 ng/ml) for 0-24 
hrs in the presence of ROS detecting dyes; CFDA or DHE. Post-treatment, the entire cell 
population was harvested and prepared for analysis by flow cytometry. A significant 
increase in ROS in response to TNF-α (i-iv) and IL-6 (v-viii) treatment was observed with 
respect to time using both CFDA and DHE.  
The effect of TNF-α and IL-6 on cellular ROS production with respect to time was also 
examined by immunofluorescence microscopy (Figure A.13). HBMvECs were seeded onto 
coverslips and grown to confluency prior to stimulation with TNF-α or IL-6 (100 ng/ml) for 
0-24 hrs in the presence of ROS-detecting dyes; CFDA or DHE. Post-treatment, the cells 
were fixed and prepared for examination by immunofluorescence microscopy. A similar 
trend was observed in comparison to the flow cytometry results with significant increases in 
CFDA and DHE signals in response to TNF-α and IL-6 observed with respect to time.  
 
5.2.2 Exposure of HBMvECs to TNF- α and IL-6 increases cellular production of ROS 
in a dose-dependent manner 
The effect of TNF-α and IL-6 on cellular ROS production with respect to cytokine dose was 
examined (Figure 5.2). Confluent HBMvECs were stimulated with TNF-α or IL-6 (0-100 
ng/ml) for either 6 or 18 hrs in the presence of ROS-detecting dyes; CFDA or DHE. Post-
treatment, the entire cell population was harvested and prepared for analysis by flow 
cytometry. A significant increase in ROS in response to TNF-α (i, ii) and IL-6 (iii, iv) was 
observed with respect to dose using both CFDA and DHE.  
 
5.2.3 Pre-treatment with antioxidants can reduce the cytokine-stimulated increase in 
ROS production 
The effect of different antioxidants on TNF-α-induced increase in ROS production was 
examined Figure 5.3). Confluent HBMvECs were independently pre-treated with different 
antioxidants; Apocynin, N-Acetylcysteine, Superoxide Dismutase and Catalase for 1 hr. 
Post-treatment, the cultures were stimulated with TNF-α (100 ng/ml) for 6 or 18 hrs in the 
presence of ROS-detecting dye; CFDA. Post-treatment, the entire cell population was 
harvested and prepared for analysis by flow cytometry. A significant increase in ROS in 
response to TNF-α was observed in comparison to control cultures for both 6 and 18 hr 
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treatments. A significant increase in CFDA signals in response to TNF-α in the presence of 
each of the antioxidant treatments were also observed in comparison to untreated control 
cultures. Following antioxidant treatments, a very significant reduction in TNF-α-induced 
ROS production was observed (LHS). A similar trend was observed in parallel experiments 
utilising IL-6 in place of TNF-α (RHS), and indeed utilising DHE instead of CFDA (Figure 
A.14). The effect of the antioxidant concentration on HBMvEC viability was also examined 
by flow cytometry to determine the effective dose (Figure A.15).  
 
5.2.4 Pre-treatment with antioxidants can reduce the cytokine-driven downregulation 
of intercellular junction proteins; occludin, claudin-5 and VE-Cadherin 
The effect of antioxidants on TNF-α-induced downregulation of intercellular junction 
proteins; occludin, claudin-5 and VE-Cadherin were examined (Figure 5.4). Confluent 
HBMvECs were independently pre-treated with different antioxidants; Apocynin, N-
Acetylcysteine, Superoxide Dismutase and Catalase for 1 hr. Post-treatment, the cultures 
were stimulated with TNF-α (100 ng/ml) for 18 hrs before being harvested for whole cell 
protein lysate. The translational levels of each protein in response to TNF-α in the absence 
and presence of each antioxidant were then examined by western blot (i, v, ix, xiii). Each 
protein demonstrated a significant decrease in their expression following cytokine exposure 
in comparison to untreated control cultures. Following antioxidant treatments, the cytokine-
induced reduction in protein expression was partially attenuated (ii-iv, vi-viii, x-xii, xiv-xvi). 
A similar trend was observed in parallel experiments utilising IL-6 in place of TNF-α 
(Figure 5.5) and also following the earlier 6 hr cytokine treatment time for either cytokine 
(Figure A.16, A.17). 
 
5.2.5 Pre-treatment with antioxidants can reduce the cytokine-driven downregulation 
of barrier function 
The effect of antioxidants on TNF-α-induced downregulation of HBMvEC barrier function 
was examined (Figure 5.6). HBMvECs were seeded at a known density into transwell inserts 
and left to adhere overnight. The following day the confluent HBMvECs were pre-treated 
with antioxidants; Apocynin, N-Acetylcysteine, Superoxide Dismutase and Catalase, 1 hr 
prior to cytokine treatment (100 ng/ml) for 18 hrs. Post-treatment, the cellular monolayers 
were assessed for transendothelial permeability. Exposure of HBMvECs to TNF-α resulted 
in a significant increase in FITC-Dextran paracellular flux (%TEE of FD40) across the cell 
monolayer. Following antioxidant treatment, the cytokine-induced permeabilisation of 
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HBMvECs was significantly attenuated (i-viii). A similar trend is observed in parallel 
experiments utilising IL-6 in place of TNF-α (Figure 5.7; i-viii) and also following the 
earlier 6 hr treatment time for either cytokine (Figure A.18, A.19).  
 
5.2.6 Exposure of HBMvECs to TNF-α induces an upregulation in IL-6 expression 
The effect of TNF-α on the expression in HBMvECs of IL-6 in HBMvECs was examined 
(Figure 5.8). Confluent HBMvECs were stimulated with TNF-α (0-100 ng/ml) for 0-24 hrs 
before being harvested for whole cell mRNA or protein lysate. The transcriptional level of 
IL-6 mRNA was examined by qPCR. IL-6 mRNA levels significantly increased following 
exposure to TNF-α in both a time- and dose-dependent manner in comparison to untreated 
control cultures (i, ii). The translational levels of IL-6 protein in response to TNF-α were 
then examined in HBMvECs by western blot (iii). A similar trend was observed in that IL-6 
experienced a significant increase in protein levels following TNF-α treatment in both a 
time- and dose-dependent manner in comparison to untreated control cultures (iv). A similar 
trend was observed in parallel experiments utilising IL-6 in place of TNF-α (Figure A.20). 
 
5.2.7 Treatment with an IL-6 neutralising antibody (NtAb) can partially reduce TNF-
α-induced damage of HBMvECs 
The effect of an IL-6 NtAb on TNF-α induced damage of HBMvEC barrier properties was 
examined (Figure 5.9, 5.10). Confluent HBMvECs were stimulated with TNF-α (100 ng/ml) 
in the absence and presence of 250 ng of IL-6 NtAb for 18 hrs in the additional presence of 
ROS detecting dyes; CFDA or DHE (Figure 5.9). Post-treatment, cells were harvested and 
prepared for analysis by flow cytometry. A significant increase in ROS levels in response to 
TNF-α was observed and indeed was partially attenuated by IL-6 NtAb treatment (i-iv). The 
effect of the IL-6 NtAb on TNF-α induced downregulation of HBMvEC barrier function was 
also examined. HBMvECs were seeded at a known density into transwell inserts and left to 
adhere overnight. The following day the confluent HBMvECs were treated with TNF-α (100 
ng/ml) in the absence and presence of 250 ng of IL-6 NtAb for 18 hrs. Post-treatment, the 
HBMvEC monolayers were assessed for transendothelial permeability. Exposure of 
HBMvECs to TNF-α resulted in a significant increase in FITC-Dextran paracellular flux 
(%TEE of FD40) across the cell monolayer, an effect that was partially attenuated by IL-6 
NtAb treatment (v, vi). Similar results were also observed for the earlier 6 hr treatment with 
TNF-α (Figure A.22).  
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Further studies focused on the effect of IL-6 NtAb on TNF-α-induced downregulation of 
intercellular junction proteins; occludin, claudin-5 and VE-Cadherin (Figure 5.10). 
Confluent HBMvECs were stimulated with TNF-α (100 ng/ml) in the absence and presence 
of 250 ng of IL-6 NtAb for either 6 or 18 hrs before being harvested for whole cell protein 
lysate. The translational levels of each protein in response to TNF-α in the absence and 
presence of the IL-6 NtAb were then examined by western blot (i, ii). Each protein 
demonstrated a significant decrease in expression following treatment with TNF-α in 
comparison to untreated control cultures. Moreover, this decrease was partially attenuated by 
treatment with IL-6 NtAb (iii-viii).  
Finally, the specificity of the IL-6 NtAb against recombinant forms of both IL-6 and TNF-α 
was also investigated by western blot (Figure A.21, i). The working concentration of the IL-
6 NtAb was also determined based on efficacy in ablating IL-6-driven barrier disruption as 
monitored by transwell permeability assay (ii-v). 
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Figure 5.1: The effect of TNF-α and IL-6 on ROS production-Time Response. 
Confluent HBMvECs were stimulated with TNF-α or IL-6 (100 ng/ml, 0-24 hrs) in the 
presence of either CFDA or DHE. Post-treatment, cells were harvested and subsequently 
prepared for flow cytometry. The histograms (LHS) represent the intensity of ROS-detecting 
dyes prepared from the representative FACS scans (RHS). The cytokine-treated samples 
were analysed using FlowJo Flow Cytometry Analysis Software to quantify the respective 
signal from CFDA- (i, ii, v, vi)  and DHE- (iii, iv, vii, viii) stained cell populations in 
response to TNF-α and IL-6 from 0-24 hrs. Results are averaged from three independent 
experiments ± SD. *P≤0.05 vs. 0hr Control. 
Legend: FITC-A = CFDA; PE-Texas Red-A = DHE 
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Figure 5.2: The effect of TNF-α and IL-6 on ROS production-Dose Response. Confluent 
HBMvECs were stimulated with TNF-α or IL-6 (0-100 ng/ml) for 6 or 18 hrs in the presence 
of either CFDA or DHE. Post-treatment cells were harvested and subsequently prepared for 
flow cytometry. The histograms represent the intensity of ROS-detecting dyes prepared from 
the representative FACS scans.  The cytokine-treated samples were analysed using FlowJo 
Flow Cytometry Analysis Software to quantify the respective signal from CFDA- (i, iii) or 
DHE- (ii, iv) stained cell populations in response to TNF-α and IL-6 at 6 and 18 hrs. Results 
are averaged from three independent experiments ± SD. *P≤0.05 vs. 0 ng/ml Control. 
Legend: FITC-A = CFDA; PE-Texas Red-A = DHE 
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Figure 5.3: The effect of antioxidants on TNF-α- and IL-6-induced ROS production-
CFDA. Confluent HBMvECs were stimulated with TNF-α or IL-6 (100ng/ml) for 6 or 18 
hrs in the presence of CFDA and a range of antioxidant compounds. Post-treatment, cells 
were harvested and subsequently prepared for flow cytometry. The histograms represent the 
intensity of the CFDA dye prepared from the corresponding representative FACS scans. The 
cytokine-treated samples were analysed using FlowJo Flow Cytometry Analysis Software to 
quantify the respective signal from CFDA-stained cell populations in response to TNF-α (ii, 
iv) and IL-6 (v, vii) at 6 (upper) and 18 (lower) hrs. Results are averaged from three 
independent experiments ± SD. *P≤0.05 vs. Untreated Control. δP≤0.05 vs. TNF-α or IL-6 
treatment. 
Legend: FITC-A = CFDA 
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Figure 5.4: The effect of antioxidants on TNF-α-induced downregulation of TJ/AJ 
proteins. Confluent HBMvECs were treated with TNF-α (100 ng/ml) for 18 hrs in the 
presence of a number of antioxidant compounds. Post-treatment, cells were harvested for 
whole cell protein lysate. The translational effect on particular intercellular junction proteins 
was investigated by western blot. The histograms represent the changes in relative protein 
expression for VE-Cadherin (ii, vi, x, xiv), occludin (iii, vii, xi, xv) and claudin-5 (iv, viii, 
xii, xvi). Results are averaged from three independent experiments ± SD; *P≤0.05 vs. 
Untreated Control, δP≤0.05. Blots are representative. 
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Figure 5.5: The effect of antioxidants on IL-6-induced downregulation of TJ/AJ 
proteins. Confluent HBMvECs were treated with IL-6 (100 ng/ml) for 18 hrs in the 
presence of a number of antioxidant compounds. Post-treatment, cells were harvested for 
whole cell protein lysate. The translational effect on particular intercellular junction proteins 
was investigated by western blot. The histograms represent the changes in relative protein 
expression for VE-Cadherin (ii, vi, x, xiv), occludin (iii, vii, xi, xv) and claudin-5 (iv, viii, 
xii, xvi). Results are averaged from three independent experiments ± SD; *P≤0.05 vs. 
Untreated Control, δP≤0.05. Blots are representative. 
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Figure 5.6: The effect of antioxidants on TNF-α-induced disruption of HBMvEC 
barrier function. HBMvECs were seeded at a known density and allowed to adhere prior to 
examination by transendothelial permeability. HBMvECs were then pre-treated with TNF-α 
(100 ng/ml) for 18 hrs in the presence of a number of antioxidant compounds. Post-
treatment, monolayers were examined by transendothelial permeability assay. The 
histograms (LHS) and line graphs (RHS) show the change in permeability (% TEE FD40) at 
a given time point(s) (t) = 180 mins or 0-180 mins, respectively. Results are averaged from 
three independent experiments ± SD; *P≤0.05 vs. Untreated Control, δP≤0.05. 
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Figure 5.7: The effect of antioxidants on IL-6-induced disruption of HBMvEC barrier 
function. HBMvECs were seeded at a known density and allowed to adhere prior to 
examination by transendothelial permeability. HBMvECs were then pre-treated with IL-6 
(100 ng/ml) for 18 hrs in the presence of a number of antioxidant compounds. Post-
treatment, monolayers were examined by transendothelial permeability assay. The 
histograms (LHS) and line graphs (RHS) show the change in permeability (% TEE FD40) at 
a given time point(s) (t) = 180 mins or 0-180 mins, respectively. Results are averaged from 
three independent experiments ± SD; *P≤0.05 vs. Untreated Control, δP≤0.05. 
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Figure 5.8: The effect of TNF-α on IL-6 expression. Confluent HBMvECs were 
stimulated with TNF-α (0-100 ng/ml) for 0-24 hrs following which they were harvested for 
whole cell mRNA and protein lysate. The histograms represent the changes in IL-6 mRNA 
over time (i) and with respect to dose at 6 and 18 hrs (ii). The translational effect of TNF-α 
on IL-6 protein was investigated by western blot (iii, iv). Results are averaged from three 
independent experiments ± SD; *P≤0.05 vs. 0 hrs (i), 0 ng/ml (ii) and Untreated Control (iv). 
Blots are representative. 
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Figure 5.9: The effects of an IL-6 NtAb on TNF-α-induced disruption of HBMvEC 
barrier properties. Confluent HBMvECs were stimulated with TNF-α (100 ng/ml) for 18 
hrs in the presence of CFDA or DHE, and in the absence and presence of an IL-6 NtAb Post-
treatment, cells were harvested and subsequently prepared for flow cytometry. The 
histograms represent the intensity of the CFDA (iii) and DHE (iv) ROS signals prepared 
from the corresponding FACS scans (i, ii). The TNF-α-treated samples were analysed using 
FlowJo Flow Cytometry Analysis Software. Results are averaged from three independent 
experiments ± SD. *P≤0.05 vs. Untreated Control. In a parallel study, HBMvECs were 
seeded into transwell inserts at a known density and allowed to adhere prior to examination 
by transendothelial permeability assay. HBMvECs were then treated with TNF-α (100 
ng/ml) for 18 hrs in the presence of the IL-6 NtAb. The histogram (v) and line graph (vi) 
show the change in permeability (% TEE FD40) at a given time point(s) (t) = 180 mins or 0-
180, respectively. Results are averaged from three independent experiments ± SD; *P≤0.05 
vs. Untreated Control, δP≤0.05.  
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Figure 5.10: The effect of an IL-6 NtAb on TNF-α-induced disruption of HBMvEC 
barrier properties. Confluent HBMvECs were stimulated with TNF-α (100 ng/ml) for 6 
and 18 hrs in the absence and presence of an IL-6 NtAb. Post-treatment, cells were harvested 
for whole cell protein lysate. The translational effect on particular intercellular junction 
proteins was investigated by western blot (i, ii). The histograms represent the changes in 
relative protein expression for VE-Cadherin (iii, vi), occludin (iv, vii) and claudin-5 (v, viii) 
on a expressional level in response to TNF-α (100ng/ml) for 18 hrs in the presence of an IL-
6 NtAb. Results are averaged from three independent experiments ± SD; *P≤0.05 vs. 
Untreated Control, δP≤0.05. Blots are representative. 
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5.3 Discussion 
Having characterised how the brain microvascular endothelium responds to both protective 
(Chapter 3) and injurious stimuli (Chapter 4), we next decided to examine those mechanisms 
mediating inflammatory damage to the endothelium. The mechanisms that mediate this 
inflammatory response during the early stages of endothelial dysfunction are often sustained 
and become exacerbated as damage to barrier phenotype continues. The increased 
production of ROS is a well established mechanism coinciding with inflammatory-based 
activation and sustained dysfunction of the endothelium (see Chapter 1). During the 
inflammatory initiation of CVD, cytokines and growth factors such as TNF-α, IL-1β and 
IFNγ have been shown to trigger ROS-producing molecules such as NADPH oxidase 
resulting in a surge of ROS in the area of injury. ROS can regulate a number of redox-
sensitive genes to produce inflammatory mediators and activate several signalling pathways 
that promote vascular inflammation (Sun, Oberley 1996, Winyard, Blake 1997, Kunsch, 
Medford 1999). For example, peroxynitrite and superoxide have been shown to directly 
activate pro-inflammatory transcription factors such as NFκB and AP-1, which regulate the 
genes for most cytokines and is regularly implicated in endothelial dysfunction and vascular 
inflammation (Collins 1993). In addition to inducing the production and release of pro-
inflammatory cytokines, increased ROS production has also been demonstrated to directly 
induce the upregulation of adhesion molecules (e.g. ICAM-1) and chemoattractants (i.e. 
MCP-1) (Marui, Offermann et al. 1993, Satriano, Shuldiner et al. 1993, Weber, Erl et al. 
1994). The induction, release and actions of these factors in addition to those pertaining to 
local levels of ROS can in turn cause the exacerbation of vascular oxidative stress, creating a 
vicious circle of oxidative and inflammatory processes which are fundamental in the 
development and manifestation of CVD in both peripheral and cerebrovascular beds. It was 
therefore felt the influence of ROS was likely to be central to our inflammatory studies and 
so we decided to investigate the degree of impact, if any, it had on our HBMvEC/cytokine 
injury model. Whilst much data is available on the general ROS mechanisms associated with 
the endothelium, published mechanistic studies involving ROS in the microvasculature, and 
particularly in the human cerebral microvasculature, are limited. Thus, the effect of 
inflammatory cytokines (TNF-α and IL-6) on the ROS formation leading to consequences 
for BBB phenotype were investigated in vitro.  
Two means of tracking and quantifying ROS production were employed; DCFDA, a probe 
which following cellular deacetylation is free to be oxidised by available ROS into a highly 
fluorescent compound, and DHE; which in the presence of superoxide becomes reduced to 
form the highly fluorescent DNA binding ethidium. Using these dyes, a fluorimetric signal 
proportionate to the intracellular levels of ROS could be easily measured by flow cytometry 
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(Carter, Narayanan et al. 1994). In response to TNF-α treatment we saw significant dose- 
and time-dependent increases in DCFDA and DHE signal. This increase in signal was 
sustained and propagated to a 4-fold change in DCFDA signal and a 15+ fold change in 
DHE signal by 24 hrs. A similar trend was observed in response to IL-6 treatment over 24 
hrs. TNF-α is a well-documented initiator of ROS production in endothelial cells (Busik, 
Mohr et al. 2008, Montiel-Davalos, de Jesus Ibarra-Sanchez et al. 2010) although little data 
is available on the ROS-inducing effect of IL-6 in endothelial cells (Christov, Ottman et al. 
2004). Based on these findings, we hypothesized that ROS production may play an integral 
part in cytokine induced-endothelial injury.  
ROS have been identified as secondary messengers in a number of signalling pathways, 
having been shown to participate in a number of physiological functions such as regulation 
of blood flow, coagulation, inflammation and cellular growth (Griendling, Sorescu et al. 
2000, Griendling, Sorescu et al. 2000). Whilst ROS surges have been characteristically 
looked upon as risk factors, a controlled increase may have beneficial effects. Zahler (2000) 
demonstrated acute pre-conditioning of endothelial cells to oxidative stress attenuated 
subsequent cytokine-induced damage. In order to examine this concept, a number of agents 
that are capable of scavenging for and/or disrupting the mechanisms that produce ROS were 
employed to elucidate whether ablation of the induced ROS production may attenuate (or 
exacerbate) the damage inflicted on HBMvEC barrier phenotype. A broad range of 
antioxidants compounds were employed; Apocynin; an inhibitor of the superoxide 
producing enzyme NAPDH oxidase, N- Acetyl-L-cysteine; a broad spectrum antioxidant 
that increases cellular levels of the major detoxification enzyme gluthathione, Superoxide 
dismutase; which catabolises superoxide anion to yield oxygen and water, and catalase; 
which catalyses the breakdown of hydrogen peroxide into oxygen and water. In the case of 
each compound, we found a significant decrease in DCFDA and DHE ROS signal following 
either acute (6 hrs) or chronic (18 hrs) exposure to TNF-α and IL-6 (100 ng/ml). The main 
source of cytokine-induced ROS within the microvasculature therefore appears to originate 
from NADPH oxidase. A number of earlier studies have implicated it in contributing to the 
development of a host of microvascular dysfunctions (Ishikawa, Stokes et al. 2004, Wood, 
Hebbel et al. 2005, Collins-Underwood, Zhao et al. 2008). Consistent with our study, 
Basuroy (2009) also demonstrated that porcine microvascular endothelial cells treated with 
TNF-α underwent oxidative damage, which could be ameliorated via direct inhibition of 
NADPH oxidase using either apocynin or diphenylene iodonium.  
We next looked at whether cytokine-induced ROS production had any influence on the 
expression of proteins located at the intercellular junctions. Previous studies in BBMvECs 
reported that direct induction of oxidative stress by H2O2 treatment significantly increased 
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occludin and actin expression but was seen to disrupt their (and ZO-1’s) localisation at the 
tight junctions (Lee, Namkoong et al. 2004). In contrast, models utilising Aβ to induce ROS 
production in cortical capillaries reported a dramatic loss of occludin, claudin-5 and ZO-1 
expression at the tight junction (Carrano, Hoozemans et al. 2011). Synonymous with this, 
Schreibelt (2007) observed both an overall reduction in occludin and claudin-5 protein 
expression and localisation at rat BMvEC cell-cell junctions following induced increase in 
the microenvironment’s ROS levels. We found for each antioxidant treatment that a partial, 
but significant, recovery in the cytokine-induced reduction in expression of VE-Cadherin, 
occludin and claudin-5 was achieved thus implicating the fold change in intracellular ROS 
levels to be damage-inducing. This effect was shown in both acute (6 hrs) and chronic (18 
hrs) treatment with TNF-α and IL-6 in the presence of the different antioxidant compounds.     
Based on the partial recovery of intercellular junction protein levels, the antioxidant 
strategies were next implemented to assess whether the recovery in protein was enough to 
attenuate TNF-α- and IL-6-induced loss of barrier function in HBMvECs. Studies examining 
the mechanism of IL-17A-induced ROS release on BBB disruption reported loss of barrier 
function due to cell contractility and loss of occludin at the tight junction, a pathway which 
could be prevented by inhibition of IL-17A activation of NADPH oxidase and xanthine 
oxidase production of ROS (Huppert, Closhen et al. 2010). Similar reversible effects on the 
tight junction and BBB permeability were observed using oxidised low-density lipoprotein 
to induce ROS-production in mouse BMvECs (Wang, Sun et al. 2012). Schreibelt (2007) 
also noted a reduction in BMvEC barrier integrity via ROS-induced reductions in claudin-5 
and occludin. We found for each antioxidant treatment of HBMvECs exposed to TNF-α and 
IL-6 (100 ng/ml), a very significant recovery in barrier function was achieved, once again 
highlighting the negative impact of cytokine-induced ROS production on cerebrovascular 
homeostasis. We observed this once again for both acute (6 hrs) and chronic (18 hrs) 
treatments with TNF-α and IL-6. Whilst studies examining the direct effect of cytokine-
induced ROS production on BBB barrier function are scarce, the majority of existing work 
focuses on ischemia/reperfusion experimental paradigms that corroborate our observations 
regarding the influence of oxidative stress on BBB barrier modulation (Witt, Mark et al. 
2003, Witt, Mark et al. 2008).     
Based on these collective findings, pharmacological intervention of cytokine-induced ROS 
using antioxidant compounds was shown to partially restore intercellular junction expression 
and BBB phenotype. While exploration into the actions of ROS within the cerebral 
microvasculature has been scarce, some mechanisms have been elucidated. Nagyoszi (2010) 
demonstrated how increased concentrations of ROS can induce the upregulation of certain 
TLRs in cerebral endothelial cells, which upon activation were shown to mediate the 
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ablation of tight junction proteins; claudin-5 and occludin. Haorah (2007) also reported 
increased permeability in HBMvECs in response to induced oxidative stress. Interestingly, a 
dual mechanism involving the enhanced activity of MMPs and protein tyrosine kinases on 
proteins of the tight junction was demonstrated. The effects observed in this paper, and 
others by Haorah (2005, 2005, 2007), regarding tyrosine and threonine phosphorylation of 
tight junction proteins, provides an interesting link between the effects of ROS on barrier 
function and our own earlier findings on tyrosine levels in response to shear (Chapter 3) and 
cytokine injury (Chapter 4). These mechanisms may apply in the actions of cytokines on 
HBMvEC and may be worth exploring. A number of related articles also make similar 
claims regarding ROS induction in the cerebrovascualture and disruption of vascular 
homeostasis yet the focus lies squarely on unnatural means of inducing oxidative stress 
(Haorah, Ramirez et al. 2007) or agents of abuse (i.e. alcohol (Haorah, Knipe et al. 2005, 
Haorah, Heilman et al. 2005) and methamphetamines (Zhang, Banerjee et al. 2009)).  
Based on our results, and the wealth of existing data on this subject, the impact of oxidative 
stress in the disruption of vascular homeostasis and barrier phenotype makes it an ideal 
candidate for therapeutic intervention. A number of studies have yielded strategies that 
restore the balance of ROS within the vascular system. One pioneering study involved the 
administration of a polyethyleneglycol-superoxide dismutase conjugate to atheroprone 
animal models that restored impaired endothelial function (Mugge, Elwell et al. 1991). 
Despite the consistency and successes achieved using in vitro and in vivo (Mugge, Elwell et 
al. 1991) models in negating and reversing the effect of oxidative stress, the translation of 
findings into clinical trials has been disappointing thus far with very few drug candidates 
achieving significant impact (Steinhubl 2008) (lipid-lowering drugs such as simvastatin and 
pravastatin have been shown to demonstrate secondary pleiotropic anti-oxidant effects; 
increasing local SOD, eNOS and gluthione peroxidise activity (Tandon, Bano et al. 2005)). 
With regards to the cerebrovasculature, the prevention of oxidative stress is of utmost 
importance as many of the debilitating diseases of the cerebral tissues derive from oxidative 
stress in their progression and disruption (e.g. Parkinson’s disease, Alzheimer’s disease etc 
(Ali, Barnham et al. 2004)). Delivery of potential compounds to the afflicted areas remains 
difficult due to the problems typically associated with traversing the BBB, however great 
progress has been made in the field of nanotechnology with breakthroughs such as 
‘nanozymes’ at the forefront of solving this problem (Manickam, Brynskikh et al. 2012, 
Klyachko, Manickam et al. 2012). In the meantime, antioxidant treatment is now looked 
upon as a risk reducer more so than a damage repairer, and dietary studies involving vitamin 
supplementation has transferred relatively well into human models with clinical studies 
demonstrating increases in vitamin C and E in the diet can drastically improve negative 
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aspects imparted by oxidative damage caused by chronic smoking, type 1 and 2 diabetes 
mellitus, hypercholesterolemia and chronic heart failure amongst others (Frei, England et al. 
1989, Packer, Valacchi 2002, Zaidi, Banu 2004), although there are conflicting reports 
regarding the efficacy (Behrendt, Krawinkel 2007, Behrendt, Ganz 2007). 
To summarise at this point, we find we have clearly demonstrated that TNF-α and IL-6 are 
capable of elevating ROS production of HBMvECs in both a time- and dose-dependent 
manner. Having demonstrated a controlled means of significantly reducing ROS presence 
using antioxidant compounds, we verified the elevated levels induced by TNF-α and IL-6 
were enough to sufficiently cause a reduction in tight junction protein levels; occludin, 
claudin-5 and VE-Cadherin, and subsequently cause a reduction in barrier function. We feel 
this data presents a comprehensive outlook on the cytokine-induced mechanisms in the acute 
and chronic stages of microvascular injury and underlines the importance of developing 
antioxidant treatments which are capable of effectively treating oxidative stress in the 
cerebral tissue. 
In addition to the release of ROS, we extensively examined the secretory profile of 
HBMvECs in response to a range of different cytokines (TNF-α, IL-6, MCP-1) over 
different exposure times (6 and 18 hrs). A relationship that we found interesting, and 
relatively unexplored, was the TNF-α-induced release of IL-6 (Chapter 4). To expand on this 
concept, further studies on this pathway were conducted. The transcription of IL-6 in 
response to TNF-α was examined first; IL-6 mRNA levels were significantly increased in a 
dose- and time-dependent manner following treatment with TNF-α (100 ng/ml) with an 
overall fold change of over 25 achieved by 24 hrs. Earlier studies in HUVECs reported 
similar fold changes in IL-6 transcription levels in response to TNF-α (Yamagishi, Inagaki et 
al. 2004). IL-6 protein expression in response to TNF-α was also investigated with a dose-
dependent increase observed following both acute and chronic treatment of HBMvECs. This 
is consistent with earlier studies (Modur, Zimmerman et al. 1996, van den Berghe, 
Vermeulen et al. 2000). Earlier studies in HAECs have demonstrated the ability of IL-4 to 
upregulate IL-6 levels and induce its release (Lee, Lee et al. 2010). The same study also 
demonstrated the ability of IL-4 to drive up ROS production, whilst treatment with 
antioxidants, particularly those targeting NADPH oxidase, attenuated HAEC IL-6 release. It 
is possible therefore that TNF-α-mediated IL-6 production in our HBMvEC model may 
proceed in part via ROS production (examined later). 
TNF-α is a potent cytokine within the acute phase of cerebrovascular injury with elevated 
levels recorded within the first hour in the area of inflicted injury (Shohami, Novikov et al. 
1994, Fassbender, Rossol et al. 1994, Hallenbeck 2002). Our observation of TNF-α inducing 
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the production of IL-6 in HBMvECs is of great interest therefore. Between the IL-6 
expression data in this chapter and the HBMvEC secretory profile reported in Chapter 4, we 
have demonstrated that HBMvECs are a reliable source for IL-6 in response to inflammatory 
cytokines such as TNF-α. We have also demonstrated that IL-6 within certain concentration 
and incubation ranges (1-100ng/ml, 6 and 18 hrs) has a damaging effect on HBMvEC 
cultures at both molecular and functional levels. Therefore it is imperative to investigate the 
response of the TNF-α-induced level of IL-6 on the homeostasis of HBMvECs to understand 
the potential mechanisms within the NVU. This pertains to the complex biology of IL-6 with 
much conflicting data describing it as having both protective and damaging effects within 
the NVU (Barkhudaryan, Dunn 1999, Erta, Quintana et al. 2012). 
Given the role of IL-6 in the pathogenesis of several disease states, targeted inhibition of IL-
6 activity is an attractive prospective therapeutic strategy (Kishimoto 2005, Tanaka, 
Narazaki et al. 2011, Tanaka, Narazaki et al. 2012). Due to the complex signalling nature of 
IL-6, a number of potential molecules (i.e. gp130, sIL-6R, tIL-6R, IL-6) were readily 
targetable for developing novel interventions in the blockade of IL-6 signalling (Ataie-
Kachoie, Pourgholami et al. 2013). To date, the most famous of the IL-6 therapeutics comes 
in the forms of tocilizumab, a humanised anti-human IL-6R monoclonal antibody which 
competes with freely available tIL-6R and sIL-6R. Tocilizumab is readily available in over 
90 countries and its efficacy is such that it is the first line biologic in Japan, India, USA and 
the EU for treating various forms of arthritis (Tanaka, Narazaki et al. 2012).  
Initially, clinical trials involving IL-6 therapeutics, in particular tocilizumab, targeted 
automimmune diseases such as rheumatoid arthritis (Nakahara, Song et al. 2003, Nishimoto, 
Miyasaka et al. 2009, Nishimoto, Miyasaka et al. 2009) and systemic juvenile arthritis 
(Yokota, Miyamae et al. 2005). Data accumulated from these trials reported interesting 
secondary effects opening the door for additional treatment of other IL-6-based diseases. 
Improvements in the levels of HbA1c (Ogata, Morishima et al. 2011) and reactive oxygen 
metabolites (Hirao, Nampei et al. 2011) have sparked a number of new trials investigating 
the potential of targeted IL-6 therapy in halting atheroprogressive mechanisms subsequently 
decreasing the chances of developing a form of CVD (Boekholdt, Stroes 2012). The efficacy 
of these therapies in combating CVD has been so successful that a number of other cytokine-
targeting therapies developed for autommunity-based diseases have been considered and 
trialled for similar purposes (i.e. TNF-α inhibitor, etanercept).  
On the basis of the proven pathological role of IL-6 in conjunction with the proven 
beneficial effect of anti-IL-6 therapies such as tocilizumab, IL-6 targeting is now considered 
a rational strategy in the treatment of various diseases with a number of IL-6 inhibitors being 
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developed (Jones, Scheller et al. 2011).  As part of our study, an IL-6 NtAb was employed to 
investigate the impact of TNF-α-induced injury when IL-6 activity was ablated. We began 
by identifying an effective concentration of IL-6 NtAb whilst ensuring specificity to IL-6 
was maintained (and direct interference in the activity of TNF-α was ruled out). We 
confirmed the specificity of the NtAb by western blot in which HBMvEC lysate and 
recombinant IL-6 (1 ng/ml) were run out on a SDS-PAGE gel along with our working 
concentrations of TNF-α (1-100 ng/ml) and subjected to immunblot analysis. Only the 
HBMvEC lysate and recombinant IL-6 displayed a band in the correct size region 
confirming our NtAb would not interfere with TNF-α activity. We then optimised our 
working antibody concentration based on its ability to prevent IL-6-mediated barrier 
disruption and permeabilisation. Different doses of NtAb were tested against a fixed 
concentration (20 ng/ml) of IL-6 with the concentration of NtAB chosen on the basis of 
effective barrier restoration and insignificant impact of the NtAb on the HBMvEC cultures 
themselves.  
The IL-6 NtAb was first utilised in examining the effect of TNF-α on ROS production. 
Cultures exposed to TNF-α (100 ng/ml) in the presence of the IL-6 NtAb demonstrated a 
reduction in ROS levels in both acute (6hrs) and chronic (18 hrs) experimental paradigms. 
Our earlier data obtained for IL-6 over the working concentration range (1-100 ng/ml) 
clearly demonstrated IL-6 could induce an increase in ROS production. With the 
employment of the NtAb therefore, TNF-α-mediated induction of IL-6 could now be 
partially attributed to the elevation in ROS production by TNF-α. The effect of TNF-α-
induced reduction in HBMvEC barrier function in the presence of the IL-6 NtAb was next 
explored. Cultures incubated with the IL-6 NtAb in the presence of TNF-α clearly 
demonstrated a significant restoration in barrier function following exposure to TNF-α alone 
in both acute and chronic treatments. This experimental paradigm was further explored to 
investigate the impact of TNF-α on the proteins involved at the intercellular junctions. 
Attenuating IL-6 activity with the NtAb during TNF-α treatment demonstrated a partial 
recovery in occludin, claudin-5 and particularly VE-Cadherin levels. As mentioned in 
chapter 4, the biology of IL-6 is complex, with several studies outlining both its beneficial 
and harmful inductive properties. An in vivo study by Paul (Paul, Koedel et al. 2003) 
addresses this utilising a similar strategy to ours in which the BBB is injured in the absence 
of IL-6 activity and subsequently characterised. Whilst certain inflammatory aspects (such 
as cytokine release) were exacerbated, a concurrent reduction in BBB disruption was 
observed. Therefore, whilst we have categorically identified IL-6 as having a disruptive role 
in HBMvEC homeostasis, there are several arguments that can be made indicating its 
beneficial effects (Woodroofe, Sarna et al. 1991, Taupin, Toulmond et al. 1993, Klein, 
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Moller et al. 1997, Penkowa, Moos et al. 1999, Hans, Kossmann et al. 1999, Penkowa, 
Giralt et al. 2000, Swartz, Liu et al. 2001, Galiano, Liu et al. 2001).      
In conclusion, we found the impact of TNF-α-induced IL-6 release on HBMvECs significant 
across a number of molecular and functional aspects. The levels of IL-6 released in response 
to inflammatory mediators such as TNF-α may therefore contribute to the overall damage 
inflicted by TNF-α on HBMvEC barrier phenotype.            
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Chapter 6: 
The role of 14-3-3 in shear- and cytokine-
induced modulation of HBMvEC junction 
assembly and barrier function. 
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6.1 Introduction 
As evidenced from the works of chapters 3, 4, and 5, the junctions of the BBB are dynamic 
structures. Following exposure to our local (shear stress) and systemic (TNF-α, IL-6, ROS) 
factors of interest, the proteins that comprise these junctions were demonstrated to become 
subject to molecular changes in expression, subcellular localisation, and post-translational 
modification, under both physiological (shear) and pathophysiological (cytokine) conditions. 
A number of intracellular signalling pathways regulate these processes with the BBB 
endothelium.  
The regulation of paracellular permeability is indeed subject to the complex interactions 
between several agonist-activated signalling pathways and key structural components of the 
endothelial cells. Phosphorylation is one such regulatory mechanism. Many of the proteins 
located in the interendothelial junctions of the BBB are classified as phosphoproteins, and 
possess several phosphorylation sites which can be affected during these complex signalling 
cascades. Several studies have identified the phosphorylation state of both the 
transmembrane and adapter proteins located at the interendothelial junction in several 
important functional events, from mediating subcellular localisation of tight junction 
proteins to overall junction assembly (Staddon, Herrenknecht et al. 1995). Given the 
multiple sites for phosphorylation on these proteins, it is likely that the cumulative 
phosphorylation levels of distinct tyrosine, threonine and serine residues on each protein 
have distinct functional consequences for BBB phenotype (Sakakibara, Furuse et al. 1997). 
Shifts in the equilibrium of phosphorylation state of certain proteins can lead to significant 
cellular dysfunction and ultimately cell death. These imbalances in phosphorylation state 
have been identified as a driving force in the development of several neurodegenrative 
diseases. A common trait in such disorders, hyperphosphorylation of fundamental proteins 
are indicative of disease and is generally believed to lead to their misfolding and 
aggregation. Several cerebral pathologies have identified hyperphosphorylation of BBB 
proteins as a hallmark in their development (e.g. stroke, MS, Alzheimer’s disease) and as a 
result are at the forefront of the rationale for modulating phosphorylation for therapeutic 
benefit. Together, all these events can contribute to abnormal phosphorylation states that can 
either cause or exacerbate disease. Therefore, homeostatic control of phosphorylation is vital 
in maintaining the physiological functions of the BBB and the associated wide range of 
cellular signalling processes it partakes in (Luissint, Artus et al. 2012). 
To date, the majority of CNS molecular studies pertaining to tyrosine, threonine and serine 
phosphorylation events have focussed on their role in the initiation and progression of 
cerebral pathologies, with ample evidence pertaining to their effect on BBB dysfunction. In 
contrast, there is very little information on the effects of protective influences, such as 
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laminar shear stress, on mediating these phosphorylation events (Walsh, Murphy et al. 
2011). These post-translational modifications are invariably mediated by a multitude of 
binding partners; kinases, phosphatases and facilitative adapter proteins that can mediate 
these phosphorylative events. Within our model of shear-induced enhancement of HBMvEC 
barrier function, our attention for chapter 6 turned to identifying the potentially novel 
binding partners that mediate the shear-mediated dephosphorylation of junction proteins, 
resulting in enhanced barrier function. Sophisticated co-immunoprecipitation techniques 
coupled with advanced liquid chromatography-mass spectrometry analysis identified the 14-
3-3 family of proteins as having a substantial presence at the interendothelial junction 
complex during shear-mediated events. The nature of 14-3-3 binding, coupled with its 
extensively documented relationship with regards to phosphorylation events, made it an 
ideal candidate for further investigation as a potential mediator of phosphorylation-driven 
events at the interendotheial junction of the BBB (Yaffe 2002).   
 
6.1.1 Study Aims 
In this chapter we examine the potential role of the 14-3-3 family in the shear- and cytokine-
induced modulation of HBMvEC interendothelial junction assembly and barrier function. 
Therefore, the overall aims of this chapter include: 
 To identify novel binding partners of TJ/AJ proteins following pre-conditioning by 
physiological levels of laminar shear stress.  
 To clarify the relationship between the identified potential binding partners (14-3-3) 
and the TJ/AJ protein (occludin, claudin-5, VE-Cadherin, ZO-1). 
 To investigate the effect of physiological levels of laminar shear stress, and TNF-α 
and IL-6, on 14-3-3 family isoforms transcriptional expression. 
 To investigate the effect of the inhibition of 14-3-3 binding by R18 peptide on 
HBMvEC barrier function during exposure to physiological levels of laminar shear 
stress or TNF-α and IL-6.  
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6.2.1 The 14-3-3 family of proteins interact with a number of interendothelial junction 
proteins in response to shear 
The identification of novel binding partners to a number of the interendothelial junction 
proteins was carried out (Figure 6.1, 6.2). Confluent HBMvECs were maintained in static 
cultures or subjected to laminar shear stress (8 dynes cm
-2
) for 24 hrs before being harvested 
for whole cell protein lysate.  Samples were then subjected to immunoprecipitation for each 
protein of interest; occludin, claudin-5, VE-Cadherin and ZO-1 with successful pulldown 
confirmed by SDS-PAGE and subsequent staining with coomassie reagent (Figure 6.1, i, ii). 
Protein bands of interest were excised from the SDS-PAGE gels and sent with IP elutions 
for analysis by LC-MS/MS (iii-v). Peptide libraries for each sample set were cross-
referenced to identify a novel binding partner (vi). The 14-3-3 family of proteins appeared in 
the peptide libraries for each junction protein with an elevated peptide frequency routinely 
observed in samples exposed to laminar shear stress (Fig. 6.2, i). The co-association of 14-3-
3 with the intercellular junction proteins was confirmed by western blot using the IP eluates 
(ii).  
 
6.2.2 Exposure of HBMvECs to laminar shear stress increases the association between 
14-3-3 and the intercellular junction proteins-an effect which can be blocked by R18 
peptide 
The effect of laminar shear stress on 14-3-3 association with the intercellular junction 
proteins was examined (Figure 6.3, 6.4).  Confluent HBMvECs were maintained in static 
environments or subjected to laminar shear stress (8 dynes cm
-2
) for 24 hrs before being 
harvested for whole cell protein lysate. Samples were then subjected to immunoprecipitation 
for each protein of interest; occludin, claudin-5, VE-Cadherin and ZO-1. The 14-3-3 levels 
were then examined by western blot.  14-3-3 showed a significant increase in protein levels 
(and thus association) in response to laminar shear stress for each of the interendothelial 
junction proteins (Figure 6.3, i-iv). A complimentary reverse study in which samples were 
immunoprecipitated for 14-3-3 showed a similar trend, whereby interendothelial junction 
protein association with 14-3-3 underwent a significant increase in response to laminar shear 
stress (Figure 6.4, i-iv).  
In order to explore the impact of 14-3-3 association with junctions, inhibition of its binding 
was necessary. R18 peptide is a commercially available inhibitor which effectively binds to 
14-3-3 to inhibit its association with other ligands. Confluent HBMvECs were maintained in 
static environments or subjected to laminar shear stress (8 dynes cm
-2
) for 24 hrs in the 
absence or presence of 100 nM R18 peptide before being harvested for whole cell protein 
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lysate. Samples were then subjected to immunoprecipitation for each protein of interest; 
occludin, claudin-5, VE-Cadherin and ZO-1. The 14-3-3 levels were then examined by 
western blot.  Exposure of HBMvECs to laminar shear stress resulted in a significant 
increase in 14-3-3 association with each of the interendothelial junction proteins of interest, 
an association that was completely blocked by R18 peptide (Figure 6.3, 6.4, i-iv). 
  
6.2.3 Pro-longed exposure of HBMvECs to laminar shear stress induces the 
downregulation of transcriptional levels of 14-3-3 family isoforms 
The effect of laminar shear stress on 14-3-3 family isoforms over time was examined on a 
transcriptional level (Figure 6.5). Confluent HBMvECs were maintained in static 
environments or subjected to laminar shear stress (8 dynes cm
-2
) for 0-24 hrs before being 
harvested for whole cell mRNA. The mRNA levels of five members of the 14-3-3 family; ζ, 
γ, ε, β and θ were examined from 0-24 hrs by qPCR. A significant change was observed for 
all five receptors in response to acute shear exposure (0-4 hrs); levels initially increased in 
response to acute laminar shear stress. All levels returned to baseline levels within 8 hrs of 
shear stress onset with a continued reduction in mRNA levels resulting in a moderate 
decrease in levels at 24 hrs in comparison to static cultures (i-v).  
 
6.2.4 R18-inhibition of 14-3-3 causes a downregulation in barrier function  
The effect of R18 inhibition of 14-3-3 in relation to barrier function was examined (Figure 
6.6). HBMvECs were seeded at a known density onto transwell inserts and left to adhere 
overnight. The following day the cultures were treated with R18 peptide (0-1000 nM) for 6 
hrs before being assessed for transendothelial permeability. Exposure of HBMvECs to R18 
results in a significant increase in FITC-Dextran paracellular flux (%TEE of FD40) across 
the cell monolayer (i, ii).   
The effect of laminar shear stress on the barrier function of HBMvECs in the presence of 
R18 was then examined. Confluent HBMvECs were maintained in static environments or 
subjected to laminar shear stress (8 dynes cm
-2
) for 24 hrs in the absence or presence of R18 
peptide (0-1000 nM) before being assessed for transendothelial permeability. Exposure of 
HBMvECs to R18 results in a significant increase in FITC-Dextran paracellular flux (%TEE 
of FD40) across the cell monolayer. Exposure of HBMvECs to laminar shear stress 
decreases permeability as expected, an effect that is completely blocked by R18 peptide in a 
dose-dependent manner (iii-vi). Complimentary studies conducted after 18 hrs incubation 
with R18 peptide show a similar trend which corroborates this data (Figure A.23). 
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Moreover, the effect of the R18 peptide concentration on HBMvEC viability was also 
examined by flow cytometry to determine the effective dose (Figure A.24).  
 
6.2.5 Exposure of HBMvECs to TNF-α induces the upregulation of transcriptional 
levels of 14-3-3 family isoforms 
The effect of TNF-α on members of the 14-3-3 family over time was examined on a 
transcriptional level (Figure 6.7). Confluent HBMvECs were stimulated with TNF-α (0-100 
ng/ml) for 0-24 hrs before being harvested for whole cell mRNA. The transcriptional levels 
of five members of the 14-3-3 family; ζ, γ, ε, β and θ were examined from 0-24 hrs by 
qPCR. An initial increase was observed for all five members in response to acute shear 
exposure (0-4 hrs). Transcription levels across all five members continued to increase 
robustly with respect to time and dose (i-x). A similar trend was observed in parallel 
experiments utilising IL-6 in place of TNF-α (Figure A.25).    
 
6.2.6 R18-inhibition of 14-3-3 can potentiate the injury caused by TNF-α and IL-6 
The effect of R18 inhibition of 14-3-3 in relation to TNF-α and IL-6 induced barrier 
dysfunction was examined (Figure 6.8). HBMvECs were seeded at a known density onto 
transwell inserts and left to adhere overnight. The following day the cultures were stimulated 
with TNF-α or IL-6 (100ng/ml) in the absence or presence of R18 peptide (0-1000 nM) for 6 
hrs before being assessed for transendothelial permeability. Exposure of HBMvECs to 
cytokines also results in a significant increase in FITC-Dextran paracellular flux (%TEE of 
FD40) across the cell monolayer. Furthermore, exposure of HBMvECs to cytokines in the 
presence of R18 resulted in a further moderate increase in permeability (i-iv).   
Complimentary studies conducted after 18 hrs incubation with TNF-α and IL-6 show a 
similar trend which corroborates this data (Figure A.26). 
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Figure 6.1: The experimental paradigm for identifying novel binding partners of 
interendothelial junction proteins. Confluent BBMvECs and HBMvECs were maintained 
in static conditions or exposed to laminar shear stress (8 dynes cm
-2
, 24 hr) following which 
they were harvested for whole cell protein lysate. The lysates were subjected to IP with 
successful pulldown confirmed by coomassie staining of SDS-PAGE gels (i, ii). IP eluates 
(iii) and isolated bands of interest on the coomassie stained gels (iv) were prepared and 
analysed by LC-MS/MS (v) with the resulting spectrum cross referenced with peptide 
databases (vi). Note: Gels above shown for occludin IP. 
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Figure 6.2: The identification and verification of novel binding partner interaction with 
interendothelial junction proteins. The resulting peptide libraries for each interendothelial 
junction protein were cross-referenced between one another and in the absence and presence 
of shear stress. The 14-3-3 family of proteins were identified as having a greater presence in 
the interendothelial junction plaque following the application of shear stress (i). The 
interaction of 14-3-3 with interendothelial junction proteins was confirmed by western blot 
(ii). Note: Gels above are shown for occludin IP.  
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Figure 6.3: The effect of laminar shear stress on 14-3-3/interendothelial junction 
protein co-association and the subsequent effect of 14-3-3 inhibition. Confluent 
HBMvECs were either maintained in static cultures or exposed to laminar shear stress (8 
dynes cm
-2
, 24 hr) in the absence and presence of R18 peptide, following which they were 
harvested for whole cell protein lysate. The lysates were subjected to IP/IB analysis for 
relative 14-3-3 levels against total target interendothelial junction protein levels. The 
histograms represent the relative 14-3-3 levels to total Claudin-5 (i), Occludin (ii), VE-
Cadherin (iii) and ZO-1 (iv) derived by scanning densitometry from western blots. Results 
are averaged from three independent experiments ± SD; *P≤0.05 vs. Untreated Control. 
δP≤0.05. Blots are representative. 
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Figure 6.4: The effect of laminar shear stress on interendothelial junction protein/14-3-
3 co-association and the subsequent effect of 14-3-3 inhibition. Confluent HBMvECs 
were either maintained in static cultures or exposed to laminar shear stress (8 dynes cm
-2
, 24 
hr) in the absence and presence of R18 peptide, following which they were harvested for 
whole cell protein lysate. The lysates were subjected to a reverse IP/IB analysis for relative 
interendothelial junction protein levels against total target 14-3-3 levels. The histograms 
represent the relative Claudin-5 (i), Occludin (ii), VE-Cadherin (iii) and ZO-1 (iv) levels to 
total 14-3-3 derived by scanning densitometry from western blots. Results are averaged from 
three independent experiments ± SD; *P≤0.05 vs. Untreated Control. δP≤0.05. Blots are 
representative. 
229 
 
 
Figure 6.5: The effect of laminar shear stress on specific 14-3-3 isoform expression. 
Confluent HBMvECs were exposed to laminar shear stress (8 dynes cm
-2
, 0-24 hr), 
following which they were harvested for whole cell mRNA. The samples were analysed by 
qPCR for the transcriptional levels of specific 14-3-3 isoforms that were present in the 
peptide libraries for each intercellular junction protein; 14-3-3ζ (i), 14-3-3γ (ii), 14-3-3ε (iii) 
14-3-3θ (iv) and 14-3-3β (vi). Results are averaged from three independent experiments ± 
SD; *P≤0.05 vs. 0 hrs. 
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Figure 6.6: The effect of 14-3-3 inhibition on HBMvEC barrier function. HBMvECs 
were seeded at a known density and allowed to adhere prior to addition of R18 peptide for 6 
hrs. Following this the HBMvEC sultures were examined by transendothelial permeability 
assay. The histogram (i) and line graph (ii) show the change in permeability (% TEE FD40) 
at a given time point(s) (t) = 180 mins or 0-180 mins, respectively in response to R18 (0-
1000 nM). Results are averaged from three independent experiments ± SD; *P≤0.05 vs. 0 
nM. In a parallel study, HBMvECs were either maintained under static conditions or 
exposed to laminar shear stress (8 dynes cm
-2
, 24 hr) in the absence and presence of R18 
peptide and examined by transendothelial permeability assay. The histogram (iii) and line 
graphs (iv, v, vi) show the change in permeability (% TEE FD40) at a given time point(s) (t) 
= 180 mins and 0-180 mins, respectively. Results are averaged from three independent 
experiments ± SD; *P≤0.05 vs. Untreated Control.      
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Figure 6.7: The effect of TNF-α on specific 14-3-3 isoform transcription. Confluent 
HBMvECs were stimulated with TNF-α (0-100 ng/ml) for 0-24 hr, following which they 
were harvested for whole cell mRNA. The LHS histograms represent the mRNA changes in 
14-3-3ζ (i), 14-3-3γ (ii), 14-3-3ε (iii) 14-3-3θ (iv) and 14-3-3β (vi) in response to 100 ng/ml 
TNF-α. The RHS histograms represent the mRNA changes in 14-3-3ζ (vi), 14-3-3γ (vii), 14-
3-3ε (viii) 14-3-3θ (ix) and 14-3-3β (x) in response to TNF-α (0-100 ng/ml) at 6 and 18 hrs. 
Results are averaged from three independent experiments ± SD; *P≤0.05 vs. 0 hrs (i-v) or 0 
ng/ml (vi-x).  
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Figure 6.8: The effect of 14-3-3 inhibition on TNF-α- and IL-6-induced HBMvEC 
damage-Barrier Function. HBMvECs were seeded at a known density and allowed to 
adhere prior to examination by transendothelial permeability. HBMvECs were then 
maintained in the presence of TNF-α or IL-6 (100ng/ml) for 6 hrs in the absence and 
presence of R18 peptide. Post-treatment the HBMvEC cultures were examined by 
transendothelial permeability assay. The histograms (LHS) and line graphs (RHS) show the 
change in permeability (% TEE FD40) at a given time point(s) (t) = 180 mins or 0-180 mins, 
respectively, in response to TNF-α (i, ii) or IL-6 (iii, iv). Results are averaged from three 
independent experiments ± SD; *P≤0.05 vs. Control. δP≤0.05.  
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6.3 Discussion 
There is now much evidence demonstrating how the endothelium can discriminate among 
the various fluid mechanical forces acting upon it leading it to transduce these forces into 
cellular responses (Davies 1995, Gimbrone, Topper et al. 2000). This has been a primary 
focus within the endothelium biology field and, within our own research group, we have 
published on the positive effects exerted by both cyclic strain (Collins, Cummins et al. 2006) 
and laminar shear stress (Colgan, Ferguson et al. 2007, Walsh, Murphy et al. 2011) on 
endothelial barrier phenotype. One recent publication from our group examined the effects 
of laminar shear stress on brain endothelium and demonstrated how VE-Cadherin-mediated 
regulation of Rac1 had subsequent consequences for BBMvEC levels of pTyr-occludin and 
barrier function (Walsh, Murphy et al. 2011). As such, post-translational modification of the 
interendothelial junction proteins has been a consistent mechanism and a key interest in our 
group in recent studies (Colgan, Ferguson et al. 2007, Colgan, Collins et al. 2008, Walsh, 
Murphy et al. 2011) and we aimed to build on our findings by indentifying novel kinases, 
phosphatases or other binding partners which interact at the interendothelial junction and 
mediate the post-translational modification-dependent modulation of endothelial barrier 
function (Mehta, Malik 2006, Komarova, Malik 2010, Luissint, Artus et al. 2012). 
Our strategy for identifying potential binding partners was to employ IP techniques to ‘pull 
down’ our proteins of interest in HBMvEC and BBMvEC cultures maintained both in static 
conditions and under laminar shear stress (8 dynes cm
-2
). Immunoprecipitation techniques 
have been utilised to great effect in examining the relationship between novel binding 
partners and proteins of the interendothelial junctions; for example density enhanced 
phosphatase-1 (DEP-1) (Chabot, Spring et al. 2009, Spring, Chabot et al. 2012). However, in 
contrast to our approach, these studies used immunoprecipitation to examine the relationship 
between two pre-hypothesised binding partners. In our approach, the resulting precipitates 
would then be analysed by mass spectrometry to generate peptide libraries of proteins 
directly (and indirectly) binding to each of our proteins of interest. Prior to mass spec 
analysis, we implemented numerous controls to ensure proper binding specificity. IP’s were 
typically conducted using an antibody-coupled resin immobilised on a centrifugal spin 
column. To identify any non-specific binding proteins, control resin with antibody and 
antibody-free resin columns were prepared for each of our IP target proteins (occludin, 
claudin-5, VE-Cadherin, ZO-1) and used with our generated lysates from both sets of 
species (bovine and human). Following the standard IP protocol, spun out lysate, wash steps 
and elutions were separated on SDS-PAGE gels and stained using colloidal coomassie. 
Typically, we were able to identify our bands of interest based on their size however some 
proteins required western blot analysis for verification of presence.   
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Following optimisation of our technique and confirmation of successful 
immunoprecipitations, elutions of our target protein and excised bands of interest were 
analysed by LC-MS/MS with subsequent generation of peptide libraries. We then compared 
our peptide libraries for each condition against one another (i.e. static vs. shear), across 
protein targets (occludin vs. claudin-5 vs. VE-Cadherin vs. ZO-1) and across species (human 
vs. bovine). Whilst a number of trends and potentially novel binding partners were present in 
the mass spec data, a prominent protein which appeared in all sheared samples and was 
absent in static (or significantly reduced in claudin-5’s case) was identified as 14-3-3. The 
14-3-3 family is comprised of seven isoforms, five of which appeared in our mass spec 
profiles depending on the detection limits set. As a result of the variety of isoforms observed 
across the intercellular junction proteins, we assessed the potential association by western 
blot using a general 14-3-3 antibody which had the ability to detect all isoforms. Following 
SDS-PAGE and western blot analysis of IP-treated samples, we confirmed 14-3-3 
association with each of the intercellular junction proteins.     
The widespread occurrence of 14-3-3 proteins in eukaryotes and their involvement in 
multiple cellular processes (Darling, Yingling et al. 2005, van Heusden 2005) have 
prompted researchers to examine them with two perspectives; first and foremost, there 
remains a lot to be uncovered with regards to the pathways in which the members of the 14-
3-3 family are involved; secondly, a clearer understanding of 14-3-3 proteins will reveal 
their association with cellular homeostasis and pathology of human diseases (Wilker, Yaffe 
2004, Foote, Zhou 2012). The complexity of this field, in conjunction with the complexity of 
14-3-3’s binding capabilities (i.e. dimer formation (Jones, Ley et al. 1995, Chaudhri, 
Scarabel et al. 2003, Wilker, Grant et al. 2005) and ligand binding (Furukawa, Ikuta et al. 
1993, Muslin, Tanner et al. 1996, Aitken, Baxter et al. 2002) made the job of elucidating 14-
3-3’s interaction with interendothelial junction proteins quite difficult. 
Luckily, a large volume of current 14-3-3 information derives from brain models (Baxter, 
Liu et al. 2002, Baxter, Fraser et al. 2002, Berg, Holzmann et al. 2003, Steinacker, Aitken et 
al. 2011). Given its initial discovery in the brain and the large percentage of total brain 
protein that 14-3-3 accounts for (1% (Martin, Rostas et al. 1994)), in conjunction with its 
initial function indentified to be regulation of neuronal activity, it was of no surprise that the 
14-3-3 protein activity would play a critical role in a number of cerebral functions (Moore 
BW and Perez VJ 1967). As more and more functional roles for 14-3-3 were discovered it 
was not long before it was implicated in disease pathogenesis. 14-3-3 involvement has been 
reported for a number of cerebral-based diseases, with 14-3-3 assemblies found in lesions 
and protein aggregates within the brain (Berg, Holzmann et al. 2003). An elevated presence 
of 14-3-3 has been reported within the neurofibrillary tangles seen in patients suffering from 
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Alzheimers disease (Layfield, Fergusson et al. 1996), and a possible link to polymorphisms 
in certain 14-3-3 isoforms has been suggested for early onset of schizophrenia (Toyooka, 
Muratake et al. 1999). Other in vitro, in vivo and post-mortem analyses have identified 14-3-
3 involvement in cerebral disease development (e.g. Parkinson’s disease, Amyotrophic 
Lateral Sclerosis). Elevated levels of 14-3-3 proteins have also been detected in the 
cerebrospinal fluid of patients suffering from stroke (Boston, Jackson et al. 1982, Collins, 
Boyd et al. 2000), subarachnoid haemorrhage (Hsich, Kinney et al. 1996) and Multiple 
Sclerosis (Boston, Jackson et al. 1982, Satoh, Kurohara et al. 1999). This reported elevation 
in levels, particularly in areas of injury, initially lead to some confusion as we had believed 
14-3-3 was a positive benefactor in cell functions. It was therefore critical to establish 
whether 14-3-3 presence in our HBMvEC cultures was acting as a general marker for brain 
injury and local tissue destruction or if they are actually involved in the pathogenesis of 
these debilitating neurological diseases.  
We decided to first examine the role of 14-3-3 in our shear model and subsequently the 
potential effect in our cytokine-injury model. To date little or no information exists on the 
role of 14-3-3 at the interendothelial junction. The majority of data available examines the 
relationship between 14-3-3 and the tight junction-associated PAR proteins in maintaining 
and regulating cell polarity, typically in epithelial models (Hurd, Fan et al. 2003, Suzuki, 
Hirata et al. 2004, Izaki, Kamakura et al. 2005, Cohen, Fernandez et al. 2011).  The trend 
observed in the mass spectrum data was maintained in our examination of the effect of 
laminar shear stress on 14-3-3 association with each of the intercellular tight junction 
proteins. Upon exposure to laminar shear stress (8 dynes cm
-2
), a significant increase in the 
association between 14-3-3 family (verified by western) and each of the intercellular tight 
junction proteins (IP target) was observed. We also further confirmed 14-3-3’s association 
with each of the intercellular junction proteins by ‘reverse’ IP. Moreover, identical results 
were obtained when 14-3-3 was used as the IP target, and the junctional protein designated 
as western blot targets.     
In order to assess the impact of 14-3-3 on the interendothelial junction, it was necessary to 
find a means of interfering with its function and extrapolating the subsequent effect. 14-3-3 
has been shown to bind to a wide variety of proteins and a number of characteristics have 
been identified in the ligands which permit 14-3-3 binding. For many years, successful 14-3-
3-ligand association was believed to be dictated by the phosphorylation state of the ligand 
(Muslin, Tanner et al. 1996). Consequently, research focussed on the phosphorylation-
dependency of 14-3-3 binding and subsequent production of inhibitors attempted to 
capitalise on this mechanism. However, the binding capabilities of 14-3-3 were subsequently 
discovered to operate independently of the phosphorylation of certain ligands. As a result, a 
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number of unphosphorylated ligands were developed which can dock to in the binding 
groove of 14-3-3 proteins and act as an antagonist regardless of their phosphorylation state. 
R18 is one such antagonist and was identified from a phage display library by virtue of its 
high affinity for 14-3-3 proteins (Petosa, Masters et al. 1998, Wang, Yang et al. 1999). R18 
exhibits a high affinity for all the 14-3-3 isoforms with estimated Kd values of 70-90 nM, 
which is as effective as some of its phosphopeptide equivalents. Studies which looked at 14-
3-3 ζ-R18 binding showed successful association similar to that of phosphorylated peptides, 
without affecting the overall protein structure (Petosa, Masters et al. 1998). Thus R18 
functionally acts as an effective blocking agent to both phosphorylated and 
unphosphorylated protein ligands associating with 14-3-3 (Masters, Pederson et al. 1999, 
Wang, Yang et al. 1999, Zhang, Chen et al. 1999). Employment of this peptide in our studies 
was preferred over siRNA silencing for two reasons; firstly; we wanted to completely 
eradicate all 14-3-3 activity, which R18 peptide facilitates in one treatment and secondly; 
while the knockout of individual 14-3-3 isoforms has proven effective, there are no 
assurances that functional overlap between isoforms may not confound results.  
Despite the efficacy of the R18 peptide computationally calculated to work within the nM 
concentration range, numerous studies have reported effective 14-3-3 inhibition only 
occurring in the mM range (Petosa, Masters et al. 1998, Du, Khuri et al. 2008, Mu, Andrews 
et al. 2008, Mancini, Corradi et al. 2011). Therefore we first examined the effect of R18 
peptide concentration on HBMvEC viability (as 14-3-3 could potentially regulate hundreds 
of functions in HBMvECs). We therefore we tested a range of published effective 
concentrations (10-5000 nM) of R18 peptide on HBMvEC viability by flow cytometry, 
aiming to assess the limits at which we could administer the peptide without having a 
significant impact on cell viability. We found we could examine up to nearly 10-times the 
recommended concentration (70-90 nM) without having a significant impact on cell 
viability.  
We also decided to further confirm our working concentrations (10-1000 nM) by first 
looking at the effect of R18 on cellular adhesion using an assay based upon the principle of 
cellular uptake of a crystal violet solution. We looked at the effect of R18 concentration on 
adhered HBMvEC cell numbers over 24 hrs of incubation, and were surprised to see a ~20% 
drop in crystal violet retention over this time course. Brightfield microscopy confirmed 
cellular monolayer compromise however this did not correlate with previous monolayer 
integrity of HBMvECs in response to R18 when viability was examined by flow cytometry. 
Assay parameters that may have contributed to this observation include variance in initial 
cell number, variance between plates, variance in technique etc. To eliminate these potential 
problems and further clarify the effect of R18 on our cell populations we examined the effect 
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of R18 on confluent HBMvECs using the xCelligence® system to monitor the monolayers 
response in real time. According to the xCelligence®, R18 peptide caused a neglible 
reduction in monolayer integrity (at our highest working concentration of 1000 nM, 
monolayer integrity did not drop below 98% after 24 hrs). These results not only confirmed 
our working concentrations were within a suitable range and that monolayer integrity was 
not lost, but further confirmed the efficacy of the xCelligence® system over cruder 
established protocols for assessing similar functions.  
With the working concentration range firmly established we examined the effect of R18 
peptide on the association of 14-3-3 with each of the interendothelial junction proteins. 
Upon IP of static and sheared HBMvEC for each of the interendothelial targets, a significant 
reduction in 14-3-3 association was observed in the presence of R18 peptide. In essence, 
R18 peptide completely ablated the shear-induced co-association of 14-3-3 with each of the 
target junctional proteins.  
To summarise at this point, our data clearly indicated that 14-3-3 family isoforms associate 
with interendothelial tight junction proteins in response to laminar shear stress. Given that 
laminar shear stress enhances barrier phenotype, this interaction would suggest a ‘pro-
barrier’ role for these proteins. With this in mind, the effect of laminar shear stress on 
expression of 14-3-3 isoforms was therefore examined. We observed a significant increase 
in the transcription levels of each of the five 14-3-3 isoforms (ζ, γ, θ, ε, β) within 4 hrs of 
laminar shear stress onset. This increase returned to baseline levels within 8 hrs and by 24 
hrs each of the five isoforms experienced an overall moderate decrease in their transcription 
levels. Interestingly, the trend observed in the 14-3-3 isoforms resembled that of the 
cytokine receptors in response to laminar shear stress (Chapter 3). It is entirely possible that 
during the early (0-4 hr) endothelial remodelling associated with inflammatory signalling, an 
initial spike in 14-3-3 levels can regulate the adaptive process before creating a negative 
feedback to restore 14-3-3 to new baseline levels in chronically sheared cells. We can only 
claim this based on transcription levels – we have not conducted studies on the overall 
translational levels of the 14-3-3 proteins to date. However a study by Nakamuta (2008) 
demonstrated the HIV-induced gp120-mediated disruption of ZO-1 and ZO-2 in HBMvECs. 
In response to elevated levels of gp120, significant increases in 14-3-3τ were observed and 
silencing of 14-3-3τ accelerated the gp120-mediated breakdown of the tight junction.      
With our current model for laminar shear stress on HBMvEcs potentially expanded to 
include a role for 14-3-3, we next decided to assess the degree of influence 14-3-3 had on 
barrier function by inhibiting its binding via R18 peptide and measuring the changes in 
HBMvEC permeability. Very little data is available on the role of 14-3-3 and barrier 
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modulation. Wong (2009) demonstrated that 14-3-3θ silencing in a blood-testis barrier 
model induced the mislocalisation of N-cadherin and ZO-1 from the cell-cell interface to the 
cytosol leading to disruption of the adhesion profile of Sertoli cells.  Moreover, Ngok (2013) 
demonstrated the regulation of the junction-coordinating protein; Syx, by 14-3-3 dependent 
binding. We demonstrated in static cultures that R18 could significantly decrease the 
association of 14-3-3 with the intercellular junction proteins. We further demonstrated that 
in HBMvEC static cultures, R18 caused a significant increase in permeability in a dose-
dependent (0-1000 nM) manner (and in a time-dependent manner). A similar trend was also 
observed in HBMvECs exposed to laminar shear stress in that R18 exposure appeared to 
completely reverse the shear-dependent reduction in permeability in parallel with the 
junction proteins.  
Based on these collective observations, we conclude that 14-3-3 family isoforms can 
modulate HBMvEC barrier phenotype particularly under shear conditions via interaction 
with junctional proteins. We then decided to investigate whether the 14-3-3 family had a role 
in modulating cytokine-driven disruption of barrier function. We first examined the effect of 
TNF-α (100 ng/ml) on the transcription levels of members of the 14-3-3 family that had a 
confirmed presence in HBMvECs via mass spectroscopy; ζ, γ, ε, θ and β. We found TNF-α 
(and IL-6) significantly and robustly increased the transcription of each of the five isoforms 
examined within 4 hours of TNF-α exposure, with 5+ fold change observed across all 
isoforms by 24 hrs.  
Considering the ‘barrier-weakening’ effect displayed by cytokines, we next considered if the 
cytokine-induced expression of 14-3-3 protein had a contributory effect to the cytokine-
induced damage. We therefore examined the effect of R18 inhibition of 14-3-3 on barrier 
function in the presence of both inflammatory cytokines. A slight but significant increase in 
monolayer permeability was observed in HBMvECs exposed to either TNF-α or IL-6 in the 
presence of R18 in comparison to the absence of R18. We concluded that if 14-3-3 had a 
damage-exacerbating effect, inhibition of its function would likely result in a decrease in 
permeability following exposure to TNF-α or IL-6. Instead, a significant increase was 
observed. We therefore hypothesised that the increase in transcription of 14-3-3 members 
reflected in-part a cellular defence mechanism to compensate for cytokine exposure. In 
response to inflammation HBMvECs increase endogenous levels of 14-3-3 in an attempt to 
restore barrier function (amongst other things), although the expression and increased 
phosphorylation of interendothelial junction proteins may prevent attempts at barrier 
restoration. Interestingly, Liu (Liu, Yin et al. 2001) demonstrated 14-3-3 could actively 
inhibit TNF-α signalling in endothelial cells via binding to ASK1. TNF-α partly mediates its 
effects through ASK1 dissociation from 14-3-3, a process that could be inhibited following 
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exposure to laminar shear stress. This adds credence to our hypothesis that increased 
transcription of these proteins is a pro-homeostatic feature in our model. Future investigation 
will undoubtedly reveal the mechanistic relationship between AJ/TJ dynamics and 14-3-3 
isoforms under barrier-strengthening (shear) and –weakening (cytokines) influences.    
In conclusion, we have comprehensively demonstrated how the 14-3-3 family plays a pivotal 
role in the maintenance of vascular homeostasis and BBB phenotype through association 
with proteins of the interendothelial junction, with consequences for BBB barrier function. 
In addition, we also demonstrated how the 14-3-3 family may play a pivotal anti-
inflammatory role in response to cytokine injury. 
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Chapter 7: 
Final Summary. 
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7.1 Final Summary 
Global CNS diseases account for approximately US$2 trillion a year (The Neurotechnology 
Industry Report 2009). This economic burden coincides with the fact that the CNS is 
currently regarded as one of the most difficult areas in which to achieve clinical success 
(Kola, Landis 2004). Between 1991 and 2000, only 8% of clinical trial developing drugs for 
CNS based therapeutics successfully achieved registration (Kola, Landis 2004). More than 
90% of developed CNS therapies are abandoned between Clinical Phases I and III incurring 
extravagant loss of capital and time (CNS drug development exceeds the average time frame 
for normal drugs of 10-12 years to 12-16 years) (Kola, Landis 2004).     
While drug companies strive to formulate a way of crossing the blood brain barrier by 
targeted drug delivery means, a number of radical therapies are currently in use and have 
shown a respectable success rate despite their impracticality and flaws.  These can range 
from direct injection into the brain or CSF (Liebert, Wahl et al. 1990, Schroeder, Weinger et 
al. 1991, Gabathuler 2010) to targeted modulation of the microvasculatures tight junctions 
by osmotic or chemical means (Saija, Princi et al. 1995, Sanovich, Bartus et al. 1995, 
Rapoport 2000). Osmotic disruption of the tight junctions remains the favoured and more 
clinically implemented strategies, particularly in the delivery of anticancer therapeutics to 
cerebral tumours (Hall, Doolittle et al. 2006, Hall, Sherr 2006). This method is still highly 
flawed however in that it often results in widespread disruption of the tight junctions in areas 
that are not identified to require treatment. This results in non-specific delivery of the drug 
in questions diluting its target dose and opens up healthy areas of the brain to invading 
blood-present toxic products.   
The latter mentioned therapy highlights one of the key problems associated with successful 
targeted drug delivery to the brain, notably the degree of difficulty maintaining drug 
accumulation in the injured area of the brain as opposed to other organs. It is estimated that 
over 98% of currently available drugs are ineffective at achieving the required therapeutic 
concentrations in the CNS while close to 100% of biological drugs fail (Pardridge 2003). 
Therefore most drugs actually fail at treating the intended disease and more often invoke 
secondary effects or even toxicity should higher doses be administered to counteract the 
problem. While many strategies have been able to overcome this problem they have 
encountered others such as the compound maintaining stability en route to the area of 
interest, evading potential disruptive proteins and their binding actions, and perhaps most 
difficult of all, passing across the membranes of the already well established endothelial 
barrier. The problem herein lies with developing a strategy that overcomes ALL of these 
problems at once and it is for this reason that It is for this reason that some of the more 
radical therapies have been resorted to. There has been moderate success in achieving this in 
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the form of ‘trojan horse’ drug delivery (Pardridge 2006). Pharmaceutical companies are 
currently developing non-viral vectors with unique chemical and surface properties which 
maximise stability and plasma solubility while avoiding eliciting an immune response. 
Already these therapies have been used to deliver DNA-, peptide- and protein- based 
therapeutics (Schroeder, Sommerfeld et al. 1998, Schroeder, Sommerfeld et al. 1998, Liu, 
Huang 2002). These agents have been used to successfully treat chronic pain, insomnia, and 
epilepsy in addition to several affective disorders such as schizophrenia and depression. 
However treatment for the damage caused by the more severe injuries such as brain cancer 
and stroke remains quite limited.    
To date, controlling the permeability of the BBB remains a clinically unmet challenge. Since 
the NVU is comprised of a number of different cell types which contribute by regulating and 
modulating a number of different cell signalling cascades, BBB dysfunction can arise from 
many a ways. While much progress has been made in understanding these cell types and the 
respective pathways that they are involved in, there still remain a lot of unanswered 
questions or conflict on certain aspects. Whether or not it may be beneficial or contradictory, 
new avenues are being explored with the miRNA field opening up a fresh perspective on the 
development and functionality of the NVU. Already several miRNA have redefined some of 
the ideas that were held for so long with a number shown to influence angiogenesis 
(Caporali, Meloni et al. 2011) and other vascular functions (Hartmann, Thum 2011).   
Despite these difficulties, progress has been made with regards to some pathologic diseases. 
For example administration of anti-inflammatory medication has been shown to restore BBB 
function in certain animal models and these studies have been taken forward into humans, 
successfully controlling seizures associated with drug-refractory epilepsy (Sotgiu, 
Murrighile et al. 2010, Marchi, Granata et al. 2011). Cases like this demonstrate that there is 
hope in eventually understanding the BBB and translating this knowledge in to therapeutics.      
The homeostasis of the CNS environment is regulated and maintained by the BBB, a 
complex cellular system comprised of astrocytes, pericytes, neurons and at the forefront, 
microvascular endothelial cells. The BBB separates the brain from the systemic blood 
circulation, protecting the brain from blood-borne compounds which may disrupt the strict 
homeostasis of the neural environment. Therefore it is critical that the barrier remains intact 
and fully operational in order to preserve neuronal activity and brain function.  
The focal point of this thesis is the cerebral endothelium of the microvasculature. These 
BMvECs display a number of functional and morphological differences in comparison to 
endothelial cells of the peripheral vasculature; an increase in cytosolic mitochondria, the 
absence of fenestrae of the membrane, and a reduction in pinocytotic vesicular activity. 
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Perhaps the most well known trait of the BMvECs is their enhanced barrier properties. 
BMvECs present restrictive intercellular junction complexes often collectively referred to as 
the ‘tight junction’. These tight junctions, in partnership with the adherens junction, form a 
continuum of intercellular junction complexes between adjacent endothelial cells to generate 
a uniform monolayer of substantially higher barrier function. The enhanced junctions restrict 
the passage of charged particles, proteins, ions, hydrophilic molecules and hormones, all of 
which may act as neurotransmitters and thus destabilise the neural environment. However 
the brain has a high metabolism rate and requires a constant source of nutrition and waste 
removal, which in turn requires passage across this seemingly impermeable barrier.  The 
phenotypic barrier of BMvECs can dynamically defend the brain from blood-born antigens, 
enable the passage of essential nutrients and filter waste products or harmful substances 
from the cerebral tissue into the blood stream, whilst maintaining the impedance of 
paracellular transport of aforementioned agents.  
It is said the BBB was born from the selective evolutionary process, giving those species an 
evolutionary advantage. However its highly effective barrier properties make it a major 
obstacle in the development and delivery of CNS drugs. Overcoming the barrier-impeded 
delivery and subsequent enzymatic degradation of targeted therapeutics represents a major 
rate-limiting step in translating potential drug candidates into an effective neurotherapeutic. 
Conversely, BBB disruption has been associated with the pathophysiology of a number of 
neurological disorders, including ischemia, tumours, HIV-encephalitis, multiple sclerosis 
and neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease (Persidsky, 
Heilman et al. 2006, Abbott 2002, Abbott 2013). Therefore, progression of targeted 
therapeutics for the treatment of these disorders hinges on the delineation of the mechanisms 
behind the brain microvascular endothelium maintenance and regulation of junctions, as 
well as the environmental factors which impact this.  
This thesis aimed to explore both physiological and pathophysiological factors impacting on 
the microvascular endothelium’s intercellular junctions at both a molecular and functional 
level via employment of an in vitro HBMvEC culture model. In this regard, the apical 
location of the cerebral endothelium places it in immediate contact with frictional shear 
stress imparted by blood and its constituents. A host of factors can mediate the fluctuation in 
levels of the various blood-borne components; diet, exercise, injury and infection to name 
but a few. These components can exact their effect via the appropriate cellular receptor, 
which in turn can initiate one or more signalling cascades and ultimately yield a cellular 
response. For better or worse, the independent effect of each component depends on its 
cumulative interaction with other agents in the cellular vicinity. In the instance where 
inflammatory agents may exceed that of anti-inflammatory defences, the imbalance can 
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disrupt vascular homeostasis and lead to the onset and progression of CVD. Sites where the 
level of force exerted by the blood is subject to inconsistencies and fluctuation can generate 
areas of low or ‘disturbed’ shear stress. These areas are subject to dysfunctional tendencies 
i.e. a reduction in barrier, promotion of coagulant activity and the release of inflammatory 
mediators (Fig. 7.1). Thus we hypothesised that a physiological level of laminar shear 
stress and pathophysiological levels of inflammatory mediators impact on BBB function 
by directly (and indirectly) modulating the expression and biochemical properties of the 
intercellular junctions which comprise the BBB.  
 
Figure 7.1: Schematic depiction of experimental approach. Primary human brain 
microvascular endothelial cells (HBMvECs) were subjected to different experimental 
paradigms; physiological shear conditions (dark green, chapter 3) and pathophysiological 
inflammatory cytokines (red, chapter 4) and monitored for genetic, molecular, structural and 
functional changes in BBB phenotype, particularly pertaining to the interendothelial 
junction. The effect of co-exposing the HBMvECs to both stimuli was then investigated on 
barrier function, in parallel with further mechanistic studies related to each stimulus’s 
experimental outcomes; the influence of ROS of cytokine-induced damage (orange, chapter 
5) and the role of 14-3-3 in shear-mediated barrier enhanced (light green, chapter 6). 
 
Hemodynamic forces are a fundamental stimulus of the entire vascular system. Varying in 
magnitude, frequency and direction, these fluid-driven mechanical forces have been 
demonstrated to significantly impact on vessels at several levels; molecular, genetic, 
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structural and functional (Davies 1995, Chiu, Wang et al. 1998, Chiu, Chen et al. 2003, 
Chiu, Usami et al. 2009). Thus haemodynamic forces are regarded as critical mediators of 
BBB induction and regulation (Krizanac-Bengez, Kapural et al. 2003, Krizanac-Bengez, 
Mayberg et al. 2004, Krizanac-Bengez, Hossain et al. 2006, Krizanac-Bengez, Mayberg et 
al. 2006). In this regard, previous work in our laboratory has demonstrated that simulation of 
physiological levels of in vivo haemodynamic forces act as a positive stimulus to bovine 
endothelial cultures, mediating the putative mechanisms involved in endothelial junction 
assembly/enhancement and thus barrier function (Collins, Cummins et al. 2006, Colgan, 
Ferguson et al. 2007, Walsh, Murphy et al. 2011). We decided to expand on these studies. 
By employing human cultures in place of bovine, we were taking a step closer towards 
translational relevance. As this was the first time our laboratory had employed human 
cerebral tissue in our studies, an extensive characterisation of biomarkers typically found in 
the same cultures in vivo was carried out. Of particular importance was the expression of the 
proteins integral in the formation of intercellular junctions; occludin, claudin-5, VE-
Cadherin and ZO-1 (Weksler, Subileau et al. 2005). The expression of the aforementioned 
proteins was subsequently investigated and confirmed for our primary derived HBMvECs.  
In chapter 3, our initial studies focussed on the trends observed in our laboratory’s previous 
bovine endothelial cell model and whether they translated into a comparative human 
endothelial cell model. Exposure to physiological levels of laminar shear stress 
demonstrated a similar induced pattern of cellular realignment in the direction of the flow. 
Each protein; occludin, claudin-5, VE-Cadherin and ZO-1 was also observed to be 
significantly increased at the mRNA and protein levels in response to laminar shear stress 
(Schnittler 1998, Cucullo, Hossain et al. 2011). This increase in expression/localisation in 
response to shear stress suggested a correlative increase in barrier function (Colgan, 
Ferguson et al. 2007, Siddharthan, Kim et al. 2007, Colgan, Collins et al. 2008). This theory 
was substantiated when cultures exposed to laminar shear stress exhibited a significant 
reduction in permeability in comparison to control static cultures.  
At this point, the bulk of this preliminary data corroborated a number of characteristics 
attributed to BMvECs previously observed in similar models by our laboratory and others. 
We next decided to focus our efforts on novel mechanisms and pathways previously 
explored in our laboratory, in particular post-translational modifications of the proteins at the 
cell-cell junction. Previous work in our laboratory demonstrated haemodynamic modulation 
of phosporylation of tyrosine, threonine and serine residues in occludin and ZO-1 in bovine 
endothelial cells of macro and microvascular origin (Collins, Cummins et al. 2006, Walsh, 
Murphy et al. 2011). We demonstrated in HBMvECs a significant reduction in tyrosine and 
threonine phosphorylation of all four junctional proteins in response to laminar shear stress. 
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The impact of such an event was partially explored via the inhibition of tyrosine phosphatase 
activity, in which laminar shear-induced enhancement of HBMvEC barrier was partially 
attenuated, corroborating previous studies (Collins, Cummins et al. 2006, Walsh, Murphy et 
al. 2011). In summation, a wealth of data currently exists regarding the effect of 
hemodynamic forces on the endothelium, (though the majority of studies focus on the 
macrovasculature (Davies 1995, Chiu, Wang et al. 1998, Chiu, Chen et al. 2003, Chiu, 
Usami et al. 2009)). Regarding the microvasculature, studies have primarily focussed on 
inductive effect of the surrounding cell types that along with the endothelium comprise the 
NVU (Bauer, Bauer 2000, Abbott 2002). However the inductive influence of hemodynamic 
forces, in particular, shear stress, on the microvasculature is increasingly becoming an area 
of interest with several studies replicating and/or corroborating several findings presented in 
this thesis (Krizanac-Bengez, Mayberg et al. 2004, Krizanac-Bengez, Hossain et al. 2006, 
Krizanac-Bengez, Mayberg et al. 2006, Cucullo, Hossain et al. 2011). However, the data 
presented here represents one of the first extensive characterisations conducted on the 
influence of laminar shear stress on HBMvEC barrier modulation, detailing consequences 
for the proteins that form the crucial interendothelial junctions on genetic, molecular, 
structural and functional levels.     
Having characterised our HBMvEC barrier phenotype model with respect to an anti-
inflammatory stimulus (shear), we next turned our attention in chapter 4 to a pro-
inflammatory stimulus, namely cytokines. Having conducted an extensive literature search 
on the inflammatory mediators which are locally produced in the neural environment, we 
selected cytokines based on a number of criteria; the source of the mediator, the established 
role of the mediator in disease progression, and whether it had a proven effect on endothelial 
cells. Based on these criteria, we chose TNF-α, IL-6 and MCP-1 (Fabry, Fitzsimmons et al. 
1993, Shohami, Novikov et al. 1994, Fassbender, Rossol et al. 1994, Simpson, Newcombe et 
al. 1998, Reyes, Fabry et al. 1999, Lee, Hennig et al. 2001, Hallenbeck 2002, Weber, 
Blumenthal et al. 2003, Verma, Nakaoke et al. 2006). Our overall aim was to expose our 
cultures to varying concentrations of these cytokines and monitor barrier phenotype (as for 
shear stress). As this was previously unexplored in our laboratory, the incubation times and 
cytokine concentrations were subject to much scrutiny and were run through a battery of 
viability and functional assays to assess to overall impact of the aforementioned variables on 
whole cell well-being. Membrane integrity, metabolism and adhesion were all deemed stable 
in our set conditions (1-100ng/ml, 6 or 18 hrs incubations) allowing for the assessment of an 
intact monolayer in response to each mediator. In addition to exploring the molecular and 
functional aspects affecting the intercellular junctions, we also conducted a screen of the 
secretory profile of the HBMvEC cultures to identify what additional, if any, mediators may 
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play a part in the overall consequential effect of our primary cytokines. TNF-α, IL-6, IFNγ 
and IL-1β secretory levels were screened in tandem using a novel Multiplex ELISA platform 
with each cytokine levels observed to increase in a time- and dose-dependent manner 
following exposure to either TNF-α, IL-6 or MCP-1. Interesting trends observed from this 
data bank were subsequently investigated using standard single-plex ELISA, the strong 
release of IL-6 in response to TNF-α being particularly noteworthy. We subsequently 
decided to investigate the individual effects of TNF-α and IL-6 on the molecular and 
functional aspects of endothelial junction expression and function. 
Overall, HBMvEc barrier function decreased as cytokine concentration and incubation time 
increased, an inverse to the relationship established in our laminar shear model (Brett, 
Mizisin et al. 1995, Mark, Miller 1999). We therefore decided to advance our study, using 
three different concentrations to investigate the impact on the previously studied proteins 
comprising intercellular junction assembly.  We found mRNA and protein expression of 
occludin, claudin-5, VE-Cadherin and ZO-1 was reduced following exposure to our 
inflammatory cytokines, TNF-α and IL-6, in a dose- and time-dependent manner, correlating 
with the previously demonstrated reduction in barrier function (i.e. increase in permeability 
(Duchini, Govindarajan et al. 1996, Aveleira, Lin et al. 2010). Moreover, given the impact of 
laminar shear on tyrosine and threonine phosphorylation levels of some of the proteins of 
interest, we decided to investigate the impact of cytokines in the context. Once again, in 
contrast to the effect seen with laminar shear, cytokines robustly increased the 
phosphorylation of both tyrosine and threonine residues of occludin, claudin-5 and VE-
Cadherin, functional modifications which could impact barrier integrity/permeability as 
dictated by use of the tyrosine kinase inhibitor genistein (Soma, Chiba et al. 2004, Persidsky, 
Heilman et al. 2006, Willis, Meske et al. 2010, Yukitatsu, Hata et al. 2013). Overall, the 
inflammatory mediated opening of HBMvEC barriers may present an ideal opportunity to 
explore the size restrictiveness of the cytokine-induced opening of the paracellular pathway. 
Utilisation of dextran tracers that vary in size may allow the degree of barrier failure to be 
calibrated. This may present a potential opportunity to explore the effect of these barrier 
disrupting mediators on diapedesis mechanisms via employment of whole blood primary 
derived immune cells or immune cell cell lines. In summation, inflammatory cytokines are a 
well characterised promoter of injury within the CNS (Kim, Wass et al. 1992, Megyeri, 
Abraham et al. 1992, Deli, Descamps et al. 1995, DeVries, BlomRoosemalen et al. 1996). 
Whilst a wealth of data currently exists detailing their pathophysiological (and 
physiological) effects within the NVU, much like our reasons for laminar shear stress, the 
data presented here represents one of the first extensive characterisations conducted on the 
influence of TNF-α, and in particular, IL-6, on HBMvEC barrier modulation, again detailing 
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the consequences for the proteins that form the crucial interendothelial junctions on genetic, 
molecular, structural and functional levels.      
 
Figure 7.2: The polarising effects of an anti-inflammatory (shear stress, LHS) and pro-
inflammatory (TNF-α/IL-6, RHS) on HBMvEC BBB phenotype-barrier. 
To summarise at this point, our work corroborated (and expanded) a number of observations 
in a human model which had been previously observed in bovine endothelial models 
(Colgan, Ferguson et al. 2007, Walsh, Murphy et al. 2011). Vascular homeostasis 
encompasses a multitude of functionalities aside from maintenance of barrier function 
(Ryan, Ryan 1984, Hunt, Jurd 1998). Recently, concurrent work to this thesis has focussed 
on the release of the anti-coagulant molecule thrombomodulin from endothelial cells of 
aortic origin in response to varying levels of cyclic strain. We decided to test aspects of this 
model in our cerebral model to further elucidate the pro-homeostasis effects of laminar shear 
stress on our HBMvEC cultures. We found that in response to physiological levels of shear 
stress, a surge in thrombomodulin release occurred, a response which correlated with an 
increase in intracellular levels suggesting that laminar shear stress was perhaps promoting 
anti-coagulant activity (Takada, Shinkai et al. 1994, Kawai, Matsumoto et al. 1997, 
Ishibazawa, Nagaoka et al. 2011, Giwa, Williams et al. 2012). In examining this paradigm, 
we tested the activity of the shear-induced medium levels of soluble thrombomodulin by 
introducing pro-inflammatory/pro-coagulant thrombin into our barrier function assays and 
observed a significant reduction in thrombin-induced disruption of HBMvEC barrier 
function. In parallel with this, another factor involved in the coagulation cascade; vWF was 
249 
 
investigated with a significant reduction in the mRNA levels of this pro-coagulant molecule 
following exposure to shear stress (Rand, Badimon et al. 1987, Wu, Drouet et al. 1987, 
Badimon, Badimon et al. 1993). These trends offered another dimension in assessing 
vascular homeostasis independently of barrier function. Parallel studies demonstrated that 
inflammatory cytokines increased the release of soluble thrombomodulin (Nawroth, Stern 
1986, Bauer, Rosenberg 1987) (although not to the degree seen following exposure to 
laminar shear stress). Conversely, intracellular levels were reduced following cytokine 
exposure suggesting that production of the anti-coagulant molecule ceases, leaving it prone 
to coagulative activity over chronic periods of time. Concurrently, the pro-coagulant 
molecule vWF is seen to increase at both a transcriptional and translational level following 
exposure to our cytokine regime, further intensifying our coagulation paradigm in cerebral 
cultures (Tsuchida, Salem et al. 1992, Faust, Levin et al. 2001, Isermann, Hendrickson et al. 
2001).  
 
Figure 7.3: The polarising effects of an anti-inflammatory (shear stress, LHS) and pro-
inflammatory (TNF-α/IL-6, RHS) on HBMvEC BBB phenotype-hemostasis. 
Based on our efforts thus far revolving around the exposure of our HBMvEC cultures to 
laminar shear and inflammatory cytokines we decided to combine the two stimuli in one 
model and investigate if shear can ameliorate cytokine injury in vitro. We explored this from 
two approaches; the concurrent effect of inflammatory cytokines and laminar shear stress on 
pre-sheared HBMvEC cultures and the effect of inflammatory cytokines on pre-sheared 
cultures. In both instances, a significant reduction in cytokine-mediated barrier dysfunction 
was observed, suggesting the protective influence of laminar shear stress towards 
inflammatory mediators (Surapisitchat, Hoefen et al. 2001, Berk, Abe et al. 2001, Berk, Min 
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et al. 2002, Yamawaki, Lehoux et al. 2003, Ni, Hsieh et al. 2004). We subsequently 
investigated the effects of each stimulus on the expression of the respective signal 
transducing cytokine receptors to explore whether that might have any potential bearing on 
these events. Interestingly, on a transcriptional level, laminar shear stress and inflammatory 
cytokines drove the expression of certain receptors in opposite directions. gp130 and TNFR1 
were significantly unregulated in cultures exposed to inflammatory cytokines, whilst TNFR2 
displayed a significant reduction. Laminar shear stress by contrast invoked an inverse 
response. These findings may offer an interesting aspect for further exploration. For 
example, TNFR1 facilitates the induction of apoptotic pathways – reduction or increase of 
such would therefore have an enormous bearing on the overall induced immune response 
(Pradillo, Romera et al. 2005, Cook, Stahl et al. 2008, Wang, Young et al. 2011).  
 
Figure 7.4: The polarising effects of an anti-inflammatory (shear stress, LHS) and pro-
inflammatory (TNF-α/IL-6, RHS) on HBMvEC BBB phenotype-cytokine receptors. 
In summary, these studies not only expanded on the impact imparted by a healthy (shear) 
and injurious (cytokines) stimuli on BBB homeostasis, but highlighted in one of the few in 
vitro studies available, the protective effect that shear exudes in an inflammatory BBB 
model. For example, much of the existing knowledge on hemostasis in the vasculature was 
based on data derived from the macrovasculature. Whilst much of the knowledge has 
translated quite well to the microvasculature, the extreme difference in phenotype between 
the endothelium of the brain and the peripheral vasculature has lead for some of these 
hemostatic aspects to be revaluated (Abbott 2005). While not extensively investigated, the 
data presented offers a fresh perspective on the influence of both a healthy (shear) and 
injurious (cytokines) stimuli on regulation of hemostasis by HBMvECs. The observed anti-
inflammatory effects of shear were further investigated in one of the few in vitro studies 
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existing that examines the overall effect of laminar shear stress on cytokine-induced 
modulation of HBMvEC barrier function. In addition, preliminary work on the effects of 
each stimulus on each cytokine-signalling receptor offers encouraging data that with further 
work may unearth novel signalling processes involved in HBMvECs immune response. 
Together, these effects, in conjunction with the characterisation of each stimulus on 
HBMvEC barrier function, comprise an extensive profiling of the behaviour of HBMvECs 
in response to environmental stimuli encountered at the BBB with the crux that shear stress 
can ameliorate the disruptive effects induced by CNS-produced cytokines.            
In chapter 5, we set out to explore potential mechanisms mediating the injurious effects of 
cytokines on HBMvEC barrier characteristics. As noted earlier, we used a Multiplex ELISA 
to investigate a focal group of inflammatory mediators previously identified as being 
involved in the onset and progression of CVD. A key inflammatory mediator not present on 
this panel however, so not considered until now were ROS. The acute phase of vascular 
injury is the point at which surges in cytokines and chemokines occur. ROS are integral 
players in the acute phase of injury and thus could not be ignored in our attempts to further 
understand inflammatory pathways in our model. Via employment of ROS-tracking dyes, 
we observed a significant increase in the fold-change of levels of intracellular ROS 
following exposure to our cytokine regime. This increase was later deemed injury-
progressive as inhibition/catabolism of ROS in the presence of inflammatory cytokines 
demonstrated a reduction in the cytokine-induced injury imparted on both barrier function 
and intercellular junction protein expression. Once again, this work was undertaken in order 
to add another dimension to our inflammatory study. It is worth noting that previous work in 
our laboratory explored the influence of laminar shear stress on the role of NADPH oxidase 
in ROS-dependent endothelial dysfunction (Fitzpatrick, Guinan et al. 2009, Guinan, 
Rochfort et al. 2013) yet this pertained to endothelial cultures of a macrovascular origin. For 
the first time in our lab, the effect of naturally occurring, injurious stimuli on ROS 
production in the microvasculature was comprehensively covered. Several studies 
corroborate certain aspects of the data presented in this thesis (Haorah, Knipe et al. 2005, 
Haorah, Ramirez et al. 2007, Schreibelt, Kooij et al. 2007, Basuroy, Bhattacharya et al. 
2009) yet for the first time, a detailed examination of the role of cytokine-induced ROS on 
human BBB phenotype, particularly with regards to barrier modulation, is covered here.  
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Figure 7.5: The contributory effect of ROS release in pro-inflammatory (TNF-α/IL-6) 
induced injury to HBMvECs. 
As addressed earlier, a trend of particular interest was the TNF-α-induced expression and 
release of IL-6. Having extensively characterised the effect of IL-6 on HBMvEC barrier 
properties we shifted our focus to explore the hypothesis that the effects of TNF-α are 
mediated in-part through IL-6 production. In addressing this hypothesis we took the 
approach of neutralising any TNF-α-induced release of IL-6. Following IL-6 neutralisation, 
a significant reduction in the TNF-α-induced generation of intracellular ROS was observed. 
In addition, each of the examined proteins at the intercellular junctions demonstrated a 
significant recovery in expression following TNF-α treatment in the presence of the IL-6 
NtAb, an effect which also imparted a correlative recovery in barrier function. IL-6 has a 
detailed complex role in the CNS (Barkhudaryan, Dunn 1999, Erta, Quintana et al. 2012). 
Whilst several studies have outlined its beneficial effects in coordinating the CNS immune 
response (Woodroofe, Sarna et al. 1991, Taupin, Toulmond et al. 1993, Klein, Moller et al. 
1997, Hans, Kossmann et al. 1999, Penkowa, Moos et al. 1999, Penkowa, Giralt et al. 2000, 
Galiano, Liu et al. 2001, Swartz, Liu et al. 2001) very few have examined the effects of 
endothelial IL-6 release on the endothelium itself in the acute phase of BBB injury. Some in 
vitro studies have demonstrated the direct disruptive effect of IL-6 on BMvEC barrier 
function (Brett, Mizisin et al. 1995, Saija, Princi et al. 1995), whilst some in vivo studies 
have explored similar barrier-disruptive effects following injury in IL-6 knockout models 
(Paul, Koedel et al. 2003). Our data shows for the first time that TNF-α-induced IL-6 release 
not only has a direct negative impact on BBB phenotype, particularly pertaining to barrier 
function (~30% of overall impact), but it does so through the release of inflammatory 
mediators such as ROS. This adds a fresh dimension to the already existing data, in that 
while IL-6 might have an overall beneficial impact on the NVU, its acute release sustains 
negative consequences for the endothelium, and potentially neighbouring cell types via its 
subsequent secretory events.    
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Figure 7.6: The contributory effect of IL-6 release in TNF-α-induced injury to 
HBMvECs. 
In the final chapter of this thesis (chapter 6), our objective was to identify novel binding 
partners of the junctional proteins that maintain BBB phenotype (such binding partners 
potentially facilitating the post-translational modification observed in response to shear and 
cytokine treatments). Samples from shear and control cultures were prepared and subjected 
to optimised IP protocols for each of the junction proteins of interest. IP eluates and protein 
bands of interest isolated from SDS-PAGE gels run for IP eluates were subject to digestion 
and subsequent analysis by LC-M/MS. The peptide libraries generated yielded a substantial 
amount of potential targets. We therefore extrapolated targets from the bulk of the data 
based on cross relativity between species (bovine cultures were also prepared to investigate 
any overlap), trends observed between static and shear samples, and trends across the four 
proteins of interest. Numerous isoforms of the 14-3-3 family met each of these criteria, in 
particular an increase in 14-3-3 association with each of the junctional targets was observed 
following exposure to laminar shear stress. This relationship was clarified by repeat 
immunoprecipitation and reverse-immunprecipitation (pull-down of 14-3-3) with subsequent 
analysis of eluates by immunoblot techniques. Based on these screening studies, we 
concluded that 14-3-3 plays a role in the upregulation of barrier function through interaction 
with TJ/AJ proteins within the interendothelial complex.  
In order to fully conceptualise the role of 14-3-3 at the intercellular junction plaque, we 
optimised an established inhibitor of 14-3-3 interaction; R18 peptide (Petosa, Masters et al. 
1998, Wang, Yang et al. 1999), and simulated laminar shear stress in the presence of 
inhibitor. As validated by immunoblot analysis, R18 inhibited the laminar-shear induced 
association with each of the intercellular junction proteins of interest, a mechanism which 
could now be utilised in establishing 14-3-3’s role in junction formation/enhancement. 
Based on the efficacy of R18, initial studies focussed on whether R18 inhibition of 14-3-3 
could induce barrier dysfunction. Indeed, R18 could increase permeability of HBMvEC 
monolayers in both a dose- and time-dependent manner and completely reverse the barrier-
strengthening effects of shear stress, adding credence to a pro-barrier role of 14-3-3.  
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Our studies with 14-3-3 up to this point utilised an antibody capable of detecting all seven 
isoforms. We therefore referred to our mass spectrometry data bank and noted that five of 
the seven isoforms surpassed the threshold as valid binding partners for each of the 
intercellular junction proteins of interest. We shifted our focus to examining the 
transcriptional levels of each isoform in response to laminar shear stress. Each isoform 
demonstrated an overall increase in mRNA levels in the acute stages of laminar shear onset 
prior to an overall moderate reduction following sustained shear exposure. The impact of 
this on respective proteins levels has yet to be investigated but it should be noted that 14-3-3 
plays a role in numerous functions within the cell and while global levels of 14-3-3 may 
fluctuate, this may have no bearing on the increased association observed at the junction 
complex. This theory could be applied to the preliminary studies in effect in our laboratory 
in which 14-3-3 association at the junction complex following exposure to our inflammatory 
mediators; TNF-α and IL-6, is being investigated. Early work has demonstrated a surge in 
14-3-3 transcription levels in both a dose- and time-dependent manner following exposure to 
these cytokines. Subsequent assessments of barrier function following exposure to TNF-α 
and IL-6 in the presence of R18 has demonstrated a slight but significant increase in 
permeability of the HBMvEC cultures. As inhibition of 14-3-3 binding in the presence of 
cytokines exacerbates barrier injury, this may suggest that increased transcription of these 
five isoforms following cytokine treatment is perhaps a defensive mechanism to reduce 
injury. Overall, studies have identified 14-3-3 as having a critical role in maintaining cell 
polarity in epithelial models (Hurd, Fan et al. 2003, Suzuki, Hirata et al. 2004, Izaki, 
Kamakura et al. 2005, Cohen, Fernandez et al. 2011), some studies of which have identified 
consequences for some of the intercellular proteins of interest in this thesis (i.e. ZO-1 
(Wong, Sun et al. 2009)). One of the few studies in endothelial cells pertaining to 14-3-3 
identified it as having a protective role in response to inflammatory injury (Liu, Yin et al. 
2001), a process that could be interestingly enhanced following exposure to shear stress. 
Apart from the aforementioned studies, evidence of 14-3-3 participation in intercellular 
junction modulation is scarce and the work conducted in our laboratory to date, and 
presented in this thesis, suggests for the first time such association is plausible. Given its 
substantial presence in the brain (Martin, Rostas et al. 1994), in conjunction with evidence 
that elevated levels coincide with the onset of CNS pathologies (Boston, Jackson et al. 1982, 
Collins, Boyd et al. 2000), newly identified functions of 14-3-3 in the BBB may be detailed 
in this thesis, functions that may lead to better understanding of the physiology and 
pathophysiology of the BBB.  
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Figure 7.7: The contributory effect of 14-3-3 in shear-mediated stabilisation of 
HBMvECs barrier.  
For future considerations, our laminar shear model is a well-published and validated means 
of examining the effect of said haemodynamic forces on our cerebral cultures (Pearce, 
McIntyre et al. 1996, Hendrickson, Cappadona et al. 1999, Colgan, Ferguson et al. 2007, 
Fitzpatrick, Guinan et al. 2009), however it presents some limitations. With regard to the 
real-time assessment of barrier function, pre-sheared cultures required replating into 
transwell inserts in which they were evaluated for transendothelial permeability. Exposure of 
the HBMvEC cultures in transwell inserts to orbital shear stress was not option due to the 
introduction of basolateral turbulence. Whilst not 100% ideal, previous studies have 
demonstrated that endothelial cultures retain ‘mechanical memory’ (Collins, Cummins et al. 
2006) and indeed a consistent and significant improvement in barrier function is observed in 
our basic assessment of the effect of laminar shear on cerebral cultures despite the 
requirement for replating the cells post-shearing. A cone and plate viscometer offers a means 
of navigating this problem facilitating the in situ application of uniform shear stress profiles 
to cultures prepared for barrier assessment by the transwell permeability assay (Dewey, 
Bussolari et al. 1981, Blackman, Barbee et al. 2000, Orr, Stockton et al. 2007).  
An additional criterion not explored in this thesis is the influence of the other cell 
populations which comprise the NVU on the MvECs. The influence of these diverse cell 
types on the MvECs in establishing the BBB is well documented, ranging from the impact of 
their released soluble factors to their physical contact. Colgan (2007) noted an improvement 
in paracellular permeability and TEER levels of BBMvECs following co-culture with 
astrocytes cultures or astrocyte-conditioned medium. In vivo levels of TEER with regards to 
the BBB are estimated to exceed 1000 Ω/cm2. Colgan (2008) however observed a maximum 
electrical resistance of 80 Ω/cm2 with BBMvECs in vitro. The presence of these factors, and 
indeed as we have shown, the hemodynamic forces associated with the blood flow of the 
microvasculature, are thus imperative in recreating the BBB microenvironment. Several 
apparatuses acknowledge this in that they are designed to facilitate both stimuli in 
experimental paradigms.   
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Figure 7.8: The DIV-BBB perfusion system. (i) The DIV-BBB is a small scale system that 
facilitates the (ii) simulation of hemodynamic forces found at the BBB. (iii) The cartridges 
allow for TEER measurements to be made whilst allowing for the (iv) 3D replication of 
anatomical aspects found at the BBB, (http://flocel.com/).      
 
The CellMax artificial capillary system is a closed perfusion system currently employed in 
our lab for assessment of macrovascular environments. It facilitates not only the 3D co-
culturing of cell populations, but allows the application of haemodynamic forces to the 
cultures. While we have achieved success with this system to date (Collins, Cummins et al. 
2006, Colgan, Ferguson et al. 2007, Colgan, Collins et al. 2008), the DIV-BBB (Flocel Inc. 
Cleveland, Ohio) offers a similar setup, on a smaller, more anatomically correct scale, with 
the added feature of real-time measurement of TEER (Fig. 7.1). This system has been 
utilised in studies that corroborate some of the data in this thesis (Santaguida, Janigro et al. 
2006, Krizanac-Bengez, Hossain et al. 2006, Krizanac-Bengez, Mayberg et al. 2006, Desai, 
Marroni et al. 2002, Cucullo, Hossain et al. 2011).    
In conclusion, we have attempted to generate a detailed model, in vitro, of how the brain 
microvascular endothelium responds to positive and negative regulators of barrier 
phenotype. Our main findings can be summarised as follows: 
 Laminar shear stress plays a pivotal role in the maintenance of vascular homeostasis 
and BBB phenotype through modulation and post-translational modification of 
interendothelial protein expression. 
 Inflammatory cytokines, such as TNF-α and IL-6, play a pivotal role in the 
disruption of vascular homeostasis and BBB phenotype by directly (and indirectly 
via the release of pro-inflammatory mediators) promoting an injured BBB 
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phenotype through the modulation and post-translational modification of 
interendothelial protein expression.  
 Laminar shear stress is also involved in the modulation of endothelial anti-
inflammatory mechanisms and responsiveness to cytokine injury. TNF-α and IL-6 
exert an opposite effect on the aspects examined promoting pro-inflammatory 
mechanisms and responsiveness to cytokine injury. Together, laminar shear stress 
had a protective effect against the influence of inflammatory cytokines as observed 
via the interendothelial junction.  
 TNF-α and IL-6 are capable of elevating ROS production of HBMvECs. Using 
antioxidant strategies, the elevated levels of ROS induced by TNF-α and IL-6 were 
verified to sufficiently cause a reduction in tight junction protein levels and 
subsequently cause a reduction in barrier function. In addition, the levels of TNF-α-
induced IL-6 on HBMvECs impacts significantly across a number of BBB 
molecular and functional aspects. We feel this data presents a comprehensive 
outlook on the cytokine-induced mechanisms in the acute and chronic stages of 
microvascular injury and underlines the importance of developing antioxidant 
treatments which are capable of effectively treating oxidative stress in the cerebral 
tissue 
 The 14-3-3 family plays a pivotal role in the maintenance of vascular homeostasis 
and BBB phenotype through association with proteins of the interendothelial 
junction, with consequences for BBB barrier function. In addition, the 14-3-3 family 
may play a pivotal anti-inflammatory role in response to cytokine injury. 
We find the effect of laminar shear stress on several aspects of cerebral endothelium 
homeostasis was explored comprehensively with physiological levels proven to be a 
dynamic regulator of intercellular junction assembly and consequently barrier function, in 
addition to anti-inflammatory and anti-coagulative mechanisms. Conversely, at an injury-
induced level, locally produced inflammatory mediators induce adverse regulation of these 
mechanisms, promoting endothelial barrier dysfunction and at the molecular and functional 
level.   
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Figure A.1: Assessment of transfection viability and efficiency. HBMvECs were grown 
to 70-80% confluency and subjected to electroporation for recombinant GFP protein and 
pEGFPN1 plasmid as described in section XXX. The following day cells were harvested and 
prepared for flow cytometry analysis using PI stain to measure cytotoxicity.  The dot plots 
represent the spread of the cell populations as a result of successful expression of GFP and 
PI staining, which reflect the degree of transfection efficiency and the viability, respectively. 
Moreover, GFP expression was also verified by immunofluorescence microscopy for both 
recombinant GFP protein (ii) and pEGFPN1 plasmid (ii). 
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Figure A.2: The effect of laminar shear stress on TNF-α-induced injury of HBMvECs. 
Confluent HBMvECs were pre-conditioned by laminar shear stress (8 dynes cm
-2
, 24 hr), 
following which the cultures were replated into transwell inserts and left to adhere 
overnight. TNF-α (0-100 ng/ml) was then added to the cultures for an additional 6 or 18 hr 
before they were examined by transendothelial permeability assay. The histograms and line 
graphs show the change in permeability (%TEE FD40) at a given time point(s) (t) = 180 
mins and 0-180 mins after 6 hr (i) and 18 hr (ii) exposure to TNF-α (0-100 ng/ml). Results 
are averaged from three independent experiments ± SD; *P≤0.05 vs. Unsheared Control. 
εP≤0.05 vs. Sheared Control. 
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Figure A.3: The effect of laminar shear stress on IL-6-induced injury of HBMvECs. 
Confluent HBMvECs were pre-conditioned by laminar shear stress (8 dynes cm
-2
, 24 hr), 
following which the cultures were replated into transwell inserts and left to adhere 
overnight. IL-6 (0-100 ng/ml) was then added to the cultures for an additional 6 or 18 hr 
before they were examined by transendothelial permeability assay. The histograms and line 
graphs show the change in permeability (%TEE FD40) at a given time point(s) (t) = 180 
mins and 0-180 mins after 6 hr (i) and 18 hr (ii) exposure to IL-6 (0-100 ng/ml). Results are 
averaged from three independent experiments ± SD; *P≤0.05 vs. Unsheared Control. 
εP≤0.05 vs. Sheared Control. 
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Figure A.4: The effect of laminar shear stress on IL-6 expression and secretion. 
Confluent HBMvECs were maintained under static conditions or exposed to laminar shear 
stress (8 dynes cm
-2
, 0-24 hr) following which they were harvested for whole cell protein 
lysate and conditioned medium. The samples were analysed by western blot for the 
translational levels of IL-6. The conditioned medium was examined by ELISA to monitor 
the effect on IL-6 release in the absence or presence of shear forces (iii) Results are averaged 
from three independent experiments ± SD; δP≤0.05 vs. Unsheared Control. *P≤0.05 vs. 0 
hrs. Blot is representative. 
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Figure A.5: The effect of laminar shear stress on vWF expression. Confluent HBMvECs 
were maintained under static conditions or exposed to laminar shear stress (8 dynes cm
-2
, 0-
24 hr) following which they were harvested for whole cell mRNA and protein lysate. The 
samples were analysed by western blot for the translational levels (i, ii) and qPCR for the 
transcriptional levels (iii) of vWF. Results are averaged from three independent experiments 
± SD; δP≤0.05 vs. Unsheared Control. *P≤0.05 vs. 0 hrs. Blot is representative. 
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Figure A.6: The effect of TNF-α and IL-6 on thrombomodulin expression and 
secretion. Confluent HBMvECs were stimulated with TNF-α (LHS) or IL-6 (RHS) (0-100 
ng/ml) for 0-24 hrs following which they were harvested for whole cell protein lysate and 
conditioned medium. Post-treatment, the samples were analysed by western blot for the 
translational levels of thrombomodulin. The conditioned medium was examined by ELISA 
to monitor the effect on thrombomodulin release in response to both cytokines (100 ng/ml) 
over 24 hrs (v, vi) or in response to both cytokines (0-100 ng/ml) at 6 and 18 hrs (vii, viii), 
respectively. Results are averaged from three independent experiments ± SD. *P≤0.05 vs. 
Untreated Control (iii, iv) and 0 hrs (v-viii) respectively. Blots are representative. 
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Figure A.7: The effect of TNF-α and IL-6 on vWF expression and secretion. Confluent 
HBMvECs were stimulated with TNF-α (LHS) or IL-6 (RHS) (0-100 ng/ml) for 0-24 hrs 
following which they were harvested for whole cell protein lysate and mRNA. Post-
treatment, the samples were analysed by western blot for the translational levels (i-iv) and by 
qPCR for the transcriptional levels (v-viii) of vWF. Results are averaged from three 
independent experiments ± SD. *P≤0.05 vs. Untreated Control (iii, iv) and 0 hrs (v-viii), 
respectively. Blots are representative. In addition, confluent HBMvECs were stimulated with 
TNF-α or IL-6 (0-100 ng/ml) for 6 or 18 hrs following which they were examined for 
changes in the expression and localisation patterns of vWF (green). Untreated control 
cultures were employed as a control (ix). All cultures were counterstained for nuclei (blue). 
Images are representative.  
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Figure A.8: The effect of TNF-α and IL-6 on cytokine signal-transducing receptors.  
Confluent HBMvECs were stimulated with TNF-α (LHS) or IL-6 (RHS) (0-100 ng/ml) for 
0-24 hrs following which they were harvested for whole cell mRNA. The samples were 
analysed by qPCR for the transcriptional levels of TNFR1 (i-iv), TNFR2 (v-viii) and GP130 
(ix-xii). The histograms represent the changes in the respective signal-transducing receptors 
on a transcriptional level over time (i, iii, v, vii, ix, xi) and with respect to dose at 6 and 18 
hrs (ii, iv, vi, viii, x). Results are averaged from three independent experiments ± SD; 
*P≤0.05 vs. 0 hrs (i, iii, v, vii, ix, xi) or 0ng/ml (ii, iv, vi, viii, x, xii) respectively. 
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Figure A.9: The effect cytokines and claudin-5 knockout on HBMvEC Barrier 
Function. HBMvECs were grown to 70-80% confluency and subjected to electroporation 
for claudin-5 siRNA as described in section XXX. The following day the transfected 
cultures were replated into transwell inserts and left to adhere overnight. The following day, 
the cultures were treated with TNF-α or IL-6 (100 ng/ml) for 6 or 18 hrs before being 
examined by transendothelial permeability assay. The histograms (LHS) and line graphs 
(RHS) show the change in permeability (%TEE FD40) at a given time point(s) (t) = 180 
mins and 0-180 mins, respectively. Results are averaged from three independent experiments 
± SD; *P≤0.05 vs. Untreated Control, δP≤0.05. 
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Figure A.10: The effect cytokines and VE-Cadherin knockout on HBMvEC Barrier 
Function. HBMvECs were grown to 70-80% confluency and subjected to electroporation 
for VE-Cadherin siRNA as described in section XXX. The following day the transfected 
cultures were replated into transwell inserts and left to adhere overnight. The following day, 
the cultures were treated with TNF-α or IL-6 (100 ng/ml) for 6 or 18 hrs before being 
examined by transendothelial permeability assay. The histograms (LHS) and line graphs 
(RHS) show the change in permeability (%TEE FD40) at a given time point(s) (t) = 180 
mins and 0-180 mins, respectively. Results are averaged from three independent experiments 
± SD; *P≤0.05 vs. Untreated Control, δP≤0.05. 
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Figure A.11: The effect of TNF-α and IL-6 on ROS production-Time Response, 
Immunofluorescence. Confluent HBMvECs were treated with TNF-α or IL-6 (100 ng/ml) 
for 6 or 18 hrs in the presence of CFDA (i) or DHE (ii). Images are representative. 
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Figure A.12: The effect of antioxidants on TNF-α- and IL-6-induced ROS production-
DHE. Confluent HBMvECs were stimulated with TNF-α or IL-6 (100 ng/ml) for 6 or 18 hrs 
in the presence of DHE and a range of antioxidant compounds. Post-treatment, cells were 
harvested and subsequently prepared for flow cytometry. The histograms represent the 
intensity of the DHE dye prepared from the corresponding representative FACS scans.  The 
cytokine-treated samples were analysed using FlowJo Flow Cytometry Analysis Software to 
quantify the respective signal from DHE-stained cell populations in response to TNF-α (ii, 
iv) and IL-6 (v, vii) at 6 (upper) and 18 (lower) hrs. Results are averaged from three 
independent experiments ± SD. *P≤0.05 vs. Untreated Control. δP≤0.05 vs. TNF-α or IL-6 
treatment.  
Legend: PE-Texas Red-A = DHE 
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Figure A.13: The effect of antioxidants on HBMvEC viability-Flow Cytometry 
Analysis. Confluent HBMvECs were stimulated with antioxidants for 18 hr. Post-treatment 
cells were harvested and subsequently prepared for flow cytometry analysis using PI stain.  
Samples were analysed using FlowJo Flow Cytometry Analysis Software to identify the 
viable and cytotoxic  cell populations in response to a range of concentrations of apocynin 
(i), catalase(ii), N-acetylcysteine (iii) and superoxide dismutase (iv). Results are averaged 
from three independent experiments ± SD; *P≤0.05 vs. Untreated Control. 
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Figure A.14: The effect of antioxidants on TNF-α-induced downregulation of TJ/AJ 
proteins. Confluent HBMvECs were treated with TNF-α (100 ng/ml) for 6 hrs in the 
presence of a number of antioxidant compounds. Post-treatment, cells were harvested for 
whole cell protein lysate. The translational effect on particular intercellular junction proteins 
was investigated by western blot. The histograms represent the changes in relative protein 
expression for VE-Cadherin (ii, vi, x, xiv), occludin (iii, vii, xi, xv) and claudin-5 (iv, viii, 
xii, xvi). Results are averaged from three independent experiments ± SD; *P≤0.05 vs. 
Untreated Control. δP≤0.05. Blots are representative. 
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Figure A.15: The effect of antioxidants on IL-6-induced downregulation of TJ/AJ 
proteins. Confluent HBMvECs were treated with IL-6 (100 ng/ml) for 6 hrs in the presence 
of a number of antioxidant compounds. Post-treatment, cells were harvested for whole cell 
protein lysate. The translational effect on particular intercellular junction proteins was 
investigated by western blot. The histograms represent the changes in relative protein 
expression for VE-Cadherin (ii, vi, x, xiv), occludin (iii, vii, xi, xv) and claudin-5 (iv, viii, 
xii, xvi). Results are averaged from three independent experiments ± SD; *P≤0.05 vs. 
Untreated Control. δP≤0.05. Blots are representative. 
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Figure A.16: The effect of antioxidants on TNF-α-induced disruption of HBMvEC 
barrier function. HBMvECs were seeded at a known density and allowed to adhere prior to 
examination by transendothelial permeability. HBMvECs were then pre-treated with TNF-α 
(100 ng/ml) for 6 hrs in the presence of a number of antioxidant compounds. Post-treatment, 
monolayers were examined by transendothelial permeability assay. The histograms (LHS) 
and line graphs (RHS) show the change in permeability (% TEE FD40) at a given time 
point(s) (t) = 180 mins or 0-180 mins, respectively. Results are averaged from three 
independent experiments ± SD; *P≤0.05 vs. Untreated Control. δP≤0.05.  
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Figure A.17: The effect of antioxidants on IL-6-induced disruption of HBMvEC 
barrier function. HBMvECs were seeded at a known density and allowed to adhere prior to 
examination by transendothelial permeability. HBMvECs were pre-treated with IL-6 (100 
ng/ml) for 6 hrs in the presence of a number of antioxidant compounds. Post-treatment, 
monolayers were examined by transendothelial permeability assay. The histograms (LHS) 
and line graphs (RHS) show the change in permeability (% TEE FD40) at a given time 
point(s) (t) = 180 mins or 0-180 mins, respectively. Results are averaged from three 
independent experiments ± SD; *P≤0.05 vs. Untreated Control. δP≤0.05.  
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Figure A.18: The effect of IL-6 on IL-6 expression. Confluent HBMvECs were stimulated 
with IL-6 (0-100 ng/ml) for 0-24 hrs following which they were harvested for whole cell 
mRNA. The histograms represent the changes in IL-6 on a transcriptional level over time (i) 
and with respect to dose at 6 and 18 hrs (ii). Results are averaged from three independent 
experiments ± SD; *P≤0.05 vs. 0 hrs (i), 0 ng/ml (ii) respectively.  
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Figure A.19: The optimisation of an IL-6 NtAb on IL-6-Induced disruption of 
HBMvEC barrier function. The efficacy of the particular IL-6 NtAb was investigated by 
western blot. HBMvEC lysate, recombinant IL-6 and recombinant TNF-α were run out on 
an SDS-PAGE gel and subjected to immunoblot analysis. In a parallel study, HBMvECs 
were seeded at a known density and allowed to adhere overnight. HBMvECs were then 
treated with IL-6 (20ng/ml) for 6 hrs and 18 hrs in the presence of a range of IL-6 NtAb 
concentrations. Post-treatment, the HBMvEC cultures were examined by transendothelial 
permeability assay. The histograms (ii, iii, iv, v) show the change in permeability (% TEE 
FD40) at a given time point (t) = 180 mins. Results are averaged from three independent 
experiments ± SD; *P≤0.05 vs. Untreated Control. δP≤0.05.  
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Figure A.20: The effects of an IL-6 NtAb on TNF-α-induced disruption of HBMvEC 
barrier properties. Confluent HBMvECs were stimulated with TNF-α (100 ng/ml) for 6 hrs 
in the presence of CFDA or DHE, and in the absence and presence of an IL-6 NtAb. Post-
treatment, cells were harvested and subsequently prepared for flow cytometry. The 
histograms represent the intensity of the CFDA (iii) and DHE (iv) ROS signals prepared 
from the corresponding FACS scans. The TNF-α-treated samples were analysed using 
FlowJo Flow Cytometry Analysis Software. Results are averaged from three independent 
experiments ± SD. *P≤0.05 vs. Untreated Control. In a parallel study, HBMvECs were 
seeded into transwell inserts at a known density and allowed to adhere prior to examination 
by transendothelial permeability assay. HBMvECs were then treated with TNF-α (100 
ng/ml) for 6 hrs in the presence of the IL-6 NtAb. The histogram (v) and line graph (vi) 
show the change in permeability (% TEE FD40) at a given time point(s) (t) = 180 mins or 0-
180, respectively. Results are averaged from three independent experiments ± SD; *P≤0.05 
vs. Untreated Control. δP≤0.05.  
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Figure A.21: The effect of 14-3-3 inhibition on HBMvEC barrier function. HBMvECs 
were seeded at a known density and allowed to adhere prior to addition of R18 peptide for 
18 hrs. Following this the HBMvEC sultures were examined by transendothelial 
permeability assay. The histogram (i) and line graph (ii) show the change in permeability (% 
TEE FD40) at a given time point(s) (t) = 180 mins or 0-180 mins, respectively, in response 
to R18 (0-1000 nM). Results are averaged from three independent experiments ± SD; 
*P≤0.05 vs. 0 nM. 
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Figure A.22: The effect of R18 peptide on HBMvEC viability-Flow Cytometry and 
Adhesion Analysis. Confluent HBMvECs were treated with R18 for 18 hr. Post-treatment 
cells were harvested and subsequently prepared for flow cytometry analysis using PI stain. 
The cytokine treated samples were analysed using FlowJo Flow Cytometry Analysis 
Software to identify the viable and cytotoxic cell populations in response to R18 (i). In a 
parallel experiment HBMvECs were seeded at a known density on 96-well plates and treated 
with R18 at different concentrations over 24 hrs. Post-treatment, the plates were stained with 
a crystal violet solution to assess cell number. HBMvECs were also seeded at a known 
density on xCelligence® plates and had their Cell Index (%) monitored in real-time in 
response to a range of R18 peptide concentrations. Results are averaged from three 
independent experiments ± SD; *P≤0.05 vs. Untreated Control. 
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Figure A.23: The effect of IL-6 on specific 14-3-3 isoform transcription. Confluent 
HBMvECs were stimulated with IL-6 (0-100ng/ml) for 0-24 hrs, following which they were 
harvested for whole cell mRNA. The LHS histograms represent the mRNA changes in 14-3-
3ζ (i), 14-3-3γ (ii), 14-3-3ε (iii) 14-3-3θ (iv) and 14-3-3β (vi) in response to 100 ng/ml TNF-
α. The RHS histograms represent the mRNA changes in 14-3-3ζ (vi), 14-3-3γ (vii), 14-3-3ε 
(viii) 14-3-3θ (ix) and 14-3-3β (x) in response to IL-6 (0-100 ng/ml) at 6 and 18 hrs. Results 
are averaged from three independent experiments ± SD; *P≤0.05 vs. 0 hrs (i-v) or 0 ng/ml 
(vi-x).  
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Figure A.24: The effect of 14-3-3 inhibition on TNF-α- and IL-6-induced HBMvEC 
damage-Barrier Function. HBMvECs were seeded at a known density and allowed to 
adhere prior to examination by transendothelial permeability. HBMvECs were then 
maintained in the presence of TNF-α or IL-6 (100ng/ml) for 18 hrs in the absence and 
presence of R18 peptide. Post-treatment the HBMvEC cultures were examined by 
transendothelial permeability assay. The histograms (LHS) and line graphs (RHS) show the 
change in permeability (% TEE FD40) at a given time point(s) (t) = 180 mins or 0-180 mins, 
respectively, in response to TNF-α (i, ii) or IL-6 (iii, iv). Results are averaged from three 
independent experiments ± SD; *P≤0.05 vs. Control. δP≤0.05.  
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Target Primer Set Efficiency 
Human GAPDH 97% 
Human Occludin 94% 
Human Claudin 5  94% 
Human VE-Cad  95% 
Human ZO-1  94% 
Human vWF  93% 
Human TNF-α  91% 
Human IL-6  95% 
Human TNFR1  95% 
Human TNFR2  94% 
Human GP130  94% 
Human sIL-6R  93% 
Human 14-3-3β  95% 
Human 14-3-3γ  95% 
Human 14-3-3ζ  96% 
Human 14-3-3θ  94% 
Human 14-3-3ε  95% 
Bovine GAPDH  95% 
Bovine Occludin  94% 
Bovine Claudin 5  95% 
Bovine VE-Cad  94% 
Bovine ZO-1  93% 
 
Figure A.25: Primer Efficiencies. To conduct primer efficiency curves the same reaction 
mixture used for qPCR is utilised with the exception that the template cDNA is omitted. 
Instead, a dilution of a PCR product which had been run previously using the same primer 
set is substituted. Briefly, the PCR product was excised from the reaction plate and a 1/1000 
dilution was made in RNase-free water. From here a 7-fold 1/10 serial dilution of this 
1/1000 dilution was made with 6.5 µl of each dilution substituting for the raw cDNA in each 
reaction mixture. An additional reaction mixture was made substituting the PCR product for 
RNase-free water. This acted as a non-template control. The temperature profile run for 
standard qPCR was utilised and the software was programmed to recognise the serial 
dilutions and plot their Threshold Cycle (CT Value) versus the immunofluorescent signal 
(number of copies of the target gene). Ideally primer sets should have an efficiency of 
between 90 and 105%.   
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